{"meta":{"query_hash":"4aa5585a87ca","filters":{"venue":"SKIN The Journal of Cutaneous Medicine"},"cohort_total":247,"direct_labels_cover":0,"predictions_cover":247,"exported":247,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4aa5585a87ca","api":"https://metacan.xera.ac/api/v1/cohort?venue=SKIN+The+Journal+of+Cutaneous+Medicine"},"results":[{"id":"W2765131124","doi":"10.25251/skin.2.supp.54","title":"Omalizumab Retreatment of Patients with Chronic Idiopathic Urticaria/Spontaneous Urticaria (CIU/CS) Following Return of Symptoms: Primary Results of the Optima Study","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada; European Academy of Allergy and Clinical Immunology","keywords":"Medicine; Chronic urticaria; Omalizumab; Dermatology; Primary care; Immunology; Immunoglobulin E; Antibody; Family medicine","score_opus":0.005904810974161413,"score_gpt":0.23462561414136235,"score_spread":0.22872080316720095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765131124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993935,0.0013972293,0.00005574955,0.0011615136,0.0007266892,0.0011642709,0.00002496721,0.000013158089,0.0015214565],"genre_scores_gemma":[0.99901456,0.0001374512,0.00013240994,0.00007732818,0.00039661815,0.0000037144655,0.00000814828,0.000046787773,0.00018298566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99509346,0.00047066592,0.0020114947,0.00024184963,0.0018042846,0.00037821877],"domain_scores_gemma":[0.99516386,0.00056921516,0.0018104666,0.001057965,0.0012004928,0.00019798361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010215446,0.0003393616,0.0012730508,0.0002453299,0.0001722546,0.0000052480805,0.0005443678,0.00017796157,0.000072998],"category_scores_gemma":[0.0008590728,0.00015033614,0.00031071014,0.0006792409,0.001156098,0.00006628292,0.00011129858,0.0006885854,0.0000019960971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18780021,0.02876003,0.260639,0.0011277819,0.13541016,0.026669249,0.15032627,0.0014432997,0.18884909,0.000848964,0.003664108,0.014461809],"study_design_scores_gemma":[0.099113144,0.26568782,0.3371435,0.0218755,0.17430696,0.06001182,0.011220979,0.00095078314,0.027404368,0.00096581713,0.00031036805,0.001008955],"about_ca_topic_score_codex":0.000107775246,"about_ca_topic_score_gemma":0.000048727597,"teacher_disagreement_score":0.23692778,"about_ca_system_score_codex":0.00037286564,"about_ca_system_score_gemma":0.0007374072,"threshold_uncertainty_score":0.613053},"labels":[],"label_agreement":null},{"id":"W2788512183","doi":"10.25251/skin.2.supp.52","title":"Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada; Novartis Pharma","keywords":"Omalizumab; Medicine; Chronic urticaria; Dermatology; Pediatrics; Immunology; Immunoglobulin E; Antibody","score_opus":0.009935159998666033,"score_gpt":0.253629792716605,"score_spread":0.24369463271793898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788512183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893819,0.00129323,0.000034149114,0.0073860665,0.00049324054,0.0011125127,0.000026916556,0.000017463184,0.00025451437],"genre_scores_gemma":[0.9979677,0.0004418613,0.00006981544,0.0002657652,0.00085743034,0.0000063263847,0.0000103121565,0.000037980724,0.0003428095],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966909,0.00082154927,0.0010040493,0.0002690906,0.0008412053,0.00037315828],"domain_scores_gemma":[0.9963676,0.0017693014,0.0004975611,0.0006992095,0.0004164812,0.00024985016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011116295,0.0003216515,0.00068847096,0.00018120921,0.00028023173,0.000022308192,0.0002727592,0.00013184114,0.00009096167],"category_scores_gemma":[0.0009483855,0.00013010524,0.00007020398,0.00035571863,0.00079024094,0.00006029157,0.000052333737,0.0006619685,0.000013632265],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7325503,0.0052571343,0.029377237,0.000014900492,0.010511588,0.055542998,0.11885106,0.00021928048,0.002654956,0.00006607563,0.0025077271,0.042446714],"study_design_scores_gemma":[0.12304262,0.2667753,0.49626508,0.0031875395,0.021624152,0.065392144,0.018065272,0.0013528813,0.0001950174,0.0002422771,0.0032652866,0.0005924089],"about_ca_topic_score_codex":0.0005280019,"about_ca_topic_score_gemma":0.000697636,"teacher_disagreement_score":0.6095077,"about_ca_system_score_codex":0.0004698091,"about_ca_system_score_gemma":0.00046181603,"threshold_uncertainty_score":0.53055376},"labels":[],"label_agreement":null},{"id":"W2788759478","doi":"10.25251/skin.2.supp.11","title":"Patient Preferences for Vehicle and Overall Preference of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam and Gel in the PSO-INSIGHTFUL Study","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Betamethasone dipropionate; Preference; Dermatology; Psychology; Medicine; Mathematics; Statistics","score_opus":0.2444633296620573,"score_gpt":0.39722299043489334,"score_spread":0.15275966077283604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788759478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818532,0.005344133,0.00038049297,0.010777257,0.0003109636,0.0010095257,0.000031772037,0.0000033560482,0.0002893153],"genre_scores_gemma":[0.9969289,0.0007182093,0.0003149384,0.0016270925,0.0003353821,0.000017396633,0.0000012339274,0.000012488677,0.00004438185],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9960508,0.00055222114,0.0027254065,0.00021565585,0.0002219004,0.0002340685],"domain_scores_gemma":[0.99391705,0.0030767212,0.0024070248,0.0003033853,0.00020034335,0.00009545882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011558493,0.00015833954,0.0008581198,0.00021547845,0.00014617335,0.000022131904,0.00031866354,0.00006856382,0.000052733787],"category_scores_gemma":[0.0031012923,0.000096092954,0.00004290907,0.00014677498,0.00033998,0.0001608735,0.000052184234,0.00022894915,0.0000041671997],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043568076,0.0031225958,0.34299102,0.0021183186,0.0014585365,0.000091575195,0.5643688,0.0004785592,0.0007066055,0.029572701,0.016882455,0.033852022],"study_design_scores_gemma":[0.017752882,0.04861501,0.5286905,0.0022323765,0.00049448607,0.0026294633,0.09380899,0.011044667,0.00039620014,0.2648218,0.02834773,0.0011659053],"about_ca_topic_score_codex":0.00058429263,"about_ca_topic_score_gemma":0.00036883124,"teacher_disagreement_score":0.4705598,"about_ca_system_score_codex":0.000077645556,"about_ca_system_score_gemma":0.00008058107,"threshold_uncertainty_score":0.4005966},"labels":[],"label_agreement":null},{"id":"W2789068895","doi":"10.25251/skin.2.supp.4","title":"Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Term (time); Dermatology; Clinical efficacy; Internal medicine; Physics","score_opus":0.04899517628077045,"score_gpt":0.37599208035405723,"score_spread":0.3269969040732868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789068895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99409395,0.0028573985,0.000009101562,0.00035310953,0.0020969089,0.0004346944,0.00011943441,0.000009256863,0.000026150414],"genre_scores_gemma":[0.994324,0.004112081,0.000088379486,0.00013309173,0.0009420916,0.0000022247264,0.000049364637,0.000023281737,0.00032547166],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99673253,0.0008172934,0.0017094967,0.0002844732,0.00014702986,0.00030914586],"domain_scores_gemma":[0.99380994,0.004327535,0.0009439155,0.00050662406,0.00032120434,0.00009079792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008944496,0.0002644093,0.0011790761,0.00018752518,0.00009591384,0.0000032325436,0.0003338789,0.00022019168,0.000277026],"category_scores_gemma":[0.0014526478,0.00012570118,0.0001780389,0.00025053998,0.0008516892,0.0000458978,0.00006420112,0.00030907305,0.00005918706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19862837,0.0056907656,0.107711054,0.000014681691,0.007369402,0.0012935995,0.008446081,0.000020464608,0.0009259249,0.00000429537,0.007372333,0.66252303],"study_design_scores_gemma":[0.10463065,0.094757035,0.7885587,0.0015737184,0.0030009768,0.00067286537,0.00036496628,0.0000018535258,0.0011163845,0.000027276257,0.0050168694,0.00027865794],"about_ca_topic_score_codex":0.00011698504,"about_ca_topic_score_gemma":0.0007730796,"teacher_disagreement_score":0.6808477,"about_ca_system_score_codex":0.0001819322,"about_ca_system_score_gemma":0.0002658611,"threshold_uncertainty_score":0.5125945},"labels":[],"label_agreement":null},{"id":"W2793020549","doi":"10.25251/skin.2.supp.13","title":"Psoriasis Patients on Chronic Biologic Therapy May Benefit from Additional Treatment-Study Design and Baseline Characteristics","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Celgene; Amgen; Pfizer; Allergan; Eli Lilly and Company","keywords":"Psoriasis; Baseline (sea); Medicine; Plaque psoriasis; Physical therapy; Internal medicine; Dermatology; Biology","score_opus":0.06000297180320597,"score_gpt":0.3419998588694396,"score_spread":0.28199688706623366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793020549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892354,0.0029826942,0.0001021067,0.005845945,0.00069723086,0.00061307434,0.00018157552,0.000012215424,0.00032977818],"genre_scores_gemma":[0.9799963,0.013847785,0.00019280812,0.0016988994,0.0040605254,0.000005892427,0.000044317574,0.000017021073,0.00013641141],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983907,0.00030373572,0.0004996052,0.0001544537,0.0004385411,0.00021298898],"domain_scores_gemma":[0.99558073,0.0032424394,0.0004732671,0.0001763571,0.00035098477,0.00017622272],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006082531,0.00022331538,0.0005193904,0.00007087458,0.00022287694,0.000010533939,0.00012355056,0.00005820587,0.004622313],"category_scores_gemma":[0.0007260319,0.00009825157,0.000058892194,0.00010933722,0.00030226444,0.000044180844,0.000024218098,0.00026605243,0.000028509556],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035698105,0.0041263197,0.01741427,0.000021385824,0.0032612546,0.000888566,0.003659354,0.000011636141,0.0014793109,0.000016999638,0.028318472,0.90510434],"study_design_scores_gemma":[0.033120535,0.30851194,0.143454,0.001090812,0.004257349,0.0034160193,0.0017950921,0.0012314419,0.0018394405,0.0008502294,0.49988708,0.00054605573],"about_ca_topic_score_codex":0.00004519253,"about_ca_topic_score_gemma":0.000009920681,"teacher_disagreement_score":0.90455824,"about_ca_system_score_codex":0.00013959529,"about_ca_system_score_gemma":0.000057456473,"threshold_uncertainty_score":0.9962876},"labels":[],"label_agreement":null},{"id":"W2890005351","doi":"10.25251/2.5.7","title":"Nab-paclitaxel/Gemcitabine Induced Acquired Ichthyosis","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Skin and Cellular Biology Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Ichthyosis; Gemcitabine; Paclitaxel; Medicine; Dermatology; Endocrine system; Disease; Drug; Oncology; Internal medicine; Chemotherapy; Pharmacology; Hormone","score_opus":0.01681145973259187,"score_gpt":0.29562266937997045,"score_spread":0.2788112096473786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890005351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824316,0.0038620487,0.00035081976,0.0028747816,0.0007966044,0.00013941174,0.000002601888,0.0000053655017,0.0037252048],"genre_scores_gemma":[0.99259865,0.0011741839,0.000103243794,0.0007655403,0.0036653548,0.0000015475747,0.000009484799,0.00002487254,0.0016571259],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998273,0.00032118848,0.00047749485,0.00016889462,0.00040602457,0.0003533573],"domain_scores_gemma":[0.9984186,0.00011489381,0.00029999175,0.00045375834,0.00054387935,0.00016883854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013273233,0.00018187989,0.00029948604,0.00010439514,0.00016137116,0.000008976289,0.0006634482,0.0001912737,0.00035230455],"category_scores_gemma":[0.00090215396,0.00010030914,0.0001116928,0.00020874917,0.00072797213,0.000003587085,0.00013138939,0.00021493516,0.000036427453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009510621,0.000051349765,0.00033551143,0.000008251862,0.0002092967,0.00016110323,0.00036282686,0.0000012145515,0.9735485,0.000022652,0.018460942,0.005887294],"study_design_scores_gemma":[0.0031441362,0.017087517,0.0012237172,0.00019535006,0.0003026839,0.043366965,0.0018051176,0.0000407723,0.77944094,0.0008101162,0.1521905,0.00039220185],"about_ca_topic_score_codex":0.000022373046,"about_ca_topic_score_gemma":0.000022069458,"teacher_disagreement_score":0.19410756,"about_ca_system_score_codex":0.000021902018,"about_ca_system_score_gemma":0.00012496828,"threshold_uncertainty_score":0.4090488},"labels":[],"label_agreement":null},{"id":"W2899771516","doi":"10.25251/skin.2.6.5","title":"Efficacy of a Silicone-Based Gel Containing Pracaxi Oil (Pentaclethra macroloba) for Treating Post-Surgical Scars","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatologic Treatments and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Scars; Silicone; Surgery; Silicone oil; Randomized controlled trial","score_opus":0.022799221518680992,"score_gpt":0.3523882437653737,"score_spread":0.32958902224669273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899771516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979988,0.0016709877,0.000099728226,0.013788117,0.0002716989,0.0003875644,0.000010828387,0.000016162148,0.0037669237],"genre_scores_gemma":[0.99676454,0.00024520763,0.0007279586,0.00065930537,0.0009081685,0.000005021998,0.000009731518,0.000030361203,0.000649702],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99736196,0.00022855868,0.0009538719,0.00016918182,0.0008558287,0.00043062447],"domain_scores_gemma":[0.99495316,0.0026735426,0.000780205,0.00032060253,0.0010129701,0.0002595018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013403689,0.0002284624,0.00089542754,0.00021051183,0.00019904334,0.000010293845,0.00028919484,0.0001300289,0.00024862855],"category_scores_gemma":[0.0013877406,0.00010800842,0.00025246566,0.00022896675,0.0008975844,0.0000428443,0.000039987845,0.000398391,0.000006574149],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.188064,0.0048452565,0.026564624,0.0015190559,0.0052294447,0.024419883,0.014052185,0.00019608098,0.09670761,0.0005732552,0.012733165,0.6250954],"study_design_scores_gemma":[0.15434162,0.13839589,0.012138299,0.010704203,0.0070814514,0.51728815,0.014696591,0.0048794015,0.08653474,0.0005397243,0.05247739,0.0009225489],"about_ca_topic_score_codex":0.000078853875,"about_ca_topic_score_gemma":0.000010961584,"teacher_disagreement_score":0.6241729,"about_ca_system_score_codex":0.0001013415,"about_ca_system_score_gemma":0.00034218546,"threshold_uncertainty_score":0.44044554},"labels":[],"label_agreement":null},{"id":"W2982882356","doi":"10.25251/skin.3.supp.36","title":"Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Psoriasis; Plaque psoriasis; Term (time); Internal medicine; Gastroenterology; Dermatology; Adalimumab; Disease","score_opus":0.029787239770012654,"score_gpt":0.29823996114461543,"score_spread":0.2684527213746028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982882356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893037,0.0073276325,0.000022132203,0.0005762492,0.0013988125,0.0008893598,0.0003789561,0.000013799907,0.00008933621],"genre_scores_gemma":[0.9977297,0.0009610716,0.000037888836,0.0000698373,0.0003480079,0.000003115985,0.00052983064,0.00004248911,0.00027803666],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99586946,0.0014269232,0.0015610236,0.00039293407,0.00029228433,0.00045739423],"domain_scores_gemma":[0.99385333,0.0031750826,0.0017122946,0.0009664126,0.00018922397,0.00010367318],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009699291,0.00045412948,0.001817219,0.0003252046,0.00011570285,0.000012613486,0.00085141807,0.00021667192,0.00130389],"category_scores_gemma":[0.000552984,0.00024428996,0.00014078636,0.00022469265,0.0003412187,0.00018294428,0.00020258453,0.0004634489,0.000051333274],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37875092,0.00622211,0.30623323,0.00018783324,0.0120786,0.0032414882,0.009118052,0.00008561026,0.14848706,0.000017407898,0.0048545585,0.13072315],"study_design_scores_gemma":[0.5840867,0.029190363,0.31664664,0.004078182,0.014324304,0.019429045,0.0012810454,0.000049954448,0.027898658,0.0002615584,0.0014527191,0.0013008178],"about_ca_topic_score_codex":0.00033498285,"about_ca_topic_score_gemma":0.0002853623,"teacher_disagreement_score":0.2053358,"about_ca_system_score_codex":0.00012588086,"about_ca_system_score_gemma":0.0001754954,"threshold_uncertainty_score":0.99960905},"labels":[],"label_agreement":null},{"id":"W2984127608","doi":"10.25251/skin.3.supp.35","title":"Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Double blinded; Randomized controlled trial; Quality of life (healthcare); Psoriasis; Physical therapy; Surgery; Dermatology; Alternative medicine; Pathology; Nursing","score_opus":0.032285454393292966,"score_gpt":0.30489723420023906,"score_spread":0.2726117798069461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984127608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954482,0.00051986123,0.000020157377,0.0005512821,0.00048129758,0.0029034403,0.000044376975,0.00000806076,0.000023368055],"genre_scores_gemma":[0.9992953,0.00019786948,0.000067667585,0.00015198052,0.000030975065,0.000014596805,0.00003275272,0.000021643893,0.00018723065],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954535,0.0018264115,0.0018166427,0.0003345696,0.00026864134,0.0003002522],"domain_scores_gemma":[0.99486995,0.0028636388,0.0014728067,0.00040141697,0.00030939386,0.00008278703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034392092,0.00032831682,0.00209809,0.00029146226,0.00006257348,0.000009277391,0.0002415666,0.00017266949,0.000038439743],"category_scores_gemma":[0.0007391517,0.00015028668,0.000097242475,0.00021137818,0.00021601348,0.00011326256,0.0000662846,0.00043570696,0.0000036604058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84795535,0.0027789688,0.13642947,0.00001828947,0.0016948294,0.000119821365,0.006309092,0.0001399069,0.00035855395,0.0000017390241,0.000036563957,0.004157437],"study_design_scores_gemma":[0.81893533,0.015150602,0.15807207,0.00045964975,0.0008296122,0.00006496798,0.0058880327,0.000027093594,0.0002861392,0.00006974315,0.0000073647775,0.00020937891],"about_ca_topic_score_codex":0.0010630059,"about_ca_topic_score_gemma":0.0005904361,"teacher_disagreement_score":0.029019978,"about_ca_system_score_codex":0.000060823357,"about_ca_system_score_gemma":0.00019222777,"threshold_uncertainty_score":0.61285126},"labels":[],"label_agreement":null},{"id":"W2985177726","doi":"10.25251/skin.3.supp.12","title":"An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Psoriasis; Tyrosine-kinase inhibitor; Medicine; Phase (matter); Pharmacology; Quality of life (healthcare); Chemistry; Internal medicine; Dermatology; Cancer; Organic chemistry","score_opus":0.021637576214507306,"score_gpt":0.3057167029094791,"score_spread":0.2840791266949718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985177726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918427,0.0053057303,0.00000846131,0.0004315218,0.0015342977,0.0005890011,0.0001390299,0.0000142368435,0.00013503667],"genre_scores_gemma":[0.9988429,0.00035688482,0.000041700398,0.00012017631,0.00034258055,0.0000039371525,0.00006108634,0.000022565942,0.00020817731],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99581105,0.0017939111,0.0015969614,0.00027551941,0.00021083468,0.00031175764],"domain_scores_gemma":[0.99636763,0.0013484468,0.0013286563,0.0005492589,0.00032883388,0.00007719416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023145876,0.0002979044,0.0011512466,0.0002643356,0.00008259317,0.0000066455927,0.0004695479,0.000199944,0.00020623858],"category_scores_gemma":[0.0009954617,0.00017139236,0.00012386226,0.00037002243,0.00021996045,0.00012801932,0.00004495204,0.00047965103,0.000026536045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054413624,0.005757739,0.011697106,0.000026751299,0.0015562008,0.0002196479,0.022669028,0.00004748825,0.87856966,0.000013308104,0.0018363358,0.023193104],"study_design_scores_gemma":[0.2712149,0.11089132,0.1315891,0.0015869482,0.004688921,0.0022397535,0.08751549,0.000057047437,0.3839948,0.0015338429,0.0032324996,0.0014553801],"about_ca_topic_score_codex":0.0024833542,"about_ca_topic_score_gemma":0.00063172966,"teacher_disagreement_score":0.49457487,"about_ca_system_score_codex":0.00008562269,"about_ca_system_score_gemma":0.00019795743,"threshold_uncertainty_score":0.69891775},"labels":[],"label_agreement":null},{"id":"W2985715279","doi":"10.25251/skin.3.supp.15","title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Medicine; Dermatology; Randomized controlled trial; Psoriasis; Disease; Internal medicine","score_opus":0.011130336037182963,"score_gpt":0.27348718798880434,"score_spread":0.2623568519516214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985715279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665062,0.029645918,0.000068916735,0.0011840212,0.00065409415,0.001807305,0.0001177331,0.0000042009688,0.000011638042],"genre_scores_gemma":[0.97747386,0.021693677,0.0000143495845,0.000058946567,0.00014575406,0.0000173913,0.000050235933,0.000015506772,0.00053028954],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809265,0.00073567725,0.0007588361,0.00014521663,0.000081172366,0.00018645164],"domain_scores_gemma":[0.99416274,0.0048874626,0.00053969683,0.00023952834,0.000119498305,0.00005110144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013727776,0.0002258154,0.0010188363,0.00010025436,0.0000986277,0.000004873883,0.00014731995,0.000076464356,0.00013712588],"category_scores_gemma":[0.000492897,0.000099051,0.00009376184,0.00009955133,0.000280008,0.00002652644,0.000017735929,0.00011753325,0.0000029593862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8262022,0.0063676476,0.0025201684,0.00007114744,0.0032290965,0.00014521582,0.012214812,0.00001362251,0.01094925,0.00003139121,0.0013444178,0.13691103],"study_design_scores_gemma":[0.9051995,0.039366536,0.006367724,0.0005677834,0.010500172,0.0020183714,0.006045252,0.00022880215,0.0028475642,0.00015248258,0.026340306,0.00036548407],"about_ca_topic_score_codex":0.00006275055,"about_ca_topic_score_gemma":0.000017199842,"teacher_disagreement_score":0.13654555,"about_ca_system_score_codex":0.000036920494,"about_ca_system_score_gemma":0.000061835206,"threshold_uncertainty_score":0.40391827},"labels":[],"label_agreement":null},{"id":"W2986283446","doi":"10.25251/skin.3.supp.38","title":"Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Nail (fastener); Dermatology; Outcome (game theory); Internal medicine; Infliximab; Tumor necrosis factor alpha; Materials science","score_opus":0.03094004696178332,"score_gpt":0.2977013145001826,"score_spread":0.2667612675383993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986283446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893681,0.0016232056,0.00006977749,0.005178492,0.0021117975,0.00075201556,0.00022663968,0.000015055355,0.000654929],"genre_scores_gemma":[0.9957656,0.00032581846,0.00010435794,0.0002996592,0.00034814747,0.000007615065,0.00006888507,0.000028970684,0.0030509222],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967054,0.00088398886,0.0015541634,0.00026074666,0.0001988721,0.00039682045],"domain_scores_gemma":[0.99669,0.0015990753,0.0010148212,0.00045071528,0.00016608484,0.00007930567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009442305,0.00033264753,0.0012923043,0.00025969133,0.000093426694,0.000012063842,0.00045937803,0.00019912259,0.00067567866],"category_scores_gemma":[0.00060379575,0.00016343156,0.00013231902,0.00022048898,0.00008121947,0.00008934942,0.000047045298,0.0004267138,0.00018419493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45776156,0.0019398922,0.0033614535,0.00007523,0.0064146486,0.008692917,0.029325297,0.0011965253,0.27639934,0.00005803592,0.017841674,0.19693342],"study_design_scores_gemma":[0.5484016,0.052193437,0.0032263831,0.00469904,0.008350138,0.11472994,0.017232018,0.00014891704,0.18584138,0.0024677548,0.06023131,0.0024781034],"about_ca_topic_score_codex":0.00051181833,"about_ca_topic_score_gemma":0.00025361349,"teacher_disagreement_score":0.19445531,"about_ca_system_score_codex":0.00013217005,"about_ca_system_score_gemma":0.0001350416,"threshold_uncertainty_score":0.7398207},"labels":[],"label_agreement":null},{"id":"W2986312172","doi":"10.25251/skin.3.supp.39","title":"Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Certolizumab pegol; Placebo; Medicine; Psoriasis; Plaque psoriasis; Randomized controlled trial; Multicenter study; Internal medicine; Dermatology; Adalimumab; Pathology; Alternative medicine","score_opus":0.028946586606599847,"score_gpt":0.2972223779139177,"score_spread":0.2682757913073179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986312172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9210989,0.071719855,0.00011576295,0.0029837207,0.001982027,0.0016649378,0.00020686425,0.00001482035,0.00021313928],"genre_scores_gemma":[0.9838032,0.015318657,0.000073464515,0.00011523019,0.00026286626,0.000011833202,0.00008919304,0.00003233581,0.0002931826],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99546087,0.0016323825,0.0018816617,0.00033352242,0.0002335488,0.00045800093],"domain_scores_gemma":[0.9894268,0.007847318,0.0015848924,0.0008221078,0.00023793931,0.000080927515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018083118,0.0004714509,0.0031211562,0.00034340072,0.00011912549,0.000010296135,0.00084917864,0.00024609722,0.0006445017],"category_scores_gemma":[0.0020764966,0.00024359518,0.00024377414,0.00018076398,0.000620013,0.00018430487,0.00021154166,0.00052836834,0.000031936594],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9392323,0.00089561305,0.0010056677,0.00006927414,0.010245815,0.000698123,0.0073253796,0.000032087755,0.019986944,0.000026479935,0.0022620407,0.018220281],"study_design_scores_gemma":[0.96740294,0.0028900772,0.00035947096,0.0012379894,0.006990627,0.007827056,0.008017326,0.00041690888,0.0030957,0.0006407458,0.0008034573,0.00031769593],"about_ca_topic_score_codex":0.00046862836,"about_ca_topic_score_gemma":0.0006016374,"teacher_disagreement_score":0.06270436,"about_ca_system_score_codex":0.000104193714,"about_ca_system_score_gemma":0.000157261,"threshold_uncertainty_score":0.9933523},"labels":[],"label_agreement":null},{"id":"W2987175910","doi":"10.25251/skin.3.supp.37","title":"Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Dermatology; Internal medicine; Oncology; Adalimumab; Disease","score_opus":0.038676375836139795,"score_gpt":0.3220570760310816,"score_spread":0.28338070019494177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987175910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795854,0.013946404,0.00013563868,0.0027053703,0.002098683,0.0011262028,0.00024047439,0.000016344307,0.00014545071],"genre_scores_gemma":[0.9963656,0.002167189,0.00014703842,0.000047583268,0.00054334797,0.00001121907,0.00006230647,0.000034003417,0.00062171783],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997393,0.000608121,0.0012815425,0.00022429918,0.00014503629,0.0003479767],"domain_scores_gemma":[0.9926362,0.0053986832,0.0012826428,0.0004261844,0.0001789474,0.000077353616],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005621527,0.0003859189,0.002007395,0.00020635236,0.00012241842,0.000009108314,0.0003115982,0.00020150932,0.0010959883],"category_scores_gemma":[0.00056406937,0.00018875851,0.0004337946,0.00010351998,0.00021828103,0.00006033141,0.000027237342,0.00012892301,0.00004040095],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12526841,0.0035656667,0.012179745,0.00011304263,0.023944775,0.0007001122,0.013906574,0.000056646248,0.33872405,0.0004278621,0.0051644873,0.47594863],"study_design_scores_gemma":[0.5755968,0.07733867,0.010468001,0.0013726917,0.03684415,0.028847659,0.0073225964,0.00007369266,0.21499744,0.005583938,0.040213164,0.0013411958],"about_ca_topic_score_codex":0.0002516262,"about_ca_topic_score_gemma":0.00006438011,"teacher_disagreement_score":0.47460744,"about_ca_system_score_codex":0.00008826118,"about_ca_system_score_gemma":0.00012319854,"threshold_uncertainty_score":0.99981713},"labels":[],"label_agreement":null},{"id":"W2987595422","doi":"10.25251/skin.3.supp.14","title":"Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Medicine; Randomized controlled trial; Demographics; Placebo; Plaque psoriasis; Internal medicine; Psoriasis; Dermatology; Pathology; Alternative medicine","score_opus":0.007098689643237144,"score_gpt":0.2681841225595791,"score_spread":0.26108543291634195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987595422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949878,0.000050293118,0.00014684374,0.00057501893,0.00039860036,0.0037275816,0.000047062935,0.000009256735,0.000057553993],"genre_scores_gemma":[0.99879634,0.000056199067,0.0001384118,0.00042390745,0.0004684674,0.00001863513,0.000025536212,0.000037365775,0.000035159057],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99603623,0.0007452125,0.0017767957,0.00022005815,0.0009597239,0.00026198768],"domain_scores_gemma":[0.99422807,0.0021810695,0.0015167592,0.00038643077,0.0013406961,0.00034698847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020964115,0.00032241663,0.002082235,0.0006699185,0.00005089112,0.000007911386,0.00021458675,0.000091507594,0.000089940295],"category_scores_gemma":[0.0037316303,0.00017090948,0.0002457378,0.0004959204,0.00018882795,0.0001210103,0.000021255308,0.0006825945,0.0000025677627],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9738322,0.0028155737,0.0006631829,0.000068687594,0.000510291,0.00012090005,0.0011835216,0.017348519,0.0026689777,0.000017254839,0.000102038524,0.000668865],"study_design_scores_gemma":[0.96235466,0.025656296,0.0011857316,0.0028061348,0.0014990832,0.00027690845,0.00016829508,0.0038236973,0.0019686883,0.000050790535,0.000030285897,0.00017943769],"about_ca_topic_score_codex":0.000053562155,"about_ca_topic_score_gemma":0.000016241922,"teacher_disagreement_score":0.022840722,"about_ca_system_score_codex":0.00009452246,"about_ca_system_score_gemma":0.00040651398,"threshold_uncertainty_score":0.69694865},"labels":[],"label_agreement":null},{"id":"W2989334748","doi":"10.25251/skin.3.supp.26","title":"Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Term (time); Medicine; Phase (matter); Intensive care medicine; Chemistry; Physics","score_opus":0.11277680321458737,"score_gpt":0.4069110720091389,"score_spread":0.2941342687945515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989334748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698837,0.002138052,0.00006585017,0.008742662,0.00067807734,0.0009591497,0.000013143051,0.000005044937,0.00040967474],"genre_scores_gemma":[0.9982571,0.00031659933,0.00003784328,0.0010784689,0.000111681264,0.00000214792,0.0000019045589,0.000020325513,0.00017392264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927836,0.0004423973,0.0060953223,0.00020616777,0.00023814122,0.0002343933],"domain_scores_gemma":[0.9915233,0.0022166453,0.0055563375,0.0004575425,0.00011666378,0.00012948742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009592621,0.0001748813,0.0016709132,0.0004678594,0.0000555109,0.000010561704,0.00029344665,0.00007121297,0.0003606239],"category_scores_gemma":[0.0031170151,0.00013145746,0.000074325086,0.00019611519,0.000106079235,0.00013990267,0.00005318357,0.00029614143,0.000034773457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011523217,0.001963842,0.95490366,0.00022875906,0.0005136567,0.00015493705,0.035688896,0.0005331865,0.000033374472,0.00036926064,0.00084394973,0.0036141472],"study_design_scores_gemma":[0.037820477,0.013833156,0.9171206,0.0010167843,0.00018978957,0.0038425424,0.021191044,0.0008270861,0.000015153992,0.0017556302,0.0019030442,0.00048472584],"about_ca_topic_score_codex":0.0004898249,"about_ca_topic_score_gemma":0.00017996237,"teacher_disagreement_score":0.037783105,"about_ca_system_score_codex":0.0001911447,"about_ca_system_score_gemma":0.000087796056,"threshold_uncertainty_score":0.53606796},"labels":[],"label_agreement":null},{"id":"W2989489239","doi":"10.25251/skin.3.supp.17","title":"Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Phase (matter); Medicine; Physics","score_opus":0.012942369372670017,"score_gpt":0.31888104224857944,"score_spread":0.3059386728759094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989489239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898077,0.0007022126,0.00005659308,0.007062837,0.00053308456,0.001054104,0.0001451601,0.0000055898718,0.0006327235],"genre_scores_gemma":[0.9944867,0.00026411877,0.00018109626,0.00035090663,0.00037164075,0.000003960178,0.000011314547,0.000022328444,0.004307965],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981141,0.0002156545,0.0007842529,0.00013027704,0.0005760882,0.00017959875],"domain_scores_gemma":[0.9961297,0.0020117238,0.00084555586,0.00053446565,0.00035332362,0.00012523534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007553619,0.00016019397,0.0007059192,0.000103808365,0.00003718889,0.0000041798585,0.00021649717,0.000045980683,0.00013956825],"category_scores_gemma":[0.0008157492,0.00006499343,0.00011783931,0.00024195667,0.00019963535,0.00003206071,0.000015743062,0.00016316344,0.00000852434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9307609,0.00058844336,0.0002081722,0.000014874403,0.0015061038,0.00083525816,0.029539412,0.00012909403,0.013802449,0.000023472328,0.007817005,0.014774779],"study_design_scores_gemma":[0.6775671,0.17453691,0.0059005083,0.0046121744,0.0082312375,0.008448963,0.021379618,0.000058396374,0.014036639,0.00021751657,0.08470988,0.00030104868],"about_ca_topic_score_codex":0.00051819114,"about_ca_topic_score_gemma":0.000054683846,"teacher_disagreement_score":0.25319383,"about_ca_system_score_codex":0.00015614236,"about_ca_system_score_gemma":0.00039448767,"threshold_uncertainty_score":0.2650355},"labels":[],"label_agreement":null},{"id":"W2990965204","doi":"10.25251/skin.3.6.20","title":"Reply: Terra Firma-Forme Dermatosis, Keratotic Form","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Genetic and rare skin diseases.","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Dermatology; Medicine; Art","score_opus":0.004164474139625888,"score_gpt":0.22426806103967611,"score_spread":0.22010358690005022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990965204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98376477,0.0066082515,0.00031615165,0.0033985728,0.0008597992,0.00021839706,0.0000043539144,0.0000056490776,0.0048240763],"genre_scores_gemma":[0.9928219,0.001470488,0.00011211795,0.0032236285,0.00084102707,0.000001124737,0.000011587285,0.000024705456,0.0014934702],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986572,0.000079784404,0.00049109774,0.00013354367,0.00037500108,0.0002633209],"domain_scores_gemma":[0.9987953,0.000056440196,0.00035459877,0.00044702608,0.00018516285,0.00016147191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037756047,0.00017728959,0.0002764926,0.00005893951,0.000076741766,0.000009852835,0.0004376751,0.00008782949,0.0004306735],"category_scores_gemma":[0.00016397226,0.00009654615,0.00013610022,0.000090709305,0.00014805165,0.0000045852926,0.00007578949,0.00018961477,0.000037026137],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024554913,0.00035512183,0.019402603,0.00032524756,0.0011218026,0.0006915723,0.0025696633,0.0009892797,0.43503365,0.00008034356,0.5155079,0.021467352],"study_design_scores_gemma":[0.006577634,0.0077068633,0.011875268,0.0008868141,0.0009904853,0.09909459,0.003989005,0.0002891062,0.120268956,0.0017305237,0.74566877,0.0009219547],"about_ca_topic_score_codex":0.0000109921775,"about_ca_topic_score_gemma":0.000004144424,"teacher_disagreement_score":0.3147647,"about_ca_system_score_codex":0.000019140698,"about_ca_system_score_gemma":0.00013725019,"threshold_uncertainty_score":0.4715573},"labels":[],"label_agreement":null},{"id":"W2993441120","doi":"10.25251/skin.3.6.2","title":"Transitioning Between Biologics","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Adverse effect; Intensive care medicine; Biologic Agents; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Disease","score_opus":0.014640119302499015,"score_gpt":0.2405203201935189,"score_spread":0.2258802008910199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993441120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878605,0.0065103713,0.00017473557,0.0017500615,0.001327727,0.000113762406,0.000008143099,0.000012278272,0.0022423924],"genre_scores_gemma":[0.99732506,0.00059767143,0.000040154613,0.00019698855,0.00033789407,3.976998e-7,0.000016294936,0.00000880318,0.0014767546],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990299,0.00027177966,0.00037608837,0.00007359155,0.00006086957,0.000187823],"domain_scores_gemma":[0.9987538,0.0006861282,0.00029048728,0.00015941788,0.00008792554,0.000022227505],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000602916,0.00012433206,0.00037003052,0.00008758895,0.00010057473,0.0000025838106,0.00024856656,0.00012888688,0.001097739],"category_scores_gemma":[0.00006657048,0.000060023856,0.0000932572,0.00010831463,0.00015698627,0.00003234027,0.000013390792,0.0002588069,0.00023669064],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025565804,0.0002082233,0.04498101,0.000062779094,0.003541962,0.0004563006,0.011117792,0.00017848515,0.668529,0.0005346371,0.014389755,0.2534435],"study_design_scores_gemma":[0.029745152,0.029369451,0.07684063,0.0022542188,0.009644493,0.119167216,0.015760966,0.000013515401,0.28228566,0.009504699,0.42386734,0.0015466477],"about_ca_topic_score_codex":0.000014377905,"about_ca_topic_score_gemma":0.0000024932733,"teacher_disagreement_score":0.4094776,"about_ca_system_score_codex":0.000025618818,"about_ca_system_score_gemma":0.000033547785,"threshold_uncertainty_score":0.9998154},"labels":[],"label_agreement":null},{"id":"W3003414630","doi":"10.25251/skin.4.supp.46","title":"Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira","keywords":"Certolizumab pegol; Medicine; Placebo; Term (time); Randomized controlled trial; Psoriasis; Plaque psoriasis; Internal medicine; Dermatology; Adalimumab; Alternative medicine; Pathology; Disease; Physics","score_opus":0.017923057379120415,"score_gpt":0.28185330641825046,"score_spread":0.26393024903913004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003414630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94491667,0.04990585,0.0004578817,0.0030822346,0.00076187565,0.000709052,0.000057423436,0.00001297512,0.00009604614],"genre_scores_gemma":[0.9920671,0.0072553507,0.00003116397,0.00014186754,0.0003309917,0.000011265871,0.00003747087,0.000019835627,0.000104977335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99632245,0.0013321365,0.00162405,0.00021535445,0.00021113607,0.0002948751],"domain_scores_gemma":[0.9941315,0.0039971694,0.0013251483,0.00029559218,0.00018470777,0.000065905566],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007780848,0.00032762857,0.0031343314,0.00037072555,0.00007923176,0.000005062611,0.000457323,0.0001928373,0.0010703902],"category_scores_gemma":[0.0011697966,0.00017654442,0.0006827635,0.0005062169,0.000469249,0.00006106638,0.000062403844,0.00040314105,0.000018146151],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90479493,0.00034839395,0.00279513,0.00003101001,0.051805336,0.002534863,0.011833825,0.0002444038,0.011338796,0.000024803303,0.00065171666,0.013596774],"study_design_scores_gemma":[0.93404293,0.0017330853,0.0039849114,0.00043851454,0.05146915,0.0021426335,0.0021764673,0.00016585452,0.0030103829,0.00041469885,0.00012084171,0.00030055383],"about_ca_topic_score_codex":0.00016024055,"about_ca_topic_score_gemma":0.0005223415,"teacher_disagreement_score":0.04715042,"about_ca_system_score_codex":0.00008345892,"about_ca_system_score_gemma":0.00009727266,"threshold_uncertainty_score":0.99984276},"labels":[],"label_agreement":null},{"id":"W3004321152","doi":"10.25251/skin.4.supp.60","title":"Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Pharmacokinetics; Medicine; Dermatology; Pharmacology","score_opus":0.018450507292060808,"score_gpt":0.2905141314512494,"score_spread":0.27206362415918856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004321152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823269,0.008777083,0.0001188853,0.007862733,0.0001523571,0.0006438502,0.00002180595,0.0000024730246,0.000093861236],"genre_scores_gemma":[0.9865857,0.012654432,0.0000794644,0.00017627307,0.00043693473,0.0000026419657,0.0000065880777,0.000010093415,0.00004791966],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988489,0.000053729793,0.0005759519,0.00008204563,0.0003110047,0.00012835371],"domain_scores_gemma":[0.9984381,0.0007813548,0.0003667059,0.00011047287,0.00017644362,0.00012691948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118434975,0.000120799705,0.00043159752,0.000068920104,0.000035641817,0.00000146619,0.00008981603,0.000034034052,0.00008229143],"category_scores_gemma":[0.00025349183,0.000055162556,0.000116547184,0.00014437154,0.00011027331,0.000016293972,0.000014220378,0.00007838391,7.225952e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058731813,0.008792471,0.42493236,0.0009523405,0.0019398945,0.00032218476,0.009957265,0.00033987436,0.0021927066,0.00007172626,0.008283365,0.483484],"study_design_scores_gemma":[0.08741963,0.060008056,0.81494045,0.00055979815,0.01321861,0.0005652111,0.00061305676,0.002603716,0.0029587245,0.00022277517,0.01665707,0.00023289757],"about_ca_topic_score_codex":0.00002894784,"about_ca_topic_score_gemma":0.000003732998,"teacher_disagreement_score":0.4832511,"about_ca_system_score_codex":0.00005907159,"about_ca_system_score_gemma":0.00005606223,"threshold_uncertainty_score":0.22494638},"labels":[],"label_agreement":null},{"id":"W3023963563","doi":"10.25251/skin.4.3.4","title":"Enhancing Patient Compliance for Usage of Laundry Detergents Free of Dyes and Perfumes: Potential Impact of Better Cleaning Performance","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Skin Protection and Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Laundry; Sensitive skin; Compliance (psychology); Free access; Medicine; Business; Dermatology; Computer science; Waste management; Psychology; World Wide Web; Engineering","score_opus":0.02408597449184304,"score_gpt":0.28284296534816117,"score_spread":0.25875699085631815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023963563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934717,0.0009240802,0.0038201234,0.0012664561,0.00018012521,0.0002657707,0.0000070831343,0.000004266059,0.000060394388],"genre_scores_gemma":[0.9977209,0.0002726102,0.0013030765,0.00036960113,0.00030103987,8.2188694e-7,9.321885e-7,0.000017289703,0.000013758525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983567,0.00006328456,0.0008792531,0.00009216523,0.00044845184,0.00016014175],"domain_scores_gemma":[0.9981886,0.00023178023,0.0009834126,0.00016081598,0.0003109688,0.00012442243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044480615,0.00013606306,0.00060065585,0.00010596693,0.000054692555,0.0000023608056,0.00015967632,0.00004336787,0.00010600577],"category_scores_gemma":[0.0005627116,0.00007811111,0.00014962819,0.00014008686,0.00019134277,0.000058542977,0.00004843324,0.00024610444,2.7273774e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004949546,0.00012014923,0.013688811,0.0017838939,0.00055288884,0.000101420344,0.013024436,0.0008328298,0.92583245,0.0000023044338,0.0009218979,0.038189355],"study_design_scores_gemma":[0.013918884,0.042679083,0.03993405,0.016539963,0.0020805898,0.019004487,0.010090356,0.027513942,0.8271005,0.0002766768,0.0004298748,0.00043155928],"about_ca_topic_score_codex":0.000030145316,"about_ca_topic_score_gemma":0.000002038817,"teacher_disagreement_score":0.098731935,"about_ca_system_score_codex":0.00003091693,"about_ca_system_score_gemma":0.00006742521,"threshold_uncertainty_score":0.31852785},"labels":[],"label_agreement":null},{"id":"W3084505162","doi":"10.25251/skin.4.supp.69","title":"Efficacy of Tapinarof Cream by Body Region in Subjects With Plaque Psoriasis in a Phase 2b Randomized Controlled Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Plaque psoriasis; Randomized controlled trial; Medicine; Dermatology; Psoriasis; Internal medicine","score_opus":0.013928592941656437,"score_gpt":0.25692015283320085,"score_spread":0.24299155989154442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084505162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861184,0.00065303885,0.000019970625,0.011422857,0.00003110889,0.0014684382,0.0000043235204,0.000006505582,0.00027537622],"genre_scores_gemma":[0.9990378,0.00036404328,0.0000067906526,0.00022795126,0.00030271278,0.000021496788,0.000007507757,0.0000016818072,0.000029989737],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99764085,0.0004969658,0.0010146924,0.00014377592,0.0005229976,0.00018070449],"domain_scores_gemma":[0.9949671,0.0037946156,0.00090702233,0.00007087192,0.000121694036,0.00013870091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00139638,0.00017254664,0.0014101535,0.000032830638,0.000039711544,0.0000050920794,0.00039605016,0.000054739914,0.000057703008],"category_scores_gemma":[0.0015599036,0.00004709631,0.00009519461,0.0005565937,0.00022057883,0.000038097893,0.000020093317,0.00036541504,6.877982e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64519364,0.0023381151,0.0006355052,0.00002342334,0.00021550628,0.0007967695,0.0039231665,0.000074573654,0.34227556,0.000009736584,0.002624568,0.0018894494],"study_design_scores_gemma":[0.9410999,0.020484522,0.0013674593,0.001139425,0.0010297635,0.00425043,0.015257964,0.00066452386,0.013428798,0.00032805264,0.00061284413,0.00033634182],"about_ca_topic_score_codex":0.00024002165,"about_ca_topic_score_gemma":0.00012873088,"teacher_disagreement_score":0.32884675,"about_ca_system_score_codex":0.000030868694,"about_ca_system_score_gemma":0.000032321248,"threshold_uncertainty_score":0.19205317},"labels":[],"label_agreement":null},{"id":"W3084796437","doi":"10.25251/skin.4.supp.31","title":"Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Medicine; Psoriasis; Randomized controlled trial; Dermatology; Surgery","score_opus":0.009909449047611192,"score_gpt":0.2376766184769342,"score_spread":0.227767169429323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084796437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928171,0.0019115893,0.0002687529,0.0006684618,0.00028157365,0.0038900916,0.00004080856,0.000007574823,0.00011402014],"genre_scores_gemma":[0.99834543,0.001237871,0.00010124127,0.00004633402,0.000062468804,0.000031077383,0.00005445095,0.000019161605,0.000101956866],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967566,0.0010579416,0.0014053569,0.00023168948,0.00029715506,0.00025123276],"domain_scores_gemma":[0.9956487,0.0018675957,0.0018621403,0.00021153878,0.00034173467,0.000068284295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011367352,0.00030139828,0.0017391383,0.00023073696,0.00008389341,0.0000043264095,0.0002225884,0.00013023356,0.000036452664],"category_scores_gemma":[0.00061593606,0.00014702424,0.00013403269,0.0003049958,0.0004874848,0.00009146023,0.00004758532,0.0003007427,8.5472715e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9534757,0.0024148342,0.0011730967,0.000058706635,0.004195041,0.00013806981,0.0049099675,0.0000501283,0.0009082785,0.0000137746,0.000032995267,0.032629386],"study_design_scores_gemma":[0.9712476,0.015129243,0.0040611033,0.000528928,0.0044307015,0.00011153766,0.00062900205,0.00005106002,0.0036284064,0.000018360988,0.00001838183,0.00014564182],"about_ca_topic_score_codex":0.00005696231,"about_ca_topic_score_gemma":0.000023472321,"teacher_disagreement_score":0.032483745,"about_ca_system_score_codex":0.00006263402,"about_ca_system_score_gemma":0.000066511326,"threshold_uncertainty_score":0.59954745},"labels":[],"label_agreement":null},{"id":"W3085427446","doi":"10.25251/skin.4.5.25","title":"Norman Orentreich: Father of Hair Modern Transplantation","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"U.S. Navy; York University","keywords":"Transplantation; Art; Psychoanalysis; Medicine; Psychology; Internal medicine","score_opus":0.015460385247458052,"score_gpt":0.24912535440307318,"score_spread":0.23366496915561513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085427446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94083744,0.0029966447,0.012716252,0.031364918,0.00026384107,0.0002963691,0.0000066567877,0.000021959631,0.011495921],"genre_scores_gemma":[0.9953325,0.0007981694,0.0001508501,0.0031132232,0.00047569972,3.4405545e-7,0.000004406182,0.000018277435,0.000106567924],"study_design_codex":"qualitative","study_design_gemma":"case_report","domain_scores_codex":[0.9985586,0.00006900888,0.00057574926,0.00007260583,0.00056624523,0.00015780736],"domain_scores_gemma":[0.9989591,0.00016391241,0.00033159857,0.000127475,0.00018909639,0.00022876536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025721523,0.00012729967,0.00041743333,0.00008765914,0.000034609962,0.0000020140262,0.00016406983,0.000054775075,0.00034980057],"category_scores_gemma":[0.00020219301,0.00006730161,0.00010636506,0.00019412709,0.00016898585,0.000045218032,0.000007547553,0.00028210957,0.0000093804065],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051340982,0.0012926657,0.027451335,0.004299736,0.002558647,0.010220255,0.35899964,0.00583469,0.29480156,0.0010022778,0.06220559,0.17999262],"study_design_scores_gemma":[0.115865655,0.09135411,0.024622781,0.012329476,0.025801716,0.2879044,0.08199392,0.058250282,0.15567489,0.018390022,0.12508775,0.0027249833],"about_ca_topic_score_codex":0.000025220814,"about_ca_topic_score_gemma":0.000012836944,"teacher_disagreement_score":0.27768415,"about_ca_system_score_codex":0.000016014033,"about_ca_system_score_gemma":0.000096746124,"threshold_uncertainty_score":0.38300708},"labels":[],"label_agreement":null},{"id":"W3085571220","doi":"10.25251/skin.4.supp.42","title":"Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"XBiotech; Kyowa Kirin Pharmaceutical Development; National Institutes of Health; Incyte; Dermira; Valeant Pharmaceuticals International; Celgene; Allergan; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Post-hoc analysis; Psoriasis; Post hoc; Medicine; Internal medicine; Dermatology","score_opus":0.040734554695007204,"score_gpt":0.31283860531457386,"score_spread":0.27210405061956666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085571220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76348555,0.23033534,0.000008093038,0.0049537835,0.00028417708,0.00016232485,0.0007452808,0.000006934009,0.000018502167],"genre_scores_gemma":[0.959379,0.03986433,0.00005640911,0.00032388172,0.000077694676,8.648072e-7,0.0002042423,0.000016364009,0.00007719647],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973196,0.0010196591,0.0008938123,0.0002702013,0.00019504369,0.00030171074],"domain_scores_gemma":[0.99547184,0.0028967415,0.00074410596,0.0006411221,0.00017877128,0.00006743776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010915023,0.0002576199,0.0012439217,0.00014872987,0.00013441575,0.000008091738,0.00080222706,0.0001167122,0.00019485816],"category_scores_gemma":[0.0013729332,0.00012656556,0.00011144579,0.0007697897,0.0005118694,0.00008810936,0.00020276284,0.0003936715,0.000011906249],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08276822,0.0024257991,0.012615088,0.0001493218,0.14616744,0.002755989,0.14297384,0.0011877159,0.40307644,0.000099231096,0.11939249,0.08638843],"study_design_scores_gemma":[0.15804851,0.036618613,0.110009395,0.002885924,0.21870674,0.011249167,0.19363247,0.0005743319,0.04503962,0.0005454126,0.22013123,0.0025586025],"about_ca_topic_score_codex":0.00044518762,"about_ca_topic_score_gemma":0.00019166183,"teacher_disagreement_score":0.35803682,"about_ca_system_score_codex":0.000027860659,"about_ca_system_score_gemma":0.00008056683,"threshold_uncertainty_score":0.51611936},"labels":[],"label_agreement":null},{"id":"W3085734793","doi":"10.25251/skin.4.supp.48","title":"Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Forskningsrådet om Hälsa, Arbetsliv och Välfärd; LEO Pharma; Galderma; Incyte; Pfizer Pharmaceuticals; Valeant Pharmaceuticals International; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Kyowa Hakko Kirin; Eli Lilly and Company","keywords":"Atopic dermatitis; Dupilumab; Medicine; Dermatology","score_opus":0.028430559652954792,"score_gpt":0.29233794816178915,"score_spread":0.2639073885088344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085734793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973259,0.007418998,0.00032102215,0.01758752,0.00028835525,0.0008290701,0.000080086094,0.000029577008,0.0001863736],"genre_scores_gemma":[0.98893195,0.00057503016,0.00025412143,0.009511461,0.00059020927,0.0000047729536,0.000074163756,0.00003690824,0.000021380127],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971918,0.0003787777,0.000981779,0.00031419026,0.00077618554,0.00035726355],"domain_scores_gemma":[0.99761075,0.00033831305,0.00046407102,0.00067314,0.00018020156,0.0007334968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031738024,0.00031725716,0.0009836523,0.00018254797,0.0000957284,0.00001792406,0.00075141276,0.00010458569,0.0003668158],"category_scores_gemma":[0.0015699619,0.00017623448,0.000089723624,0.00041486925,0.00026762736,0.00017347386,0.0001305891,0.0005563055,0.000023724077],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6895381,0.0057843183,0.032849185,0.0008035605,0.004152219,0.0968468,0.0061958632,0.00017457349,0.0011670656,0.0000039681586,0.15139824,0.0110860625],"study_design_scores_gemma":[0.74338955,0.01814661,0.02032928,0.024098916,0.013466488,0.15456405,0.0060255546,0.0066997614,0.0019308911,0.0007095459,0.009413567,0.0012258126],"about_ca_topic_score_codex":0.00012396554,"about_ca_topic_score_gemma":0.0001553407,"teacher_disagreement_score":0.14198467,"about_ca_system_score_codex":0.000041203537,"about_ca_system_score_gemma":0.00045827194,"threshold_uncertainty_score":0.71866333},"labels":[],"label_agreement":null},{"id":"W3086123339","doi":"10.25251/skin.4.supp.45","title":"Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"UCB Pharma; Dermira","keywords":"Certolizumab pegol; Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Dermatology; Gastroenterology","score_opus":0.021227095897562276,"score_gpt":0.27338008013662973,"score_spread":0.25215298423906746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086123339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921414,0.0037438218,0.000022342234,0.00240933,0.00051678426,0.00089172827,0.00006661219,0.000013287142,0.0001946601],"genre_scores_gemma":[0.99858475,0.00080918474,0.00002635108,0.00017955595,0.00021701213,0.000006904437,0.000036206377,0.000039636318,0.0001004058],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960221,0.0011930882,0.0016898899,0.00029190225,0.00028412323,0.00051892037],"domain_scores_gemma":[0.9953949,0.0025531081,0.0014174209,0.00033577078,0.00015524692,0.00014358546],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009052276,0.00045516767,0.0019878843,0.00039269295,0.00012292362,0.000010058904,0.00039918086,0.00026656137,0.00091718644],"category_scores_gemma":[0.0011741585,0.00024724012,0.00019784368,0.0004641253,0.0003212093,0.00013175444,0.00008149436,0.0005588165,0.000011555566],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55466557,0.004780024,0.15668531,0.0002537322,0.005661899,0.004276026,0.024726951,0.0003879889,0.17033505,0.00004110762,0.00784704,0.07033929],"study_design_scores_gemma":[0.66506577,0.04214854,0.22870557,0.002436849,0.005612807,0.014042276,0.002641189,0.00012876363,0.035157997,0.0005380766,0.0021973206,0.0013248454],"about_ca_topic_score_codex":0.0003025172,"about_ca_topic_score_gemma":0.00040222678,"teacher_disagreement_score":0.13517705,"about_ca_system_score_codex":0.00018732263,"about_ca_system_score_gemma":0.0001954957,"threshold_uncertainty_score":0.999998},"labels":[],"label_agreement":null},{"id":"W3086473472","doi":"10.25251/skin.4.supp.49","title":"Long-Term Effect of Dupilumab With Concomitant Topical Corticosteroids on POEM in Adults With Moderate-to-Severe Atopic Dermatitis: LIBERTY AD CHRONOS Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University","funders":"LEO Pharma; Sanofi Genzyme; American Academy of Dermatology; Incyte; Dermira; Kiniksa Pharmaceuticals; Celgene; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Coherus Biosciences; Amgen; Regeneron Pharmaceuticals","keywords":"Dupilumab; Atopic dermatitis; Concomitant; Dermatology; Medicine; Term (time); Internal medicine","score_opus":0.008855377549419742,"score_gpt":0.25195703451807683,"score_spread":0.2431016569686571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086473472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98627615,0.0009922424,0.00013210517,0.010870596,0.00018271357,0.001061413,0.00000440977,0.000014130185,0.00046622264],"genre_scores_gemma":[0.9959683,0.00016519366,0.000041878684,0.003414304,0.00031078662,0.000009064642,0.0000054638726,0.000026200949,0.00005880795],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976917,0.0003573871,0.0008406953,0.00018625379,0.00064654765,0.00027742237],"domain_scores_gemma":[0.9978803,0.00085458206,0.00043581548,0.00028198108,0.00016125063,0.00038610402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022097879,0.00027737385,0.0011655737,0.00012521443,0.000049809376,0.000006988892,0.00024626678,0.00009723692,0.00016391656],"category_scores_gemma":[0.0005055574,0.00012726292,0.00009322489,0.0002290058,0.0002930726,0.00006123155,0.000030237921,0.0005905184,0.0000081406715],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82099116,0.0006524932,0.11974513,0.0014081367,0.00079249,0.03525522,0.006176755,0.0004093489,0.00021979575,0.00001264559,0.00526796,0.009068843],"study_design_scores_gemma":[0.39181927,0.17725706,0.26731646,0.022084152,0.0030092741,0.12879373,0.00094180414,0.0009038569,0.0067997477,0.00006207817,0.0003423099,0.000670261],"about_ca_topic_score_codex":0.000009718597,"about_ca_topic_score_gemma":0.000046047902,"teacher_disagreement_score":0.42917192,"about_ca_system_score_codex":0.00007250863,"about_ca_system_score_gemma":0.000216637,"threshold_uncertainty_score":0.5189631},"labels":[],"label_agreement":null},{"id":"W3086665346","doi":"10.25251/skin.4.supp.32","title":"Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Medicine; Randomized controlled trial; Psoriasis; Dermatology; Surgery","score_opus":0.01589909687135234,"score_gpt":0.2637209916648256,"score_spread":0.24782189479347327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086665346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98682,0.007065303,0.0008216535,0.001599894,0.0005705935,0.002829168,0.00008727854,0.000010025464,0.00019610733],"genre_scores_gemma":[0.9961609,0.0031358632,0.0001483053,0.00005263181,0.00014968251,0.000033371074,0.00007526746,0.000017525566,0.00022641431],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99662673,0.0011737603,0.0015300123,0.00021451274,0.00025519045,0.00019977457],"domain_scores_gemma":[0.99415326,0.0029453104,0.0023091563,0.00022429688,0.0003015595,0.00006638929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013957042,0.00028483378,0.0023397452,0.000152176,0.000095490905,0.0000049135115,0.00024716486,0.00014572628,0.00012092748],"category_scores_gemma":[0.00066290033,0.00013831585,0.00024483676,0.00021441109,0.00059575523,0.00006429791,0.000050114875,0.00026395704,0.0000014841706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94930816,0.0007600821,0.000029069517,0.000042552037,0.009478606,0.00021171922,0.004969739,0.000010999198,0.015541883,0.00004654543,0.00012883986,0.019471789],"study_design_scores_gemma":[0.95502853,0.008019251,0.00016614486,0.0004383769,0.009584313,0.00034680258,0.00082714134,0.000030682193,0.025254259,0.00013990542,0.000038034163,0.00012652636],"about_ca_topic_score_codex":0.000087426735,"about_ca_topic_score_gemma":0.000006829847,"teacher_disagreement_score":0.019345263,"about_ca_system_score_codex":0.000033676755,"about_ca_system_score_gemma":0.00006966603,"threshold_uncertainty_score":0.56403565},"labels":[],"label_agreement":null},{"id":"W3086667064","doi":"10.25251/skin.4.supp.67","title":"Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Oncology; Internal medicine; Medicine; Progression-free survival; Disease; Duration (music); Overall survival","score_opus":0.01571963843424404,"score_gpt":0.2695627125944479,"score_spread":0.25384307416020385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086667064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872905,0.0029616724,0.0001465865,0.0071954625,0.00015796632,0.0021591086,0.000021889531,0.0000048579336,0.00006194606],"genre_scores_gemma":[0.9982992,0.00053422817,0.0007589693,0.00009668826,0.00018555367,0.000008299908,0.0000041773014,0.000036933645,0.00007595271],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958825,0.0005661762,0.001415504,0.00024582355,0.0016360926,0.00025392164],"domain_scores_gemma":[0.9945771,0.0016890868,0.0022418632,0.00047118973,0.00076799525,0.0002527734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013934444,0.00031471637,0.0013305168,0.0001502939,0.00007382188,0.0000056578865,0.00034554218,0.00006373404,0.000013329732],"category_scores_gemma":[0.0017945915,0.00012154681,0.00008694021,0.0005761238,0.00092666957,0.000107821535,0.00009755779,0.00040289346,1.04638204e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89596236,0.00034741004,0.09469686,0.00030367944,0.00015467072,0.00026574254,0.004773819,0.00036646408,0.0010109375,0.0000012399842,0.0003616001,0.001755213],"study_design_scores_gemma":[0.7537016,0.024769163,0.20280059,0.0073380126,0.00087335915,0.00023291256,0.0016375832,0.00026128616,0.008067212,0.00002996019,0.000076299344,0.00021202184],"about_ca_topic_score_codex":0.00006434984,"about_ca_topic_score_gemma":0.00012320312,"teacher_disagreement_score":0.14226076,"about_ca_system_score_codex":0.000058484315,"about_ca_system_score_gemma":0.0011330415,"threshold_uncertainty_score":0.4956535},"labels":[],"label_agreement":null},{"id":"W3086843644","doi":"10.25251/skin.4.5.22","title":"Plant Fiber Contaminants in Morgellons Disease Skin Samples","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Body Image and Dysmorphia Studies","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Contamination; Fiber; Environmental science; Environmental chemistry; Biology; Chemistry; Materials science; Composite material; Ecology","score_opus":0.0349688850334671,"score_gpt":0.297023505548507,"score_spread":0.26205462051503986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086843644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87351066,0.018868465,0.00034148444,0.093284346,0.0016585002,0.0004552695,0.00008766121,0.000030975505,0.011762658],"genre_scores_gemma":[0.9929906,0.0006345953,0.000046496945,0.0038018322,0.001160154,0.0000024687827,0.0000039351708,0.000022309021,0.0013376166],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982445,0.0002528017,0.0006547604,0.00014497853,0.00038655457,0.0003163652],"domain_scores_gemma":[0.99823236,0.00082896877,0.00035718526,0.00022409843,0.00009441014,0.00026294365],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046113916,0.00019169379,0.0005132353,0.00010421393,0.000085401174,0.000007062758,0.00037849392,0.00004951796,0.0021644647],"category_scores_gemma":[0.00056105206,0.00010482805,0.00008947376,0.00022569511,0.00030484976,0.000045637393,0.000058346744,0.00045371655,0.00013282121],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00948797,0.0005789446,0.03077398,0.00013222639,0.0009787246,0.04983454,0.08356371,0.00016387737,0.001388335,0.0008497305,0.79390293,0.028345037],"study_design_scores_gemma":[0.0142701585,0.0060745385,0.24413353,0.001722014,0.0022609688,0.033873387,0.043619823,0.00024087846,0.00054549903,0.0037200362,0.648422,0.0011171456],"about_ca_topic_score_codex":0.00016930902,"about_ca_topic_score_gemma":0.000079077254,"teacher_disagreement_score":0.21335955,"about_ca_system_score_codex":0.00002887412,"about_ca_system_score_gemma":0.00005498617,"threshold_uncertainty_score":0.9987477},"labels":[],"label_agreement":null},{"id":"W3099895352","doi":"10.25251/skin.4.supp.71","title":"Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Dermatology; Roflumilast; Sleep (system call); Psoriasis; Internal medicine; COPD","score_opus":0.006867902839453745,"score_gpt":0.2579631344631116,"score_spread":0.2510952316236578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099895352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98195404,0.00439595,0.000023320981,0.012218654,0.00019196453,0.000968241,0.0000074775967,0.000021985568,0.00021834712],"genre_scores_gemma":[0.99760324,0.00092639535,0.000025300866,0.0010124628,0.0003436388,0.000008864272,0.0000067299507,0.00003517412,0.00003819394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727756,0.00037539913,0.0011190115,0.00029029977,0.0005306287,0.00040712403],"domain_scores_gemma":[0.9980606,0.00051778776,0.0005119236,0.00028957854,0.000192869,0.00042724764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066731375,0.00033699482,0.0011453861,0.00025895864,0.0000805393,0.000008596289,0.000274318,0.0001401364,0.00020857352],"category_scores_gemma":[0.0007678864,0.0001933927,0.00007114755,0.00062868657,0.00043307059,0.00011765556,0.00006175373,0.0011708861,0.0000052092487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14350176,0.010264196,0.57100636,0.0014550552,0.0021582986,0.15540798,0.07809073,0.00043604348,0.0037854142,0.000011603152,0.007075991,0.0268066],"study_design_scores_gemma":[0.2645354,0.05394318,0.29822528,0.010419462,0.0051211896,0.28944954,0.05439279,0.018454643,0.002108802,0.00049103354,0.0014631957,0.0013955],"about_ca_topic_score_codex":0.00023011626,"about_ca_topic_score_gemma":0.0008488647,"teacher_disagreement_score":0.27278104,"about_ca_system_score_codex":0.00014256482,"about_ca_system_score_gemma":0.00031385742,"threshold_uncertainty_score":0.7886326},"labels":[],"label_agreement":null},{"id":"W3101035693","doi":"10.25251/skin.4.supp.97","title":"Efficacy and Safety of Tralokinumab with Concomitant Topical Corticosteroids in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of the ECZTRA 3 Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Atopic dermatitis; Concomitant; Medicine; Dermatology; Internal medicine","score_opus":0.008115933252582475,"score_gpt":0.2339562603275287,"score_spread":0.22584032707494622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101035693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98646134,0.0004301415,0.00012946331,0.012273643,0.000038558654,0.000564004,0.000007710835,0.000004076679,0.00009104176],"genre_scores_gemma":[0.99795735,0.00018886445,0.000098539545,0.0016298111,0.00009942809,0.0000023676414,0.0000019356983,0.000012308188,0.000009374196],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9980803,0.00024774336,0.00085449446,0.0001273535,0.00051313604,0.00017697379],"domain_scores_gemma":[0.9982192,0.00050907064,0.00061604386,0.00023768927,0.00019401421,0.00022396976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013977512,0.00017136594,0.0010221354,0.00008988092,0.00004473056,0.00000390616,0.00021647914,0.000034223085,0.000029549661],"category_scores_gemma":[0.00039324354,0.00007364334,0.00007966168,0.000541447,0.00067547907,0.0000348859,0.000028199998,0.0003606839,2.9676204e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4973514,0.00062559504,0.46764487,0.00048281925,0.0014311479,0.0034867516,0.018418167,0.0017178556,0.0001554476,0.000028485601,0.0007108173,0.007946621],"study_design_scores_gemma":[0.11033928,0.015246765,0.83906287,0.002045708,0.0030011116,0.023837646,0.0044484013,0.0009833558,0.00061092427,0.000025272964,0.00017695197,0.00022173914],"about_ca_topic_score_codex":0.00006106137,"about_ca_topic_score_gemma":0.0005284807,"teacher_disagreement_score":0.38701212,"about_ca_system_score_codex":0.00002943595,"about_ca_system_score_gemma":0.00020021535,"threshold_uncertainty_score":0.30030885},"labels":[],"label_agreement":null},{"id":"W3101280111","doi":"10.25251/skin.4.supp.104","title":"Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; Sanofi Genzyme; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Sanofi","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology","score_opus":0.006721026400807642,"score_gpt":0.23449303160400473,"score_spread":0.22777200520319707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101280111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97760236,0.0033725107,0.00008381932,0.017680053,0.000074704134,0.0007444092,0.000005037119,0.000018262985,0.0004188636],"genre_scores_gemma":[0.9929001,0.0007460313,0.000107836364,0.005702511,0.00032459307,0.0000025764118,0.0000067341703,0.000023970131,0.00018567897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983374,0.00018963226,0.00060340995,0.00015972838,0.00043292262,0.0002769134],"domain_scores_gemma":[0.99866664,0.00037873868,0.00026974597,0.00020624517,0.00008541578,0.00039320835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002738029,0.00020398098,0.00077789725,0.0001392916,0.00008291469,0.000013706795,0.00022846102,0.00006858452,0.00029180507],"category_scores_gemma":[0.0005683095,0.000115043615,0.000064301654,0.00024133053,0.00022140564,0.00009118932,0.00005224904,0.00045173438,0.000010206205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009800467,0.0002675983,0.9341584,0.00020585045,0.0007342432,0.011451409,0.005973245,0.00034278803,0.00022253544,0.00001106328,0.018589932,0.018242469],"study_design_scores_gemma":[0.011744391,0.0012779534,0.9154669,0.0007551962,0.00055722817,0.06918726,0.00027687766,0.000019999114,0.00005204314,0.000023696604,0.0005098438,0.00012859695],"about_ca_topic_score_codex":0.00002687492,"about_ca_topic_score_gemma":0.000098948716,"teacher_disagreement_score":0.05773585,"about_ca_system_score_codex":0.00004902919,"about_ca_system_score_gemma":0.00015907986,"threshold_uncertainty_score":0.46913424},"labels":[],"label_agreement":null},{"id":"W3102280768","doi":"10.25251/skin.4.supp.96","title":"Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Probity Medical Research; University of Toronto","funders":"","keywords":"Atopic dermatitis; Medicine; Dermatology; Phase (matter); Physics","score_opus":0.01976814871375346,"score_gpt":0.28888757321425,"score_spread":0.26911942450049653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102280768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98193765,0.002070297,0.00018752589,0.014722011,0.00009116607,0.00071199104,0.000118649776,0.000010245712,0.00015045216],"genre_scores_gemma":[0.99433786,0.0014552452,0.0003105991,0.0035820666,0.00024822843,0.0000019221065,0.000028028566,0.000023249126,0.000012813361],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971847,0.00045767744,0.0014540234,0.00020699162,0.00047931098,0.00021730014],"domain_scores_gemma":[0.99673504,0.0017023652,0.00070946285,0.00021610058,0.00025424242,0.00038281063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050769985,0.00025009766,0.0013252693,0.0001426136,0.00006399426,0.000009211586,0.00016179681,0.000082519866,0.000079860445],"category_scores_gemma":[0.0017562535,0.00013628398,0.00006694598,0.0002071152,0.00027673595,0.00008887367,0.000020841746,0.00038562436,0.000001364013],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.693165,0.0035682826,0.07187861,0.0006911059,0.003361722,0.008808049,0.078285605,0.0019812272,0.001976402,0.00008597102,0.02039687,0.11580112],"study_design_scores_gemma":[0.6361489,0.023258934,0.29474923,0.009602846,0.0043347897,0.014783153,0.004423442,0.0028902201,0.0042130537,0.001605722,0.0030407428,0.0009489573],"about_ca_topic_score_codex":0.00007487187,"about_ca_topic_score_gemma":0.00003347752,"teacher_disagreement_score":0.22287062,"about_ca_system_score_codex":0.000026246036,"about_ca_system_score_gemma":0.00012278011,"threshold_uncertainty_score":0.55574995},"labels":[],"label_agreement":null},{"id":"W3102502247","doi":"10.25251/skin.4.supp.75","title":"Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Psoriasis; Medicine; Dermatology; Phase (matter); Clinical trial; Internal medicine; Physics","score_opus":0.06043474788367265,"score_gpt":0.3426864154785979,"score_spread":0.28225166759492526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102502247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95231736,0.0037449305,0.00006694734,0.042826064,0.000094355484,0.0007440665,0.000069207534,0.0000051737297,0.00013189162],"genre_scores_gemma":[0.9938451,0.0042990637,0.00003180363,0.00022487354,0.0015455504,0.000009914255,0.000011009943,0.0000011698505,0.00003151293],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865395,0.00014259435,0.0007201921,0.000100883146,0.00024436085,0.00013804101],"domain_scores_gemma":[0.9927329,0.0064428076,0.00056828745,0.000057182384,0.00008189099,0.00011692452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095256936,0.0001265797,0.0005355746,0.0000083214745,0.00009635734,0.000005067403,0.0002619354,0.000033589076,0.00009473869],"category_scores_gemma":[0.00091896945,0.000030613675,0.000088302295,0.00018507027,0.00018484464,0.000021857913,0.000012273823,0.00011982852,6.127043e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013619015,0.0010012634,0.00008360598,0.00003291071,0.00025012004,0.00007154657,0.00387387,0.0001368204,0.76083887,0.00007894193,0.0048711533,0.2151419],"study_design_scores_gemma":[0.08515202,0.121842295,0.006420623,0.0020262864,0.005504033,0.017196978,0.029637216,0.0032297096,0.2459576,0.005846984,0.47614965,0.0010366146],"about_ca_topic_score_codex":0.000067502755,"about_ca_topic_score_gemma":0.000056776546,"teacher_disagreement_score":0.51488125,"about_ca_system_score_codex":0.000027075948,"about_ca_system_score_gemma":0.000020622636,"threshold_uncertainty_score":0.12483895},"labels":[],"label_agreement":null},{"id":"W3102615618","doi":"10.25251/skin.4.supp.82","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; AstraZeneca","keywords":"Ustekinumab; Double blinded; Medicine; Placebo; Plaque psoriasis; Psoriasis; Dermatology; Randomized controlled trial; Internal medicine; Pathology; Disease; Alternative medicine","score_opus":0.019812991342659063,"score_gpt":0.25553552177184496,"score_spread":0.2357225304291859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102615618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924064,0.0018026248,0.00006381857,0.0023973002,0.00025204464,0.0028336295,0.00014358405,0.000010339652,0.00009023092],"genre_scores_gemma":[0.9989914,0.00045728715,0.000069169044,0.00024181342,0.00011354491,0.00001638755,0.000034678353,0.000023800305,0.00005193898],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996741,0.0011402253,0.0013342858,0.00029680305,0.00021516933,0.00027254847],"domain_scores_gemma":[0.9956234,0.002913432,0.0008903405,0.00024474433,0.0002081436,0.00011990323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001255164,0.00035452956,0.0019216154,0.00021426522,0.00013060428,0.000012024146,0.00024948892,0.00014659564,0.000058547885],"category_scores_gemma":[0.0006286766,0.00018030558,0.00008616728,0.00023880135,0.00025414565,0.00007756795,0.000069575246,0.00037673896,0.0000051312677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9652251,0.0010733558,0.0003466573,0.000011905389,0.0026267252,0.00018623167,0.022667997,0.00034236963,0.00053889654,0.0000036974743,0.00026601108,0.0067110276],"study_design_scores_gemma":[0.98176795,0.010273402,0.0007234898,0.00031678606,0.0025947134,0.0004092016,0.0029151281,0.000044930763,0.00060801714,0.000031180232,0.00012530774,0.00018989474],"about_ca_topic_score_codex":0.00022178139,"about_ca_topic_score_gemma":0.00014535544,"teacher_disagreement_score":0.019752868,"about_ca_system_score_codex":0.000039700848,"about_ca_system_score_gemma":0.000093878276,"threshold_uncertainty_score":0.73526484},"labels":[],"label_agreement":null},{"id":"W3103492266","doi":"10.25251/skin.4.supp.105","title":"Atopic Dermatitis (AD) Disease History With AD Treatment History in a Cohort of AD Patients Treated With Dupilumab From a Real-World Registry (PROSE)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Dupilumab; Atopic dermatitis; Medicine; Cohort; Dermatology; Disease; Medical history; Internal medicine","score_opus":0.011736130041749625,"score_gpt":0.22529670160066187,"score_spread":0.21356057155891225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103492266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685409,0.024416553,0.000012681372,0.0046840166,0.00015505635,0.00062485697,0.000030152372,0.000025624964,0.0015101656],"genre_scores_gemma":[0.9934273,0.0031421445,0.00009174584,0.0019482779,0.00010358432,0.000013930808,0.00005741476,0.00004015486,0.0011754963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770653,0.00023530306,0.0008425978,0.00024084299,0.00071313215,0.00026157647],"domain_scores_gemma":[0.997524,0.00032861112,0.00089372444,0.00045433405,0.00027101458,0.000528315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001055477,0.00032804455,0.0010766843,0.00020677774,0.000040336607,0.0000019863874,0.00022751103,0.000067726025,0.00057742244],"category_scores_gemma":[0.00025065988,0.00017471373,0.00011616888,0.00020063356,0.00066604617,0.00007426099,0.000020446823,0.0003567673,0.0000050639314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014063177,0.0010951658,0.90040123,0.00029768673,0.00092466903,0.019994084,0.0055108643,0.000031035328,0.000083555075,0.0000030398162,0.055839293,0.0017562165],"study_design_scores_gemma":[0.013457305,0.004798916,0.9301084,0.003895262,0.0039489195,0.0031688542,0.00050092785,0.00011038213,0.00011061791,0.000032026728,0.03959625,0.0002720877],"about_ca_topic_score_codex":0.0005762628,"about_ca_topic_score_gemma":0.00052248605,"teacher_disagreement_score":0.029707242,"about_ca_system_score_codex":0.0012411847,"about_ca_system_score_gemma":0.0008432216,"threshold_uncertainty_score":0.71246195},"labels":[],"label_agreement":null},{"id":"W3103502969","doi":"10.25251/skin.4.supp.95","title":"Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Double blind; Medicine; Dermatology; Randomized controlled trial; Internal medicine; Alternative medicine; Myelofibrosis; Pathology; Placebo","score_opus":0.05448425355856354,"score_gpt":0.3643731436587562,"score_spread":0.3098888901001927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103502969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87107843,0.085057475,0.00031141634,0.041067936,0.00030323886,0.0017217573,0.000103977145,0.000008889353,0.0003468916],"genre_scores_gemma":[0.96951056,0.028734865,0.00014526374,0.0008005761,0.0007057007,0.000008514567,0.000017847815,0.000013078241,0.00006360177],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99778754,0.00024275178,0.0013449362,0.000120931705,0.00034311204,0.00016075443],"domain_scores_gemma":[0.9878539,0.01038188,0.000987266,0.00025229694,0.00035889,0.00016578342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059031195,0.00019695707,0.0015117956,0.00006460131,0.000105376246,0.000003149645,0.00016451246,0.00004775644,0.00004505764],"category_scores_gemma":[0.0020792729,0.00008197424,0.00023499945,0.00010823269,0.001059165,0.000031702308,0.000021123664,0.00014326813,7.7009975e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9542939,0.0007501078,0.00013407329,0.00021295703,0.004678908,0.0005307205,0.022075055,0.00009237423,0.0001836497,0.00013224994,0.006620195,0.010295827],"study_design_scores_gemma":[0.9613365,0.004840501,0.00023156761,0.0010267787,0.008989877,0.0043855626,0.005316957,0.00038657367,0.0040042805,0.0009443895,0.00844028,0.00009672636],"about_ca_topic_score_codex":0.00005064168,"about_ca_topic_score_gemma":0.000008491478,"teacher_disagreement_score":0.09843213,"about_ca_system_score_codex":0.000023899098,"about_ca_system_score_gemma":0.00010495121,"threshold_uncertainty_score":0.39025375},"labels":[],"label_agreement":null},{"id":"W3103727622","doi":"10.25251/skin.4.supp.83","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Double blinded; Medicine; Randomized controlled trial; Placebo; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Alternative medicine; Pathology","score_opus":0.016129608752117178,"score_gpt":0.25199327768949914,"score_spread":0.23586366893738198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103727622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915243,0.0014236573,0.00022239813,0.002610014,0.00024482163,0.0060312594,0.000116173964,0.000017207645,0.00018202883],"genre_scores_gemma":[0.9988465,0.00032564098,0.00015561128,0.00025746707,0.00015051974,0.000053134525,0.000078275654,0.000037456957,0.00009544214],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946034,0.002440937,0.0018896655,0.0003714657,0.00034083158,0.00035368538],"domain_scores_gemma":[0.99224067,0.005374141,0.001518222,0.00034264236,0.00038025656,0.0001440818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024144023,0.0004993215,0.0037129142,0.00026938764,0.0001505884,0.000015069692,0.00035419365,0.00016791366,0.00007327519],"category_scores_gemma":[0.0009585858,0.00022252467,0.00017305199,0.000341233,0.0005073912,0.00009598711,0.00005668477,0.0004993076,0.000004703052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9653864,0.0016887916,0.000103014056,0.000012211632,0.0070738588,0.0003067539,0.021790316,0.000941129,0.00021740467,0.000009593879,0.00024518286,0.0022253701],"study_design_scores_gemma":[0.97598404,0.014153572,0.00008790965,0.00044476066,0.0057246946,0.00043856143,0.0022873096,0.00005449407,0.0005009716,0.000027885093,0.000051666786,0.00024416685],"about_ca_topic_score_codex":0.00047876596,"about_ca_topic_score_gemma":0.00022016809,"teacher_disagreement_score":0.019503007,"about_ca_system_score_codex":0.00005387553,"about_ca_system_score_gemma":0.00019108858,"threshold_uncertainty_score":0.9074293},"labels":[],"label_agreement":null},{"id":"W3104685239","doi":"10.25251/skin.4.supp.93","title":"The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research; Queen's University","funders":"","keywords":"Atopic dermatitis; Roflumilast; Proof of concept; Medicine; Dermatology; Computer science; Internal medicine","score_opus":0.012590369743052426,"score_gpt":0.2879166144450862,"score_spread":0.27532624470203376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104685239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96789604,0.018794665,0.00006745869,0.012251006,0.00012124464,0.00055211183,0.0000047601875,0.0000046995333,0.00030801832],"genre_scores_gemma":[0.99796677,0.0010484622,0.000017594766,0.00075887697,0.00016180973,0.0000012461093,0.0000013205613,0.000010906191,0.00003300629],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981578,0.00029208898,0.0009142361,0.000102444115,0.00037230915,0.00016109632],"domain_scores_gemma":[0.9976612,0.0013228754,0.00049922185,0.0001869155,0.00014743343,0.00018240561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004947384,0.00014663105,0.00069457537,0.00007649316,0.00008769201,0.000004063179,0.00015761804,0.00004700323,0.00005113156],"category_scores_gemma":[0.0013956422,0.000071758455,0.000052734078,0.00019477154,0.00075552653,0.000043864628,0.000052536598,0.00035361145,3.4817936e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042607024,0.012494076,0.2644275,0.0026408343,0.0043239486,0.034164898,0.22562447,0.0003731004,0.0026816123,0.00035198673,0.06820927,0.34210128],"study_design_scores_gemma":[0.14069183,0.05916942,0.43891776,0.0072141485,0.007870587,0.19694918,0.10157456,0.0021833235,0.01853754,0.0017517828,0.024316147,0.0008237127],"about_ca_topic_score_codex":0.000015338492,"about_ca_topic_score_gemma":0.000017639011,"teacher_disagreement_score":0.34127757,"about_ca_system_score_codex":0.000012866175,"about_ca_system_score_gemma":0.000106072344,"threshold_uncertainty_score":0.29262248},"labels":[],"label_agreement":null},{"id":"W3104939465","doi":"10.25251/skin.4.supp.102","title":"Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Concomitant; Atopic dermatitis; Medicine; Dermatology; Randomized controlled trial; Internal medicine","score_opus":0.015531852107486319,"score_gpt":0.2618408314692068,"score_spread":0.24630897936172047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104939465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720619,0.00059118733,0.00013698755,0.025790123,0.00020917083,0.00091695547,0.00007451928,0.000008541682,0.00021067112],"genre_scores_gemma":[0.99378186,0.00022929937,0.00007533294,0.0054874136,0.00036627313,0.000002824421,0.000025237714,0.000016265485,0.000015458649],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99741864,0.00033805435,0.001239432,0.0001789516,0.0005940226,0.00023089099],"domain_scores_gemma":[0.99703276,0.0016063162,0.00049888727,0.0002747657,0.00026371898,0.00032355124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023021494,0.00021740653,0.00088227587,0.00006011217,0.00008066787,0.000009557561,0.00026135228,0.000090784335,0.00006869316],"category_scores_gemma":[0.0019063168,0.000102463215,0.00007124175,0.00018622013,0.00035940966,0.000063336964,0.000041525247,0.000537801,0.000002502557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93350655,0.001485883,0.013498759,0.00013792947,0.00072520995,0.0042814305,0.022551395,0.0004125375,0.00013821141,0.00004508285,0.012485297,0.010731709],"study_design_scores_gemma":[0.8010223,0.022128891,0.15565996,0.003525668,0.0021434408,0.007405617,0.0032194448,0.0017451426,0.0005089834,0.0003009153,0.0019463742,0.00039327223],"about_ca_topic_score_codex":0.00005200917,"about_ca_topic_score_gemma":0.00004692279,"teacher_disagreement_score":0.1421612,"about_ca_system_score_codex":0.00005361547,"about_ca_system_score_gemma":0.00020444798,"threshold_uncertainty_score":0.41783285},"labels":[],"label_agreement":null},{"id":"W3105819045","doi":"10.25251/skin.4.supp.113","title":"A Comparative Clinical Demonstration of the Spreadability of Tazarotene Lotion 0.045% versus Trifarotene Cream 0.005%","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Horticultural and Viticultural Research","field":"Agricultural and Biological Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Lotion; Tazarotene; Spreadability; Dermatology; Medicine; Chemistry; Pharmacology; Food science","score_opus":0.11917702147513479,"score_gpt":0.35474508486735823,"score_spread":0.23556806339222344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105819045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96966606,0.00029492227,0.000012091191,0.029082244,0.00022020223,0.00031020233,0.000011492519,0.0000049817863,0.00039781674],"genre_scores_gemma":[0.9988101,0.00028236845,0.000029707942,0.00015447242,0.00067298097,9.135096e-7,0.0000041715602,7.3496955e-7,0.000044565575],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971425,0.00072041666,0.0010353238,0.00012341583,0.0008012137,0.00017714842],"domain_scores_gemma":[0.9966077,0.0017071833,0.000818748,0.000077979916,0.0006197229,0.00016865651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011583585,0.00013400239,0.0005510816,0.000007719666,0.00013036911,0.000007555145,0.000525828,0.00008950027,0.00022899765],"category_scores_gemma":[0.0015991458,0.000029396926,0.00023781402,0.00045777034,0.00071060815,0.000082012884,0.00006749757,0.00044062498,0.0000029313237],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005980251,0.00043266884,0.0032837885,0.000047981932,0.00022713035,0.00001830522,0.0023905847,0.00023500135,0.93048525,0.00012558255,0.0028297477,0.05394371],"study_design_scores_gemma":[0.0053659687,0.05506673,0.46456409,0.0010249955,0.0012080955,0.0014790418,0.025941357,0.0018336592,0.43394008,0.0012894069,0.0077226297,0.0005639401],"about_ca_topic_score_codex":0.00019352732,"about_ca_topic_score_gemma":0.0002429936,"teacher_disagreement_score":0.49654517,"about_ca_system_score_codex":0.000026206928,"about_ca_system_score_gemma":0.00004095867,"threshold_uncertainty_score":0.26182655},"labels":[],"label_agreement":null},{"id":"W3106177555","doi":"10.25251/skin.4.supp.70","title":"Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Roflumilast; Dermatology; Psoriasis; Pediatrics; Internal medicine; COPD","score_opus":0.008240515777240696,"score_gpt":0.23637852521625272,"score_spread":0.22813800943901202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106177555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855826,0.012549203,0.0000150826445,0.0011120071,0.00015030804,0.0005180868,0.0000144786345,0.0000063843877,0.000051838328],"genre_scores_gemma":[0.99795234,0.0017080748,0.00001384113,0.000063026906,0.00018448912,0.0000064346987,0.000005789427,0.000017615821,0.000048390233],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984464,0.0003599968,0.0006578685,0.00019272034,0.00009339383,0.00024962839],"domain_scores_gemma":[0.998779,0.0004869201,0.00043422868,0.00015484144,0.000080179816,0.0000648413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044536262,0.00023413567,0.00074511586,0.00018882344,0.000055161825,0.000004195804,0.00020128195,0.00011995778,0.00009600231],"category_scores_gemma":[0.00014362029,0.0001296274,0.000036129655,0.0002597489,0.00029975723,0.000057729176,0.00004821036,0.00035989267,0.0000018651715],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06978778,0.002925785,0.03226615,0.00039432713,0.0030132364,0.0034069198,0.1614949,0.0002113026,0.5428095,0.000019208996,0.00052337465,0.18314752],"study_design_scores_gemma":[0.33527192,0.39843708,0.034422655,0.0068673887,0.006259864,0.03978924,0.116034165,0.0007867573,0.057837944,0.00020186654,0.0025025154,0.0015885953],"about_ca_topic_score_codex":0.0005161848,"about_ca_topic_score_gemma":0.00080560165,"teacher_disagreement_score":0.48497155,"about_ca_system_score_codex":0.000051497685,"about_ca_system_score_gemma":0.00010852639,"threshold_uncertainty_score":0.5286052},"labels":[],"label_agreement":null},{"id":"W3107702560","doi":"10.25251/skin.4.supp.28","title":"BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Fungal Biology and Applications","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Medicine; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase 2; Pharmacology; Dermatology; Platelet-derived growth factor receptor; Receptor","score_opus":0.043463487994055444,"score_gpt":0.35541407204063863,"score_spread":0.31195058404658316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107702560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985497,0.0003993142,0.0000027269537,0.012266375,0.00013934544,0.0016532089,0.000022161952,0.000004031938,0.000015825899],"genre_scores_gemma":[0.9986443,0.00016851687,0.000112638656,0.0007946718,0.00018871784,0.000057781024,0.0000158509,0.000013497076,0.0000040322475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99683565,0.0014354701,0.00085691107,0.00019012061,0.00047662735,0.00020522239],"domain_scores_gemma":[0.99828225,0.00068015844,0.00036531241,0.00018332484,0.00032739947,0.00016157306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028203058,0.00017300286,0.0006654095,0.000588678,0.000020057554,0.0000023111058,0.00012662385,0.000117286785,0.000030430549],"category_scores_gemma":[0.0032554073,0.000110272136,0.000036703455,0.001265332,0.00011064462,0.00005170703,0.000015690393,0.00036099993,0.0000019277277],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71433467,0.007027923,0.019484391,0.0000495235,0.00011189283,0.00061679195,0.041821938,0.001881491,0.1861465,0.0000066984517,0.0006249431,0.02789322],"study_design_scores_gemma":[0.5701171,0.20323196,0.0690505,0.0024971776,0.0011986039,0.00037139273,0.012359274,0.0027517988,0.13582449,0.00041153684,0.0016066873,0.00057944114],"about_ca_topic_score_codex":0.00021772856,"about_ca_topic_score_gemma":0.0017124646,"teacher_disagreement_score":0.19620404,"about_ca_system_score_codex":0.0005774842,"about_ca_system_score_gemma":0.0003982754,"threshold_uncertainty_score":0.4496767},"labels":[],"label_agreement":null},{"id":"W3118983962","doi":"10.25251/skin.5.supp.20","title":"Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Term (time); Quality of life (healthcare); Internal medicine; Dermatology; Infliximab; Disease","score_opus":0.18406156033160762,"score_gpt":0.3994468664925963,"score_spread":0.2153853061609887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118983962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9503806,0.0021720582,0.00038639994,0.044660155,0.00020777858,0.0010407907,0.0010673122,0.0000052427354,0.00007963167],"genre_scores_gemma":[0.997194,0.0007089265,0.0002457379,0.0015038938,0.0001610959,0.000008021251,0.00007473986,0.000030722644,0.00007284026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9866078,0.0025395795,0.009795503,0.0003385766,0.00038466844,0.0003338922],"domain_scores_gemma":[0.979945,0.006926729,0.011727238,0.0006081844,0.00048043262,0.00031244155],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013197816,0.00027080643,0.0028807232,0.00026282723,0.00012094333,0.000023206863,0.0003385062,0.00011560801,0.00015091641],"category_scores_gemma":[0.012137691,0.00016244005,0.000097508055,0.0004292231,0.00017722316,0.00017298972,0.00004791975,0.00034552993,0.00000387522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18396091,0.0047716717,0.6537434,0.0028694943,0.006617253,0.00045163822,0.112604596,0.007913515,0.00018697784,0.0013973656,0.014739641,0.010743527],"study_design_scores_gemma":[0.22888051,0.020740027,0.7109254,0.00998311,0.00065036945,0.001997258,0.016237164,0.0023196258,0.0004677301,0.005580524,0.00075065286,0.0014676242],"about_ca_topic_score_codex":0.0062071267,"about_ca_topic_score_gemma":0.002497256,"teacher_disagreement_score":0.09636743,"about_ca_system_score_codex":0.00031260948,"about_ca_system_score_gemma":0.0006538836,"threshold_uncertainty_score":0.9961835},"labels":[],"label_agreement":null},{"id":"W3119199869","doi":"10.25251/skin.5.supp.9","title":"Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Atopic dermatitis; Placebo; Medicine; Double blind; Randomized controlled trial; Placebo-controlled study; Internal medicine; Dermatology; Alternative medicine; Pathology","score_opus":0.014391379861997315,"score_gpt":0.2972541463484196,"score_spread":0.28286276648642233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119199869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98737365,0.0030714602,0.0007016809,0.0050377166,0.00039750585,0.0023294794,0.0000045482084,0.0000145186,0.001069462],"genre_scores_gemma":[0.99763376,0.00032337793,0.00038500837,0.0009935149,0.00040471082,0.000038342117,0.000031742537,0.000038534236,0.00015099232],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932881,0.002209292,0.0030001001,0.0002495045,0.0008033667,0.00044965176],"domain_scores_gemma":[0.9921455,0.004949198,0.0016988524,0.0003429988,0.00060170534,0.00026177225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047702407,0.00039515898,0.004474279,0.0004689011,0.00007616728,0.000026861157,0.00026433423,0.00009846505,0.0005615119],"category_scores_gemma":[0.0045202924,0.00017935758,0.00036403388,0.00045740642,0.00045189625,0.00013727686,0.000029729135,0.0009287742,0.0000040514337],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9689136,0.0012195188,0.0111984005,0.000110287234,0.0012892447,0.011936052,0.0020941137,0.00023474163,0.00016126466,0.000025372481,0.0008951932,0.0019222046],"study_design_scores_gemma":[0.97819155,0.001307462,0.0012952205,0.0018721076,0.0022552707,0.011993701,0.0012795726,0.0005913409,0.00063330436,0.00020281387,0.00017160866,0.00020604246],"about_ca_topic_score_codex":0.000054303797,"about_ca_topic_score_gemma":0.00032228042,"teacher_disagreement_score":0.010260149,"about_ca_system_score_codex":0.00014413493,"about_ca_system_score_gemma":0.00041598617,"threshold_uncertainty_score":0.73139894},"labels":[],"label_agreement":null},{"id":"W3119812808","doi":"10.25251/skin.5.supp.15","title":"Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; European Academy of Dermatology and Venereology","keywords":"Medicine; Adalimumab; Plaque psoriasis; Double blinded; Multicenter study; Randomized controlled trial; Psoriasis; Internal medicine; Dermatology; Pathology; Placebo; Alternative medicine","score_opus":0.02438267293933946,"score_gpt":0.2821770173124763,"score_spread":0.25779434437313686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119812808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917649,0.0020900248,0.000052488675,0.0015073696,0.002051014,0.0021284851,0.0002029833,0.000012919976,0.00018980233],"genre_scores_gemma":[0.99853307,0.0005756876,0.00008278493,0.00015601401,0.00027372054,0.00002077482,0.0001862478,0.000024931556,0.00014677031],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959202,0.0018220162,0.0013181795,0.0003270335,0.0002453655,0.00036724],"domain_scores_gemma":[0.9929818,0.005235908,0.00089219096,0.00034652132,0.00043375403,0.00010981146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010518273,0.00039498208,0.0019954783,0.0002131031,0.00018864873,0.00002056044,0.00025051687,0.00021493992,0.00013816492],"category_scores_gemma":[0.0009052262,0.00020954797,0.00016723893,0.0002579486,0.00022688622,0.000095792886,0.000053584925,0.00048489825,0.0000093618255],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9822502,0.0013561742,0.000013482362,0.0000045754437,0.003889935,0.00035104307,0.005616577,0.0003315484,0.0006247316,0.000009238737,0.0003727782,0.005179698],"study_design_scores_gemma":[0.98716,0.004643722,0.00013394932,0.000329196,0.0024352502,0.0003583305,0.0010381272,0.000032561282,0.0032180762,0.00002149828,0.00041020187,0.0002190669],"about_ca_topic_score_codex":0.00024376,"about_ca_topic_score_gemma":0.0003935746,"teacher_disagreement_score":0.006768156,"about_ca_system_score_codex":0.00014122277,"about_ca_system_score_gemma":0.0002567686,"threshold_uncertainty_score":0.85451186},"labels":[],"label_agreement":null},{"id":"W3120199534","doi":"10.25251/skin.5.supp.18","title":"Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; European Academy of Dermatology and Venereology","keywords":"Post-hoc analysis; Scalp; Medicine; Dermatology; Nail (fastener); Psoriasis; Post hoc; Dentistry; Internal medicine; Structural engineering; Engineering","score_opus":0.02446779732439922,"score_gpt":0.27520131174977336,"score_spread":0.2507335144253741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120199534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96360934,0.023785137,0.000665667,0.009790182,0.00074201764,0.0008144661,0.00054791785,0.0000072117587,0.00003804401],"genre_scores_gemma":[0.9851497,0.012328113,0.00028351546,0.00094039796,0.00053324114,0.00003721789,0.00018525225,0.000023344832,0.00051923475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99810433,0.00052046985,0.00067044835,0.00023531455,0.00018503734,0.0002844168],"domain_scores_gemma":[0.9955289,0.0030652208,0.0005399192,0.00048165984,0.00033195814,0.00005234331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046939842,0.000313614,0.0008935965,0.00008844387,0.00041348411,0.000017737042,0.000311134,0.00012684293,0.00036078654],"category_scores_gemma":[0.00009560064,0.000118443386,0.0002800132,0.00035430043,0.00027428006,0.00004909351,0.00003458877,0.00015406101,0.000002768678],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6853713,0.0030049523,0.00034358303,0.000038103015,0.064470865,0.0007643308,0.06418259,0.0012162961,0.029573614,0.00012859724,0.009241121,0.14166468],"study_design_scores_gemma":[0.38214722,0.12502676,0.0007865437,0.0007125029,0.108966514,0.012191459,0.059575383,0.0002004439,0.18415135,0.0013562009,0.12387398,0.0010116519],"about_ca_topic_score_codex":0.0007099506,"about_ca_topic_score_gemma":0.0015486904,"teacher_disagreement_score":0.30322406,"about_ca_system_score_codex":0.00008794812,"about_ca_system_score_gemma":0.00018952604,"threshold_uncertainty_score":0.4829981},"labels":[],"label_agreement":null},{"id":"W3120229153","doi":"10.25251/skin.5.1.16","title":"Toluidine blue for extramammary Paget’s disease in Mohs micrographic surgery","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cancer and Skin Lesions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University Health Centre","funders":"McGill University","keywords":"Extramammary Paget's disease; Medicine; Toluidine; Paget Disease; Mohs surgery; Staining; Dermatology; Surgery; Pathology; Disease; Chemistry","score_opus":0.02265867169664513,"score_gpt":0.28611245384520917,"score_spread":0.263453782148564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120229153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91286147,0.041865796,0.0007989153,0.042350966,0.0013689053,0.00042218572,0.000020100364,0.000016677985,0.00029498868],"genre_scores_gemma":[0.9855991,0.0092910705,0.00022311162,0.0023344413,0.0016272381,0.0000073709652,0.000022971648,0.00003791182,0.0008567895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978218,0.00016050646,0.00096089125,0.00016680245,0.0005380448,0.00035192934],"domain_scores_gemma":[0.9969103,0.0015659624,0.00031278314,0.00039006516,0.00042942713,0.00039151285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011679723,0.00020053686,0.0007969488,0.0003633865,0.00009019159,0.0000094326915,0.00015007798,0.00007709419,0.00035094866],"category_scores_gemma":[0.0016868981,0.00012091578,0.00038168178,0.0005632739,0.0002259507,0.000050410294,0.00003151189,0.0004559084,0.000002353279],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023141537,0.003685692,0.06597596,0.0023780847,0.0020552424,0.14541104,0.007839604,0.00086716213,0.14481844,0.00040535018,0.5215626,0.08185934],"study_design_scores_gemma":[0.024813114,0.0059780483,0.0918755,0.020200066,0.008948407,0.38330173,0.008871491,0.0015152959,0.022002578,0.009912032,0.42099383,0.001587912],"about_ca_topic_score_codex":0.00004174437,"about_ca_topic_score_gemma":0.00007835027,"teacher_disagreement_score":0.23789069,"about_ca_system_score_codex":0.0001005211,"about_ca_system_score_gemma":0.00069257605,"threshold_uncertainty_score":0.49308023},"labels":[],"label_agreement":null},{"id":"W3120319462","doi":"10.25251/skin.5.supp.21","title":"Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Pooled analysis; Psoriasis; Clinical trial; Medicine; Phase (matter); Dermatology; Internal medicine; Meta-analysis; Chemistry","score_opus":0.05098681300665635,"score_gpt":0.34998676432880144,"score_spread":0.2989999513221451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120319462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266547,0.0047029085,0.00025610498,0.0008449683,0.0005196907,0.00019446718,0.0007598831,0.00000348966,0.00005301426],"genre_scores_gemma":[0.9971928,0.0015480452,0.00019095904,0.0002011267,0.00012479494,6.76279e-7,0.0006047899,0.000011048997,0.00012575378],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956467,0.0022414674,0.0015477263,0.00024021376,0.00014417444,0.00017971253],"domain_scores_gemma":[0.99509585,0.0030755168,0.00089812686,0.0005856468,0.00028012833,0.00006470248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029784578,0.00018270068,0.0016178187,0.00025814265,0.00006398266,0.0000056471295,0.00036097068,0.0001475418,0.00069992064],"category_scores_gemma":[0.001897697,0.00009331974,0.00012852854,0.00055211503,0.00014511503,0.00006300708,0.00010574374,0.0002590408,0.000004786091],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2352805,0.0052447976,0.123916596,0.00003788811,0.09449304,0.0014448822,0.0064987093,0.0007677189,0.009321412,0.000027597498,0.0074282135,0.51553863],"study_design_scores_gemma":[0.2751969,0.022442216,0.45234534,0.0024126763,0.21025015,0.0031154535,0.006780257,0.00078320195,0.012391777,0.00086171227,0.012049235,0.0013710809],"about_ca_topic_score_codex":0.00011014783,"about_ca_topic_score_gemma":0.00038103832,"teacher_disagreement_score":0.51416755,"about_ca_system_score_codex":0.000029981304,"about_ca_system_score_gemma":0.00014275654,"threshold_uncertainty_score":0.766364},"labels":[],"label_agreement":null},{"id":"W3120762381","doi":"10.25251/skin.5.1.15","title":"A Case Report of a Primary Cutaneous Adenoid Carcinoma: A Diagnostic and Management Challenge","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Adenoid cystic carcinoma; Medicine; Distant metastasis; Surgical excision; Metastasis; Neoplasm; Pathology; Adenoid; Carcinoma; Radiology; Cancer; Internal medicine","score_opus":0.018560229466235603,"score_gpt":0.2573513841221511,"score_spread":0.2387911546559155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120762381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95259994,0.03373213,0.000031368312,0.007431936,0.0003399573,0.000417073,0.000006566967,0.000010301409,0.0054307487],"genre_scores_gemma":[0.9813722,0.016754827,0.0003829586,0.00048119278,0.00043932803,0.0000071933323,0.00000968561,0.000029237655,0.00052339863],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9977602,0.00014197805,0.00095946837,0.00020823695,0.00067769224,0.0002524661],"domain_scores_gemma":[0.9969321,0.0013433195,0.0006197593,0.00048893754,0.0003570351,0.00025884257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048161842,0.00024181124,0.0008897944,0.00016550024,0.000087329114,0.0000066285156,0.0001030718,0.000065458604,0.00015805745],"category_scores_gemma":[0.0005940293,0.00013446313,0.00014447271,0.00022186962,0.0002305287,0.000032643493,0.00008829825,0.00029319347,0.0000023730859],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045179782,0.0006825376,0.010581101,0.0005607605,0.00065488875,0.9791502,0.001603549,0.000007328754,0.00008155249,0.00011148091,0.001825022,0.0042897775],"study_design_scores_gemma":[0.0029880565,0.0027721336,0.0071792593,0.0011180998,0.0028747304,0.979096,0.0016283529,0.000012388572,0.00054381817,0.00031070775,0.0013688959,0.00010754629],"about_ca_topic_score_codex":0.00008473651,"about_ca_topic_score_gemma":0.000030797568,"teacher_disagreement_score":0.028772261,"about_ca_system_score_codex":0.00011203508,"about_ca_system_score_gemma":0.00015385673,"threshold_uncertainty_score":0.5483247},"labels":[],"label_agreement":null},{"id":"W3120771989","doi":"10.25251/skin.5.supp.16","title":"Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; McMaster University","funders":"","keywords":"Ustekinumab; Plaque psoriasis; Medicine; Double blinded; Psoriasis; Internal medicine; Randomized controlled trial; Multicenter study; Dermatology; Pathology; Placebo; Disease; Alternative medicine","score_opus":0.03190225859256773,"score_gpt":0.2984405727850189,"score_spread":0.26653831419245116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120771989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888836,0.0022053719,0.00012339998,0.002646456,0.0040966715,0.0013790559,0.00052871223,0.000015252399,0.000121490055],"genre_scores_gemma":[0.99788135,0.0005807195,0.00009642528,0.00024500632,0.00057959516,0.00001449581,0.0002719466,0.00003458888,0.00029587757],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99595577,0.0014868454,0.0014263205,0.00031129294,0.00036483564,0.00045492445],"domain_scores_gemma":[0.9910256,0.006199824,0.001306662,0.0006624338,0.0007125935,0.000092885115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014460563,0.00040503463,0.0013981871,0.00008884984,0.0003419107,0.000024815565,0.00061411917,0.00023228448,0.00022363228],"category_scores_gemma":[0.0012581783,0.00018378904,0.0003139418,0.00032656404,0.0004527362,0.00009009501,0.00010703229,0.0005097665,0.000017400222],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97170275,0.0012301006,0.000013880042,0.0000074583827,0.0035988844,0.00022315011,0.012056299,0.0003144739,0.0014009543,0.0000105264335,0.0014253998,0.0080160955],"study_design_scores_gemma":[0.9710951,0.004536327,0.000070195616,0.00033209848,0.002732539,0.0004963829,0.0023478558,0.00001153112,0.016080867,0.000024898369,0.002066207,0.00020601232],"about_ca_topic_score_codex":0.00028838043,"about_ca_topic_score_gemma":0.0003209525,"teacher_disagreement_score":0.014679913,"about_ca_system_score_codex":0.000094102405,"about_ca_system_score_gemma":0.00023004417,"threshold_uncertainty_score":0.74947},"labels":[],"label_agreement":null},{"id":"W3121057262","doi":"10.25251/skin.5.supp.3","title":"Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Basal cell carcinoma; Interim; Vismodegib; Internal medicine; Oncology; Medicine; Interim analysis; Basal cell; Clinical trial; History","score_opus":0.01888602988988578,"score_gpt":0.2952838839229059,"score_spread":0.2763978540330201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121057262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974299,0.00058668666,0.0005488606,0.0007576163,0.00015648505,0.00036931224,0.00008987979,0.0000018019163,0.000059473772],"genre_scores_gemma":[0.99885017,0.000045701465,0.00039952068,0.00033729826,0.00015989525,0.000007864739,0.000055755754,0.00002444673,0.00011932595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979855,0.00019659709,0.0008849313,0.00024641366,0.00043582005,0.00025075738],"domain_scores_gemma":[0.9977557,0.0002640203,0.00072321214,0.000347373,0.0007905083,0.00011919445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006150085,0.00022748564,0.00077357225,0.00030000138,0.00005363309,0.000007473439,0.00024949014,0.000056988672,0.000009575705],"category_scores_gemma":[0.0010694382,0.00012214777,0.00014202458,0.0006335467,0.00013542888,0.000003835395,0.000067169494,0.00016748968,3.4101927e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23532449,0.009366279,0.028833311,0.0012639639,0.009653066,0.0035533123,0.030619927,0.02600154,0.6168078,0.0000057673437,0.023054006,0.015516498],"study_design_scores_gemma":[0.03162481,0.054087006,0.009028679,0.0020621258,0.0043985182,0.00023950732,0.0074566114,0.00073725695,0.8866415,0.0000175943,0.0031263141,0.00058005034],"about_ca_topic_score_codex":0.000011701548,"about_ca_topic_score_gemma":0.00017177501,"teacher_disagreement_score":0.26983368,"about_ca_system_score_codex":0.000051716783,"about_ca_system_score_gemma":0.00016670304,"threshold_uncertainty_score":0.49810418},"labels":[],"label_agreement":null},{"id":"W3135451264","doi":"10.25251/skin.5.supp.32","title":"Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Mental Health and Psychiatry","field":"Arts and Humanities","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Disease; Perception; Medicine; Psoriasis; Dermatology; Psychology; Pathology; Neuroscience","score_opus":0.05909140626378356,"score_gpt":0.2805296217580594,"score_spread":0.22143821549427584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135451264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775047,0.012397507,0.00073785917,0.0048403395,0.003034887,0.0004826056,0.00065158523,0.000005749902,0.0003447938],"genre_scores_gemma":[0.99731857,0.00097169005,0.000028464656,0.00018616066,0.0011847266,0.0000036342806,0.000091621936,0.000013340542,0.00020178512],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9979482,0.0004217968,0.0008929738,0.00011104088,0.00045913033,0.00016683944],"domain_scores_gemma":[0.99628377,0.002023333,0.00095647585,0.0002822256,0.00026556556,0.00018864968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047407433,0.00014311192,0.00035082627,0.0000677537,0.00041982348,0.000012884412,0.00014858773,0.000020819414,0.0002460711],"category_scores_gemma":[0.00048380237,0.00007023681,0.00013861051,0.00007360999,0.00021544313,0.00005454289,0.0000159265,0.00009756244,0.0000012642482],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037223827,0.003261702,0.017224,0.0016045149,0.0021379883,0.0002626077,0.8169367,0.004360942,0.00027001466,0.068384364,0.03745087,0.010882495],"study_design_scores_gemma":[0.022851536,0.0101965545,0.101493634,0.010771963,0.007840861,0.00029522466,0.54098344,0.0066577736,0.00011821832,0.27140027,0.026474401,0.00091613876],"about_ca_topic_score_codex":0.0010916692,"about_ca_topic_score_gemma":0.0024256203,"teacher_disagreement_score":0.27595326,"about_ca_system_score_codex":0.000318724,"about_ca_system_score_gemma":0.00040041414,"threshold_uncertainty_score":0.3228985},"labels":[],"label_agreement":null},{"id":"W3200049481","doi":"10.25251/skin.5.supp.58","title":"COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Coronavirus disease 2019 (COVID-19); Dermatology; Term (time); Series (stratigraphy); Extension (predicate logic); 2019-20 coronavirus outbreak; Pediatrics; Internal medicine; Virology; Disease; Computer science","score_opus":0.014492670223765958,"score_gpt":0.27155961202400886,"score_spread":0.2570669418002429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200049481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773186,0.002119621,0.000079886224,0.019277835,0.00038800185,0.00062766386,0.000032686745,0.000017290658,0.00013843368],"genre_scores_gemma":[0.9886126,0.0003031819,0.00006246502,0.010335586,0.0003622164,0.0000062463673,0.000055653232,0.000025227908,0.00023683632],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.997613,0.0005547856,0.0007505519,0.00020164458,0.0005916854,0.00028831486],"domain_scores_gemma":[0.9973759,0.0009764401,0.000336784,0.0004548763,0.0003922901,0.00046373325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029787686,0.00025584697,0.000721169,0.00011651811,0.00022886676,0.000020325524,0.00019924664,0.00010372384,0.0005850488],"category_scores_gemma":[0.0016498601,0.00011781592,0.00009499869,0.00033380036,0.00030144007,0.00011350864,0.00004624253,0.0005105798,0.000007573327],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09741579,0.0010679046,0.34553218,0.00019188684,0.0008221847,0.4995396,0.009776805,0.00079822127,0.00006939195,0.000013807586,0.041677985,0.0030942366],"study_design_scores_gemma":[0.07254878,0.0020833528,0.22193334,0.0015785104,0.0015817308,0.6947395,0.0030422509,0.000054160228,0.00032985583,0.0006566411,0.0011782032,0.00027364274],"about_ca_topic_score_codex":0.00018513828,"about_ca_topic_score_gemma":0.0011522988,"teacher_disagreement_score":0.19519992,"about_ca_system_score_codex":0.00014982511,"about_ca_system_score_gemma":0.00064826704,"threshold_uncertainty_score":0.6405874},"labels":[],"label_agreement":null},{"id":"W3211411127","doi":"10.25251/skin.5.supp.39","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Apremilast; Medicine; Placebo; Psoriasis; Plaque psoriasis; Pharmacology; Internal medicine; Dermatology; Pathology; Psoriatic arthritis","score_opus":0.050049962194994205,"score_gpt":0.33098603349030825,"score_spread":0.28093607129531406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211411127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98773485,0.0083157355,0.00003079715,0.0025113511,0.0007308512,0.00047069765,0.000086714965,0.0000072354624,0.0001117575],"genre_scores_gemma":[0.99556863,0.0036546695,0.00010702394,0.00028413505,0.0002066875,0.000010948574,0.00004589756,0.000019537727,0.00010247697],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957256,0.0026103258,0.0009482902,0.00025030997,0.00015482875,0.0003106664],"domain_scores_gemma":[0.9965729,0.0023432826,0.00054009195,0.00025210553,0.00021975247,0.0000718495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002625236,0.0002919082,0.0009560025,0.00028825528,0.00014760916,0.000017248807,0.00020078754,0.0002327104,0.000075600656],"category_scores_gemma":[0.0012433222,0.00016836257,0.00007780107,0.00043559485,0.00022141995,0.00013271515,0.000044902463,0.0004979689,0.0000026405528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25621584,0.002662924,0.0014064142,0.00015802024,0.002022088,0.003252879,0.042442244,0.0004843229,0.566616,0.00017757012,0.009452563,0.115109116],"study_design_scores_gemma":[0.18263412,0.027850699,0.0045718444,0.0025042284,0.004297609,0.083501585,0.058385327,0.00013312708,0.6241031,0.0021326274,0.008751862,0.0011338544],"about_ca_topic_score_codex":0.00019524689,"about_ca_topic_score_gemma":0.0013059546,"teacher_disagreement_score":0.113975264,"about_ca_system_score_codex":0.000093353345,"about_ca_system_score_gemma":0.00019395283,"threshold_uncertainty_score":0.68656266},"labels":[],"label_agreement":null},{"id":"W3211412243","doi":"10.25251/skin.5.supp.34","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Allergan; Genentech; Astellas Pharma; Glenmark Pharmaceuticals; Pfizer; Biogen; Incyte; Sun Pharma; Dermira; Coherus Biosciences; Valeant Pharmaceuticals International; Ablynx; Celgene; Novartis; GlaxoSmithKline; Astellas Pharma US; Amgen; Galderma; LEO Pharma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; Bausch Health; Bayer HealthCare; Sanofi; Regeneron Pharmaceuticals; Abbott Laboratories","keywords":"Demographics; Plaque psoriasis; Medicine; Baseline (sea); Psoriasis; Disease; Internal medicine; Clinical trial; Dermatology; Demography","score_opus":0.03108208345977064,"score_gpt":0.32647029681699785,"score_spread":0.2953882133572272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211412243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97682685,0.00374273,0.00024486537,0.018190708,0.00017056525,0.00034192813,0.00044354686,0.000008699329,0.00003011367],"genre_scores_gemma":[0.9942127,0.0031805302,0.00008583318,0.0005650179,0.0016063472,0.000010011785,0.00025076573,0.000002299032,0.000086529995],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808496,0.0002976839,0.0008735863,0.0001712584,0.0003527152,0.00021977555],"domain_scores_gemma":[0.993176,0.005593452,0.00062267884,0.00008916405,0.00023794718,0.00028075575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021455889,0.00016900864,0.00057746586,0.00001828756,0.00013277435,0.000017716162,0.00026347503,0.000049855218,0.00008684712],"category_scores_gemma":[0.0047692815,0.00005973144,0.00009704235,0.00031084512,0.00018694032,0.000047008805,0.000029853736,0.00029277577,5.456654e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004425922,0.0012070882,0.00086084113,0.0000608345,0.00010858973,0.00053974485,0.0002678793,0.000012943021,0.8980996,0.000056684443,0.0229983,0.07136158],"study_design_scores_gemma":[0.08080178,0.021264154,0.029992599,0.011290175,0.009134811,0.058640745,0.015408269,0.00807957,0.112130225,0.016244203,0.6334092,0.0036042738],"about_ca_topic_score_codex":0.000014971204,"about_ca_topic_score_gemma":0.000044193435,"teacher_disagreement_score":0.7859694,"about_ca_system_score_codex":0.000023735198,"about_ca_system_score_gemma":0.000055146902,"threshold_uncertainty_score":0.570962},"labels":[],"label_agreement":null},{"id":"W3211628515","doi":"10.25251/skin.5.supp.42","title":"Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Roflumilast; Dermis; Psoriasis; Medicine; Pharmacology; Phosphodiesterase inhibitor; Dermatology; Internal medicine; Pathology","score_opus":0.01646162550159773,"score_gpt":0.301729772481566,"score_spread":0.2852681469799683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211628515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797246,0.016531048,0.00021918102,0.0025704703,0.0003389136,0.00045944058,0.000009357431,0.0000017681314,0.00014523025],"genre_scores_gemma":[0.99115855,0.0076515726,0.00007750999,0.0003753931,0.0005005593,0.000009928881,0.000013819257,0.000011457362,0.00020122268],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99801713,0.0007467144,0.00067361345,0.00016149979,0.00025651316,0.00014451114],"domain_scores_gemma":[0.9984088,0.00059188565,0.0005058309,0.00020701076,0.00020746986,0.000079033336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010154708,0.00018670711,0.0005315599,0.000059593433,0.00009015379,0.000015192989,0.00008384697,0.00009342413,0.000014508857],"category_scores_gemma":[0.00078687153,0.000089542584,0.00010116909,0.00011627891,0.00020581609,0.0000075677162,0.000026737307,0.00010605823,2.1830999e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010412011,0.0015126702,0.0013770675,0.0001297824,0.00078221,0.0007834822,0.011258457,0.00013691683,0.75508094,0.000022261216,0.0039154757,0.21458873],"study_design_scores_gemma":[0.02179771,0.015908029,0.0034410828,0.00057154935,0.0010484608,0.020365914,0.0073519405,0.00009918057,0.8971017,0.000322338,0.031726237,0.00026583244],"about_ca_topic_score_codex":0.000038057882,"about_ca_topic_score_gemma":0.00008178385,"teacher_disagreement_score":0.2143229,"about_ca_system_score_codex":0.000038457903,"about_ca_system_score_gemma":0.00011412684,"threshold_uncertainty_score":0.36514404},"labels":[],"label_agreement":null},{"id":"W3211829948","doi":"10.25251/skin.5.supp.48","title":"Long-term Safety and Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Patients With Clinically Meaningful Improvement in Plaque Psoriasis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Lotion; Medicine; Psoriasis; Plaque psoriasis; Dermatology; Adverse effect; Fixed-dose combination; Pharmacology","score_opus":0.006887610117860704,"score_gpt":0.23037279793076346,"score_spread":0.22348518781290275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211829948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969873,0.0016429061,0.00006186563,0.00068531296,0.00028582136,0.0002932687,0.0000064058554,0.0000028365241,0.00003430371],"genre_scores_gemma":[0.99785334,0.0018905691,0.00005572185,0.00004644559,0.00003161883,0.0000016732986,0.00003616937,0.000009264019,0.0000751721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985171,0.00033282986,0.0007483703,0.00013923817,0.0001111841,0.00015129706],"domain_scores_gemma":[0.99861175,0.0004828031,0.0005401791,0.00013016605,0.00020871607,0.000026381931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006684447,0.00014130885,0.00044394704,0.00013679988,0.000051263167,0.000003554873,0.000090428846,0.00011356291,0.00004543972],"category_scores_gemma":[0.00025911318,0.000080029495,0.00003123805,0.0001486889,0.00017351976,0.00005689802,0.00003697275,0.00023589778,8.112083e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017827168,0.0014727701,0.62584746,0.00011519823,0.0006224012,0.0003316921,0.003362929,0.000067503235,0.0236797,0.00007272187,0.000026090307,0.32657436],"study_design_scores_gemma":[0.020142844,0.0054028104,0.9642402,0.0007982306,0.00035661148,0.00073736656,0.00022287623,0.000005063989,0.007835651,0.00011527986,0.000032789278,0.000110272944],"about_ca_topic_score_codex":0.000027600458,"about_ca_topic_score_gemma":0.00009121052,"teacher_disagreement_score":0.33839273,"about_ca_system_score_codex":0.000054742002,"about_ca_system_score_gemma":0.00006425867,"threshold_uncertainty_score":0.3263508},"labels":[],"label_agreement":null},{"id":"W3211979812","doi":"10.25251/skin.5.supp.94","title":"A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology","funders":"","keywords":"Roflumilast; Double blind; Seborrheic dermatitis; Medicine; Randomized controlled trial; Dermatology; Surgery; Internal medicine; Placebo; Alternative medicine","score_opus":0.023237423125617,"score_gpt":0.3309825190124378,"score_spread":0.3077450958868208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211979812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087954,0.0018136043,0.00016015625,0.002690714,0.00023979173,0.0037657176,0.000009452603,0.000013407857,0.00042759342],"genre_scores_gemma":[0.99756306,0.00015871762,0.0002378293,0.0012504952,0.0002735658,0.000060680835,0.000019512536,0.000047538677,0.00038856655],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955503,0.00081020355,0.0013898868,0.00027030433,0.001572338,0.00040696422],"domain_scores_gemma":[0.99615985,0.0010897536,0.00074071286,0.00043711436,0.0011520613,0.00042050704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001494719,0.00036896934,0.0019647267,0.00027956304,0.00016245493,0.000035232053,0.00020431478,0.000060850514,0.00021301705],"category_scores_gemma":[0.001176624,0.0001873132,0.00021125912,0.0005778446,0.00010445265,0.00012808364,0.00005941057,0.0004771054,0.000012784296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96142966,0.0036871997,0.012043213,0.000055180506,0.0018505547,0.0059433673,0.0048795673,0.001758965,0.00008705268,0.0000030381202,0.0002953984,0.007966817],"study_design_scores_gemma":[0.97482455,0.008999308,0.0024464729,0.001449671,0.0042640385,0.003255877,0.0024462098,0.0019426383,0.00008983794,0.00007048026,0.00002245567,0.0001884421],"about_ca_topic_score_codex":0.00011608164,"about_ca_topic_score_gemma":0.00013624647,"teacher_disagreement_score":0.013394922,"about_ca_system_score_codex":0.00022815473,"about_ca_system_score_gemma":0.0004999273,"threshold_uncertainty_score":0.76384103},"labels":[],"label_agreement":null},{"id":"W3212033307","doi":"10.25251/skin.5.supp.57","title":"Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Placebo; Double blind; Term (time); Randomized controlled trial; Placebo-controlled study; Dermatology; Pediatrics; Internal medicine; Alternative medicine; Pathology","score_opus":0.023699825724071356,"score_gpt":0.32221820947727425,"score_spread":0.2985183837532029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212033307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900781,0.0025440168,0.0010306702,0.0038630578,0.0001654967,0.002089366,0.000022090644,0.000011044899,0.0001961725],"genre_scores_gemma":[0.9979937,0.0005615884,0.00043266825,0.00068167504,0.00015715053,0.000015336862,0.000051032424,0.000032758573,0.00007405819],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99516755,0.001372787,0.0021900744,0.00025315795,0.0007152075,0.00030122243],"domain_scores_gemma":[0.9914002,0.0056786835,0.0016592373,0.00037726958,0.0006273669,0.00025725865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020762514,0.00034802986,0.0037691775,0.00026117865,0.00008748089,0.000037742575,0.00018548725,0.00009454657,0.00008938483],"category_scores_gemma":[0.0021068298,0.00016161046,0.00020422801,0.0002849368,0.0004236052,0.00016901617,0.000019577841,0.00046100898,7.924486e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9795773,0.0009144003,0.006792844,0.00006971723,0.001836493,0.0050954255,0.0023320334,0.00059359794,0.00008233081,0.000010252418,0.00023631386,0.0024592609],"study_design_scores_gemma":[0.9721555,0.0014693404,0.010743995,0.004319325,0.0025764816,0.006855749,0.0004252538,0.00031057507,0.0007819691,0.00017744782,0.000006179831,0.00017817819],"about_ca_topic_score_codex":0.000040713072,"about_ca_topic_score_gemma":0.000059022437,"teacher_disagreement_score":0.007915648,"about_ca_system_score_codex":0.00005963391,"about_ca_system_score_gemma":0.0003933935,"threshold_uncertainty_score":0.65902835},"labels":[],"label_agreement":null},{"id":"W3212061951","doi":"10.25251/skin.5.supp.63","title":"Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Medicine; Dermatology; Term (time); Disease; Disease control; Internal medicine; Environmental health; Myelofibrosis; Physics","score_opus":0.014321010066676652,"score_gpt":0.3113860671939269,"score_spread":0.2970650571272503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212061951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.912238,0.056503884,0.00013149735,0.030107507,0.00023205616,0.00024397016,0.000076380966,0.000012429587,0.0004542891],"genre_scores_gemma":[0.9873936,0.0076635573,0.00005434196,0.0040930593,0.0005148182,0.0000019174747,0.000035363035,0.000016611297,0.00022673006],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99786973,0.00036061322,0.0008892483,0.00017982682,0.00044490676,0.0002556725],"domain_scores_gemma":[0.99653244,0.0018978396,0.00042049348,0.00033414568,0.00036856346,0.00044652753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039452856,0.0002146967,0.0008718275,0.000112593494,0.00010421118,0.000009153534,0.00012491719,0.000043092954,0.0001180587],"category_scores_gemma":[0.0027015174,0.00011448111,0.00007132498,0.00016035794,0.00060869876,0.00007971571,0.000033846176,0.00039974056,0.0000031332552],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069552645,0.0027655254,0.40952218,0.0007650895,0.003855157,0.46535245,0.0111833215,0.00019822504,0.0003263746,0.00020123793,0.017918408,0.0183594],"study_design_scores_gemma":[0.14459962,0.0030911032,0.6327455,0.012034632,0.0069690165,0.18433829,0.0070625492,0.00029557702,0.00053973746,0.004113757,0.0037254884,0.0004847112],"about_ca_topic_score_codex":0.00002343201,"about_ca_topic_score_gemma":0.00011990237,"teacher_disagreement_score":0.28101417,"about_ca_system_score_codex":0.00005479657,"about_ca_system_score_gemma":0.00034389188,"threshold_uncertainty_score":0.46684042},"labels":[],"label_agreement":null},{"id":"W3212333063","doi":"10.25251/skin.5.supp.52","title":"Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Plaque psoriasis; Interim; Open label; Medicine; Psoriasis; Extension (predicate logic); Internal medicine; Dermatology; Interim analysis; Clinical trial; Surgery; History","score_opus":0.02578579340508559,"score_gpt":0.280982458042791,"score_spread":0.2551966646377054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212333063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912731,0.0016604624,0.00003250443,0.0048737098,0.00096772925,0.0007727454,0.00029754746,0.0000058067058,0.00011640539],"genre_scores_gemma":[0.9954759,0.00055333995,0.000226129,0.00078242976,0.00014645312,0.000017083452,0.00006413401,0.000029007533,0.0027055102],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961419,0.0020940164,0.000942503,0.00031487647,0.00018586153,0.00032084138],"domain_scores_gemma":[0.9960536,0.0022483547,0.00063092995,0.00066743005,0.0003516791,0.000048001628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010115585,0.00029289856,0.0008468934,0.000110315035,0.000114116934,0.000018354756,0.0005081244,0.0001469661,0.00019019927],"category_scores_gemma":[0.0007740013,0.00013795902,0.000085841195,0.00033422088,0.00021514567,0.00011146612,0.00013581563,0.00028787096,0.000012802804],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96030205,0.0008000081,0.00013116655,0.0000024469512,0.0008325861,0.0010060389,0.0115194,0.00007075848,0.0066966317,0.00001078295,0.004411722,0.014216397],"study_design_scores_gemma":[0.789921,0.05468094,0.031876728,0.0049208784,0.002721223,0.0050659175,0.006015945,0.000012617303,0.055686224,0.0013302614,0.046904147,0.0008641569],"about_ca_topic_score_codex":0.0010573912,"about_ca_topic_score_gemma":0.0009834452,"teacher_disagreement_score":0.1703811,"about_ca_system_score_codex":0.00033260035,"about_ca_system_score_gemma":0.0003700863,"threshold_uncertainty_score":0.5625805},"labels":[],"label_agreement":null},{"id":"W3212399069","doi":"10.25251/skin.5.supp.49","title":"Long-term Outcomes of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Stratified by Baseline Signs and Symptoms of Psoriasis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Lotion; Psoriasis; Medicine; Dermatology; Internal medicine; Pharmacology","score_opus":0.011908172349742327,"score_gpt":0.24588944887510455,"score_spread":0.23398127652536221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212399069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829442,0.014729377,0.00040594596,0.0012128549,0.00045756705,0.00016266447,0.000038026366,0.0000048279835,0.00004456285],"genre_scores_gemma":[0.9969101,0.00225402,0.000056463286,0.000046947247,0.00004490511,0.0000014803381,0.000065755674,0.000009979925,0.00061033666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860996,0.0004041212,0.0006210765,0.00011543149,0.00011754405,0.00013187827],"domain_scores_gemma":[0.9982478,0.00060238736,0.0006410067,0.00015569833,0.0003217567,0.000031335887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056174165,0.00015794543,0.0005383826,0.000099020705,0.00007642626,0.0000037148081,0.000105223684,0.00012640699,0.00016764268],"category_scores_gemma":[0.00027821944,0.00009029194,0.00006500276,0.00011139514,0.00028370306,0.000058269354,0.000027504131,0.00014965964,0.0000010835571],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000759311,0.00039904716,0.029987147,0.00012623916,0.0012560292,0.00010904534,0.0010977965,0.000009186795,0.8323974,0.000121694284,0.00041819987,0.1333189],"study_design_scores_gemma":[0.012513999,0.0074727554,0.114031896,0.0008640971,0.0036248781,0.012103397,0.0010661198,0.000026006011,0.84678805,0.000924716,0.0002607178,0.0003233729],"about_ca_topic_score_codex":0.000022754592,"about_ca_topic_score_gemma":0.00001861647,"teacher_disagreement_score":0.13299553,"about_ca_system_score_codex":0.000017680875,"about_ca_system_score_gemma":0.000054728876,"threshold_uncertainty_score":0.36819983},"labels":[],"label_agreement":null},{"id":"W3212504077","doi":"10.25251/skin.5.supp.51","title":"Efficacy of Brodalumab vs Ustekinumab by Prior TNFα Inhibitor Exposure: Post hoc Analysis of Two Phase 3 Psoriasis Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Allergan; LEO Pharma; Eli Lilly and Company; Ortho Dermatologics; Galderma; Incyte; Dermira; Tulane University; Celgene; Regeneron Pharmaceuticals; Bausch Health; Novartis; Amgen; Pfizer","keywords":"Ustekinumab; Post-hoc analysis; Medicine; Psoriasis; Post hoc; Dermatology; Pharmacology; Internal medicine; Tumor necrosis factor alpha; Adalimumab","score_opus":0.016614763979763615,"score_gpt":0.2994205924946756,"score_spread":0.282805828514912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212504077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9110542,0.08607382,0.000032789958,0.0011426008,0.0013316218,0.00015591923,0.00012593309,0.000008899544,0.0000742219],"genre_scores_gemma":[0.9915291,0.0070087896,0.000088502304,0.00012397932,0.00026482437,0.0000020886337,0.00008159992,0.00002152722,0.00087959063],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99701494,0.0008061534,0.0013931919,0.00021682298,0.00026165217,0.00030721095],"domain_scores_gemma":[0.9950235,0.0019191973,0.0014443275,0.00050137186,0.0010557695,0.000055872355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008927546,0.00030572835,0.0016637204,0.00041828232,0.00015080234,0.0000043882783,0.00039067102,0.00016101969,0.0006299298],"category_scores_gemma":[0.0009829394,0.00017909602,0.00049894257,0.00097152387,0.0005611218,0.000057492576,0.0000810657,0.00029551538,0.000008464118],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016065536,0.0019872007,0.00086003484,0.00010251365,0.03812851,0.0006366907,0.011993747,0.000110958375,0.814668,0.00004212807,0.01026257,0.1051421],"study_design_scores_gemma":[0.058324564,0.019190744,0.0022556875,0.0010487139,0.06368402,0.010490914,0.01495014,0.000009395035,0.8188608,0.00013463864,0.010490101,0.0005602445],"about_ca_topic_score_codex":0.00005353682,"about_ca_topic_score_gemma":0.00007401161,"teacher_disagreement_score":0.104581855,"about_ca_system_score_codex":0.000082906925,"about_ca_system_score_gemma":0.00018524965,"threshold_uncertainty_score":0.73033243},"labels":[],"label_agreement":null},{"id":"W3212595479","doi":"10.25251/skin.5.supp.50","title":"Retreatment With Brodalumab Results in Skin Clearance and Improvements in Quality of Life in Patients With Psoriasis After Treatment Interruption","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Psoriasis; Medicine; Dermatology; Quality of life (healthcare); Intensive care medicine; Nursing","score_opus":0.01449934001659458,"score_gpt":0.2550851118258947,"score_spread":0.24058577180930013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212595479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547446,0.003495413,0.000003242683,0.00044371342,0.00017413375,0.00030138597,0.00002709513,0.000002428905,0.000078103985],"genre_scores_gemma":[0.9984646,0.001184101,0.00005206543,0.000060084614,0.000029018944,0.000009745112,0.000025682697,0.000012277882,0.00016242669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979581,0.00058023166,0.0008946153,0.00020306281,0.00013988452,0.00022410069],"domain_scores_gemma":[0.9987724,0.00026937664,0.00054712093,0.0002448224,0.00013287457,0.000033446246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005310158,0.00021377683,0.0006721224,0.00020648228,0.000026421394,0.0000034672164,0.00008970375,0.000105107494,0.000044388824],"category_scores_gemma":[0.00012668649,0.00010910817,0.00004189942,0.00027319408,0.00016524777,0.00006328012,0.00002417204,0.00018189123,0.0000016776177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10115456,0.0022993763,0.79670995,0.000060903927,0.0007845904,0.000510297,0.011492859,0.00007971934,0.002205799,0.0000069459825,0.000027554317,0.08466742],"study_design_scores_gemma":[0.039843634,0.007138128,0.9459407,0.0008467331,0.00019702691,0.0002526591,0.0017408755,0.0000015570354,0.0037948205,0.000031391588,0.000087802364,0.00012468669],"about_ca_topic_score_codex":0.0009442771,"about_ca_topic_score_gemma":0.0053796936,"teacher_disagreement_score":0.1492307,"about_ca_system_score_codex":0.00024047545,"about_ca_system_score_gemma":0.000107017564,"threshold_uncertainty_score":0.4449302},"labels":[],"label_agreement":null},{"id":"W3212964692","doi":"10.25251/skin.5.supp.64","title":"Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Dermatology; Medicine; Internal medicine; Myelofibrosis","score_opus":0.005396938450692176,"score_gpt":0.2249584020200947,"score_spread":0.21956146356940254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212964692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989237,0.0014976491,0.000052766554,0.0046104384,0.00009573131,0.0002199149,0.000010750557,0.000014015173,0.004261714],"genre_scores_gemma":[0.9965186,0.00031609766,0.00014109822,0.002150098,0.00011253023,0.0000020614243,0.000021845857,0.000025366473,0.00071231584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814355,0.00020824363,0.0005827703,0.00012808664,0.00063993497,0.00029740646],"domain_scores_gemma":[0.99806243,0.00037196995,0.00035793474,0.00043095104,0.0005527842,0.00022390232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018847747,0.00020432875,0.00064578693,0.00015851,0.000066841356,0.000007737375,0.00020482848,0.00005383129,0.00038515023],"category_scores_gemma":[0.0004268068,0.00009794056,0.0000540258,0.00035707204,0.00033514723,0.00007767966,0.000031409956,0.0004228183,0.000006574305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025880048,0.0008695482,0.9418117,0.00016219135,0.00048149825,0.032642405,0.0014756932,0.00006210811,0.000023515262,0.000029949193,0.017408388,0.002445035],"study_design_scores_gemma":[0.017380597,0.002616222,0.8937974,0.002433506,0.0009458685,0.076432005,0.00095219165,0.000018168566,0.0009787425,0.001092975,0.0031542662,0.00019806225],"about_ca_topic_score_codex":0.000052654206,"about_ca_topic_score_gemma":0.00013203883,"teacher_disagreement_score":0.04801427,"about_ca_system_score_codex":0.00006432734,"about_ca_system_score_gemma":0.00028340713,"threshold_uncertainty_score":0.4217125},"labels":[],"label_agreement":null},{"id":"W3212995571","doi":"10.25251/skin.5.supp.35","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Term (time); Extension (predicate logic); Aryl hydrocarbon receptor; Aryl; Psoriasis; Hydrocarbon; Medicine; Combinatorial chemistry; Pharmacology; Chemistry; Computer science; Dermatology; Organic chemistry; Physics; Biochemistry","score_opus":0.034237871899152575,"score_gpt":0.2839932816325126,"score_spread":0.24975540973336002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212995571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752696,0.017197339,0.00175599,0.0013644609,0.003757588,0.0005105709,0.000021949947,0.0000136901635,0.000108794746],"genre_scores_gemma":[0.9952649,0.0026252368,0.0003104121,0.00019521298,0.0008335171,0.000010347832,0.000046064044,0.00003249851,0.00068179454],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979897,0.00030237145,0.0009870478,0.00021794371,0.00017946845,0.00032343043],"domain_scores_gemma":[0.996882,0.001279432,0.0010475346,0.00038403698,0.00035822974,0.000048720805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009608095,0.00026978605,0.000809952,0.00012896438,0.00018392566,0.000006155024,0.00030995437,0.00022472616,0.0001723606],"category_scores_gemma":[0.00046824932,0.00016151018,0.0002811085,0.00018806783,0.00020171152,0.000054041047,0.000047346948,0.0002968708,0.000005285599],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042589862,0.0010181952,0.00014020607,0.000060927334,0.0013860792,0.00014062459,0.0021743232,0.00017575083,0.90067184,0.00005658485,0.00058115885,0.05100446],"study_design_scores_gemma":[0.21004614,0.02811305,0.0028231083,0.0041458225,0.0073152767,0.032223124,0.004041005,0.00028367236,0.7043846,0.0009623784,0.004832165,0.00082962605],"about_ca_topic_score_codex":0.000023925058,"about_ca_topic_score_gemma":0.000016337746,"teacher_disagreement_score":0.1962872,"about_ca_system_score_codex":0.00008018492,"about_ca_system_score_gemma":0.00018020615,"threshold_uncertainty_score":0.6586194},"labels":[],"label_agreement":null},{"id":"W3213252676","doi":"10.25251/skin.5.supp.37","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Apremilast; Placebo; Psoriasis; Medicine; Internal medicine; Pharmacology; Dermatology; Psoriatic arthritis; Alternative medicine; Pathology","score_opus":0.024652951725289696,"score_gpt":0.29938542965671344,"score_spread":0.27473247793142375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213252676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98872805,0.0035491788,0.00015529047,0.0057311696,0.0004363708,0.0010600487,0.00022914026,0.000026611586,0.00008415289],"genre_scores_gemma":[0.9943176,0.0007635617,0.000990579,0.002525251,0.0011646523,0.000014444079,0.00007965272,0.00006409761,0.000080144964],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943459,0.0023399573,0.0015519827,0.00045841007,0.00082844426,0.00047531782],"domain_scores_gemma":[0.9924342,0.004481523,0.0008431677,0.0005393377,0.0010919351,0.00060986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045013526,0.00051870797,0.0017623928,0.00023783765,0.00021183198,0.000070861046,0.00022080846,0.00020680513,0.00005364347],"category_scores_gemma":[0.0067102136,0.00025292192,0.00007984627,0.0008070828,0.00041848517,0.00019061474,0.00006462297,0.0011767343,0.0000027939077],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5667415,0.0025062156,0.0045892047,0.00041513366,0.003171903,0.030135494,0.07827819,0.001478791,0.21460542,0.00006296755,0.066723146,0.031292006],"study_design_scores_gemma":[0.37607905,0.05101315,0.008789709,0.024963211,0.010218429,0.076040655,0.066739924,0.014363964,0.33643055,0.0015556264,0.030718515,0.0030872305],"about_ca_topic_score_codex":0.0002644749,"about_ca_topic_score_gemma":0.0009354929,"teacher_disagreement_score":0.19066249,"about_ca_system_score_codex":0.0001687203,"about_ca_system_score_gemma":0.00068710867,"threshold_uncertainty_score":0.9999923},"labels":[],"label_agreement":null},{"id":"W3213483770","doi":"10.25251/skin.5.supp.67","title":"Effects of Ruxolitinib Cream in Patients With Atopic Dermatitis With Head and/or Neck Involvement","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Medicine; Dermatology; Head and neck; Internal medicine; Surgery","score_opus":0.005928745990522907,"score_gpt":0.23804003275672872,"score_spread":0.23211128676620582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213483770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935401,0.003317868,0.000028971926,0.0022886938,0.00009269978,0.0002787065,0.0000020288614,0.0000046257237,0.00044627575],"genre_scores_gemma":[0.9972757,0.0005825317,0.00021841517,0.0016768245,0.00007876369,0.000002454223,0.0000057819852,0.000013873313,0.00014562898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859744,0.00015662353,0.00048181988,0.000098578916,0.0004775923,0.0001879149],"domain_scores_gemma":[0.9984592,0.00057259854,0.00031473057,0.00018769913,0.00030979712,0.0001559344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015100013,0.00014890767,0.0006019454,0.00011502197,0.000040052328,0.0000032731455,0.00008892989,0.000045812594,0.00009870607],"category_scores_gemma":[0.0003410785,0.00006707749,0.00003386816,0.00020876825,0.0003046724,0.000048846116,0.000025016456,0.00025322527,8.658359e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047913794,0.0021737274,0.9583886,0.001830042,0.0005949802,0.020254517,0.0031680935,0.000018465915,0.000104514045,0.00007081795,0.004261774,0.0043430626],"study_design_scores_gemma":[0.0147064375,0.0073349797,0.93951625,0.0061783954,0.0008168819,0.026033744,0.0009823674,0.000011784953,0.0027883237,0.00022283164,0.0012938036,0.000114188835],"about_ca_topic_score_codex":0.00002637977,"about_ca_topic_score_gemma":0.00008705999,"teacher_disagreement_score":0.018872363,"about_ca_system_score_codex":0.000032522035,"about_ca_system_score_gemma":0.000217485,"threshold_uncertainty_score":0.27353406},"labels":[],"label_agreement":null},{"id":"W3213530550","doi":"10.25251/skin.5.supp.53","title":"Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma","keywords":"Secukinumab; Medicine; Plaque psoriasis; Double blinded; Psoriasis; Dermatology; Randomized controlled trial; Multicenter study; Internal medicine; Psoriatic arthritis; Alternative medicine; Placebo; Pathology","score_opus":0.028914308113880276,"score_gpt":0.2928783056741451,"score_spread":0.2639639975602648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213530550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98787636,0.002930787,0.000093953655,0.0029200283,0.004033685,0.0014096852,0.00061932806,0.000014561422,0.000101626],"genre_scores_gemma":[0.997697,0.00076864666,0.00010125011,0.00026168622,0.0005900377,0.000014672373,0.00031219414,0.000034800963,0.00021969479],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961094,0.001359679,0.001406105,0.00031249138,0.00034154748,0.00047077387],"domain_scores_gemma":[0.99221736,0.0051769605,0.0012337064,0.0006495718,0.0006161959,0.00010623005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001395673,0.00040358736,0.0013890193,0.00009335079,0.00033552016,0.000024777444,0.00059616903,0.00023008068,0.00021463889],"category_scores_gemma":[0.0011548343,0.00018485884,0.0003157891,0.00032444563,0.00044511314,0.00008455113,0.00009102323,0.0005166255,0.000016840908],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96759987,0.0011409341,0.000011699969,0.00000709427,0.0036454736,0.00033204615,0.014585853,0.0003087055,0.00119083,0.00001268461,0.0015855453,0.009579252],"study_design_scores_gemma":[0.97314954,0.0038775965,0.00007925436,0.00031978436,0.002530049,0.00062086276,0.0023679642,0.000015301319,0.014340823,0.000027784581,0.0024597794,0.00021125177],"about_ca_topic_score_codex":0.00034213538,"about_ca_topic_score_gemma":0.00035053724,"teacher_disagreement_score":0.013149993,"about_ca_system_score_codex":0.00010271323,"about_ca_system_score_gemma":0.00026174294,"threshold_uncertainty_score":0.7538325},"labels":[],"label_agreement":null},{"id":"W3213541100","doi":"10.25251/skin.5.supp.43","title":"Once-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b Study","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Scalp; Double blind; Medicine; Randomized controlled trial; Roflumilast; Psoriasis; Dermatology; Surgery; Internal medicine; Pathology; Alternative medicine","score_opus":0.06720391279295425,"score_gpt":0.3627389373596417,"score_spread":0.29553502456668745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213541100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98424274,0.0047895946,0.000070954484,0.008539967,0.00027048678,0.0018800815,0.000017503375,0.0000034251,0.00018524133],"genre_scores_gemma":[0.9982558,0.0007289,0.00012667355,0.0005015071,0.00025427755,0.000026449188,0.0000032781402,0.000021293552,0.00008185099],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932785,0.0010823357,0.0048000123,0.00029044988,0.00027016955,0.00027852794],"domain_scores_gemma":[0.99259007,0.0032734054,0.0033949434,0.00030917654,0.00026993424,0.00016248874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020078264,0.00022629541,0.0030450025,0.0004785599,0.000078279874,0.000028840584,0.00021160448,0.00009734032,0.00006411023],"category_scores_gemma":[0.004255833,0.00016213092,0.00008947471,0.00031293285,0.00025366092,0.00023007326,0.000057014087,0.0003953785,0.0000030144029],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64837354,0.00309527,0.2836604,0.00064923026,0.0015586612,0.00020542882,0.05746947,0.00048421166,0.00006550568,0.00053143536,0.0006248277,0.0032820133],"study_design_scores_gemma":[0.9533383,0.0019596142,0.025344402,0.0006136899,0.00022740765,0.0002480091,0.0128677385,0.0034124693,0.000013553134,0.0015743538,0.00014674815,0.00025368054],"about_ca_topic_score_codex":0.0015209983,"about_ca_topic_score_gemma":0.0006655244,"teacher_disagreement_score":0.3049648,"about_ca_system_score_codex":0.00018497548,"about_ca_system_score_gemma":0.00019515552,"threshold_uncertainty_score":0.6958766},"labels":[],"label_agreement":null},{"id":"W3213641793","doi":"10.25251/skin.5.supp.62","title":"Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"LEO Pharma; EMD Serono; Bausch Health; Glenmark Pharmaceuticals; Sanofi Genzyme; Incyte; Dermira; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Atopic dermatitis; Medicine; Dermatology","score_opus":0.017686213655082696,"score_gpt":0.34434660661192623,"score_spread":0.3266603929568435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213641793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654814,0.016878301,0.00015741565,0.016148375,0.00021619657,0.0010049805,0.000016354334,0.0000073772308,0.00008960252],"genre_scores_gemma":[0.99053895,0.0072724675,0.0002809019,0.0012726896,0.00045731125,0.000023403873,0.0000075684447,0.000013846789,0.00013283773],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998309,0.00024530568,0.00081646425,0.00013601965,0.00027840276,0.00021476945],"domain_scores_gemma":[0.997379,0.0016103344,0.00032328733,0.00030594616,0.0002330014,0.00014843626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004718131,0.00016279194,0.0006389063,0.000056838773,0.00013360401,0.000009583782,0.00017459433,0.0000610242,0.00003483427],"category_scores_gemma":[0.0007080311,0.00006828518,0.00015403345,0.00016457237,0.00034591148,0.000039172057,0.000029104438,0.000243171,8.2803336e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013560794,0.008178055,0.12450614,0.0003128587,0.0026800898,0.004753709,0.016622813,0.00056567084,0.00014230808,0.000094676885,0.01723205,0.8113508],"study_design_scores_gemma":[0.075369194,0.04388746,0.44160938,0.0069455234,0.0068107243,0.37273213,0.016191022,0.00681327,0.003294562,0.0016118597,0.024158066,0.0005768041],"about_ca_topic_score_codex":0.00003952355,"about_ca_topic_score_gemma":0.000059974835,"teacher_disagreement_score":0.810774,"about_ca_system_score_codex":0.000037844413,"about_ca_system_score_gemma":0.00017924326,"threshold_uncertainty_score":0.2784589},"labels":[],"label_agreement":null},{"id":"W3213872593","doi":"10.25251/skin.5.supp.59","title":"Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Interim; Term (time); Interim analysis; Medicine; Dermatology; Pediatrics; Psychology; Internal medicine; Political science; Clinical trial; Physics","score_opus":0.014937053087534355,"score_gpt":0.26885961384074514,"score_spread":0.2539225607532108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213872593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967666,0.0006541827,0.00020667109,0.001651322,0.00015757306,0.00030985326,0.000013056601,0.000014534741,0.00022620324],"genre_scores_gemma":[0.99640566,0.00018941057,0.00012872287,0.0027780195,0.000100291196,0.0000045265865,0.00010607121,0.00002571108,0.00026161477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976525,0.0003311446,0.0008535943,0.00021979671,0.00060559384,0.00033738965],"domain_scores_gemma":[0.99802613,0.00018845343,0.00037575193,0.00045542864,0.0005890556,0.0003651648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002242773,0.0002645693,0.00094310986,0.00039381752,0.000085822714,0.00001968364,0.00026520656,0.000087006076,0.0005450315],"category_scores_gemma":[0.00021989181,0.0001502489,0.00013993544,0.0008362775,0.00014602371,0.00015822932,0.00004334198,0.00038014326,0.0000061710725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022233813,0.00087407057,0.97722983,0.0001276994,0.0017736545,0.012446337,0.0014473222,0.00040929546,0.00023995501,0.0000027075525,0.0007103127,0.0025154087],"study_design_scores_gemma":[0.006303816,0.0013114143,0.9783087,0.0009142324,0.0030463345,0.008109422,0.0005280891,0.00023630503,0.0009587304,0.000074946125,0.000033959874,0.00017405368],"about_ca_topic_score_codex":0.000065102286,"about_ca_topic_score_gemma":0.000959274,"teacher_disagreement_score":0.0043369145,"about_ca_system_score_codex":0.00011961015,"about_ca_system_score_gemma":0.00020183543,"threshold_uncertainty_score":0.61269724},"labels":[],"label_agreement":null},{"id":"W3213919372","doi":"10.25251/skin.5.supp.44","title":"Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Roflumilast; Open label; Plaque psoriasis; Medicine; Psoriasis; Dermatology; Adverse effect; Term (time); Pharmacology; Internal medicine; COPD","score_opus":0.016306808373359905,"score_gpt":0.2737719592662977,"score_spread":0.2574651508929378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213919372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922245,0.0057415487,0.000014418926,0.0004693222,0.00059232535,0.0006192983,0.00016897687,0.0000061914798,0.00016339654],"genre_scores_gemma":[0.99693316,0.0023351756,0.000034549703,0.000067451314,0.00016330133,0.00000382051,0.00016264887,0.00002322227,0.00027669145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99738836,0.00076314533,0.001097306,0.00028244202,0.00017793174,0.00029079395],"domain_scores_gemma":[0.9970258,0.001262745,0.00085545075,0.00043335548,0.0003588157,0.000063839274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005917135,0.00028779323,0.00091770705,0.00014307063,0.00013500324,0.000011695663,0.00046427772,0.00014630427,0.00015965161],"category_scores_gemma":[0.0004926518,0.00016122636,0.000044877797,0.0002767855,0.00026989364,0.00008639043,0.00013886037,0.00040198525,0.000006993916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36585155,0.09209711,0.12862214,0.0001377839,0.011279084,0.008752147,0.04234994,0.000090843474,0.044765636,0.00003494765,0.002067009,0.3039518],"study_design_scores_gemma":[0.52570325,0.06829153,0.36814076,0.0037453438,0.0045660306,0.005091564,0.0045338273,0.0000071673117,0.018478831,0.00004811021,0.00080108235,0.0005925102],"about_ca_topic_score_codex":0.00039601052,"about_ca_topic_score_gemma":0.0016778023,"teacher_disagreement_score":0.3033593,"about_ca_system_score_codex":0.00010756801,"about_ca_system_score_gemma":0.00024446473,"threshold_uncertainty_score":0.657462},"labels":[],"label_agreement":null},{"id":"W3214388010","doi":"10.25251/skin.5.supp.41","title":"Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Dermis; Plaque psoriasis; Medicine; Roflumilast; Psoriasis; Dermatology; Pathology; Internal medicine","score_opus":0.010570115979971097,"score_gpt":0.30207330137651917,"score_spread":0.29150318539654807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214388010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96887857,0.026148794,0.000008367689,0.004262208,0.00008772518,0.0005409838,0.000010547286,0.000004228362,0.000058578375],"genre_scores_gemma":[0.9945564,0.004788306,0.000024813986,0.00038199467,0.00017830104,0.0000050882804,0.0000046396685,0.000023898301,0.000036510723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770015,0.0004263754,0.0007787068,0.0001703785,0.00061733776,0.0003070715],"domain_scores_gemma":[0.99705535,0.0013968176,0.0005703106,0.00042686882,0.000445078,0.00010554811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010095733,0.00027085046,0.00084753707,0.00013618184,0.00011551418,0.000011846155,0.0002392136,0.00006849006,0.00005061846],"category_scores_gemma":[0.0014870976,0.00010461855,0.0000899973,0.0004148948,0.0007419866,0.000072616895,0.00008328423,0.0006043425,2.6702747e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032913726,0.0074281157,0.76285124,0.0016357988,0.0048901807,0.0091471,0.07760988,0.0003514619,0.007481475,0.00002495238,0.0075996146,0.088066466],"study_design_scores_gemma":[0.030694311,0.011223944,0.9012461,0.0032895904,0.0020042923,0.030585343,0.018505529,0.00035718776,0.0010883247,0.00036821677,0.00035715234,0.0002800683],"about_ca_topic_score_codex":0.00030318942,"about_ca_topic_score_gemma":0.0004130022,"teacher_disagreement_score":0.13839482,"about_ca_system_score_codex":0.00021195863,"about_ca_system_score_gemma":0.0005526996,"threshold_uncertainty_score":0.42662206},"labels":[],"label_agreement":null},{"id":"W3214413975","doi":"10.25251/skin.5.6.4","title":"Light and Laser-based Treatments for Hidradenitis Suppurativa: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Vancouver General Hospital; University of Toronto; University of British Columbia","funders":"","keywords":"Hidradenitis suppurativa; Medicine; Randomized controlled trial; Dermatology; Surgery; Internal medicine","score_opus":0.03419813216321437,"score_gpt":0.3506739263673362,"score_spread":0.3164757942041218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214413975","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003356726,0.9798495,0.000049773396,0.014063817,0.00038036463,0.0053330404,0.00005805782,0.000016628159,0.00024541398],"genre_scores_gemma":[0.0004189976,0.996213,0.00022009622,0.00015271996,0.00060346577,0.0001855126,0.00013985613,0.00011824859,0.0019481019],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9947979,0.00097454054,0.0025617953,0.00032652225,0.00092377304,0.000415485],"domain_scores_gemma":[0.99327695,0.0026839022,0.002351093,0.0007143966,0.0005593776,0.0004142563],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001337092,0.0008366695,0.008003967,0.00033207753,0.00019022053,0.00002706489,0.000333797,0.00027234846,0.00025049798],"category_scores_gemma":[0.0017904335,0.00037168912,0.001065138,0.00047199544,0.00013705285,0.00007505075,0.000038087903,0.0006246346,0.000013988781],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009407041,0.0002937049,0.0000012031787,0.85670245,0.004877568,0.08954249,0.00027961977,1.7802572e-8,0.0000031036138,0.000012904476,0.0064802165,0.04171265],"study_design_scores_gemma":[0.0011809547,0.0015842532,3.7687222e-8,0.44667062,0.05459616,0.41710064,0.000077817924,0.0000011645441,0.0000069890234,0.0000113508695,0.07863489,0.00013510839],"about_ca_topic_score_codex":0.000006037508,"about_ca_topic_score_gemma":0.0000040069876,"teacher_disagreement_score":0.41003183,"about_ca_system_score_codex":0.00034442393,"about_ca_system_score_gemma":0.0008819814,"threshold_uncertainty_score":0.9998735},"labels":[],"label_agreement":null},{"id":"W3214549902","doi":"10.25251/skin.5.supp.38","title":"Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Plaque psoriasis; Medicine; Domain (mathematical analysis); Dermatology; Mathematics; Mathematical analysis","score_opus":0.012569610244830129,"score_gpt":0.24920588041576186,"score_spread":0.23663627017093172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214549902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96800095,0.025278876,0.000033194596,0.0051474497,0.00072937406,0.00042810664,0.00029315706,0.000013818576,0.00007507443],"genre_scores_gemma":[0.9929716,0.0053581162,0.00021577503,0.00079595187,0.00030720132,0.0000110562205,0.00008419715,0.000032033866,0.00022408042],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971234,0.0010293144,0.00084710383,0.00037240252,0.00020848743,0.0004192675],"domain_scores_gemma":[0.99570906,0.0029506772,0.0005125427,0.00039690186,0.00033302288,0.00009778814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009594306,0.00041164027,0.0008657809,0.00014107773,0.0003575074,0.000028259243,0.00029320357,0.00018058119,0.00003364628],"category_scores_gemma":[0.0007894906,0.0001983731,0.000072178176,0.00027708703,0.00048869126,0.000119311335,0.00013753276,0.00044603818,0.0000053629137],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21188271,0.0031509704,0.045681648,0.00021529099,0.0222488,0.0051282644,0.18505026,0.00029710194,0.105237305,0.00042913022,0.023780607,0.3968979],"study_design_scores_gemma":[0.39386573,0.05748229,0.19391924,0.013524582,0.016928852,0.034655612,0.14948398,0.000057578673,0.091781795,0.021911241,0.021756459,0.004632632],"about_ca_topic_score_codex":0.00016664615,"about_ca_topic_score_gemma":0.0005121833,"teacher_disagreement_score":0.3922653,"about_ca_system_score_codex":0.00006953942,"about_ca_system_score_gemma":0.00012379832,"threshold_uncertainty_score":0.8089421},"labels":[],"label_agreement":null},{"id":"W4221049281","doi":"10.25251/skin.6.supp.20","title":"Tirbanibulin Ointment Eradicates HPV-57 (+) Periungual Squamous Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"","keywords":"Basal cell; Dermatology; Medicine; Internal medicine","score_opus":0.017191107007565896,"score_gpt":0.28836527338770396,"score_spread":0.2711741663801381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221049281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88188094,0.025606176,0.00006911987,0.03589535,0.0012330946,0.00073176937,0.000021091699,0.000032332497,0.054530155],"genre_scores_gemma":[0.99163663,0.00036365655,0.00005829983,0.001945777,0.0017406158,0.000008951659,0.000010628541,0.000044124477,0.0041912827],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962256,0.00032542637,0.0007842461,0.00018944893,0.0019989547,0.00047631294],"domain_scores_gemma":[0.99774367,0.00065798475,0.00036345315,0.00043048526,0.0003667874,0.00043764478],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014606721,0.00022942324,0.00064263924,0.00026203136,0.00037108437,0.000011387907,0.00055486447,0.00005325998,0.038044516],"category_scores_gemma":[0.00030884353,0.00013128543,0.00019988001,0.00042763655,0.00032891348,0.00003293784,0.00019357813,0.0014600593,0.00003462526],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039528403,0.004309905,0.008424333,0.0014369972,0.0007373622,0.042833585,0.04081576,0.0018320443,0.0479249,0.0005404205,0.5665327,0.24508359],"study_design_scores_gemma":[0.025577864,0.09186532,0.021829514,0.000101274796,0.0027983754,0.2499397,0.030754648,0.0015439742,0.019778082,0.0018515739,0.5531041,0.00085556606],"about_ca_topic_score_codex":0.00019247095,"about_ca_topic_score_gemma":0.000013603438,"teacher_disagreement_score":0.24422802,"about_ca_system_score_codex":0.0005154581,"about_ca_system_score_gemma":0.0005232735,"threshold_uncertainty_score":0.96283484},"labels":[],"label_agreement":null},{"id":"W4228999540","doi":"10.25251/skin.6.supp.2","title":"Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"","keywords":"Psoriasis; Malignancy; Medicine; Dermatology; Internal medicine","score_opus":0.009601773036925079,"score_gpt":0.19994825235826888,"score_spread":0.1903464793213438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4228999540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98333824,0.01165251,0.000023129884,0.00046773712,0.0021438804,0.00023441043,0.00011073937,0.00000975709,0.0020196233],"genre_scores_gemma":[0.9953852,0.00073403644,0.00006543863,0.00015439717,0.00011981176,0.000005039581,0.00007825754,0.000022816948,0.0034349724],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793786,0.0006813583,0.00073753606,0.00015270102,0.0002374805,0.00025306398],"domain_scores_gemma":[0.9981206,0.000563655,0.0008101009,0.00033957956,0.00013281182,0.000033230626],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063181436,0.00020745044,0.00062756723,0.00023594136,0.00010662665,0.0000011806507,0.00045358727,0.00009041276,0.0031352458],"category_scores_gemma":[0.00011756806,0.00012176266,0.00010328426,0.00020278824,0.0002494853,0.00004268669,0.00007644762,0.00043652306,0.000018702314],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13741685,0.006956999,0.19474532,0.00019976769,0.01050995,0.0026170053,0.1093206,0.0014700925,0.12388317,0.00062930916,0.24377708,0.16847384],"study_design_scores_gemma":[0.056269873,0.014929494,0.12178607,0.0010691273,0.0043656835,0.005347392,0.0074473713,0.0000052176943,0.0039044947,0.0011838948,0.7826861,0.0010052891],"about_ca_topic_score_codex":0.000419025,"about_ca_topic_score_gemma":0.0001649809,"teacher_disagreement_score":0.538909,"about_ca_system_score_codex":0.00049232686,"about_ca_system_score_gemma":0.00021577098,"threshold_uncertainty_score":0.99777603},"labels":[],"label_agreement":null},{"id":"W4229010470","doi":"10.25251/skin.6.supp.1","title":"Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Internal medicine; Dermatology","score_opus":0.03227119884599514,"score_gpt":0.29356994865446284,"score_spread":0.2612987498084677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229010470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978483,0.00053853006,0.000074133255,0.000108936365,0.0005927447,0.0006166799,0.0001838249,0.00000463084,0.000032263695],"genre_scores_gemma":[0.9990517,0.0005852855,0.000023989773,0.000022262751,0.000039260492,0.000029591698,0.00003147484,0.000014605167,0.00020183166],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99794644,0.0008448453,0.00086261815,0.000113554546,0.0000636073,0.00016893983],"domain_scores_gemma":[0.9975516,0.0013114429,0.0008020763,0.00016687714,0.00013605597,0.00003193212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012703205,0.00014687706,0.00073404284,0.000602644,0.000099021185,0.0000022776262,0.0001386114,0.00007252007,0.0001964708],"category_scores_gemma":[0.00093526207,0.00009168268,0.000093754155,0.00047204294,0.00013020728,0.000034923607,0.00003912762,0.00025490072,0.000001254365],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08629226,0.013857472,0.32162106,0.00025239398,0.007508897,0.0002585728,0.052977104,0.0043672267,0.16348995,0.0001000693,0.009017369,0.34025764],"study_design_scores_gemma":[0.32854906,0.22860281,0.22900875,0.0033569853,0.015056075,0.015422187,0.017052593,0.00004880444,0.11499319,0.0015884467,0.044602953,0.0017181465],"about_ca_topic_score_codex":0.00049089495,"about_ca_topic_score_gemma":0.0018913187,"teacher_disagreement_score":0.33853948,"about_ca_system_score_codex":0.000090579204,"about_ca_system_score_gemma":0.00006749863,"threshold_uncertainty_score":0.37387115},"labels":[],"label_agreement":null},{"id":"W4229015785","doi":"10.25251/skin.6.supp.s29","title":"Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Dermatology; Phase (matter); Pediatrics; Physics","score_opus":0.01069320491428947,"score_gpt":0.26975126163442137,"score_spread":0.2590580567201319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229015785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915348,0.0012458127,0.000023343675,0.0058751823,0.0002444828,0.00072574726,0.000026688931,0.0000037572295,0.00032018166],"genre_scores_gemma":[0.9988162,0.00014339098,0.000021162374,0.00082392874,0.00010643075,0.0000031139127,0.0000026601595,0.000012642071,0.000070455215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99767494,0.00044196984,0.0009449515,0.00010714366,0.00065411103,0.00017686766],"domain_scores_gemma":[0.9985798,0.00027504147,0.00060148124,0.0002923743,0.00012618049,0.0001251137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006111004,0.0001444517,0.0006512871,0.00015760452,0.000109534565,0.0000021454982,0.000270001,0.000039175557,0.000051374518],"category_scores_gemma":[0.0004525249,0.00007084042,0.000072599374,0.00031999146,0.00030800691,0.000033277272,0.000060140632,0.0004985723,2.7579588e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9425498,0.003245428,0.009631358,0.0006375422,0.00052455015,0.0042322977,0.014886137,0.004769918,0.0008107653,0.000041473762,0.011592857,0.0070778728],"study_design_scores_gemma":[0.7205837,0.017532883,0.09055467,0.009684711,0.002234746,0.14566264,0.006409325,0.00066941156,0.0028082333,0.00070374325,0.0027910906,0.0003648841],"about_ca_topic_score_codex":0.000031203854,"about_ca_topic_score_gemma":0.000026492586,"teacher_disagreement_score":0.22196615,"about_ca_system_score_codex":0.00005214063,"about_ca_system_score_gemma":0.00024595362,"threshold_uncertainty_score":0.28887886},"labels":[],"label_agreement":null},{"id":"W4229015799","doi":"10.25251/skin.6.supp.7","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Allergan; Genentech; Astellas Pharma; Glenmark Pharmaceuticals; Pfizer; Biogen; Incyte; Sun Pharma; Dermira; Coherus Biosciences; Valeant Pharmaceuticals International; Ablynx; Celgene; Novartis; GlaxoSmithKline; Astellas Pharma US; Amgen; Galderma; LEO Pharma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; Bausch Health; Bayer HealthCare; Sanofi; Regeneron Pharmaceuticals; Abbott Laboratories","keywords":"Demographics; Plaque psoriasis; Medicine; Baseline (sea); Psoriasis; Internal medicine; Disease; Dermatology; Demography; Biology","score_opus":0.029593604166776147,"score_gpt":0.31888867373731816,"score_spread":0.289295069570542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229015799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98050004,0.0022472467,0.00011998257,0.015576305,0.00019181015,0.0005280486,0.00080546254,0.0000098320115,0.000021287],"genre_scores_gemma":[0.9967528,0.0010933084,0.00003657268,0.00057889125,0.0011889881,0.000030454697,0.00024806103,0.000002428528,0.00006848008],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979079,0.0003910881,0.0008561973,0.00016099346,0.00046186658,0.00022197457],"domain_scores_gemma":[0.99373233,0.0050816056,0.00075581827,0.000081337785,0.00010748682,0.0002414267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032962398,0.00016247967,0.00052603445,0.000027598566,0.00027959983,0.00001192659,0.00039557874,0.000027970964,0.00015535606],"category_scores_gemma":[0.0023435743,0.000059356396,0.000091125316,0.00032549346,0.00017474612,0.00003957399,0.000053403084,0.00039584457,3.0128112e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015691133,0.0024784121,0.0014557863,0.00006976304,0.00016564438,0.0004718925,0.00074675755,0.000112934154,0.80541867,0.00009701169,0.0678423,0.105449714],"study_design_scores_gemma":[0.057201035,0.033449125,0.013248626,0.0024460026,0.005146097,0.032827362,0.01700373,0.010157447,0.010935152,0.010410602,0.8047138,0.0024610152],"about_ca_topic_score_codex":0.00002683801,"about_ca_topic_score_gemma":0.00002016521,"teacher_disagreement_score":0.7944835,"about_ca_system_score_codex":0.00004077234,"about_ca_system_score_gemma":0.00003938626,"threshold_uncertainty_score":0.28056467},"labels":[],"label_agreement":null},{"id":"W4229034592","doi":"10.25251/skin.6.supp.4","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Pharmacology; Dermatology","score_opus":0.04009431060346913,"score_gpt":0.302258072534325,"score_spread":0.2621637619308559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229034592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787339,0.009517833,0.000037190166,0.008610722,0.0014623391,0.00079316116,0.000682736,0.000024491157,0.00013760371],"genre_scores_gemma":[0.99614704,0.0011969932,0.00010151868,0.0011955635,0.00067377125,0.000023454273,0.00019470787,0.000039644892,0.00042730512],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931063,0.0043248283,0.0014587925,0.00038345964,0.00025596304,0.0004706522],"domain_scores_gemma":[0.9937964,0.0044946675,0.0009225261,0.0004651191,0.00019848168,0.00012281151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004356343,0.00040636086,0.0011765301,0.00026266757,0.00064764556,0.000027309734,0.00058613444,0.000173298,0.00032263392],"category_scores_gemma":[0.0019395711,0.00022060618,0.00014597946,0.0005127887,0.00024715654,0.00011429358,0.00014323184,0.000908244,0.0000151881],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30421194,0.0053113527,0.00030318083,0.0000236961,0.0037796437,0.0038019456,0.07836991,0.003346244,0.29877084,0.00016251233,0.10080077,0.20111795],"study_design_scores_gemma":[0.3430208,0.08532566,0.004715336,0.001957677,0.010158728,0.07143686,0.05474647,0.00029510073,0.22313529,0.007618408,0.19475791,0.002831766],"about_ca_topic_score_codex":0.0008022597,"about_ca_topic_score_gemma":0.00046511533,"teacher_disagreement_score":0.19828619,"about_ca_system_score_codex":0.00016973149,"about_ca_system_score_gemma":0.00024275859,"threshold_uncertainty_score":0.8996059},"labels":[],"label_agreement":null},{"id":"W4229036839","doi":"10.25251/skin.6.supp.28","title":"Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Atopic dermatitis; Ruxolitinib; Medicine; Term (time); Dermatology; Disease; Phase (matter); Pediatrics; Internal medicine; Physics; Myelofibrosis","score_opus":0.01165511170678087,"score_gpt":0.29115345297157696,"score_spread":0.2794983412647961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229036839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692076,0.02438351,0.00015945181,0.005233715,0.00027247073,0.0004067541,0.00019254361,0.0000131911265,0.00013079816],"genre_scores_gemma":[0.99596065,0.0018168555,0.000014580388,0.0017142816,0.0003388048,0.0000036989159,0.000028206476,0.000019655132,0.000103241255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974846,0.00043225635,0.00096407876,0.00016123569,0.00072237186,0.00023541988],"domain_scores_gemma":[0.9972755,0.00077071716,0.00090117374,0.00034254414,0.00028581935,0.00042426906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049256335,0.00021473877,0.00087877846,0.0001384242,0.00023276494,0.0000044051903,0.0002173131,0.000025924486,0.0001202126],"category_scores_gemma":[0.0010579149,0.00011950224,0.00009606594,0.00013723125,0.000944281,0.00006761565,0.000072278206,0.0004528473,8.339279e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061437365,0.0016179953,0.87641186,0.00070205436,0.0024354619,0.038482673,0.006447965,0.00031615747,0.00012563847,0.000035649435,0.007494298,0.004492886],"study_design_scores_gemma":[0.07866342,0.0041044015,0.857451,0.0066800495,0.006978967,0.038296144,0.005402019,0.0003059419,0.00012996615,0.0008996619,0.00079884887,0.0002895427],"about_ca_topic_score_codex":0.000036967693,"about_ca_topic_score_gemma":0.00001974146,"teacher_disagreement_score":0.026753109,"about_ca_system_score_codex":0.000060820203,"about_ca_system_score_gemma":0.00019667934,"threshold_uncertainty_score":0.48731598},"labels":[],"label_agreement":null},{"id":"W4229043584","doi":"10.25251/skin.6.supp.5","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Term (time); Aryl hydrocarbon receptor; Psoriasis; Extension (predicate logic); Medicine; Aryl; Pharmacology; Dermatology; Chemistry; Computer science; Physics; Organic chemistry; Biochemistry","score_opus":0.0328903932308255,"score_gpt":0.27828189498316785,"score_spread":0.24539150175234237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229043584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98221064,0.010562613,0.0008771007,0.001179746,0.0042484943,0.0007874269,0.0000398056,0.000015646487,0.00007850619],"genre_scores_gemma":[0.99744236,0.0009343911,0.00013566317,0.00020207895,0.00062570453,0.000030997282,0.000046107813,0.000034617042,0.00054805324],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99787134,0.00039469305,0.0009681753,0.0002052606,0.00023378443,0.00032672178],"domain_scores_gemma":[0.99701256,0.0011644992,0.0012652794,0.00035104938,0.00016458401,0.000042013922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001463294,0.00025959266,0.0007390262,0.0001928631,0.00038067275,0.0000041747808,0.00046130214,0.00012772963,0.00030514642],"category_scores_gemma":[0.00023383292,0.00016052574,0.0002642987,0.0001968083,0.00018892482,0.000045714783,0.00008359493,0.00039879902,0.0000029615028],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10730298,0.0015424269,0.0001758881,0.000052242314,0.0015705348,0.00009253256,0.0044367802,0.0010924225,0.8263216,0.000072180446,0.0012685009,0.056071926],"study_design_scores_gemma":[0.48162487,0.14008334,0.004091523,0.0029753526,0.013438878,0.058846593,0.014269614,0.0011417711,0.25958875,0.0020150756,0.02008624,0.001837967],"about_ca_topic_score_codex":0.000042234504,"about_ca_topic_score_gemma":0.0000075867943,"teacher_disagreement_score":0.5667328,"about_ca_system_score_codex":0.00013624568,"about_ca_system_score_gemma":0.00012972698,"threshold_uncertainty_score":0.654605},"labels":[],"label_agreement":null},{"id":"W4236619224","doi":"10.25251/skin.5.supp.8","title":"Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Atopic dermatitis; Ruxolitinib; Medicine; Double blind; Dermatology; Randomized controlled trial; Internal medicine; Alternative medicine; Myelofibrosis; Pathology; Placebo","score_opus":0.035284372762504644,"score_gpt":0.3721015180146055,"score_spread":0.3368171452521009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236619224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8901621,0.10262436,0.0004499396,0.0054796147,0.00017801856,0.0008308941,0.000031632455,0.0000034039238,0.00024002668],"genre_scores_gemma":[0.9687185,0.030571911,0.00012923856,0.00022685583,0.00015576757,0.00000984959,0.00001525231,0.000009761112,0.00016280718],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976317,0.00032675068,0.0013950482,0.0001050801,0.0003835267,0.00015787609],"domain_scores_gemma":[0.9900507,0.0075632236,0.0011188991,0.0003355187,0.00083012023,0.000101587924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081337435,0.00018135157,0.002259261,0.00023498248,0.000086591834,0.0000023748946,0.00012798759,0.00004745243,0.00012271211],"category_scores_gemma":[0.0011499042,0.00007926917,0.0004974126,0.00038316185,0.0010653547,0.000026333866,0.000020590878,0.00010574245,1.6425278e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8187737,0.0058066384,0.002700257,0.0011714558,0.12116045,0.0017088873,0.023128392,0.00090328575,0.0014657794,0.0011570037,0.0025931923,0.019430969],"study_design_scores_gemma":[0.8195993,0.0031280702,0.0013855575,0.0012031465,0.1391048,0.009937536,0.00754615,0.0006858218,0.01498927,0.0010429187,0.001256892,0.00012058804],"about_ca_topic_score_codex":0.000028813445,"about_ca_topic_score_gemma":0.000028547167,"teacher_disagreement_score":0.07855644,"about_ca_system_score_codex":0.000029547478,"about_ca_system_score_gemma":0.00016213,"threshold_uncertainty_score":0.39253438},"labels":[],"label_agreement":null},{"id":"W4241580772","doi":"10.25251/skin.4.supp.30","title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Medicine; Dermatology; Psoriasis; Baseline (sea); Phase (matter); Randomized controlled trial; Internal medicine; Biology; Physics","score_opus":0.01703836544243391,"score_gpt":0.27875486484144557,"score_spread":0.26171649939901165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241580772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95606244,0.036560565,0.00021334566,0.00504457,0.00039241332,0.0015495243,0.00016452323,0.0000058017326,0.0000068353875],"genre_scores_gemma":[0.97480243,0.024583131,0.000019206442,0.0001595197,0.00023202143,0.000017599505,0.000050523282,0.000015303965,0.00012026295],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980723,0.0007555825,0.00077555235,0.00014609739,0.000078191726,0.00017224887],"domain_scores_gemma":[0.99497575,0.0041639367,0.0005063724,0.00016697861,0.00011009173,0.0000768775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009728269,0.00022375629,0.00099724,0.00006574206,0.000119888035,0.0000049641294,0.00014889005,0.00006807105,0.00008641665],"category_scores_gemma":[0.00092275743,0.000099932055,0.00009281119,0.0001181801,0.00032828163,0.000023562501,0.00001912843,0.00012356772,0.0000014112582],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8233168,0.004404357,0.0007694944,0.00006377052,0.002887898,0.00025075747,0.020280544,0.000012330181,0.008662681,0.000019613097,0.0023263264,0.13700543],"study_design_scores_gemma":[0.88764703,0.046674706,0.0028887424,0.0004052815,0.0136959,0.0015631687,0.0076107318,0.00041208684,0.0035756014,0.00011078407,0.03504036,0.00037560222],"about_ca_topic_score_codex":0.000042950378,"about_ca_topic_score_gemma":0.00001214775,"teacher_disagreement_score":0.13662983,"about_ca_system_score_codex":0.000027249125,"about_ca_system_score_gemma":0.000061252504,"threshold_uncertainty_score":0.4075111},"labels":[],"label_agreement":null},{"id":"W4309313095","doi":"10.25251/skin.6.supp.104","title":"A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Phase (matter); Medicine; Dermatology; Psychology; Chemistry; Organic chemistry","score_opus":0.016322774058655832,"score_gpt":0.3044332328889435,"score_spread":0.28811045883028763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309313095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937328,0.00087448576,0.00013846064,0.0034829143,0.00019401823,0.0013780073,0.000016748914,0.000009724251,0.00017280385],"genre_scores_gemma":[0.99866706,0.000040905295,0.00014825829,0.0008018724,0.000092848786,0.000045025023,0.000007324381,0.000032127562,0.00016460454],"study_design_codex":"randomized_trial","study_design_gemma":"case_report","domain_scores_codex":[0.9975284,0.00030387193,0.00090171327,0.00016491384,0.00078840123,0.00031272322],"domain_scores_gemma":[0.9982387,0.0004734843,0.00047554274,0.0003374257,0.0002505954,0.00022429696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008569304,0.00020958896,0.0008850111,0.00034325445,0.00015595598,0.0000041769536,0.000310928,0.0000361669,0.00016547799],"category_scores_gemma":[0.00036979088,0.00011697087,0.000085849446,0.00042019505,0.0001788359,0.000039472234,0.000061645806,0.00046612363,8.694554e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56039125,0.055463362,0.07144187,0.0011424854,0.0031449834,0.08341094,0.091360904,0.033928763,0.0033436918,0.00019380482,0.08146791,0.014710055],"study_design_scores_gemma":[0.2046328,0.21792324,0.0083895335,0.0023127797,0.006574685,0.44477993,0.092852116,0.0052946075,0.002209375,0.0029702005,0.011043519,0.0010172038],"about_ca_topic_score_codex":0.000068749585,"about_ca_topic_score_gemma":0.000106143896,"teacher_disagreement_score":0.361369,"about_ca_system_score_codex":0.0000804692,"about_ca_system_score_gemma":0.00030479513,"threshold_uncertainty_score":0.47699335},"labels":[],"label_agreement":null},{"id":"W4309313322","doi":"10.25251/skin.6.supp.47","title":"Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Gastroenterology; Dermatology; Pharmacology","score_opus":0.023743141155382914,"score_gpt":0.29033300301102205,"score_spread":0.26658986185563915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309313322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988092,0.00467635,0.000016299931,0.004319676,0.001161053,0.0014353665,0.00013813663,0.000016696664,0.00014440887],"genre_scores_gemma":[0.99741435,0.00056300795,0.00003630246,0.00077039056,0.00037701483,0.0000980427,0.00011670865,0.000035129528,0.0005890485],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99524224,0.0027072905,0.0009627983,0.00031121715,0.0002540719,0.000522355],"domain_scores_gemma":[0.9978817,0.0010714306,0.00047009552,0.00038833203,0.00010362774,0.000084804735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016373715,0.00040270278,0.0008405928,0.0003634678,0.00043837036,0.000018315071,0.0005996686,0.00014596713,0.00035316372],"category_scores_gemma":[0.00023652342,0.00021817471,0.00014459273,0.0006566188,0.00014883584,0.000095174924,0.000059928378,0.0006942473,0.000015966401],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59164435,0.020917438,0.00019461715,0.00001986759,0.0014865927,0.004722721,0.07276827,0.0022815347,0.10910726,0.00009036378,0.03461926,0.16214772],"study_design_scores_gemma":[0.57763606,0.16964345,0.0004954166,0.00039912772,0.0026426252,0.039799407,0.029819317,0.00008820867,0.066760235,0.0008283017,0.11067553,0.0012123291],"about_ca_topic_score_codex":0.00061933714,"about_ca_topic_score_gemma":0.00053312496,"teacher_disagreement_score":0.16093539,"about_ca_system_score_codex":0.00047583468,"about_ca_system_score_gemma":0.0003337882,"threshold_uncertainty_score":0.88969064},"labels":[],"label_agreement":null},{"id":"W4309313508","doi":"10.25251/skin.6.supp.72","title":"Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma","keywords":"Plaque psoriasis; Medicine; Psoriasis; Clinical trial; Pooled analysis; Internal medicine; Dermatology; Meta-analysis","score_opus":0.05224517280317597,"score_gpt":0.3519867857175708,"score_spread":0.29974161291439483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309313508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722385,0.0014565598,0.000022546432,0.00016461768,0.0003056836,0.0003291975,0.00048674786,0.0000021854555,0.000008611796],"genre_scores_gemma":[0.9986297,0.0009037106,0.000034544013,0.000036599118,0.000039662227,0.0000050477693,0.00031197447,0.000008223121,0.00003057316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962072,0.00215126,0.00123634,0.00017124315,0.000106827676,0.00012716105],"domain_scores_gemma":[0.9967508,0.001897618,0.00093093136,0.00031646033,0.00007364242,0.000030596693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022653139,0.00013791035,0.0012596496,0.00052645145,0.000042641183,0.0000022920287,0.00020361286,0.000075483396,0.000285777],"category_scores_gemma":[0.00047392354,0.00007925216,0.000089090616,0.0005392276,0.00009235352,0.000046268728,0.000070676295,0.00018426639,8.606301e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16127144,0.005832577,0.52977675,0.000020488058,0.02725873,0.0003245379,0.010949467,0.008912057,0.006952492,0.00000832244,0.00089729996,0.24779584],"study_design_scores_gemma":[0.15564106,0.053423423,0.7371771,0.0005496392,0.039878417,0.000623462,0.0036682996,0.0008723104,0.005343643,0.0003722209,0.0019027244,0.00054772536],"about_ca_topic_score_codex":0.0014337421,"about_ca_topic_score_gemma":0.00094275863,"teacher_disagreement_score":0.24724811,"about_ca_system_score_codex":0.00009329552,"about_ca_system_score_gemma":0.000114313705,"threshold_uncertainty_score":0.3231809},"labels":[],"label_agreement":null},{"id":"W4309315772","doi":"10.25251/skin.6.6.5","title":"A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients with High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Internal medicine; Oncology; Risk assessment; Prospective cohort study; Population; Incidence (geometry); Personalized medicine; Intensive care medicine; Bioinformatics; Environmental health","score_opus":0.027628696026849586,"score_gpt":0.31933419288452153,"score_spread":0.29170549685767194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309315772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98694396,0.0020316422,0.00026492108,0.0017672213,0.0018262332,0.0064811534,0.00021806482,0.000043244745,0.00042357243],"genre_scores_gemma":[0.99548304,0.00061813055,0.0014568688,0.00078571995,0.0010045825,0.00019849492,0.000034522083,0.00011316923,0.00030544415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918867,0.0014560544,0.0024528804,0.0007599431,0.0026024054,0.0008420607],"domain_scores_gemma":[0.98962224,0.005224824,0.0024822683,0.0012491976,0.00089370075,0.0005278014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0047751935,0.00066534145,0.0017344726,0.00021746338,0.0010971143,0.000031399013,0.0010570437,0.00014525255,0.00027334003],"category_scores_gemma":[0.0017831443,0.00031208713,0.00040022764,0.00049799006,0.0010802279,0.000091699585,0.0006138242,0.0021738352,0.0000062233344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018882623,0.009311493,0.94332755,0.00016276879,0.0006997507,0.0020831157,0.002439822,0.000029869974,0.000025148673,6.629384e-7,0.019750286,0.003286925],"study_design_scores_gemma":[0.039366923,0.048108846,0.8879142,0.00032611305,0.0037331516,0.0055452758,0.011972959,0.00020670742,0.00055043126,0.000065644344,0.0018052188,0.00040456516],"about_ca_topic_score_codex":0.00022497217,"about_ca_topic_score_gemma":0.00017586764,"teacher_disagreement_score":0.05541337,"about_ca_system_score_codex":0.00042353288,"about_ca_system_score_gemma":0.00041611228,"threshold_uncertainty_score":0.9999331},"labels":[],"label_agreement":null},{"id":"W4309316023","doi":"10.25251/skin.6.supp.67","title":"Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Pooled analysis; Psoriasis; Clinical trial; Medicine; Dermatology; Internal medicine; Meta-analysis","score_opus":0.05999239470806655,"score_gpt":0.3657157579674115,"score_spread":0.30572336325934496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309316023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921739,0.005604554,0.00010484885,0.00033901408,0.00064193184,0.0003158437,0.00077708875,0.0000050901153,0.00003769553],"genre_scores_gemma":[0.9977575,0.0012024199,0.00010060661,0.00013506273,0.00011870045,0.0000020998568,0.00059940264,0.000014158647,0.000070082024],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942977,0.0034581348,0.001589687,0.00025017827,0.0002050468,0.00019927333],"domain_scores_gemma":[0.99376404,0.0040694666,0.0014537426,0.00056621665,0.000108772256,0.000037740472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003876375,0.00019178497,0.0015844628,0.00026333364,0.00013146333,0.000004561403,0.0005600238,0.00008606263,0.0007855361],"category_scores_gemma":[0.0008989283,0.00010656876,0.00013820881,0.00051914324,0.00027331954,0.00007666419,0.00017874615,0.00044756426,0.00000274762],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43663695,0.008690389,0.04642828,0.000021495742,0.09413091,0.0012750438,0.024146868,0.0052742576,0.0036114538,0.00006953206,0.007939227,0.37177557],"study_design_scores_gemma":[0.49356747,0.039070316,0.27135062,0.000795167,0.16580237,0.001704159,0.0106188925,0.0014970984,0.0015829914,0.0015803602,0.011158049,0.0012725078],"about_ca_topic_score_codex":0.00033641208,"about_ca_topic_score_gemma":0.000098215925,"teacher_disagreement_score":0.37050307,"about_ca_system_score_codex":0.000046859175,"about_ca_system_score_gemma":0.00010944539,"threshold_uncertainty_score":0.8601069},"labels":[],"label_agreement":null},{"id":"W4309316727","doi":"10.25251/skin.6.supp.52","title":"Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Innovaderm (Canada)","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Phase (matter); Dermatology; Surgery","score_opus":0.0751774596558274,"score_gpt":0.3329815334567032,"score_spread":0.25780407380087583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309316727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98651165,0.00084252446,0.00006061331,0.011254849,0.0000835024,0.00074841914,0.00037269946,0.0000036734605,0.00012207945],"genre_scores_gemma":[0.9990505,0.00018745732,0.00018479196,0.00017406548,0.0002371554,0.000044450226,0.000017183602,0.0000017972254,0.000102575286],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981669,0.00018127704,0.0009101264,0.00013693658,0.00043374358,0.00017096913],"domain_scores_gemma":[0.9960637,0.002882154,0.00068236707,0.00009162643,0.00013686744,0.00014324754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017206664,0.00015373033,0.0008625031,0.000053104348,0.000110362795,0.0000036023957,0.0003921889,0.00003540592,0.00013655759],"category_scores_gemma":[0.00088010996,0.000050158087,0.00011072304,0.00032746364,0.00008245867,0.000027010456,0.000044448858,0.00011656853,1.7966045e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010602204,0.0012097624,0.006448858,0.000060472397,0.00029186148,0.000083050516,0.003277448,0.0015257364,0.8966735,0.00005615271,0.004120265,0.07565068],"study_design_scores_gemma":[0.04523985,0.16958551,0.05886089,0.002683744,0.0041662473,0.02025983,0.044219315,0.0006104766,0.5292268,0.020046689,0.1032853,0.0018153533],"about_ca_topic_score_codex":0.00057809276,"about_ca_topic_score_gemma":0.00044887981,"teacher_disagreement_score":0.36744672,"about_ca_system_score_codex":0.00009980202,"about_ca_system_score_gemma":0.00004594482,"threshold_uncertainty_score":0.20453875},"labels":[],"label_agreement":null},{"id":"W4309317324","doi":"10.25251/skin.6.supp.74","title":"Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Dermatology","score_opus":0.007148115195066833,"score_gpt":0.25207674052890033,"score_spread":0.2449286253338335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964053,0.0010136543,0.000040817285,0.0017135387,0.00012464642,0.0005138373,0.000023695624,0.0000030162255,0.00016148899],"genre_scores_gemma":[0.99926466,0.0002805661,0.000054241682,0.0002530096,0.000055615994,0.0000055646483,0.0000054841266,0.000013278107,0.00006761087],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99829924,0.00020927878,0.0007339897,0.00010423131,0.00048991194,0.00016332876],"domain_scores_gemma":[0.9987417,0.000410323,0.00037595193,0.00020241381,0.00011050931,0.00015908989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018809135,0.00014711462,0.0008382209,0.0002473831,0.00004292815,0.0000011209154,0.00014462684,0.000027944647,0.00015994538],"category_scores_gemma":[0.00012286454,0.00008607861,0.00006578555,0.00022200627,0.00017191596,0.000021579353,0.000041838193,0.00019118797,3.5798905e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3028964,0.0063312254,0.23713157,0.0018726409,0.003276985,0.016866302,0.24873763,0.014597864,0.0052841087,0.0005341413,0.005299454,0.15717165],"study_design_scores_gemma":[0.06471424,0.023916325,0.8262343,0.004556753,0.0018494922,0.05980583,0.009785536,0.0003565813,0.0068646655,0.0006100103,0.000947703,0.00035860253],"about_ca_topic_score_codex":0.00011921793,"about_ca_topic_score_gemma":0.00014850376,"teacher_disagreement_score":0.5891027,"about_ca_system_score_codex":0.00008887542,"about_ca_system_score_gemma":0.00012543473,"threshold_uncertainty_score":0.35101837},"labels":[],"label_agreement":null},{"id":"W4309317622","doi":"10.25251/skin.6.supp.66","title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Plaque psoriasis; Clinical trial; Pooled analysis; Psoriasis; Internal medicine; Dermatology; Meta-analysis","score_opus":0.0520842969948615,"score_gpt":0.34155571863602985,"score_spread":0.28947142164116835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961836,0.0012236913,0.00006861441,0.00041157324,0.0003830167,0.0004953457,0.001220112,0.0000022290046,0.000011857093],"genre_scores_gemma":[0.999023,0.00042165213,0.00008357816,0.00007965424,0.000042688644,0.000004930433,0.00028456133,0.0000108133345,0.00004908949],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962757,0.001654257,0.0015223384,0.00022430802,0.00015093907,0.00017242643],"domain_scores_gemma":[0.99643683,0.0021228513,0.000820723,0.00048389478,0.00008068474,0.000054998243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026068897,0.00016812932,0.0015845819,0.00053991046,0.00004823912,0.0000022365386,0.0003995809,0.00008038556,0.0004012007],"category_scores_gemma":[0.0005276514,0.000096840675,0.000109024666,0.0006255794,0.00008753959,0.000037026628,0.00013257223,0.00020047564,0.0000016262418],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36047593,0.0042577446,0.17557369,0.000016148548,0.032901224,0.00049808976,0.017459705,0.008910816,0.0037763126,0.000014721262,0.0013534208,0.39476222],"study_design_scores_gemma":[0.22481945,0.07463846,0.6283895,0.00082230766,0.053445935,0.00070163887,0.008557209,0.0007836918,0.002378857,0.00047042864,0.004139927,0.00085258327],"about_ca_topic_score_codex":0.001052433,"about_ca_topic_score_gemma":0.002229926,"teacher_disagreement_score":0.4528158,"about_ca_system_score_codex":0.00012984156,"about_ca_system_score_gemma":0.00014895311,"threshold_uncertainty_score":0.43928662},"labels":[],"label_agreement":null},{"id":"W4309317789","doi":"10.25251/skin.6.supp.70","title":"Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Secukinumab; Plaque psoriasis; Post-hoc analysis; Medicine; Post hoc; Psoriasis; Dermatology; Physical therapy; Internal medicine","score_opus":0.015508266964146407,"score_gpt":0.2422494022651389,"score_spread":0.22674113530099252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98869914,0.0016198726,0.000008924415,0.005709999,0.0018448912,0.0008086045,0.0011995432,0.000009992086,0.000099011944],"genre_scores_gemma":[0.99802417,0.0002613158,0.00008083895,0.00065212656,0.00020307538,0.00001373625,0.00014839685,0.000030935294,0.0005854056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964428,0.001615003,0.0009550958,0.0002586472,0.00034410952,0.00038432988],"domain_scores_gemma":[0.9957498,0.0024964677,0.00089248526,0.0005124837,0.00029656582,0.000052228017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013812331,0.0002809059,0.00077697175,0.00014212911,0.00031350338,0.000006884281,0.0005873544,0.00011818132,0.000414063],"category_scores_gemma":[0.00084814476,0.00014987976,0.00012587375,0.00032392528,0.00021602988,0.00007026169,0.00014150952,0.0005176961,0.00001443889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9668945,0.0006701606,0.000039801173,0.0000032719188,0.0010001439,0.0003754385,0.014845729,0.00042421598,0.003425969,0.000011616296,0.008785756,0.0035234012],"study_design_scores_gemma":[0.8385379,0.096738555,0.002522148,0.00068217266,0.0020611193,0.0022255236,0.015282777,0.000010511316,0.0066269757,0.00018778778,0.0345204,0.00060414645],"about_ca_topic_score_codex":0.00044358772,"about_ca_topic_score_gemma":0.0002262329,"teacher_disagreement_score":0.12835662,"about_ca_system_score_codex":0.00036015842,"about_ca_system_score_gemma":0.00026601387,"threshold_uncertainty_score":0.611192},"labels":[],"label_agreement":null},{"id":"W4309317883","doi":"10.25251/skin.6.supp.57","title":"Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"","keywords":"Intertriginous; Dermis; Tolerability; Psoriasis; Dermatology; Roflumilast; Medicine; Plaque psoriasis; Discontinuation; Sex organ; Surgery; Internal medicine; Pathology; Adverse effect; Biology; COPD","score_opus":0.023313140750098885,"score_gpt":0.284818307337959,"score_spread":0.2615051665878601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043334,0.0027495718,0.000017137017,0.0045708786,0.00020903948,0.0016876644,0.00023661062,0.000012031178,0.00008375155],"genre_scores_gemma":[0.99849355,0.0005041402,0.000019831597,0.00054915826,0.00024916834,0.000016855205,0.000059371,0.000035944377,0.000071992785],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952845,0.0010002374,0.0018795544,0.00030507584,0.0012227433,0.00030786495],"domain_scores_gemma":[0.9923852,0.005008506,0.001551421,0.000607576,0.00023879403,0.00020850741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025127088,0.00034379124,0.0014095899,0.00024811848,0.00020728384,0.000014348817,0.0003535443,0.00006498067,0.00044874655],"category_scores_gemma":[0.004383297,0.00015590839,0.00010705772,0.000311763,0.0005332282,0.00005441065,0.00015540108,0.0007405888,6.719532e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8034833,0.024897577,0.031979565,0.0005137176,0.005044993,0.0041653537,0.03897624,0.0015542156,0.0047438303,0.000036852627,0.011952555,0.072651796],"study_design_scores_gemma":[0.4076375,0.21091403,0.29660776,0.009834422,0.0109105995,0.008529305,0.03521722,0.0010041319,0.00757862,0.00071717886,0.009719542,0.0013296637],"about_ca_topic_score_codex":0.00038859327,"about_ca_topic_score_gemma":0.00012385279,"teacher_disagreement_score":0.3958458,"about_ca_system_score_codex":0.00033910153,"about_ca_system_score_gemma":0.00058068556,"threshold_uncertainty_score":0.6357759},"labels":[],"label_agreement":null},{"id":"W4309317888","doi":"10.25251/skin.6.supp.45","title":"Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain; Hôtel-Dieu de Québec","funders":"XBiotech; Bristol-Myers Squibb","keywords":"Apremilast; Plaque psoriasis; Placebo; Medicine; Psoriasis; Tyrosine-kinase inhibitor; Body surface area; Internal medicine; Pharmacology; Dermatology; Pathology; Psoriatic arthritis; Alternative medicine","score_opus":0.03984404570829199,"score_gpt":0.3064452367381327,"score_spread":0.2666011910298407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077195,0.00645587,0.000025176518,0.0014500371,0.0004056958,0.0006476088,0.00017442893,0.0000061418195,0.000063102205],"genre_scores_gemma":[0.99812776,0.0012986085,0.000050992858,0.00027700578,0.00006730104,0.000019402294,0.00007456063,0.000016369831,0.00006800497],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995013,0.0030747654,0.0010903685,0.0002676285,0.00023197896,0.00032226025],"domain_scores_gemma":[0.99659663,0.0022333404,0.00067969435,0.0002825589,0.00013924028,0.00006850524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046238666,0.00029594867,0.0012368337,0.0005886096,0.00023486429,0.0000135894015,0.00032816335,0.00011541627,0.0001557864],"category_scores_gemma":[0.000481857,0.00017170032,0.0001131345,0.0010394608,0.00019101809,0.000085494445,0.00009422665,0.00049206323,6.7699875e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35061324,0.005118311,0.01018104,0.00010838054,0.014437792,0.0020821667,0.11605135,0.032135885,0.4357758,0.00022467844,0.008770233,0.024501145],"study_design_scores_gemma":[0.3672185,0.10288684,0.0138748,0.001556657,0.05000778,0.019333545,0.24015199,0.0039497497,0.18275486,0.0018910888,0.013525844,0.0028483598],"about_ca_topic_score_codex":0.00052597723,"about_ca_topic_score_gemma":0.0013677629,"teacher_disagreement_score":0.2530209,"about_ca_system_score_codex":0.0001500522,"about_ca_system_score_gemma":0.000121704805,"threshold_uncertainty_score":0.70017356},"labels":[],"label_agreement":null},{"id":"W4309317896","doi":"10.25251/skin.6.supp.50","title":"Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Insect and Pesticide Research","field":"Agricultural and Biological Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Response analysis; Psychology; Biology","score_opus":0.008707033818594471,"score_gpt":0.25483260660608825,"score_spread":0.24612557278749378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824346,0.0012581308,0.00014329073,0.0100101475,0.000044805445,0.00021204556,0.000035488614,0.0000058774863,0.000046775607],"genre_scores_gemma":[0.9989705,0.0000648789,0.000020731712,0.00042414104,0.00011057664,0.000007083637,0.000011607309,0.0000014065015,0.0003890888],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968121,0.0014589228,0.00044151116,0.00012698592,0.0009320028,0.00022844785],"domain_scores_gemma":[0.9942586,0.004929632,0.0003335373,0.00010087854,0.00022088588,0.00015646312],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029972051,0.00012128599,0.00037088804,0.00010111427,0.00032090044,0.0000074925147,0.0005152955,0.000047767007,0.0014677813],"category_scores_gemma":[0.0005065906,0.00004131904,0.00013926998,0.0012519264,0.00019995029,0.000024692023,0.00012394636,0.0002804716,0.000007512625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013197268,0.000073036514,0.0041821627,0.000007171237,0.00015316418,0.00008340507,0.0010687573,0.0008095092,0.965151,0.0000030271713,0.0051365574,0.010134943],"study_design_scores_gemma":[0.0024606162,0.07817789,0.21454151,0.00023184864,0.002850362,0.009565554,0.012106822,0.004464967,0.61776567,0.001551991,0.055374667,0.00090812804],"about_ca_topic_score_codex":0.00014895223,"about_ca_topic_score_gemma":0.00010478926,"teacher_disagreement_score":0.34738535,"about_ca_system_score_codex":0.00011320819,"about_ca_system_score_gemma":0.000031805255,"threshold_uncertainty_score":0.999445},"labels":[],"label_agreement":null},{"id":"W4309318166","doi":"10.25251/skin.6.supp.63","title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Medicine; Clinical trial; Psoriasis; Internal medicine; Allosteric regulation; Dermatology; Oncology","score_opus":0.12771938908151773,"score_gpt":0.443138186868686,"score_spread":0.3154187977871683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309318166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797747,0.00063685514,0.0001402072,0.017342202,0.00081111665,0.0011246984,0.00008628717,0.000016966747,0.00006695044],"genre_scores_gemma":[0.9949043,0.0005229941,0.00031773382,0.0032641036,0.00079436915,0.000021152728,0.00003716306,0.000038311882,0.000099911704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9890253,0.005633827,0.0038164956,0.0003715267,0.0008101878,0.00034266856],"domain_scores_gemma":[0.9869349,0.010387123,0.0014831824,0.00044422763,0.00035926138,0.00039128063],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013074091,0.00032632527,0.0016825091,0.0005683389,0.00032637658,0.000040541207,0.00024800425,0.00014795216,0.0001253542],"category_scores_gemma":[0.012324598,0.00018318492,0.00022078097,0.0007139943,0.0002800847,0.0001618374,0.00012180906,0.0020082344,0.0000012933508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1441282,0.010132447,0.5881659,0.000115134826,0.002649151,0.012537896,0.037447732,0.0012314055,0.010223286,0.00012606097,0.033539966,0.15970287],"study_design_scores_gemma":[0.12777302,0.15703495,0.45399877,0.0033538435,0.009321173,0.14128463,0.05200377,0.0064159576,0.0013133714,0.003039844,0.042672332,0.0017883361],"about_ca_topic_score_codex":0.00026273576,"about_ca_topic_score_gemma":0.00023503863,"teacher_disagreement_score":0.15791452,"about_ca_system_score_codex":0.00013221055,"about_ca_system_score_gemma":0.00043355353,"threshold_uncertainty_score":0.995995},"labels":[],"label_agreement":null},{"id":"W4309319190","doi":"10.25251/skin.6.supp.65","title":"Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Plaque psoriasis; Open label; Psoriasis; Medicine; Extension (predicate logic); Internal medicine; Dermatology; Randomized controlled trial; Computer science","score_opus":0.02902341705181288,"score_gpt":0.2578144856618625,"score_spread":0.2287910686100496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309319190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893557,0.0011810854,0.00002375372,0.0066938256,0.0011491474,0.0010036036,0.0004435516,0.000006980243,0.00014237472],"genre_scores_gemma":[0.99605125,0.00018555958,0.00011198763,0.00088390097,0.00010889575,0.000015748252,0.0000750954,0.000031374715,0.0025361744],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583346,0.002235568,0.00095066824,0.00029446444,0.00034113202,0.00034471956],"domain_scores_gemma":[0.9953974,0.002783674,0.00091118057,0.0006468034,0.00021851055,0.000042430645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022690573,0.0002599645,0.00076438393,0.00014407751,0.0003758663,0.000010211057,0.0009878527,0.000117992844,0.00032121572],"category_scores_gemma":[0.00078005594,0.0001291839,0.00007147555,0.00043707044,0.00024006773,0.00009267813,0.0003582316,0.00050733367,0.000010046971],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95362437,0.0005862732,0.00018643864,0.0000021447986,0.00048206773,0.00039279545,0.007996605,0.00039853918,0.0038697014,0.000021877606,0.027912544,0.004526641],"study_design_scores_gemma":[0.7719385,0.06323104,0.058361452,0.001663389,0.0019923383,0.005819486,0.0058721346,0.00002952478,0.011243013,0.003196271,0.075705,0.00094786787],"about_ca_topic_score_codex":0.00093200407,"about_ca_topic_score_gemma":0.0007388687,"teacher_disagreement_score":0.1816859,"about_ca_system_score_codex":0.0003342432,"about_ca_system_score_gemma":0.00022964725,"threshold_uncertainty_score":0.52679664},"labels":[],"label_agreement":null},{"id":"W4309319238","doi":"10.25251/skin.6.supp.51","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Pooled Efficacy from Three Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"LEO Pharma; EMD Serono; Bausch Health; Sanofi Genzyme; Incyte; Castle Biosciences; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Helsinn; Kiniksa Pharmaceuticals; Celgene; Sanofi; Amgen; Helsinn Therapeutics; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Plaque psoriasis; Medicine; Psoriasis; Dermatology; Internal medicine","score_opus":0.0526612199441704,"score_gpt":0.3150997554401381,"score_spread":0.2624385354959677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309319238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97044575,0.0022561094,0.00038440447,0.024902275,0.00056291814,0.0007103459,0.00038429652,0.00002349818,0.00033041544],"genre_scores_gemma":[0.9948594,0.00019827751,0.00010503125,0.00071230973,0.0037968198,0.000037819416,0.00012570898,0.000002733059,0.00016192268],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760175,0.0003128278,0.00094686635,0.00017789703,0.0007063467,0.00025432525],"domain_scores_gemma":[0.9908289,0.007581535,0.0011244135,0.0001323647,0.0001617883,0.00017099723],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002653851,0.00018296322,0.00067647744,0.000021181015,0.00047291795,0.000013257528,0.0009240474,0.000054894128,0.0013486643],"category_scores_gemma":[0.0017719207,0.00005847784,0.00019057986,0.00029284085,0.00013905048,0.00004467768,0.00007339987,0.00044224778,0.0000037911373],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046159383,0.0005562228,0.000022710046,0.0000069620783,0.00022843906,0.0001038097,0.000566561,0.00016133612,0.87193954,0.0000498501,0.056156624,0.06559203],"study_design_scores_gemma":[0.025673967,0.032189004,0.0018935683,0.0009076759,0.0050790748,0.020380026,0.018032156,0.0014472536,0.08959514,0.046006206,0.7576164,0.0011795164],"about_ca_topic_score_codex":0.00012279818,"about_ca_topic_score_gemma":0.00006692909,"teacher_disagreement_score":0.7823444,"about_ca_system_score_codex":0.00007653807,"about_ca_system_score_gemma":0.00005026087,"threshold_uncertainty_score":0.99956423},"labels":[],"label_agreement":null},{"id":"W4309681771","doi":"10.25251/skin.6.supp.68","title":"Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Open label; Plaque psoriasis; Medicine; Term (time); Randomized controlled trial; Psoriasis; Extension (predicate logic); Internal medicine; Dermatology; Computer science; Physics","score_opus":0.01666533154652453,"score_gpt":0.24956503916923573,"score_spread":0.2328997076227112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309681771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97513086,0.007907648,0.000028140017,0.01123293,0.001029036,0.004460794,0.00012385336,0.0000071005134,0.000079669786],"genre_scores_gemma":[0.99655074,0.0016974363,0.00003050354,0.0011212825,0.00017573989,0.00005554478,0.00007316717,0.000023011877,0.00027256864],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99493784,0.0032459514,0.0010158197,0.0002691983,0.00026142216,0.00026975133],"domain_scores_gemma":[0.99090034,0.007698048,0.0008253155,0.00040457436,0.00013067492,0.0000410245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034924622,0.00029381353,0.0016694674,0.00007386219,0.00058933167,0.000033162014,0.0005642364,0.000111486275,0.00011170787],"category_scores_gemma":[0.0008361199,0.00010858305,0.00009249958,0.00017989897,0.000517386,0.00007934593,0.00023630435,0.0005724932,0.0000015230195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9846197,0.00032245764,0.0001318704,0.0000020064012,0.001672179,0.00015747601,0.0068565137,0.00014133452,0.000079543686,0.00004690743,0.0014129351,0.0045570857],"study_design_scores_gemma":[0.9883619,0.0024730535,0.0045301463,0.00018722824,0.001922901,0.001074063,0.00043569264,0.000017147788,0.000029556168,0.00036956748,0.00045032086,0.00014844048],"about_ca_topic_score_codex":0.000542568,"about_ca_topic_score_gemma":0.00038867394,"teacher_disagreement_score":0.021419916,"about_ca_system_score_codex":0.00005938215,"about_ca_system_score_gemma":0.00011172337,"threshold_uncertainty_score":0.45327222},"labels":[],"label_agreement":null},{"id":"W4324057396","doi":"10.25251/skin.7.2.5","title":"Efficacy and Safety of Tralokinumab in US Adults with Moderate-to-Severe Atopic Dermatitis: A Post-hoc Analysis of ECZTRA3","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Galderma; Ortho Dermatologics; Valeant Pharmaceuticals International; Celgene; GlaxoSmithKline; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Post-hoc analysis; Placebo; Eczema Area and Severity Index; Medicine; Atopic dermatitis; Population; Randomized controlled trial; Adverse effect; Internal medicine; Dermatology; Alternative medicine","score_opus":0.006425292969851087,"score_gpt":0.2508883681065757,"score_spread":0.24446307513672463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325854,0.0017467845,0.000042233893,0.004242967,0.000058618556,0.00030486836,0.000021457283,0.000010245797,0.00031430373],"genre_scores_gemma":[0.99792033,0.0012087554,0.00008219293,0.0006401865,0.000047318303,0.0000017156615,0.000014993107,0.000014613932,0.00006988812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808836,0.0001693125,0.0008900244,0.00012667854,0.00050209026,0.00022351861],"domain_scores_gemma":[0.9980761,0.0007176592,0.00042816004,0.00026430626,0.00032578647,0.00018801201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004051342,0.00017053202,0.0010736578,0.00082288036,0.000043744385,0.0000026442501,0.00017469493,0.00007238769,0.00011501339],"category_scores_gemma":[0.00037960245,0.00009403037,0.0001068414,0.0013167269,0.00029542984,0.00004883132,0.000027426177,0.0002659843,0.0000020495463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.250001,0.002499541,0.45845145,0.0041583725,0.021316558,0.046311736,0.10035541,0.053550206,0.0031118395,0.0002873499,0.015854128,0.044102404],"study_design_scores_gemma":[0.015811529,0.004384569,0.9308268,0.004067324,0.006358119,0.02983369,0.0047426685,0.0027813308,0.0005613684,0.00018358493,0.00024288897,0.00020612046],"about_ca_topic_score_codex":0.000079110076,"about_ca_topic_score_gemma":0.00024545885,"teacher_disagreement_score":0.47237536,"about_ca_system_score_codex":0.000030576295,"about_ca_system_score_gemma":0.00014704818,"threshold_uncertainty_score":0.38344473},"labels":[],"label_agreement":null},{"id":"W4324057425","doi":"10.25251/skin.7.supp.154","title":"Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Atopic dermatitis; Medicine; Baseline (sea); Term (time); Internal medicine; Dermatology; Pediatrics","score_opus":0.007331924977722276,"score_gpt":0.25178102304082506,"score_spread":0.24444909806310278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935068,0.0008951896,0.00010166557,0.004748015,0.00010255289,0.00042459802,0.00007104507,0.000015414349,0.00013472993],"genre_scores_gemma":[0.99792653,0.00066313054,0.000038964354,0.0010800839,0.000080907994,0.0000023656962,0.000068327674,0.000020195734,0.00011951956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818504,0.00019234158,0.0006913709,0.00013808448,0.00054728036,0.00024586282],"domain_scores_gemma":[0.9983437,0.00057968334,0.00020960192,0.00024323123,0.00023822846,0.000385572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003792799,0.00018798631,0.00062192517,0.00020343359,0.00007420489,0.000004315376,0.00015439642,0.00005458592,0.000096213815],"category_scores_gemma":[0.0005791156,0.00010722983,0.000047679223,0.00034386697,0.00026432276,0.00006504107,0.0000457706,0.0002931482,0.000004201921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01372131,0.0005488436,0.92362654,0.00050290325,0.00026321458,0.0031813914,0.0014265848,0.0003306719,0.000052799154,0.0000088986935,0.047002096,0.00933473],"study_design_scores_gemma":[0.006593462,0.00059835345,0.9869627,0.0015942148,0.00042160784,0.002308099,0.00020684968,0.00024833943,0.00005911772,0.000114297596,0.00076168973,0.0001313121],"about_ca_topic_score_codex":0.0000078600615,"about_ca_topic_score_gemma":0.000009077066,"teacher_disagreement_score":0.0633361,"about_ca_system_score_codex":0.000036235655,"about_ca_system_score_gemma":0.000101192156,"threshold_uncertainty_score":0.43727055},"labels":[],"label_agreement":null},{"id":"W4324057437","doi":"10.25251/skin.7.supp.117","title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Medicine; Placebo; Apremilast; Psoriasis; Internal medicine; Plaque psoriasis; Tolerability; Randomized controlled trial; Clinical trial; Gastroenterology; Dermatology; Adverse effect; Psoriatic arthritis; Pathology","score_opus":0.030488021619105438,"score_gpt":0.3025046343398302,"score_spread":0.27201661272072475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903418,0.0025764315,0.000013028584,0.0044271927,0.0010914343,0.0013167984,0.00007750705,0.000032677617,0.0001231327],"genre_scores_gemma":[0.9964483,0.0015011514,0.00003391101,0.0005402934,0.00043449676,0.00005505331,0.00013501421,0.000040530595,0.00081125647],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961737,0.0017022875,0.0009957314,0.00031703786,0.00021180177,0.0005994383],"domain_scores_gemma":[0.9978109,0.001173486,0.00040005115,0.00040068247,0.000118413016,0.00009648483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014140436,0.00043321657,0.0008778998,0.0004629414,0.00023132413,0.000024825187,0.00053119945,0.0002324771,0.00012262347],"category_scores_gemma":[0.0003113875,0.00022384408,0.00014117888,0.0009842534,0.00016003495,0.000117230586,0.000042739415,0.0004588077,0.00007506144],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42043638,0.011945726,0.00029659047,0.000041300053,0.0015591837,0.006010541,0.051947244,0.00094027835,0.23025727,0.000042849526,0.047457315,0.22906531],"study_design_scores_gemma":[0.6298103,0.1344578,0.0020982348,0.0012581454,0.0029683423,0.027177233,0.016939737,0.00015783978,0.10398148,0.0007917529,0.07879012,0.0015690344],"about_ca_topic_score_codex":0.00039075024,"about_ca_topic_score_gemma":0.0005976993,"teacher_disagreement_score":0.22749627,"about_ca_system_score_codex":0.00024447413,"about_ca_system_score_gemma":0.00023560128,"threshold_uncertainty_score":0.91280967},"labels":[],"label_agreement":null},{"id":"W4324057454","doi":"10.25251/skin.7.supp.172","title":"Intralesional Treatment of Basal Cell Carcinoma in a Genetically Inducible Mouse Model","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada); Feldan (Canada)","funders":"University of Toronto","keywords":"GLI1; PTCH1; Basal cell carcinoma; Vismodegib; Medicine; Cancer research; Gene knockdown; Pathology; Nevoid basal-cell carcinoma syndrome; Hedgehog signaling pathway; Biology; Basal cell; Cell culture; Gene","score_opus":0.02518759387727277,"score_gpt":0.27093723948518805,"score_spread":0.2457496456079153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966812,0.0017314745,0.00022424184,0.00081685284,0.000108101456,0.00010913152,0.000010008249,0.000002502812,0.00031645884],"genre_scores_gemma":[0.9969127,0.001702436,0.00028070036,0.00010492851,0.0003139589,0.0000022470892,0.000006343739,0.000018432866,0.0006582376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878484,0.0001008885,0.0004896143,0.00012035183,0.00028893302,0.0002153708],"domain_scores_gemma":[0.99925214,0.000103649465,0.0002021826,0.0002182881,0.0001450474,0.000078690086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041695006,0.00014156326,0.00030801166,0.00013529418,0.00003613051,0.0000020224356,0.00021862687,0.00008269575,0.000012097669],"category_scores_gemma":[0.0001471107,0.00008240899,0.000079670725,0.00013644304,0.00018730744,0.00000153078,0.00005048384,0.00010389191,0.0000028486738],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044248241,0.00015454568,0.0014351506,0.000025250343,0.00005906077,0.00016982945,0.0018160786,0.018440813,0.9742046,0.0000062418753,0.002063273,0.0011826747],"study_design_scores_gemma":[0.0022072038,0.005480325,0.0016437975,0.00007174838,0.000113004826,0.0005317771,0.001005354,0.0035828357,0.98408604,0.0003930688,0.0007294356,0.00015541488],"about_ca_topic_score_codex":0.000026017122,"about_ca_topic_score_gemma":0.000036276673,"teacher_disagreement_score":0.014857978,"about_ca_system_score_codex":0.000033932065,"about_ca_system_score_gemma":0.00018825887,"threshold_uncertainty_score":0.3360541},"labels":[],"label_agreement":null},{"id":"W4324057472","doi":"10.25251/skin.7.supp.132","title":"Brodalumab: 4-Year US Pharmacovigilance Report","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Pharmacovigilance; Medicine; Pharmacology; Drug","score_opus":0.22720433651924277,"score_gpt":0.44317975554895983,"score_spread":0.21597541902971706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73794174,0.006465229,0.0015397579,0.22615659,0.0064992076,0.0006340197,0.000063657426,0.00010357357,0.02059621],"genre_scores_gemma":[0.97285944,0.0027156873,0.00039314208,0.013262449,0.0041389856,0.000007138133,0.000013191594,0.000057256155,0.006552724],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99388194,0.0003608173,0.004831999,0.00022717207,0.00029905053,0.0003990007],"domain_scores_gemma":[0.9923682,0.001990602,0.004715492,0.0005218591,0.00018219673,0.0002216066],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.028434416,0.00017866836,0.0010682546,0.00042042864,0.00019282798,0.00002202175,0.000573945,0.00008657924,0.0009502838],"category_scores_gemma":[0.0076781,0.00014216748,0.00013846136,0.00047819328,0.00018567962,0.00019486647,0.000049843275,0.00041540206,0.0016439201],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018798145,0.00006984106,0.029562792,0.00027353896,0.00034654397,0.0012673512,0.0054602777,0.0021290064,0.00013514912,0.007483305,0.95248,0.000604188],"study_design_scores_gemma":[0.0024337934,0.00063552207,0.012421902,0.00049686723,0.00009073638,0.022512097,0.003309634,0.00269095,0.00006369724,0.029516643,0.9253944,0.00043372126],"about_ca_topic_score_codex":0.00022780032,"about_ca_topic_score_gemma":0.000023063809,"teacher_disagreement_score":0.23491769,"about_ca_system_score_codex":0.00027848015,"about_ca_system_score_gemma":0.00016727451,"threshold_uncertainty_score":0.999963},"labels":[],"label_agreement":null},{"id":"W4324057475","doi":"10.25251/skin.7.supp.109","title":"Efficacy and Safety Results of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From SPROUT, a Phase 3, Randomized, Controlled Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"Galderma; Celgene; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Pfizer; Amgen","keywords":"Apremilast; Plaque psoriasis; Medicine; Randomized controlled trial; Psoriasis; Dermatology; Physical therapy; Internal medicine; Psoriatic arthritis","score_opus":0.010800901179962612,"score_gpt":0.24335464792855624,"score_spread":0.23255374674859364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944587,0.0014218577,0.000026953123,0.0007136359,0.00057906023,0.0022933795,0.0002722178,0.000016704249,0.00021753258],"genre_scores_gemma":[0.997888,0.0013101188,0.000026474445,0.000053530242,0.00020873209,0.000018300416,0.00010336682,0.000022499467,0.00036894743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957234,0.0015895889,0.0018479575,0.0002760559,0.0002453207,0.00031767067],"domain_scores_gemma":[0.99182063,0.0062928954,0.0012141395,0.00031726528,0.00027783462,0.00007722182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002990355,0.00032363107,0.0020310746,0.00047303294,0.00012122504,0.0000076086862,0.00028340722,0.000134312,0.000026579786],"category_scores_gemma":[0.002292912,0.00015598504,0.00012106547,0.00051086064,0.00016398676,0.00005424637,0.000060318594,0.00033838148,0.000013052683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9771059,0.0013855216,0.00082688784,0.000010232152,0.001536276,0.000251505,0.012163868,0.0007178791,0.0003000907,0.0000015736172,0.0012459215,0.00445434],"study_design_scores_gemma":[0.9812711,0.0072955904,0.0052878736,0.00033082292,0.0028789642,0.00024312496,0.0020578238,0.000024684156,0.00025730996,0.00006957666,0.000101222715,0.00018190942],"about_ca_topic_score_codex":0.00024976765,"about_ca_topic_score_gemma":0.00023449554,"teacher_disagreement_score":0.010106045,"about_ca_system_score_codex":0.00005708333,"about_ca_system_score_gemma":0.000099933015,"threshold_uncertainty_score":0.63608855},"labels":[],"label_agreement":null},{"id":"W4324057524","doi":"10.25251/skin.7.supp.142","title":"3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Manchester Biomedical Research Centre; LEO Pharma; European Academy of Dermatology and Venereology; National Institute for Health and Care Research","keywords":"Atopic dermatitis; Medicine; Term (time); Dermatology; Disease; Pediatrics; Internal medicine","score_opus":0.012560566447797432,"score_gpt":0.30044894912074316,"score_spread":0.28788838267294575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98131037,0.0011273456,0.000050706465,0.016431332,0.00018817557,0.000630042,0.000033334712,0.000028650824,0.00020004634],"genre_scores_gemma":[0.99623865,0.0006510615,0.000028037477,0.0023190996,0.00009132576,0.000009889023,0.000014828439,0.000024464563,0.00062266533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757034,0.00026544766,0.0011640893,0.00015601475,0.0005312851,0.0003128514],"domain_scores_gemma":[0.9974966,0.0011993865,0.00043158987,0.000297765,0.0001553592,0.00041930468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039823639,0.00022043248,0.00097278075,0.0002675472,0.000051232248,0.000007345702,0.00023613269,0.000082062455,0.00012474244],"category_scores_gemma":[0.0012292955,0.0001308418,0.00019432466,0.00029982612,0.0002524839,0.000063524305,0.000021550559,0.00026460583,0.000024628582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049065812,0.0008049918,0.9165999,0.0002258275,0.001020347,0.027162634,0.0032443008,0.0005038376,0.00041337986,0.000020106143,0.013126577,0.031971462],"study_design_scores_gemma":[0.014678951,0.0036309492,0.95666444,0.001978244,0.0019090377,0.017052958,0.001102514,0.00052496087,0.00028606178,0.0012783284,0.0006279383,0.0002655975],"about_ca_topic_score_codex":0.000059649807,"about_ca_topic_score_gemma":0.000044568744,"teacher_disagreement_score":0.040064503,"about_ca_system_score_codex":0.000094992996,"about_ca_system_score_gemma":0.00037009534,"threshold_uncertainty_score":0.53355736},"labels":[],"label_agreement":null},{"id":"W4324057567","doi":"10.25251/skin.7.supp.188","title":"Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Concert Pharmaceuticals; Pfizer; Eli Lilly and Company","keywords":"Alopecia areata; Post-hoc analysis; Post hoc; Medicine; Hair growth; Dermatology; Hair loss; Dentistry; Internal medicine; Physiology","score_opus":0.008155090515938535,"score_gpt":0.26552122042382226,"score_spread":0.2573661299078837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990411,0.00012904851,0.00005825463,0.0070367893,0.00012499606,0.0010920557,0.00002253327,0.000017365739,0.0011079744],"genre_scores_gemma":[0.99824464,0.000044177286,0.000035582187,0.0008734325,0.00015014729,0.000005856209,0.000026738666,0.00003839448,0.00058103376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966982,0.00025951926,0.0008769829,0.00021784776,0.0015260435,0.0004214196],"domain_scores_gemma":[0.9973197,0.00040678357,0.00049222336,0.0005969207,0.00089211133,0.0002922726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010058163,0.00028629022,0.001053083,0.0010967179,0.00011031221,0.0000092555665,0.0004558678,0.00005852041,0.00014631146],"category_scores_gemma":[0.0008215304,0.00011883818,0.00014140105,0.0043530534,0.0002680395,0.00006788324,0.00008500648,0.00046496262,0.0000057671928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11636953,0.00908263,0.75562876,0.00024452645,0.009667395,0.007871713,0.06003746,0.0034818312,0.00037813818,0.000061068364,0.023831576,0.013345386],"study_design_scores_gemma":[0.064716175,0.08381235,0.70153064,0.0016931911,0.012763731,0.0012964661,0.13063219,0.00032097087,0.00013449007,0.000107018735,0.0024552993,0.00053750037],"about_ca_topic_score_codex":0.0002406413,"about_ca_topic_score_gemma":0.001859198,"teacher_disagreement_score":0.07472972,"about_ca_system_score_codex":0.000106012434,"about_ca_system_score_gemma":0.00030358447,"threshold_uncertainty_score":0.48460802},"labels":[],"label_agreement":null},{"id":"W4324057575","doi":"10.25251/skin.7.supp.143","title":"Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Manchester Biomedical Research Centre; LEO Pharma; European Academy of Dermatology and Venereology; National Institute for Health and Care Research","keywords":"Atopic dermatitis; Adverse effect; Medicine; Dermatology; Safety profile; Internal medicine","score_opus":0.027101992236513023,"score_gpt":0.2916953761349444,"score_spread":0.26459338389843134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338305,0.00017584725,0.00006128049,0.0041626976,0.00027364193,0.0007814043,0.000031228265,0.000011569234,0.0011193069],"genre_scores_gemma":[0.9986967,0.00016839418,0.00014308564,0.00032218045,0.00017192656,0.000008476823,0.000010382144,0.0000178518,0.0004610085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980558,0.00019361716,0.0009779122,0.00013204751,0.00037818382,0.00026243887],"domain_scores_gemma":[0.99858785,0.00027781914,0.00041093645,0.00022728568,0.0002571306,0.000239002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030326657,0.00020669377,0.00087089936,0.00040779213,0.00005582181,0.0000014489457,0.00017108624,0.00006334172,0.00018036737],"category_scores_gemma":[0.0002831292,0.00011617731,0.00010244061,0.00055594876,0.00016067277,0.00004814455,0.000041796247,0.00019457715,0.000011033352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14578569,0.0041799373,0.3919715,0.0035682637,0.008893116,0.07399142,0.17306527,0.050170787,0.015630318,0.0005510957,0.08842285,0.043769747],"study_design_scores_gemma":[0.075315334,0.036238827,0.48473287,0.043190498,0.006517959,0.21073656,0.08485203,0.0052420488,0.04346244,0.0022496134,0.0059782974,0.0014835375],"about_ca_topic_score_codex":0.00008667795,"about_ca_topic_score_gemma":0.00045175062,"teacher_disagreement_score":0.13674514,"about_ca_system_score_codex":0.00021181461,"about_ca_system_score_gemma":0.00039237854,"threshold_uncertainty_score":0.47375733},"labels":[],"label_agreement":null},{"id":"W4324057607","doi":"10.25251/skin.7.supp.110","title":"Efficacy and Safety of Apremilast in Patients With Genital Psoriasis: Results From the Phase 3, Randomized, Placebo-Controlled, Double-blind DISCREET Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Probity Medical Research; Guenther Dermatology Research Centre","funders":"","keywords":"Apremilast; Psoriasis; Placebo; Double blind; Medicine; Randomized controlled trial; Dermatology; Internal medicine; Alternative medicine; Psoriatic arthritis; Pathology","score_opus":0.015637138701321746,"score_gpt":0.2629802931701529,"score_spread":0.24734315446883118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398226,0.00212751,0.000010890721,0.0007828507,0.00058980717,0.0022000433,0.00010871154,0.000010641018,0.00018728508],"genre_scores_gemma":[0.9988401,0.0005906253,0.000007961251,0.00002903052,0.0001836099,0.000016061895,0.000086926666,0.00001832675,0.00022734223],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968362,0.0012828686,0.0012089193,0.0001870207,0.00022374894,0.00026127492],"domain_scores_gemma":[0.992066,0.006494504,0.0009074122,0.00033765342,0.00015432523,0.000040101197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027127622,0.00026651274,0.0012637379,0.00018821412,0.00016660293,0.00000765534,0.00036320076,0.000107278735,0.00005831091],"category_scores_gemma":[0.00074185606,0.00010350749,0.0001173553,0.0003190206,0.00048744984,0.000053524447,0.000064760236,0.00034848595,0.000009325664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9761477,0.0008253544,0.00179835,0.0000036159927,0.0025992368,0.000110637804,0.010999195,0.00009621784,0.0002893666,0.0000051498887,0.00049967575,0.00662546],"study_design_scores_gemma":[0.9816991,0.003480316,0.006222317,0.00023136595,0.0026538076,0.00022469182,0.004989219,0.0000074173704,0.00020778435,0.000041171465,0.00012997435,0.00011282422],"about_ca_topic_score_codex":0.00021526212,"about_ca_topic_score_gemma":0.0002038531,"teacher_disagreement_score":0.006512636,"about_ca_system_score_codex":0.000028146585,"about_ca_system_score_gemma":0.000058733676,"threshold_uncertainty_score":0.4220913},"labels":[],"label_agreement":null},{"id":"W4324057615","doi":"10.25251/skin.7.supp.144","title":"Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Dermatology; Pediatrics; Demography","score_opus":0.008880852189369267,"score_gpt":0.26553392449584384,"score_spread":0.25665307230647455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996761,0.0005519949,0.00003611947,0.0018861891,0.00011711789,0.00047644577,0.000015507427,0.000005788019,0.00014980375],"genre_scores_gemma":[0.99896526,0.0006534118,0.00004391616,0.00015414933,0.00007204516,0.0000030999663,0.0000059194635,0.0000142498675,0.00008793816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843794,0.00013155991,0.00073617493,0.00010371682,0.00040640155,0.00018419999],"domain_scores_gemma":[0.99864614,0.0005195743,0.0003150017,0.00020173634,0.00013918774,0.00017834845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017902197,0.00015375322,0.00086416764,0.00030827612,0.000024463216,0.0000013668756,0.00012225653,0.000045874487,0.00005298108],"category_scores_gemma":[0.0002002816,0.000085033294,0.00006464752,0.00031724537,0.00019683877,0.000024963974,0.000025712272,0.00013756705,0.0000016339502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20974992,0.0035893742,0.29670978,0.003057395,0.0035751113,0.020367756,0.22931041,0.007341869,0.007188714,0.0004633097,0.008354005,0.21029237],"study_design_scores_gemma":[0.031662345,0.007919177,0.92732716,0.0061323848,0.0009377306,0.015230172,0.0033721374,0.00026940086,0.006296009,0.0004105672,0.00024900745,0.00019391213],"about_ca_topic_score_codex":0.000095444,"about_ca_topic_score_gemma":0.00020791154,"teacher_disagreement_score":0.6306174,"about_ca_system_score_codex":0.000049894174,"about_ca_system_score_gemma":0.00010042942,"threshold_uncertainty_score":0.3467557},"labels":[],"label_agreement":null},{"id":"W4324057622","doi":"10.25251/skin.7.supp.141","title":"Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"LEO Pharma; Galderma; Glenmark Pharmaceuticals; Kiniksa Pharmaceuticals; Eli Lilly and Company","keywords":"Atopic dermatitis; Placebo; Medicine; Randomized controlled trial; Internal medicine; Dermatology; Alternative medicine","score_opus":0.014477368623124837,"score_gpt":0.2926574619221865,"score_spread":0.2781800932990617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915257,0.00210305,0.00012497269,0.0031613747,0.00013211231,0.002717733,0.0000152550565,0.000008474151,0.00021132361],"genre_scores_gemma":[0.9974936,0.0021198236,0.0000303405,0.000121587655,0.00011954506,0.000033479664,0.0000101575815,0.000017548247,0.00005386545],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960625,0.0010277139,0.0020214152,0.00014453375,0.0004868099,0.00025699352],"domain_scores_gemma":[0.9930795,0.005508013,0.00088163954,0.00021718317,0.00013807535,0.00017560287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017590813,0.0002702011,0.003617663,0.00053686026,0.000040482948,0.0000034405632,0.00013445002,0.00009042483,0.00009702768],"category_scores_gemma":[0.0021196182,0.00012156519,0.00021162411,0.0003245785,0.00034877058,0.00004197514,0.000019199582,0.00023674371,0.0000011106414],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9738426,0.0008799302,0.0028523784,0.00023147048,0.0008280195,0.00293944,0.0076123956,0.0005160049,0.00013538214,0.000043146672,0.00020583393,0.0099133495],"study_design_scores_gemma":[0.96578157,0.003407609,0.014926894,0.003490274,0.0016863991,0.0066871163,0.0008281362,0.0014607892,0.00073767395,0.0008467964,0.000018252389,0.00012850277],"about_ca_topic_score_codex":0.00007870324,"about_ca_topic_score_gemma":0.0004996693,"teacher_disagreement_score":0.012074515,"about_ca_system_score_codex":0.000077273195,"about_ca_system_score_gemma":0.00016813261,"threshold_uncertainty_score":0.49572846},"labels":[],"label_agreement":null},{"id":"W4324057639","doi":"10.25251/skin.7.supp.139","title":"The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Quality of life (healthcare); Pediatrics; Dermatology; Nursing","score_opus":0.025225339208978622,"score_gpt":0.32953247423253335,"score_spread":0.3043071350235547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933259,0.0008339704,0.0000026081639,0.004713692,0.00019107522,0.00053074467,0.00007561343,0.000007149138,0.00031922836],"genre_scores_gemma":[0.99859554,0.0006348726,0.0000050962003,0.00041930118,0.000240415,0.0000023861598,0.000020201494,0.000012094516,0.00007008646],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970198,0.0007437341,0.0012291677,0.000107546664,0.0006888079,0.00021093522],"domain_scores_gemma":[0.99389094,0.004346115,0.0010060812,0.00040695505,0.0001686842,0.00018122098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014450031,0.00017057353,0.0007150376,0.00011215225,0.000115065865,0.0000067257974,0.000273597,0.000069273585,0.00005918317],"category_scores_gemma":[0.0051467256,0.000061910636,0.00013263182,0.00025186304,0.00056843605,0.000046703874,0.000023482822,0.0004994544,0.0000021009294],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51894516,0.0019386618,0.26359093,0.00014360934,0.0020984523,0.0013448849,0.0109889,0.00032982876,0.00025869513,0.000020353822,0.19371407,0.006626479],"study_design_scores_gemma":[0.11759564,0.0059504327,0.87197536,0.0009652211,0.00033178733,0.0005253682,0.0016704086,0.000054622487,0.00011089382,0.00059263676,0.00014616112,0.00008146623],"about_ca_topic_score_codex":0.00032279865,"about_ca_topic_score_gemma":0.00013282865,"teacher_disagreement_score":0.60838443,"about_ca_system_score_codex":0.00004255457,"about_ca_system_score_gemma":0.00029842055,"threshold_uncertainty_score":0.6161483},"labels":[],"label_agreement":null},{"id":"W4324057674","doi":"10.25251/skin.7.supp.177","title":"Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Basal cell carcinoma; Primary (astronomy); Oncology; Hedgehog signaling pathway; Medicine; Hedgehog; Basal (medicine); Carcinoma; Internal medicine; Cancer research; Basal cell; Biology; Physics; Cell biology","score_opus":0.015741400842797987,"score_gpt":0.2847594909094331,"score_spread":0.26901809006663513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979847,0.00024486933,0.00018181738,0.00071556773,0.00013123904,0.0005436451,0.00010945858,0.0000036972408,0.00008498679],"genre_scores_gemma":[0.9989849,0.000051748706,0.00023552387,0.00027247876,0.00016126937,0.00001019637,0.00009890846,0.000026072947,0.0001589155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99804324,0.00014501833,0.00082758185,0.00021493659,0.000493825,0.0002754054],"domain_scores_gemma":[0.99828255,0.0003423665,0.0005583332,0.0003039413,0.0004039756,0.00010881464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009373491,0.00021139704,0.00069712335,0.0004830537,0.000059548176,0.0000051416787,0.00027220877,0.000054261902,0.000004051243],"category_scores_gemma":[0.00057551736,0.00010887749,0.00012151183,0.00088019634,0.00013410443,0.0000034777797,0.000059134298,0.00014798791,7.5403483e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30780524,0.005864068,0.0305244,0.0016772584,0.009144416,0.001895501,0.03069753,0.04553792,0.4753152,0.0000064943933,0.06652167,0.0250103],"study_design_scores_gemma":[0.09890034,0.19343697,0.06415873,0.0033107698,0.011055562,0.00025319666,0.008954674,0.0024615703,0.6066154,0.000072575865,0.009188508,0.0015916717],"about_ca_topic_score_codex":0.000012079614,"about_ca_topic_score_gemma":0.000053294716,"teacher_disagreement_score":0.20890489,"about_ca_system_score_codex":0.00004630222,"about_ca_system_score_gemma":0.00014165355,"threshold_uncertainty_score":0.44398952},"labels":[],"label_agreement":null},{"id":"W4324057737","doi":"10.25251/skin.7.supp.140","title":"Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Sanofi Genzyme; Genentech; LEO Pharma; Astellas Pharma; Galderma; Eli Lilly and Company; AstraZeneca; Aimmune Therapeutics; Dermira; UCB Pharma; Regeneron Pharmaceuticals; National Institute for Health and Care Research; Teva Pharmaceutical Industries; European Commission; Sanofi; Amgen; Pfizer; Celgene; GlaxoSmithKline","keywords":"Atopic dermatitis; Medicine; Pediatrics; Dermatology","score_opus":0.013811928063855046,"score_gpt":0.2680551295444405,"score_spread":0.25424320148058543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914196,0.0004105989,0.000021817483,0.006484936,0.0004041692,0.00068827346,0.000094840136,0.000015941225,0.00045979727],"genre_scores_gemma":[0.99723804,0.0005966619,0.000043010696,0.0012500042,0.00057904323,0.0000040577265,0.00005439845,0.000020756657,0.00021400837],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974025,0.00036601312,0.0010769798,0.00014697127,0.0007332325,0.00027432424],"domain_scores_gemma":[0.99728143,0.0014698082,0.00054372824,0.00036071654,0.00016214166,0.0001821478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070733647,0.00018457061,0.0006643222,0.00023019666,0.00008406041,0.000006534996,0.00032472136,0.00008090318,0.00009022226],"category_scores_gemma":[0.0010905747,0.00009104719,0.000098960314,0.00053101877,0.00016466147,0.00006183488,0.00003403361,0.000475091,0.000011429304],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.485701,0.0016497672,0.04905749,0.00016751344,0.0008212912,0.015003507,0.033118322,0.0034150868,0.00006942753,0.000010406442,0.40063766,0.01034853],"study_design_scores_gemma":[0.31984025,0.006482011,0.6576176,0.001751225,0.0020851335,0.005388389,0.0026093437,0.0003006921,0.0001594191,0.00087766565,0.0025584097,0.00032982335],"about_ca_topic_score_codex":0.000069040296,"about_ca_topic_score_gemma":0.00014924645,"teacher_disagreement_score":0.60856014,"about_ca_system_score_codex":0.00005105775,"about_ca_system_score_gemma":0.00022536844,"threshold_uncertainty_score":0.37127966},"labels":[],"label_agreement":null},{"id":"W4324057742","doi":"10.25251/skin.7.supp.196","title":"Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Tolerability; Roflumilast; Medicine; Erythema; Scalp; Clinical endpoint; Randomized controlled trial; Adverse effect; Discontinuation; Seborrheic dermatitis; Internal medicine; Clinical trial; Dermatology","score_opus":0.008512607443391216,"score_gpt":0.27847646736367015,"score_spread":0.26996385992027894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971266,0.0006521907,0.000006313286,0.0011842424,0.00013315368,0.00071199884,0.000013136572,0.000005856767,0.00016651013],"genre_scores_gemma":[0.9986385,0.0009966976,0.000023615003,0.00013096503,0.00011989832,0.000002446327,0.000016078471,0.000016752925,0.00005502777],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99837327,0.00010897172,0.0007060224,0.00009170453,0.0005240788,0.00019594924],"domain_scores_gemma":[0.99875104,0.00046944045,0.00035252786,0.00016206893,0.00011841394,0.00014653335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036035606,0.00014115842,0.00058844057,0.00034397873,0.00002835284,0.00000269657,0.00008661729,0.00004277572,0.000056414083],"category_scores_gemma":[0.00041147726,0.000072185765,0.000044607757,0.0005158169,0.00014613879,0.000044191675,0.00002247144,0.00021743745,0.000002733061],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5795235,0.005758433,0.2930562,0.00037246724,0.00085645914,0.009371248,0.0065495777,0.00017453505,0.00021103055,0.000020541409,0.0032328821,0.10087313],"study_design_scores_gemma":[0.4822187,0.019466529,0.4915495,0.002725064,0.0007535853,0.0016299235,0.0006624156,0.00011677616,0.00007623034,0.000114892486,0.0005678524,0.000118520955],"about_ca_topic_score_codex":0.0000614994,"about_ca_topic_score_gemma":0.000041348638,"teacher_disagreement_score":0.19849329,"about_ca_system_score_codex":0.000068275585,"about_ca_system_score_gemma":0.00010846646,"threshold_uncertainty_score":0.29436502},"labels":[],"label_agreement":null},{"id":"W4324057774","doi":"10.25251/skin.7.supp.111","title":"Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Cohort; Roflumilast; Internal medicine; Psoriasis; Randomized controlled trial; Open label; Surgery; Dermatology; COPD","score_opus":0.05145775588564373,"score_gpt":0.3755849522784312,"score_spread":0.3241271963927875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98063487,0.003905123,0.000036496964,0.012911198,0.00033860205,0.0012245859,0.000060808434,0.000009066797,0.0008792478],"genre_scores_gemma":[0.9798016,0.01915753,0.00010148014,0.00017329039,0.00067709293,0.0000041337953,0.0000113676315,0.000021471511,0.00005201773],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968469,0.00043299058,0.0014544264,0.00021628548,0.00074472785,0.00030466449],"domain_scores_gemma":[0.9929587,0.0051031145,0.0010784768,0.00033223137,0.0002900855,0.00023736386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025763547,0.00023834007,0.0013288885,0.0001424122,0.00010068362,0.00000648273,0.00036574094,0.00009706446,0.0003312099],"category_scores_gemma":[0.0024818983,0.00012303203,0.000060360657,0.00061842153,0.0006401175,0.000120906945,0.00016587044,0.00072069484,0.0000022737183],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9273454,0.0044113575,0.0006507384,0.000435212,0.0010377251,0.00089350785,0.0049111433,0.00008208703,0.004323584,0.00002626714,0.0014505726,0.054432437],"study_design_scores_gemma":[0.828167,0.10767312,0.013323833,0.009735316,0.0036361243,0.004330417,0.0055633322,0.0013414866,0.004134323,0.00047107972,0.021222169,0.00040177128],"about_ca_topic_score_codex":0.0009619907,"about_ca_topic_score_gemma":0.00043600737,"teacher_disagreement_score":0.10326177,"about_ca_system_score_codex":0.0001395887,"about_ca_system_score_gemma":0.000291076,"threshold_uncertainty_score":0.50171006},"labels":[],"label_agreement":null},{"id":"W4377157506","doi":"10.25251/skin.7.3.19","title":"Disseminated Varicella-zoster Virus Infection in an Immunocompetent Host","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; University of British Columbia; University of Toronto","funders":"","keywords":"Virology; Host (biology); Virus; Varicella zoster virus; Medicine; Biology; Genetics","score_opus":0.017746574329109352,"score_gpt":0.31183783940429555,"score_spread":0.2940912650751862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377157506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512523,0.0003694813,0.000055650817,0.0013481319,0.00074680854,0.00027988202,0.0000023003283,0.000040841547,0.0020316436],"genre_scores_gemma":[0.9959315,0.0024894425,0.00002646367,0.00026571818,0.00038248935,0.000004279593,0.0000115074445,0.000028958008,0.0008596629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838126,0.00018078047,0.0006325881,0.00011635768,0.00042050437,0.0002685097],"domain_scores_gemma":[0.9987772,0.000275057,0.00027945766,0.00029379065,0.00021735016,0.00015714206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083719223,0.00017752529,0.00042425975,0.00050729123,0.00011157465,0.000011331338,0.000112767986,0.000089565714,0.0003885526],"category_scores_gemma":[0.00017186589,0.00009630943,0.00009081344,0.0008775926,0.00012074769,0.00008874499,0.0000289857,0.0004712479,0.000097226235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009235579,0.0062174774,0.30583644,0.0004363456,0.0028012418,0.039973926,0.02690642,0.0020106337,0.2948007,0.00017607969,0.015329933,0.29627523],"study_design_scores_gemma":[0.0150502445,0.01895358,0.75954235,0.0037132066,0.0025927124,0.10116273,0.003073477,0.0021434252,0.01786578,0.0009351424,0.0742949,0.00067242194],"about_ca_topic_score_codex":0.0008019573,"about_ca_topic_score_gemma":0.0003281807,"teacher_disagreement_score":0.45370594,"about_ca_system_score_codex":0.00018776656,"about_ca_system_score_gemma":0.00007367735,"threshold_uncertainty_score":0.42543787},"labels":[],"label_agreement":null},{"id":"W4384465773","doi":"10.25251/skin.7.supp.220","title":"Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2)","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; Queen's University","funders":"","keywords":"Integument; Atopic dermatitis; Roflumilast; Dermatology; Medicine; Internal medicine; Anatomy","score_opus":0.012838536675441098,"score_gpt":0.30837476925559376,"score_spread":0.29553623258015266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384465773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99214745,0.0030191322,0.000024300678,0.0039659087,0.00006808117,0.000684086,0.0000133244475,0.000008606536,0.00006912489],"genre_scores_gemma":[0.99570966,0.0034648164,0.00007076808,0.0005840561,0.00008311459,0.0000041396,0.000009729374,0.00001622526,0.000057508634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802345,0.0003684063,0.00091727794,0.00015599927,0.00031135866,0.00022347955],"domain_scores_gemma":[0.9982832,0.0009398959,0.0003293271,0.00015919989,0.00006949427,0.00021888383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011931239,0.00018144806,0.0009774759,0.0004405244,0.00004387452,0.000007894732,0.00009975053,0.00004931957,0.000048019145],"category_scores_gemma":[0.0008811114,0.00010598759,0.000035078236,0.0003215453,0.00031685375,0.00006311172,0.000051290255,0.0003285725,0.0000013532807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13672268,0.0027143045,0.6055339,0.0014297691,0.0023286003,0.021590475,0.07736318,0.0006843788,0.004203176,0.000098985765,0.030019192,0.117311396],"study_design_scores_gemma":[0.073916934,0.0037426886,0.8761744,0.009145339,0.00075010257,0.029949844,0.0038018327,0.00042531834,0.0012599136,0.00043888533,0.00015196246,0.0002427943],"about_ca_topic_score_codex":0.00013536614,"about_ca_topic_score_gemma":0.00023749979,"teacher_disagreement_score":0.27064052,"about_ca_system_score_codex":0.000029652461,"about_ca_system_score_gemma":0.00006650512,"threshold_uncertainty_score":0.43220484},"labels":[],"label_agreement":null},{"id":"W4384469487","doi":"10.25251/skin.7.supp.219","title":"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Placebo; Plaque psoriasis; Internal medicine; Psoriasis; Population; Gastroenterology; Dermatology; Pathology","score_opus":0.02762875616616525,"score_gpt":0.29977164924700356,"score_spread":0.27214289308083833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98524386,0.0071038553,0.00004121132,0.006263094,0.00042281224,0.00066673843,0.0002278764,0.000020423087,0.000010109066],"genre_scores_gemma":[0.99177164,0.006591602,0.000030731808,0.0010186034,0.000249623,0.00001883396,0.00018137107,0.000029898216,0.00010771597],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954245,0.0026265392,0.0010845545,0.00028494408,0.00015929398,0.00042014674],"domain_scores_gemma":[0.99678767,0.0021780846,0.00045949104,0.00027414665,0.00012532099,0.00017531366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039750584,0.000351746,0.00097029906,0.00049906265,0.00019828462,0.000030218967,0.0002913064,0.00016402271,0.00004427435],"category_scores_gemma":[0.0019065809,0.00019136487,0.000079503894,0.00079452124,0.00023422367,0.00011117066,0.000053220698,0.00045109913,0.000007257758],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12615818,0.0052328855,0.015375122,0.00028157808,0.0018693183,0.008512589,0.027849246,0.00018990715,0.3957217,0.00010957678,0.05936283,0.3593371],"study_design_scores_gemma":[0.3932481,0.076402225,0.21505828,0.010951271,0.019967774,0.0884439,0.02936964,0.0027912795,0.04959937,0.008777356,0.09859626,0.006794528],"about_ca_topic_score_codex":0.00007184596,"about_ca_topic_score_gemma":0.00012228914,"teacher_disagreement_score":0.35254255,"about_ca_system_score_codex":0.00003716978,"about_ca_system_score_gemma":0.00011337225,"threshold_uncertainty_score":0.7803633},"labels":[],"label_agreement":null},{"id":"W4384469537","doi":"10.25251/skin.7.4.8","title":"Beware of the “Blue Nevus”: A Case Report","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Dermatology; Medicine; Seborrheic keratosis; Melanoma; Blue nevus; Melanosis; Nevus; Cryotherapy; Lentigo; Melanocytic nevus; Biopsy; Pathology; Radiology","score_opus":0.01680851786479874,"score_gpt":0.2784894628973337,"score_spread":0.2616809450325349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97154677,0.0004598644,0.00014287293,0.020964637,0.0021399078,0.00046389905,0.0000032710275,0.000043259057,0.0042355144],"genre_scores_gemma":[0.9854824,0.00028684016,0.000042432865,0.00081785244,0.00087555364,0.0000018273502,0.0000016840927,0.000028022636,0.012463366],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99766475,0.00014937406,0.00094652164,0.000120905606,0.0008798361,0.00023863252],"domain_scores_gemma":[0.9975885,0.00038409448,0.0008574874,0.0006488443,0.0003674547,0.00015362613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013749627,0.00016789175,0.0005059711,0.00025632925,0.00015591604,0.0000054365187,0.00026622054,0.00006968958,0.00033078017],"category_scores_gemma":[0.0011969195,0.0000759888,0.00022407899,0.0007968479,0.0002939136,0.00002572344,0.000104988925,0.00047254752,0.000019106266],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012414969,0.00016671789,0.0007909819,0.00030120037,0.000767624,0.8207834,0.0073852413,0.0006425279,0.010710351,0.00010448757,0.1396612,0.017444786],"study_design_scores_gemma":[0.0009052142,0.00096957124,0.00044769532,0.0004198157,0.0007018786,0.9276367,0.006048087,0.000188004,0.0019969298,0.00019103453,0.060425483,0.00006960055],"about_ca_topic_score_codex":0.00016111435,"about_ca_topic_score_gemma":0.00009169966,"teacher_disagreement_score":0.1068533,"about_ca_system_score_codex":0.00008316248,"about_ca_system_score_gemma":0.00013343613,"threshold_uncertainty_score":0.3621811},"labels":[],"label_agreement":null},{"id":"W4384469580","doi":"10.25251/skin.7.supp.218","title":"Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Open label; Roflumilast; Medicine; Plaque psoriasis; Psoriasis; Safety profile; Dermatology; Adverse effect; Internal medicine","score_opus":0.05145775588564373,"score_gpt":0.3755849522784312,"score_spread":0.3241271963927875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98063487,0.003905123,0.000036496964,0.012911198,0.00033860205,0.0012245859,0.000060808434,0.000009066797,0.0008792478],"genre_scores_gemma":[0.9798016,0.01915753,0.00010148014,0.00017329039,0.00067709293,0.0000041337953,0.0000113676315,0.000021471511,0.00005201773],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968469,0.00043299058,0.0014544264,0.00021628548,0.00074472785,0.00030466449],"domain_scores_gemma":[0.9929587,0.0051031145,0.0010784768,0.00033223137,0.0002900855,0.00023736386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025763547,0.00023834007,0.0013288885,0.0001424122,0.00010068362,0.00000648273,0.00036574094,0.00009706446,0.0003312099],"category_scores_gemma":[0.0024818983,0.00012303203,0.000060360657,0.00061842153,0.0006401175,0.000120906945,0.00016587044,0.00072069484,0.0000022737183],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9273454,0.0044113575,0.0006507384,0.000435212,0.0010377251,0.00089350785,0.0049111433,0.00008208703,0.004323584,0.00002626714,0.0014505726,0.054432437],"study_design_scores_gemma":[0.828167,0.10767312,0.013323833,0.009735316,0.0036361243,0.004330417,0.0055633322,0.0013414866,0.004134323,0.00047107972,0.021222169,0.00040177128],"about_ca_topic_score_codex":0.0009619907,"about_ca_topic_score_gemma":0.00043600737,"teacher_disagreement_score":0.10326177,"about_ca_system_score_codex":0.0001395887,"about_ca_system_score_gemma":0.000291076,"threshold_uncertainty_score":0.50171006},"labels":[],"label_agreement":null},{"id":"W4384469618","doi":"10.25251/skin.7.supp.226","title":"Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Roflumilast; Seborrheic dermatitis; Medicine; Dermatology; Phase (matter); Internal medicine; Chemistry","score_opus":0.009433614513604138,"score_gpt":0.3102727549736702,"score_spread":0.30083914046006605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972435,0.00066216546,0.000015424495,0.00084585097,0.00010952125,0.0009052589,0.000020159794,0.0000048514876,0.00019326997],"genre_scores_gemma":[0.99821925,0.0014938576,0.00008393084,0.00006934314,0.00006118429,0.0000035816045,0.000018113018,0.000017609573,0.000033122564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978969,0.0001440195,0.0010123141,0.0000978299,0.0006591505,0.00018978462],"domain_scores_gemma":[0.9983302,0.0005242781,0.00063610624,0.00019543535,0.0001776323,0.00013639484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052750163,0.00015090984,0.00075789454,0.00038822618,0.00002265924,0.0000021730646,0.00009735397,0.00004419496,0.000045731573],"category_scores_gemma":[0.00032324909,0.000079780264,0.000053884534,0.00053653494,0.00016597481,0.000044472075,0.000027617214,0.00021666494,6.0374134e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21342282,0.010321139,0.68665016,0.00091776415,0.0013220295,0.0054427637,0.0049189753,0.00036249965,0.00055067963,0.000047783135,0.0015767046,0.07446667],"study_design_scores_gemma":[0.27046347,0.015712526,0.70816416,0.0030531653,0.0007157744,0.00068488857,0.0005345644,0.0001833421,0.000104017534,0.000080425096,0.0002168726,0.000086801905],"about_ca_topic_score_codex":0.00008101602,"about_ca_topic_score_gemma":0.00003776246,"teacher_disagreement_score":0.07437986,"about_ca_system_score_codex":0.000087831184,"about_ca_system_score_gemma":0.00018916561,"threshold_uncertainty_score":0.3253345},"labels":[],"label_agreement":null},{"id":"W4388625555","doi":"10.25251/skin.7.supp.290","title":"A Systematic Literature Review and Network Meta-Analysis of Comparative Efficacy of Topical Fixed-Dose Combination Treatments for Moderate to Severe Acne Vulgaris","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Acne; Meta-analysis; Randomized controlled trial; MEDLINE; Systematic review; Internal medicine; Dermatology","score_opus":0.048590313473708714,"score_gpt":0.3539348043226664,"score_spread":0.30534449084895765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66920906,0.30846265,0.0011689811,0.014427205,0.0002651085,0.0060328688,0.000086174354,0.000021788848,0.0003261584],"genre_scores_gemma":[0.98516965,0.012516326,0.00024238156,0.0005746243,0.00008825278,0.00002291915,0.00004387429,0.000011614028,0.0013303857],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9982254,0.0002707926,0.00086222385,0.0001142091,0.00037426178,0.0001531022],"domain_scores_gemma":[0.99728006,0.0012631005,0.0006818193,0.00023567196,0.00041476378,0.00012460127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083215884,0.0001870664,0.0028057045,0.00021264591,0.00007406085,0.000005209746,0.000095596086,0.00005989839,0.00003087263],"category_scores_gemma":[0.00026455487,0.000078410645,0.0004906281,0.0009495273,0.0000646973,0.00003225592,0.000023613562,0.00012168136,8.9392654e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008673533,0.0017432069,0.0006786962,0.07218874,0.8242111,0.0011845808,0.0383691,0.009898457,0.0013983985,0.0005906275,0.039764863,0.0012986485],"study_design_scores_gemma":[0.00516603,0.008109926,0.0021394282,0.021312976,0.9560142,0.002561196,0.0006529159,0.0032168224,0.0003010655,0.00028297468,0.00009659569,0.00014584023],"about_ca_topic_score_codex":0.0000074920304,"about_ca_topic_score_gemma":0.0000057378434,"teacher_disagreement_score":0.31596056,"about_ca_system_score_codex":0.00003316878,"about_ca_system_score_gemma":0.000029930306,"threshold_uncertainty_score":0.31974933},"labels":[],"label_agreement":null},{"id":"W4388625669","doi":"10.25251/skin.7.supp.240","title":"Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Placebo; Plaque psoriasis; Adverse effect; Apremilast; Internal medicine; Randomized controlled trial; Dosing; Dermatology; Psoriatic arthritis","score_opus":0.03578117792347708,"score_gpt":0.304577256432096,"score_spread":0.2687960785086189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97146195,0.013539832,0.0000132649,0.012695688,0.0011831011,0.00038537168,0.00026955732,0.000024203051,0.0004270347],"genre_scores_gemma":[0.97491425,0.02340287,0.000029472903,0.00030193978,0.00061782624,0.0000026568948,0.00009468864,0.000021149652,0.0006151367],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964567,0.0016579207,0.0012231419,0.00021052263,0.00013081258,0.0003209392],"domain_scores_gemma":[0.98837084,0.010500765,0.0006853243,0.00030728264,0.00007754109,0.000058244077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045923274,0.000249482,0.000877875,0.0001726254,0.00024144872,0.000013633471,0.00031452242,0.00020772459,0.00014878648],"category_scores_gemma":[0.0033296645,0.00011631626,0.000101563994,0.0003003699,0.00040525346,0.000050671537,0.00006923864,0.00045828093,0.000040438463],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.150755,0.0007928194,0.0018885055,0.000047329482,0.005110452,0.0031405604,0.054332487,0.000090243375,0.105702035,0.00060085324,0.09038245,0.58715725],"study_design_scores_gemma":[0.3591653,0.014126272,0.061298408,0.0041147172,0.009595711,0.037848715,0.041336223,0.000070910755,0.033187293,0.00915143,0.42852706,0.0015779437],"about_ca_topic_score_codex":0.00021060607,"about_ca_topic_score_gemma":0.00014012904,"teacher_disagreement_score":0.58557934,"about_ca_system_score_codex":0.000031407468,"about_ca_system_score_gemma":0.00006994304,"threshold_uncertainty_score":0.47432396},"labels":[],"label_agreement":null},{"id":"W4388625689","doi":"10.25251/skin.7.supp.272","title":"Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Dermatology; Atopic dermatitis; Adverse effect; Placebo; Head and neck; Erythema; Surgery; Internal medicine; Pathology; Alternative medicine","score_opus":0.011247788586143774,"score_gpt":0.26379962457932654,"score_spread":0.25255183599318276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968475,0.00037023553,0.0000043504724,0.0014634498,0.00017151302,0.00064857723,0.000026911752,0.000016588,0.00045086181],"genre_scores_gemma":[0.99850744,0.00053844915,0.000058409714,0.00040317717,0.00007621948,0.0000074262653,0.000032653887,0.000020298168,0.000355952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823636,0.00018196057,0.0006981391,0.00013665218,0.00047579297,0.0002711252],"domain_scores_gemma":[0.9985559,0.00028688842,0.0003462418,0.00024023383,0.0002557494,0.00031499148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017590131,0.0002265986,0.00077230367,0.0003613745,0.00007218796,0.0000015653917,0.00013028499,0.000057115252,0.00016968566],"category_scores_gemma":[0.00032594125,0.00012461418,0.00007056845,0.00040840622,0.00018126215,0.00005569983,0.00004486118,0.00015421236,0.000025873103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006824256,0.0006672144,0.97170776,0.00016460428,0.00045345246,0.0034821162,0.002330561,0.00017782685,0.0000900689,0.0000026462333,0.0115983775,0.0025011448],"study_design_scores_gemma":[0.019681545,0.0033612603,0.9637411,0.0020573668,0.00076900044,0.005848026,0.0012097743,0.00017602714,0.0002675574,0.00007394005,0.0026470101,0.00016735581],"about_ca_topic_score_codex":0.00031070513,"about_ca_topic_score_gemma":0.00020917559,"teacher_disagreement_score":0.012857289,"about_ca_system_score_codex":0.00009650738,"about_ca_system_score_gemma":0.00011427703,"threshold_uncertainty_score":0.5081619},"labels":[],"label_agreement":null},{"id":"W4388625690","doi":"10.25251/skin.7.supp.239","title":"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Bristol-Myers Squibb","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Internal medicine; Gastroenterology; Randomization; Randomized controlled trial; Plaque psoriasis; Pharmacology; Dermatology; Psoriatic arthritis; Pathology","score_opus":0.02818460525731643,"score_gpt":0.30724518295219083,"score_spread":0.2790605776948744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902143,0.0012415367,0.00001424977,0.0055715763,0.0018092251,0.00082699396,0.0000538504,0.00003249001,0.00023578785],"genre_scores_gemma":[0.99642557,0.0007521456,0.000032941196,0.0013021571,0.00046281822,0.00003249295,0.00006196412,0.00003903381,0.00089087075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99630535,0.001459584,0.0010725339,0.0002908222,0.00025317367,0.00061855774],"domain_scores_gemma":[0.9978124,0.0011035771,0.00043486233,0.00042393338,0.00013745141,0.000087809916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020774726,0.00040861344,0.00091775693,0.00057807734,0.0002065257,0.00002571829,0.0006370804,0.0002752011,0.00020315444],"category_scores_gemma":[0.0004553294,0.00021406673,0.00015854412,0.0009850978,0.00016461257,0.0001607817,0.0000708068,0.000709793,0.00006427762],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49620166,0.007073758,0.0052163675,0.000110699264,0.0031532305,0.014739481,0.06854842,0.0026127794,0.17763256,0.00028345207,0.100853115,0.123574495],"study_design_scores_gemma":[0.7043308,0.07007825,0.042664606,0.002140155,0.003976422,0.041734684,0.02545769,0.00051273505,0.031009682,0.0055769286,0.069619775,0.00289828],"about_ca_topic_score_codex":0.00036683894,"about_ca_topic_score_gemma":0.001044987,"teacher_disagreement_score":0.20812914,"about_ca_system_score_codex":0.00013941196,"about_ca_system_score_gemma":0.00018130364,"threshold_uncertainty_score":0.8729388},"labels":[],"label_agreement":null},{"id":"W4388625692","doi":"10.25251/skin.7.supp.297","title":"Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Retinal and Optic Conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology","funders":"Incyte; Eli Lilly and Company","keywords":"Eyelash; Eyebrow; Medicine; Dermatology; Computer science; Surgery; Biology","score_opus":0.019071533120826826,"score_gpt":0.29880478806053223,"score_spread":0.2797332549397054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955781,0.0009694213,0.000065980166,0.038389836,0.00036517243,0.0003208781,0.000010503453,0.000037128124,0.00406007],"genre_scores_gemma":[0.9849237,0.0025229608,0.00013585793,0.0012641012,0.0011105656,0.0000051111224,0.000010275645,0.000024601628,0.010002791],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9984342,0.0000990208,0.00052845775,0.00013317046,0.0005276494,0.00027753945],"domain_scores_gemma":[0.9979562,0.00094399566,0.0002116715,0.0002460483,0.00022365272,0.0004184429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005319327,0.0001951933,0.0005334185,0.00032156365,0.0001552134,0.000011164895,0.00013768056,0.00005798917,0.00041274363],"category_scores_gemma":[0.000838886,0.000096490316,0.0001013798,0.00048721596,0.00021363932,0.000035570138,0.000044604418,0.00024453516,0.00007464598],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014998294,0.0013337584,0.028864168,0.0006901591,0.0039233607,0.04327937,0.048006814,0.00033182168,0.06533993,0.0036741698,0.55897635,0.23058179],"study_design_scores_gemma":[0.021360194,0.06917349,0.12861924,0.0064818403,0.009073788,0.43701407,0.035870563,0.00084006076,0.007425252,0.013280375,0.26975855,0.0011025731],"about_ca_topic_score_codex":0.00018104384,"about_ca_topic_score_gemma":0.00003454738,"teacher_disagreement_score":0.3937347,"about_ca_system_score_codex":0.0000859224,"about_ca_system_score_gemma":0.00012654619,"threshold_uncertainty_score":0.45192534},"labels":[],"label_agreement":null},{"id":"W4388625695","doi":"10.25251/skin.7.6.24","title":"Beyond Acne Vulgaris: Role of Cutibacterium Acnes in Atopic Dermatitis and Psoriasis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Acne; Atopic dermatitis; Dermatology; Psoriasis; Medicine","score_opus":0.007171880382064845,"score_gpt":0.2555385961651061,"score_spread":0.24836671578304126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98176605,0.0065259687,0.0000055299356,0.009252128,0.0003751064,0.00015519446,0.0000050323997,0.000015629359,0.0018993851],"genre_scores_gemma":[0.99421746,0.004445964,0.000035782024,0.0007324847,0.00028273763,0.0000017372889,0.0000054154366,0.000015395717,0.00026302476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984337,0.0001571743,0.0007079154,0.00009332545,0.00037974666,0.00022811512],"domain_scores_gemma":[0.998529,0.0005945713,0.00035692978,0.00022090647,0.00015257903,0.00014601434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049625646,0.00014745511,0.00064276514,0.00035184878,0.000052712905,0.0000040051236,0.00017532005,0.00008888046,0.00017209444],"category_scores_gemma":[0.0005940809,0.00008665107,0.00007213814,0.00038877662,0.00037945688,0.00006887076,0.000051947092,0.00032088958,0.000009285224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030764618,0.00078413205,0.7042369,0.0018848267,0.001614082,0.023570837,0.035161003,0.000096151394,0.033897255,0.0007151485,0.12458129,0.07038191],"study_design_scores_gemma":[0.007620251,0.0016761913,0.7827667,0.0027095096,0.0016579727,0.13992132,0.014353349,0.0004254845,0.013120461,0.018902326,0.0165326,0.00031381074],"about_ca_topic_score_codex":0.000037542308,"about_ca_topic_score_gemma":0.000025789,"teacher_disagreement_score":0.11635048,"about_ca_system_score_codex":0.000022389328,"about_ca_system_score_gemma":0.0000918248,"threshold_uncertainty_score":0.35335281},"labels":[],"label_agreement":null},{"id":"W4388625848","doi":"10.25251/skin.7.supp.294","title":"Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Alopecia areata; Placebo; Phase (matter); Medicine; Open label; Dermatology; Randomized controlled trial; Psychology; Internal medicine; Alternative medicine; Physics; Pathology","score_opus":0.0338854993569062,"score_gpt":0.3409284818206344,"score_spread":0.3070429824637282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98570293,0.005756375,0.00029816222,0.0051265266,0.00017620056,0.002229989,0.0001154911,0.000015525275,0.00057881314],"genre_scores_gemma":[0.9918164,0.006463264,0.00011653189,0.0010635818,0.00016636826,0.000019053588,0.00016630342,0.000032819455,0.00015568308],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583906,0.00086809584,0.0017110831,0.00025743197,0.0009583965,0.00036591353],"domain_scores_gemma":[0.99293524,0.004896823,0.00092039374,0.00042844244,0.00059476716,0.00022431658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034807213,0.0003703355,0.003057154,0.00060752797,0.00015844869,0.00002174995,0.0004932599,0.00008502168,0.00020066567],"category_scores_gemma":[0.004300119,0.00015111516,0.00018642379,0.0015213685,0.0007069624,0.000101507954,0.00012713559,0.00059810973,0.0000021474782],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9430765,0.0020939826,0.0034816482,0.000067236666,0.013487531,0.00092596636,0.01137443,0.00026489526,0.00033147988,0.00002645615,0.00655074,0.018319152],"study_design_scores_gemma":[0.95448315,0.0029741067,0.0011573621,0.002330482,0.01291296,0.0002057627,0.018282773,0.005533533,0.00004696218,0.00012310655,0.0017397803,0.00021001253],"about_ca_topic_score_codex":0.00034936165,"about_ca_topic_score_gemma":0.0013489431,"teacher_disagreement_score":0.018109139,"about_ca_system_score_codex":0.00009383495,"about_ca_system_score_gemma":0.00021595684,"threshold_uncertainty_score":0.6162298},"labels":[],"label_agreement":null},{"id":"W4388625988","doi":"10.25251/skin.7.supp.254","title":"Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"Amgen","keywords":"Apremilast; Medicine; Double blind; Placebo; Psoriasis; Plaque psoriasis; Dermatology; Randomized controlled trial; Placebo-controlled study; Double blind study; Internal medicine; Alternative medicine; Pathology; Psoriatic arthritis","score_opus":0.017666931991307977,"score_gpt":0.2602192344788104,"score_spread":0.24255230248750242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913584,0.0017636871,0.000036148816,0.0020673282,0.0008338368,0.003624635,0.00008802125,0.000024295969,0.00020367464],"genre_scores_gemma":[0.9975478,0.001178234,0.000012505598,0.00014774634,0.00044262607,0.000051298957,0.00008627725,0.00002950534,0.0005040156],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99613,0.0016335923,0.0012795394,0.0002993179,0.00026212333,0.00039545583],"domain_scores_gemma":[0.9915262,0.007034663,0.0007726141,0.0003741299,0.00020998945,0.00008241393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003155552,0.0003751835,0.001410337,0.0003117681,0.00030063916,0.000021318228,0.00042736542,0.00014494956,0.00005928901],"category_scores_gemma":[0.0008800704,0.00015714187,0.00011480552,0.00053414993,0.00017509199,0.000069149464,0.00008104365,0.00051712035,0.00004057656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9768241,0.0009190974,0.0011127695,0.000005263616,0.0015481502,0.00021146983,0.012645379,0.0009611091,0.00006742055,0.000003029689,0.0016397964,0.004062392],"study_design_scores_gemma":[0.9873233,0.0037499347,0.0020496803,0.00017497371,0.0030699342,0.00035315086,0.0027190251,0.000021806056,0.00008835235,0.000060098835,0.0001951437,0.00019459493],"about_ca_topic_score_codex":0.00023633549,"about_ca_topic_score_gemma":0.00043805037,"teacher_disagreement_score":0.010499181,"about_ca_system_score_codex":0.000075231175,"about_ca_system_score_gemma":0.00011011598,"threshold_uncertainty_score":0.64080596},"labels":[],"label_agreement":null},{"id":"W4388625991","doi":"10.25251/skin.7.supp.253","title":"How Labeling Warnings and Precautions May Impact the Proportion of Psoriasis Patients Initiating New Treatments","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Mental Health and Psychiatry","field":"Arts and Humanities","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.03492004508033811,"score_gpt":0.29667873088430535,"score_spread":0.2617586858039672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98957783,0.00095819513,0.0000060807724,0.0072707417,0.00097508053,0.00022426849,0.000012752178,0.000010191751,0.0009648778],"genre_scores_gemma":[0.996032,0.0006596477,0.00001651615,0.00016716705,0.0010429752,0.0000011337613,0.0000094444495,0.000010786402,0.0020603356],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99888,0.00010513016,0.0004083572,0.00005466334,0.0003846229,0.00016721664],"domain_scores_gemma":[0.99874586,0.00025442016,0.0006547402,0.0000952424,0.00014988675,0.000099825425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051909,0.00010301307,0.00020006082,0.00009769605,0.0003963445,0.000022132397,0.00010923621,0.000023847271,0.00017243871],"category_scores_gemma":[0.00016658854,0.0000431924,0.000053128686,0.000084671614,0.00015327301,0.00009165646,0.000016555448,0.00018330173,0.0000028111995],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015010673,0.00038509915,0.07453951,0.0005747543,0.0010645961,0.00007254388,0.6201224,0.0001115782,0.0003062121,0.0029323774,0.07166824,0.22672167],"study_design_scores_gemma":[0.031331982,0.06114659,0.14121234,0.01382694,0.008299051,0.008515902,0.41789192,0.0020438854,0.0017783461,0.06562451,0.24654242,0.0017860777],"about_ca_topic_score_codex":0.0003192264,"about_ca_topic_score_gemma":0.00010725536,"teacher_disagreement_score":0.22493559,"about_ca_system_score_codex":0.000034331184,"about_ca_system_score_gemma":0.000077875135,"threshold_uncertainty_score":0.30484015},"labels":[],"label_agreement":null},{"id":"W4388626014","doi":"10.25251/skin.7.supp.236","title":"Time to Onset of a Minimal Clinically Important Difference in DLQI with Guselkumab Treatment in VOYAGE 1","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; Dalhousie University; Probity Medical Research","funders":"Janssen Scientific Affairs","keywords":"Dermatology Life Quality Index; Minimal clinically important difference; Medicine; Quality of life (healthcare); Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Randomized controlled trial; Internal medicine; Placebo; Randomization; Physical therapy; Surgery; Dermatology; Disease; Pathology","score_opus":0.015940636727592213,"score_gpt":0.26762430941817744,"score_spread":0.2516836726905852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996524,0.0011656153,0.0000024808874,0.001640514,0.00017516392,0.00025951097,0.000025155063,0.000008941766,0.00019864747],"genre_scores_gemma":[0.9958423,0.00090218976,0.00004670416,0.00009696511,0.000051870058,0.0000065572845,0.000014950493,0.000014095554,0.0030243704],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99806386,0.00033740257,0.001063202,0.00013815619,0.00010764132,0.00028971417],"domain_scores_gemma":[0.998009,0.0011591521,0.00048237105,0.00023888817,0.00006552984,0.000045021385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091700867,0.00019116563,0.0007079929,0.00034549335,0.000033758595,0.0000018410906,0.00027214948,0.000111960966,0.00039436683],"category_scores_gemma":[0.00026273666,0.00009191303,0.00007588906,0.00044827818,0.00021383929,0.000016920832,0.000031309282,0.00019150713,0.00010060812],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074651584,0.0039850404,0.2683896,0.00010572476,0.0035453818,0.02743063,0.052263897,0.0005092402,0.40439376,0.000033563618,0.013382528,0.15130903],"study_design_scores_gemma":[0.04902955,0.111997254,0.70851195,0.004628877,0.0030161985,0.055078816,0.009929539,0.000106731204,0.04314523,0.0007250833,0.012667482,0.0011633122],"about_ca_topic_score_codex":0.00014331288,"about_ca_topic_score_gemma":0.0004005527,"teacher_disagreement_score":0.4401223,"about_ca_system_score_codex":0.00008135793,"about_ca_system_score_gemma":0.00015847398,"threshold_uncertainty_score":0.43180403},"labels":[],"label_agreement":null},{"id":"W4388626033","doi":"10.25251/skin.7.supp.286","title":"Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Hidradenitis suppurativa; Medicine; Placebo; Internal medicine; Dosing; Intertriginous; Adverse effect; Gastroenterology; Adalimumab; Surgery; Pathology; Tumor necrosis factor alpha","score_opus":0.03057522950790823,"score_gpt":0.3238723228457288,"score_spread":0.29329709333782056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90637654,0.0020383939,0.00086718856,0.08212325,0.0016120829,0.004483123,0.000069685,0.00007590964,0.0023538447],"genre_scores_gemma":[0.99601287,0.00009056086,0.00018370306,0.000028923214,0.0009767329,0.00001787066,0.000019142793,0.00004722571,0.0026229573],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99734765,0.00020025045,0.0010310791,0.00016339456,0.0008879285,0.00036970456],"domain_scores_gemma":[0.99720603,0.001103735,0.00062576757,0.0003566863,0.00050433056,0.00020345706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102436534,0.00026403507,0.0009557949,0.00034574769,0.00014575587,0.00000798836,0.00028815167,0.000077768746,0.00029965426],"category_scores_gemma":[0.0008327432,0.00013728101,0.0002089379,0.00062695425,0.00032623293,0.00009486969,0.00003987289,0.0003360164,0.000012774279],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016301518,0.0072002583,0.015631422,0.0009425809,0.007824472,0.46388426,0.19618994,0.00007726997,0.01670035,0.00039043103,0.1106866,0.16417089],"study_design_scores_gemma":[0.018902186,0.042755462,0.0014341832,0.0013125022,0.0035792077,0.86824584,0.03401554,0.0002736573,0.022016833,0.001989752,0.00516825,0.0003065751],"about_ca_topic_score_codex":0.000030738553,"about_ca_topic_score_gemma":0.000017545315,"teacher_disagreement_score":0.40436158,"about_ca_system_score_codex":0.000086188076,"about_ca_system_score_gemma":0.000220659,"threshold_uncertainty_score":0.5598157},"labels":[],"label_agreement":null},{"id":"W4388626054","doi":"10.25251/skin.7.supp.291","title":"Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Alopecia areata; Phase (matter); Dermatology; Medicine; Chemistry; Organic chemistry","score_opus":0.08132641213904793,"score_gpt":0.4348392751947991,"score_spread":0.35351286305575114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825345,0.0043529607,0.00076930603,0.009232134,0.00048299445,0.0019103938,0.00044696414,0.000018698136,0.00025200838],"genre_scores_gemma":[0.9830878,0.014466613,0.0002262489,0.00037650438,0.0012768144,0.000021738766,0.00030645682,0.000025412277,0.0002124359],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719155,0.00031546637,0.0015275322,0.00016330171,0.0005644382,0.0002377183],"domain_scores_gemma":[0.99139494,0.006905908,0.000712804,0.00047865635,0.00032712106,0.00018055506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018924569,0.00021381886,0.0012383139,0.00020286486,0.00012340817,0.000007783135,0.00030088058,0.00010153354,0.00033136253],"category_scores_gemma":[0.0019537446,0.00007728092,0.0005333757,0.0009542325,0.0007399565,0.000024467985,0.000021009679,0.00026048132,0.0000010078246],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19965026,0.004082253,0.0009227951,0.000030103301,0.010567023,0.00025695292,0.0057789763,0.000050501407,0.00045644343,0.000032132164,0.015894273,0.7622783],"study_design_scores_gemma":[0.33731574,0.09068259,0.0019908813,0.0005295298,0.04830418,0.00068910787,0.02197047,0.015161432,0.0005040145,0.00045948016,0.48215494,0.00023764693],"about_ca_topic_score_codex":0.00023554423,"about_ca_topic_score_gemma":0.00029151014,"teacher_disagreement_score":0.7620407,"about_ca_system_score_codex":0.00003439566,"about_ca_system_score_gemma":0.00022256456,"threshold_uncertainty_score":0.36281875},"labels":[],"label_agreement":null},{"id":"W4388626055","doi":"10.25251/skin.7.supp.258","title":"Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Adverse effect; Maintenance therapy; Interim analysis; Clinical trial; Randomized controlled trial; Gastroenterology; Surgery; Chemotherapy; Immunology","score_opus":0.20484667369043627,"score_gpt":0.48630819427542,"score_spread":0.28146152058498375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763529,0.00078370905,0.00029638925,0.020446172,0.00044141433,0.001439156,0.00003082918,0.0000074106024,0.00020202145],"genre_scores_gemma":[0.9958058,0.0019234717,0.0003391767,0.00085502333,0.00020866278,0.000015109635,0.000001977667,0.000024054361,0.0008267232],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9964265,0.0009437361,0.0014385126,0.00022768755,0.0006927745,0.00027079106],"domain_scores_gemma":[0.99120486,0.005888263,0.0013937318,0.000550586,0.00081890874,0.00014367576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043277787,0.0002270947,0.0017456659,0.00012003402,0.00015946123,0.000010907826,0.0005202076,0.00006616449,0.00006198376],"category_scores_gemma":[0.0037532952,0.000087757675,0.00023433926,0.0011891713,0.00032805276,0.00007224455,0.00018110189,0.00034351225,0.0000018079926],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8674122,0.006302472,0.0076810066,0.00014601956,0.027855154,0.001238533,0.024263594,0.0018284967,0.005824398,0.000044621487,0.020075906,0.037327606],"study_design_scores_gemma":[0.17695898,0.27435404,0.16199179,0.0074877,0.14015678,0.007134027,0.13174498,0.016877394,0.008055367,0.0010660425,0.07313075,0.0010421361],"about_ca_topic_score_codex":0.00019670007,"about_ca_topic_score_gemma":0.00018782332,"teacher_disagreement_score":0.69045323,"about_ca_system_score_codex":0.00009242189,"about_ca_system_score_gemma":0.00018569465,"threshold_uncertainty_score":0.4493316},"labels":[],"label_agreement":null},{"id":"W4388626067","doi":"10.25251/skin.7.supp.257","title":"Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Janssen Biotech; Glenmark Pharmaceuticals; LEO Pharma; Incyte; Dermira; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Apremilast; Psoriasis; Randomized controlled trial; Body surface area; Plaque psoriasis; Internal medicine; Gastroenterology; Dermatology","score_opus":0.013720690003934744,"score_gpt":0.2400699069863114,"score_spread":0.22634921698237664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967873,0.0012560368,0.000014833587,0.0008088922,0.00033202767,0.00054679974,0.00016830007,0.000010180267,0.00007562233],"genre_scores_gemma":[0.99861246,0.0009951862,0.00002497523,0.000045014243,0.0001392669,0.0000029435146,0.000109838285,0.00001668818,0.00005363664],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981773,0.00055783865,0.0006999462,0.00017843996,0.00015717269,0.00022932747],"domain_scores_gemma":[0.99699,0.001977714,0.0006148679,0.00026095434,0.0001144789,0.00004194221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007230632,0.0002258707,0.0006428069,0.0001181411,0.0001644959,0.00000722432,0.00021201979,0.00010199294,0.00002276175],"category_scores_gemma":[0.00016069869,0.00009468616,0.000034293174,0.00023848203,0.0004477934,0.000049041355,0.000040537332,0.00030410266,0.0000021922742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9542851,0.000512567,0.0018927158,0.0000116011815,0.0013400977,0.0001880152,0.016540037,0.00032445716,0.0015165095,0.000008744134,0.0011241534,0.02225602],"study_design_scores_gemma":[0.9005765,0.021452434,0.060026556,0.0017545951,0.0026300051,0.0015998578,0.005959832,0.000101281774,0.003918255,0.0002178095,0.0013602242,0.0004026496],"about_ca_topic_score_codex":0.0001898281,"about_ca_topic_score_gemma":0.00022721362,"teacher_disagreement_score":0.05813384,"about_ca_system_score_codex":0.000028044513,"about_ca_system_score_gemma":0.000065332955,"threshold_uncertainty_score":0.38611895},"labels":[],"label_agreement":null},{"id":"W4388626087","doi":"10.25251/skin.7.supp.256","title":"A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Randomized controlled trial; Placebo; Clinical endpoint; Internal medicine; Gastroenterology; Psoriasis; Dermatology","score_opus":0.03396525115363107,"score_gpt":0.3609531808656619,"score_spread":0.32698792971203083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951435,0.0002464794,0.00006266251,0.0029131856,0.000112756636,0.0013129886,0.0000108009735,0.0000089009345,0.00018876222],"genre_scores_gemma":[0.99806243,0.0010011614,0.00016961615,0.0005272934,0.0001676235,0.000006485653,0.000007165869,0.00002531146,0.00003288497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971343,0.0002911533,0.00083564944,0.00019990644,0.0012268301,0.000312135],"domain_scores_gemma":[0.9970594,0.0014204927,0.000567573,0.00022229562,0.00049442385,0.00023579289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017584243,0.00024311444,0.0008103894,0.00021356241,0.00014958455,0.000008458778,0.00015849626,0.000041860007,0.00005405082],"category_scores_gemma":[0.0007417807,0.00011405733,0.00003433827,0.000617308,0.00013965437,0.00007470535,0.00007923994,0.00054572505,0.00000214733],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58714944,0.010466675,0.15838835,0.0008938063,0.005149178,0.0066624386,0.10680324,0.010758549,0.0012071547,0.000013466184,0.0022834097,0.110224284],"study_design_scores_gemma":[0.40042308,0.28085917,0.17745154,0.01110798,0.010499869,0.00848079,0.093159586,0.013735727,0.0010761633,0.0001410519,0.0020444077,0.0010206266],"about_ca_topic_score_codex":0.00022742072,"about_ca_topic_score_gemma":0.00017534959,"teacher_disagreement_score":0.2703925,"about_ca_system_score_codex":0.00009952914,"about_ca_system_score_gemma":0.00012395816,"threshold_uncertainty_score":0.4651123},"labels":[],"label_agreement":null},{"id":"W4388626089","doi":"10.25251/skin.7.supp.293","title":"Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Concert Pharmaceuticals; Pfizer; Eli Lilly and Company","keywords":"Alopecia areata; Eyebrow; Scalp; Eyelash; Dermatology; Post-hoc analysis; Medicine; Post hoc; Hair loss; Hair growth; Surgery; Orthodontics; Internal medicine; Biology; Physiology","score_opus":0.00823029362534534,"score_gpt":0.2649879771580626,"score_spread":0.2567576835327173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219936,0.00042424156,0.00005359233,0.005050909,0.00010564809,0.0009537931,0.0000221509,0.000019257133,0.0011710258],"genre_scores_gemma":[0.9984931,0.00021479478,0.000052733063,0.0006163644,0.00012650609,0.000005042241,0.000028176986,0.000041289546,0.0004219901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996693,0.0003032273,0.0009152337,0.00025276837,0.0014077951,0.00042795212],"domain_scores_gemma":[0.99738306,0.0005134601,0.00060125144,0.00053952687,0.00075166806,0.00021106027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008978182,0.0003254675,0.0011472413,0.0006608314,0.00014509246,0.000012532343,0.00035962867,0.000080120444,0.00010972266],"category_scores_gemma":[0.00060331874,0.00013794823,0.00013277047,0.0029990117,0.0005918305,0.00012548496,0.00009779437,0.0005557794,0.0000023679072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06813146,0.0059542754,0.8434971,0.00031458895,0.008220202,0.0043944847,0.050616752,0.0007596446,0.00019489584,0.000099660276,0.008709582,0.009107338],"study_design_scores_gemma":[0.080262594,0.064090945,0.70203936,0.0018629091,0.0152320955,0.001858555,0.13140568,0.00046327684,0.00011272167,0.00041026593,0.0016845533,0.0005770215],"about_ca_topic_score_codex":0.00024032776,"about_ca_topic_score_gemma":0.0013002027,"teacher_disagreement_score":0.14145774,"about_ca_system_score_codex":0.00007992147,"about_ca_system_score_gemma":0.00025695466,"threshold_uncertainty_score":0.56253654},"labels":[],"label_agreement":null},{"id":"W4388626102","doi":"10.25251/skin.7.supp.246","title":"Flare Frequency and Duration in Patients with Generalized Pustular Psoriasis (GPP)","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Flare; Psoriasis; Erythema; Generalized pustular psoriasis; Sepsis; Pediatrics; Dermatology; Internal medicine","score_opus":0.008628953416183355,"score_gpt":0.21938818921263625,"score_spread":0.2107592357964529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952218,0.0027055405,0.000012763978,0.0010935953,0.0006396739,0.00017518774,0.000007939282,0.000013500059,0.00012998532],"genre_scores_gemma":[0.9981599,0.0011219345,0.00004725784,0.000087757464,0.000121542456,0.0000026661935,0.00004578016,0.000013244024,0.00039994062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989039,0.0002835786,0.00040775264,0.00009920251,0.000106273495,0.000199316],"domain_scores_gemma":[0.99919844,0.00021707924,0.00028534836,0.00014583784,0.00012677521,0.000026499181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047242583,0.00014337833,0.0003247092,0.00021183328,0.00011025699,0.000004486129,0.00013941524,0.00010212978,0.0001549563],"category_scores_gemma":[0.00014170159,0.0000716583,0.000033845216,0.00029524148,0.00013371218,0.000060148235,0.000019064435,0.00017633443,0.000023994016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011806223,0.0006479561,0.69739366,0.00012438143,0.00306523,0.0020917186,0.021166062,0.00023551652,0.09640268,0.00050107384,0.018275337,0.14829017],"study_design_scores_gemma":[0.03881378,0.008661794,0.91682655,0.0009097826,0.0022189105,0.006987388,0.0034774994,0.000019438608,0.011567297,0.002690392,0.0071893753,0.00063782005],"about_ca_topic_score_codex":0.00007581354,"about_ca_topic_score_gemma":0.00008389338,"teacher_disagreement_score":0.21943288,"about_ca_system_score_codex":0.000037305817,"about_ca_system_score_gemma":0.000036671034,"threshold_uncertainty_score":0.2922141},"labels":[],"label_agreement":null},{"id":"W4388627102","doi":"10.25251/skin.7.supp.255","title":"Efficacy of Apremilast in Patients with Moderate-to-Severe Genital Psoriasis: Body Surface Area Subgroup Results from the Phase 3 DISCREET Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Probity Medical Research; Guenther Dermatology Research Centre","funders":"Amgen","keywords":"Apremilast; Psoriasis; Body surface area; Medicine; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.016358601469401518,"score_gpt":0.24945393813424263,"score_spread":0.2330953366648411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959295,0.00063063565,0.000022854041,0.0010409406,0.0011532467,0.0006725329,0.0003953199,0.000015996719,0.00013900863],"genre_scores_gemma":[0.998834,0.00018205267,0.000021899275,0.00007042078,0.00028169018,0.000003241986,0.00025848576,0.000024978008,0.00032323386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99766093,0.000608536,0.0009236144,0.00020738727,0.00025281575,0.00034668634],"domain_scores_gemma":[0.996222,0.0024814324,0.00062669575,0.00043003043,0.00018246232,0.000057369092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009175367,0.0002713863,0.00066932495,0.00013444145,0.00015005842,0.000008021379,0.0005330419,0.00014497846,0.00010093694],"category_scores_gemma":[0.00067508325,0.00012048215,0.00011382752,0.00048301942,0.00022804053,0.00006041739,0.00006641811,0.00036530782,0.00003456892],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94279945,0.0015626211,0.0041621765,0.000009150834,0.0018049126,0.00033731194,0.012061474,0.0026980771,0.011819803,0.000009407008,0.012840092,0.009895515],"study_design_scores_gemma":[0.8630683,0.031362295,0.074197166,0.0016083763,0.0035436952,0.0011562092,0.0069417176,0.00011426498,0.01378497,0.00033917997,0.003085522,0.000798303],"about_ca_topic_score_codex":0.00023681995,"about_ca_topic_score_gemma":0.00014879818,"teacher_disagreement_score":0.07973115,"about_ca_system_score_codex":0.000052959353,"about_ca_system_score_gemma":0.00009258661,"threshold_uncertainty_score":0.49131197},"labels":[],"label_agreement":null},{"id":"W4388627217","doi":"10.25251/skin.7.supp.237","title":"PASI Improvement in the First 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE Guselkumab Clinical Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University; Dalhousie University; Probity Medical Research","funders":"Amgen","keywords":"Medicine; Placebo; Clinical trial; Interquartile range; Internal medicine","score_opus":0.06724673980502993,"score_gpt":0.35733990167381413,"score_spread":0.2900931618687842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665389,0.008425148,0.00001773041,0.020832146,0.0032307568,0.0005776609,0.000059968177,0.00001612271,0.00030157928],"genre_scores_gemma":[0.9839822,0.011167676,0.000007067263,0.0015444598,0.0023952078,0.000010721827,0.000044646207,0.000018643284,0.0008293542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953229,0.0025034186,0.0014752169,0.00018993484,0.00018082601,0.00032771795],"domain_scores_gemma":[0.98654836,0.012026713,0.0008729109,0.0004475827,0.00006367478,0.00004075712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011514389,0.00024389598,0.00082417665,0.00010624383,0.00033209173,0.000019344201,0.0006266251,0.00021474202,0.00040900428],"category_scores_gemma":[0.002144985,0.000090775924,0.0002168527,0.00022719707,0.00040755043,0.000046397596,0.00008228464,0.00066761725,0.00007453901],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013697786,0.001301117,0.00576492,0.00003467038,0.0033005225,0.0027699796,0.028866896,0.000019561367,0.028828233,0.00017594048,0.3210238,0.5942166],"study_design_scores_gemma":[0.07269132,0.019029805,0.027852885,0.001157044,0.0077959253,0.010631874,0.02592444,0.00006603242,0.0059917993,0.007062823,0.8210792,0.00071683316],"about_ca_topic_score_codex":0.0001687097,"about_ca_topic_score_gemma":0.000390876,"teacher_disagreement_score":0.5934998,"about_ca_system_score_codex":0.00003784146,"about_ca_system_score_gemma":0.00006645382,"threshold_uncertainty_score":0.447831},"labels":[],"label_agreement":null},{"id":"W4388627467","doi":"10.25251/skin.7.supp.251","title":"Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; Probity Medical Research; Queen's University","funders":"","keywords":"Roflumilast; Tolerability; Dermatology; Seborrheic dermatitis; Medicine; Atopic dermatitis; Psoriasis; Apremilast; Internal medicine; Adverse effect","score_opus":0.014233596826854404,"score_gpt":0.2521682519196282,"score_spread":0.2379346550927738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546784,0.0029118112,0.00001902853,0.00094030704,0.00029657554,0.00030533303,0.000030138293,0.0000069111406,0.000022072618],"genre_scores_gemma":[0.99897623,0.0007478158,0.000022731801,0.00017227941,0.0000275311,0.0000040375417,0.00002791561,0.000008367884,0.000013101453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752384,0.000985219,0.0010569483,0.000120471865,0.00011111829,0.00020241615],"domain_scores_gemma":[0.9982689,0.0009407672,0.00049086974,0.00013834199,0.00009964778,0.000061470084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077325664,0.00016487254,0.0008050663,0.0002170679,0.000054162083,0.000003888813,0.000106502026,0.0001305446,0.000060315444],"category_scores_gemma":[0.00076362945,0.000091750386,0.000036958132,0.0003021919,0.00049033994,0.00006303087,0.00003490938,0.00022186135,0.0000021850547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018390322,0.00062253576,0.75904375,0.00016409044,0.00047505944,0.00042873947,0.01422463,0.000054576507,0.003457832,0.00004937126,0.002369861,0.21727054],"study_design_scores_gemma":[0.027558342,0.0047201896,0.94606197,0.0010030587,0.00043235798,0.0017773302,0.0031680942,0.00003774064,0.01312029,0.00066061446,0.0012329653,0.00022704148],"about_ca_topic_score_codex":0.00014535493,"about_ca_topic_score_gemma":0.0002031287,"teacher_disagreement_score":0.21704349,"about_ca_system_score_codex":0.000044366294,"about_ca_system_score_gemma":0.000082191764,"threshold_uncertainty_score":0.3741472},"labels":[],"label_agreement":null},{"id":"W4388627499","doi":"10.25251/skin.7.supp.241","title":"Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Placebo; Clinical endpoint; Apremilast; Clinical trial; Internal medicine; Randomized controlled trial; Tolerability; Adverse effect; Gastroenterology; Dermatology; Psoriatic arthritis","score_opus":0.03370635970462376,"score_gpt":0.3210922749445532,"score_spread":0.28738591523992946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988863,0.0063137654,0.000005830953,0.0037128201,0.00062780274,0.00029051414,0.000038176262,0.00000728826,0.0001408326],"genre_scores_gemma":[0.99388856,0.0051800027,0.000016369167,0.00026091005,0.00013586911,0.000005909298,0.000008569813,0.000013799116,0.0004900212],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99563336,0.0027691128,0.0010307999,0.00012862807,0.00014019498,0.00029789738],"domain_scores_gemma":[0.99347043,0.0055596135,0.00062627485,0.00025551522,0.0000622656,0.000025877289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008589252,0.00017496024,0.0007661364,0.00040149342,0.00005512532,0.000004732276,0.00036285628,0.00015928375,0.00015591679],"category_scores_gemma":[0.0024614714,0.00008612783,0.00010953536,0.0004965267,0.00032974742,0.00004441391,0.000034497552,0.0003708861,0.00001646522],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15977752,0.0012769533,0.0057407357,0.00012514413,0.0019067776,0.011073366,0.077103004,0.00012142765,0.4949413,0.00091921753,0.07286288,0.17415167],"study_design_scores_gemma":[0.22223976,0.027862068,0.27570346,0.007194477,0.0047808564,0.09992779,0.08342546,0.00008154492,0.066117525,0.016815102,0.19423513,0.001616825],"about_ca_topic_score_codex":0.000095055264,"about_ca_topic_score_gemma":0.00011656438,"teacher_disagreement_score":0.42882377,"about_ca_system_score_codex":0.000039044724,"about_ca_system_score_gemma":0.00009433217,"threshold_uncertainty_score":0.3512191},"labels":[],"label_agreement":null},{"id":"W4388627518","doi":"10.25251/skin.7.supp.274","title":"Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Atopic dermatitis; Baseline (sea); Medicine; Disease; Dermatology; Internal medicine; Biology","score_opus":0.009731015848385895,"score_gpt":0.24444169373603114,"score_spread":0.23471067788764524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98992985,0.0009911319,0.00004894642,0.007850427,0.00020598908,0.00051738496,0.00004499397,0.000023368671,0.00038792257],"genre_scores_gemma":[0.9976901,0.0003149836,0.000049175782,0.0013120375,0.000100869715,0.000003927432,0.00005959996,0.000026845802,0.00044246175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974639,0.000321151,0.00091848295,0.0001791681,0.00077886984,0.00033845144],"domain_scores_gemma":[0.99739665,0.00083716563,0.0004488833,0.00039284732,0.00046723196,0.00045725104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004750171,0.00024992644,0.00084006245,0.00032042104,0.000111459885,0.0000056792724,0.00023525194,0.000073063355,0.0002705781],"category_scores_gemma":[0.0009844113,0.0001418435,0.00011740525,0.00049631007,0.0004192059,0.000064340034,0.00007363736,0.00034397462,0.000021464446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021819437,0.001187159,0.86387223,0.0007786553,0.000611872,0.010059907,0.0013851624,0.0026223115,0.000044138185,0.000029987834,0.09205851,0.005530625],"study_design_scores_gemma":[0.012827123,0.0011511595,0.96888626,0.0033377912,0.0010536658,0.009076375,0.0005558593,0.0007326194,0.0003598517,0.000388444,0.0013673181,0.00026355535],"about_ca_topic_score_codex":0.000030440237,"about_ca_topic_score_gemma":0.00007318482,"teacher_disagreement_score":0.105014004,"about_ca_system_score_codex":0.00014249596,"about_ca_system_score_gemma":0.00029045486,"threshold_uncertainty_score":0.578421},"labels":[],"label_agreement":null},{"id":"W4388627525","doi":"10.25251/skin.7.supp.283","title":"Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; Innovaderm (Canada)","funders":"Sanofi Genzyme; Allergan; Genentech; Merz Pharmaceuticals; Galderma; Astellas Pharma; Coherus Biosciences; Glenmark Pharmaceuticals; Castle Biosciences; Pfizer; Biogen; Incyte; Boston Pharmaceuticals; Sun Pharma; Dermira; Les Laboratories Pierre Fabre; DUSA Pharmaceuticals; Meiji Seika Pharma; Kiniksa Pharmaceuticals; Baxalta; Novartis; Celgene; Ablynx; LEO Pharma; Ortho Dermatologics; Gilead Sciences; GlaxoSmithKline; Astellas Pharma US; Amgen; Eli Lilly and Company; Bristol-Myers Squibb; UCB Pharma; Valeant Pharmaceuticals International; Bausch Health; Bayer HealthCare; L'Oreal USA; Sanofi; Regeneron Pharmaceuticals; Abbott Laboratories","keywords":"Atopic dermatitis; Medicine; Pediatrics; Dermatology","score_opus":0.021127848193232216,"score_gpt":0.3429666336027493,"score_spread":0.3218387854095171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924163,0.002921521,0.0000027688163,0.0036395371,0.00009575685,0.0007794245,0.000016916787,0.000004432232,0.00012333672],"genre_scores_gemma":[0.99591666,0.0036055862,0.000025467953,0.00027023276,0.00012629626,0.0000070139954,0.00001069558,0.000010079009,0.000027950497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973009,0.0007181989,0.0012604663,0.00011705734,0.00039115493,0.00021221463],"domain_scores_gemma":[0.996609,0.002534997,0.00046286065,0.00024236161,0.000048945054,0.00010187507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015422149,0.00014827144,0.0011100287,0.00041703763,0.000020770667,0.0000031357717,0.00019502938,0.00004550162,0.000042508735],"category_scores_gemma":[0.0015970872,0.00007827921,0.00010293899,0.0005629467,0.00026184588,0.000029947278,0.000018928027,0.00020139462,0.0000023090447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029058866,0.018754566,0.3575504,0.0008249157,0.0012612374,0.10088771,0.21287301,0.0015128152,0.008763645,0.00016894031,0.017596282,0.25074762],"study_design_scores_gemma":[0.0376893,0.007096477,0.93118566,0.003998269,0.0004890825,0.011591757,0.005126136,0.00009365106,0.0017998333,0.0003740417,0.0004150457,0.00014076187],"about_ca_topic_score_codex":0.00041208178,"about_ca_topic_score_gemma":0.00022451737,"teacher_disagreement_score":0.5736352,"about_ca_system_score_codex":0.000050973827,"about_ca_system_score_gemma":0.00009470064,"threshold_uncertainty_score":0.31921336},"labels":[],"label_agreement":null},{"id":"W4388627625","doi":"10.25251/skin.7.supp.275","title":"Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Atopic dermatitis; Dermatology; Medicine","score_opus":0.014415897230552317,"score_gpt":0.26140892340517063,"score_spread":0.24699302617461832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9648653,0.0065352786,0.00008667094,0.027419481,0.0002389961,0.00043643833,0.000043655065,0.0000133401845,0.00036078776],"genre_scores_gemma":[0.99459845,0.0033095512,0.00004678216,0.0016035859,0.000139937,0.0000036607044,0.00003602393,0.000020465663,0.00024156357],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99778414,0.00017995469,0.0008260381,0.00017770455,0.0007429553,0.00028919897],"domain_scores_gemma":[0.9978775,0.00061611395,0.0005261441,0.000662577,0.00016908543,0.00014861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061540917,0.00020283599,0.00059996964,0.00019137209,0.0001050047,0.000008717942,0.0004411144,0.00006206263,0.0001238758],"category_scores_gemma":[0.00027189386,0.00009128768,0.000046365483,0.00038112944,0.00043330944,0.00009573663,0.00017678105,0.00037457462,0.0000058782553],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037511291,0.0010489642,0.07035964,0.0012601819,0.001954515,0.019065997,0.015807454,0.000114328155,0.0048140083,0.00021820527,0.71552837,0.1660772],"study_design_scores_gemma":[0.028879348,0.011410719,0.54290235,0.0107325995,0.0053421063,0.22862333,0.027629197,0.0029903634,0.019839674,0.0030869485,0.11744606,0.001117315],"about_ca_topic_score_codex":0.000114244256,"about_ca_topic_score_gemma":0.000080115235,"teacher_disagreement_score":0.5980823,"about_ca_system_score_codex":0.000043721342,"about_ca_system_score_gemma":0.00013399954,"threshold_uncertainty_score":0.37226036},"labels":[],"label_agreement":null},{"id":"W4388627693","doi":"10.25251/skin.7.supp.281","title":"Rapid and Early Onset of Itch Relief with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to Two Years of Age with Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Atopic dermatitis; Medicine; Pediatrics; Dermatology; Age of onset; Internal medicine; Disease","score_opus":0.01153428356414079,"score_gpt":0.30186421601574276,"score_spread":0.290329932451602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372995,0.003446575,0.000009105751,0.0020876364,0.000047075737,0.00052043487,0.00001851511,0.000007125305,0.00013358437],"genre_scores_gemma":[0.997555,0.0018575669,0.00014916924,0.00029039325,0.000080742044,0.0000036762412,0.0000067412857,0.000016476079,0.000040208608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978587,0.0003768484,0.00097449706,0.0001406031,0.00043466772,0.00021467009],"domain_scores_gemma":[0.99780476,0.0011300981,0.0005653872,0.00021192477,0.00011066841,0.00017718361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012958964,0.0001631793,0.0011692584,0.00041511416,0.000027184735,0.0000044323424,0.00013492831,0.000042747426,0.000031755182],"category_scores_gemma":[0.001002614,0.000093309725,0.000044387332,0.0005004544,0.0004520481,0.000063209874,0.00003500595,0.00030892697,9.274798e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028693689,0.0011533317,0.8659058,0.0005622015,0.00070331857,0.03586921,0.02503704,0.0001604367,0.0012087061,0.000032412667,0.0061977096,0.034476098],"study_design_scores_gemma":[0.031485133,0.0065350216,0.9004742,0.0076602018,0.0004770369,0.050303034,0.0016713368,0.000033199398,0.0009043985,0.00020959713,0.00010101121,0.00014582211],"about_ca_topic_score_codex":0.00047742898,"about_ca_topic_score_gemma":0.0003429066,"teacher_disagreement_score":0.034568362,"about_ca_system_score_codex":0.00002031345,"about_ca_system_score_gemma":0.00012541167,"threshold_uncertainty_score":0.380506},"labels":[],"label_agreement":null},{"id":"W4388627694","doi":"10.25251/skin.7.supp.271","title":"Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Atopic dermatitis; Dermatology; Medicine","score_opus":0.006471958431611242,"score_gpt":0.2525797674709807,"score_spread":0.24610780903936946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900612,0.00021721981,0.000057878897,0.008778093,0.0001042131,0.0004177742,0.000009040178,0.000010690906,0.00034387995],"genre_scores_gemma":[0.9966827,0.00012620943,0.000119835095,0.0027965698,0.00007139677,0.0000016197519,0.0000057535376,0.000017737164,0.000178201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857056,0.000103726954,0.00053177634,0.00010937954,0.00045909084,0.00022544086],"domain_scores_gemma":[0.99885184,0.00033530866,0.00018268706,0.00021386592,0.00018205182,0.00023423696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027588243,0.00013679506,0.00053993793,0.0003256525,0.000045025674,0.0000037359591,0.00014519924,0.000041286174,0.00011702543],"category_scores_gemma":[0.0003448798,0.00008037786,0.000035127654,0.0004623197,0.00014210957,0.000038164788,0.000048582235,0.00021764841,0.000015266056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058439437,0.0009763599,0.6932897,0.0006105802,0.001273962,0.015580232,0.03417121,0.0050269044,0.00023309737,0.00020590705,0.14107117,0.049121466],"study_design_scores_gemma":[0.013815772,0.0017754876,0.97321427,0.0015778963,0.00028136413,0.006432807,0.0006899354,0.00012152866,0.00013812128,0.00040874077,0.001415205,0.00012888414],"about_ca_topic_score_codex":0.000030038633,"about_ca_topic_score_gemma":0.000022791204,"teacher_disagreement_score":0.27992457,"about_ca_system_score_codex":0.00004667677,"about_ca_system_score_gemma":0.00009440503,"threshold_uncertainty_score":0.3277714},"labels":[],"label_agreement":null},{"id":"W4390904660","doi":"10.25251/skin.8.supp.323","title":"Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"LEO Pharma","keywords":"Medicine; Placebo; Internal medicine; Population; Atopic dermatitis; Adverse effect; Randomized controlled trial; Urinalysis; Immunology; Urine; Pathology; Alternative medicine","score_opus":0.017325709700609523,"score_gpt":0.2691248105297688,"score_spread":0.25179910082915924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390904660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98419076,0.00092188996,0.000114965165,0.012612104,0.0005111044,0.0012485922,0.00016330762,0.0000340911,0.00020320364],"genre_scores_gemma":[0.99357283,0.00014474179,0.00010194091,0.0054720757,0.00035753183,0.000015123725,0.000055083194,0.000041871423,0.00023879888],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971204,0.00047660945,0.0009300126,0.00027684023,0.0008195154,0.00037662408],"domain_scores_gemma":[0.9976072,0.0010394693,0.00027304463,0.0004442802,0.00024080534,0.00039523913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045985586,0.00033791785,0.0007714356,0.00024614597,0.0001273265,0.000038621463,0.00032326856,0.000096219825,0.0000761072],"category_scores_gemma":[0.0005335818,0.00014783385,0.00008775002,0.00055856124,0.00024853606,0.00010329771,0.000023581966,0.000760992,0.000015449827],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56529945,0.0020065946,0.009718058,0.0002073413,0.001645631,0.036853984,0.02771715,0.0025326074,0.00017104331,0.0000060355433,0.34549198,0.008350136],"study_design_scores_gemma":[0.692635,0.05548754,0.11800606,0.03731123,0.008721301,0.0373511,0.012533426,0.0015457676,0.004911048,0.0004511762,0.029291118,0.0017552219],"about_ca_topic_score_codex":0.00014440113,"about_ca_topic_score_gemma":0.00036091075,"teacher_disagreement_score":0.31620085,"about_ca_system_score_codex":0.00016093592,"about_ca_system_score_gemma":0.00039054282,"threshold_uncertainty_score":0.60284895},"labels":[],"label_agreement":null},{"id":"W4390904669","doi":"10.25251/skin.8.supp.313","title":"Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Eli Lilly and Company","keywords":"Medicine; Atopic dermatitis; Eczema Area and Severity Index; Internal medicine; Psoriasis Area and Severity Index; SCORAD; Placebo; Randomized controlled trial; Dermatology Life Quality Index; Confidence interval; Clinical trial; Meta-analysis; Dermatology; Disease; Psoriasis","score_opus":0.06190123348030831,"score_gpt":0.3494641162330036,"score_spread":0.2875628827526953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390904669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5615404,0.37842023,0.038222775,0.018632246,0.0010345427,0.0015665278,0.000043742584,0.000087547625,0.00045193927],"genre_scores_gemma":[0.9969552,0.00046908966,0.00073533703,0.0010239144,0.00046475665,0.0000146751145,0.000012972813,0.000034114688,0.00028991152],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971973,0.00031047722,0.0014205062,0.0001820869,0.0005746591,0.0003149765],"domain_scores_gemma":[0.9964416,0.0020439855,0.00056490296,0.0003585752,0.00039286356,0.0001980632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084596156,0.00027224267,0.0024434263,0.00045873784,0.00015852296,0.000019300463,0.00030481862,0.00010287184,0.00028866422],"category_scores_gemma":[0.0004308799,0.00014544759,0.0009920633,0.0008189539,0.00017719969,0.00006801056,0.00003850413,0.0003572742,0.00000623636],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078212265,0.00060902134,0.0049690725,0.00355417,0.52688384,0.0030049349,0.0273547,0.1782471,0.0012986409,0.0008603888,0.24052887,0.0048680385],"study_design_scores_gemma":[0.0063999533,0.0026439715,0.0025996058,0.003284367,0.83254343,0.06666557,0.005255337,0.061445184,0.0025969518,0.0046292446,0.011282588,0.00065378944],"about_ca_topic_score_codex":0.000018678935,"about_ca_topic_score_gemma":0.00001618611,"teacher_disagreement_score":0.4354148,"about_ca_system_score_codex":0.00007078534,"about_ca_system_score_gemma":0.00016774089,"threshold_uncertainty_score":0.5931181},"labels":[],"label_agreement":null},{"id":"W4390904672","doi":"10.25251/skin.8.supp.344","title":"Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adverse effect; Placebo; Discontinuation; Medicine; Pemphigus; Dosing; Myasthenia gravis; Clinical trial; Incidence (geometry); Antibody; Immunology; Internal medicine; Pemphigus vulgaris; Pharmacology","score_opus":0.09975937179068395,"score_gpt":0.40087419878286107,"score_spread":0.3011148269921771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390904672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90517586,0.08058732,0.00005120427,0.010274983,0.0016182774,0.0013945575,0.00023067894,0.000055310054,0.0006117823],"genre_scores_gemma":[0.9919407,0.006165923,0.000058516864,0.0006601846,0.0007090089,0.000008682075,0.000024372452,0.000054995504,0.00037761868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99171066,0.002618221,0.0035555963,0.0002743244,0.0013878519,0.00045332362],"domain_scores_gemma":[0.9861584,0.010553292,0.0017262403,0.00091652106,0.0003235682,0.00032202157],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0063386047,0.0003511844,0.002406086,0.0002097099,0.00009652053,0.00001647517,0.0006183687,0.00014473993,0.0015344209],"category_scores_gemma":[0.015225006,0.00014265353,0.0005980484,0.00078487577,0.0010468992,0.000100281155,0.00015747503,0.00092472305,0.000028815388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12243249,0.009377299,0.51085675,0.004760823,0.018036593,0.035539497,0.024655012,0.0019301638,0.018127235,0.0006280941,0.11873587,0.13492018],"study_design_scores_gemma":[0.020303026,0.0070513864,0.8619671,0.043385424,0.020094728,0.0056259315,0.0057863775,0.0036568227,0.001340016,0.0015859323,0.02854953,0.0006537218],"about_ca_topic_score_codex":0.0002666428,"about_ca_topic_score_gemma":0.000053828666,"teacher_disagreement_score":0.35111037,"about_ca_system_score_codex":0.00015669921,"about_ca_system_score_gemma":0.0011975478,"threshold_uncertainty_score":0.9993783},"labels":[],"label_agreement":null},{"id":"W4390904689","doi":"10.25251/skin.8.supp.349","title":"Bimekizumab Efficacy by Prior Biologic Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: 48-Week Pooled Data from the Randomized, Double-Blind, Placebo-Controlled, Multicenter BE HEARD I and II Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Cilag; Genentech; LEO Pharma; Sanofi Genzyme; Incyte; National Eczema Association; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Biogen; Amgen; Pfizer; Galderma; Eli Lilly and Company; Sanofi","keywords":"Hidradenitis suppurativa; Medicine; Double blind; Placebo; Multicenter study; Pooled analysis; Internal medicine; Multicenter trial; Dermatology; Randomized controlled trial; Pathology; Alternative medicine; Meta-analysis; Disease","score_opus":0.05229412364784481,"score_gpt":0.3412784765418269,"score_spread":0.2889843528939821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390904689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89277005,0.006604806,0.00014817624,0.09166296,0.00048117107,0.007621006,0.00057409273,0.00002879348,0.000108970344],"genre_scores_gemma":[0.9960455,0.0013276438,0.00019299512,0.00022979188,0.0005362261,0.00008508882,0.0004991328,0.000057064117,0.0010265707],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947814,0.0016755055,0.0017613632,0.0004844357,0.0008457371,0.000451602],"domain_scores_gemma":[0.9912418,0.0069227265,0.0005970751,0.000678317,0.00020303743,0.00035705825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004901931,0.000596698,0.002913124,0.00026424698,0.00028178058,0.00009817327,0.0004206743,0.00014181423,0.0004660923],"category_scores_gemma":[0.0014049577,0.00021357853,0.00022522997,0.00032600688,0.00038869597,0.00023999241,0.00012310034,0.0005555056,0.000019174284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9595632,0.0019082295,0.00017621995,0.000021429576,0.0042190584,0.011991031,0.007205081,0.000007542435,0.0002728577,0.000004501605,0.0059230104,0.0087078335],"study_design_scores_gemma":[0.9503853,0.010542909,0.000032706354,0.0013574519,0.007118355,0.026200509,0.0009210498,0.0008642299,0.00028634272,0.00005731809,0.0019857886,0.00024809118],"about_ca_topic_score_codex":0.00040216607,"about_ca_topic_score_gemma":0.00014933624,"teacher_disagreement_score":0.10327546,"about_ca_system_score_codex":0.00025438107,"about_ca_system_score_gemma":0.00028869163,"threshold_uncertainty_score":0.870948},"labels":[],"label_agreement":null},{"id":"W4390904736","doi":"10.25251/skin.8.supp.317","title":"Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of Winnipeg; Guenther Dermatology Research Centre","funders":"","keywords":"Dupilumab; Medicine; Atopic dermatitis; Eczema Area and Severity Index; Dermatology","score_opus":0.009187213847154527,"score_gpt":0.25410663789559734,"score_spread":0.2449194240484428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390904736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035984,0.001947389,0.000024240606,0.0068471082,0.00019568708,0.00029860518,0.00001777014,0.0000031769043,0.00030616898],"genre_scores_gemma":[0.99813217,0.00014061354,0.000018896795,0.0015874493,0.000042491407,0.0000031716625,0.000010269443,0.00001076757,0.000054172688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827826,0.00022987474,0.0005439438,0.00011372981,0.00063219125,0.00020202438],"domain_scores_gemma":[0.99851936,0.0008743989,0.00013546881,0.00021326561,0.00014276049,0.00011474066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032993744,0.00015199845,0.0005958635,0.00047445233,0.000042238426,0.000009238865,0.00018195123,0.000047080728,0.00013469675],"category_scores_gemma":[0.00022399162,0.000071520684,0.000055045344,0.0007133616,0.00015427181,0.0000542543,0.000016100612,0.00036512894,6.8994007e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023583386,0.00057889713,0.86729056,0.00054071157,0.0050230506,0.023625161,0.021122277,0.011664137,0.000022448043,0.00011566002,0.037352912,0.009080797],"study_design_scores_gemma":[0.0076948446,0.001089233,0.9741973,0.0009526015,0.003556348,0.0058360193,0.0026237268,0.00150378,0.000029651615,0.000086543776,0.0022785545,0.00015134951],"about_ca_topic_score_codex":0.01682504,"about_ca_topic_score_gemma":0.16982274,"teacher_disagreement_score":0.1529977,"about_ca_system_score_codex":0.00013214591,"about_ca_system_score_gemma":0.0004371974,"threshold_uncertainty_score":0.989722},"labels":[],"label_agreement":null},{"id":"W4390905440","doi":"10.25251/skin.8.supp.305","title":"Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Manchester Biomedical Research Centre; Galderma; Meiji Seika Pharma; Astellas Pharma; Celltrion; Eisai; UCB Pharma; Valeant Pharmaceuticals International; Argenx; Pfizer; Biogen; Incyte; Genentech; Torii Pharmaceutical; Dalhousie University; Castle Biosciences; Sun Pharma; Dermira; Universität zu Lübeck; Regeneron Pharmaceuticals; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Celgene; Yale University; Sanofi; Amgen; LEO Pharma; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Tolerability; Plaque psoriasis; Medicine; Term (time); Pooled analysis; Psoriasis; Internal medicine; Dermatology; Adverse effect; Meta-analysis; Physics","score_opus":0.01961196471794321,"score_gpt":0.29877832102755414,"score_spread":0.27916635630961095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390905440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97123027,0.022919819,0.0007064163,0.0031665633,0.0012303129,0.00038441198,0.00022506085,0.000021933092,0.00011523994],"genre_scores_gemma":[0.9955836,0.003012193,0.000062442625,0.00018489618,0.0003767633,0.000004862038,0.000077865705,0.00001890232,0.0006784853],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9963932,0.0015290771,0.0013310425,0.00030366232,0.00013998795,0.0003030546],"domain_scores_gemma":[0.9963096,0.0027684132,0.00037351015,0.00033382658,0.00012446716,0.0000902006],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025086734,0.00030120867,0.0015514833,0.000523536,0.00012506712,0.00002684867,0.00028573364,0.00022468276,0.0011994074],"category_scores_gemma":[0.0006378078,0.00016595196,0.0002754641,0.00063662697,0.00015673196,0.000087044784,0.00005548027,0.00043624738,0.000040700153],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16418763,0.0016845841,0.010310795,0.0002168282,0.06506763,0.008295439,0.053837854,0.004234194,0.090410024,0.0001979818,0.0075231665,0.5940339],"study_design_scores_gemma":[0.23607317,0.0374241,0.15067454,0.012713721,0.29177672,0.06296548,0.023685714,0.0028543596,0.13616192,0.017780988,0.021966416,0.0059228875],"about_ca_topic_score_codex":0.00030333098,"about_ca_topic_score_gemma":0.00048149878,"teacher_disagreement_score":0.588111,"about_ca_system_score_codex":0.00014213292,"about_ca_system_score_gemma":0.00012785704,"threshold_uncertainty_score":0.99971366},"labels":[],"label_agreement":null},{"id":"W4390933271","doi":"10.25251/skin.8.supp.309","title":"Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; Probity Medical Research; Queen's University","funders":"","keywords":"Tolerability; Dermatology; Medicine; Atopic dermatitis; Roflumilast; Dermis; Seborrheic dermatitis; Psoriasis; Erythema; Transepidermal water loss; Stratum corneum; Adverse effect; Pharmacology; Pathology; Internal medicine","score_opus":0.011008101040012647,"score_gpt":0.27515729889299273,"score_spread":0.2641491978529801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390933271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855482,0.009458244,0.00008312581,0.0041842265,0.00021633282,0.00040852829,0.00001550517,0.00000795048,0.000077904035],"genre_scores_gemma":[0.9983903,0.00060616335,0.00006704991,0.00084380223,0.000062280335,0.0000032899861,0.000009069743,0.000011838589,0.000006173543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734825,0.0005867525,0.001353175,0.00014128779,0.00038654747,0.00018397515],"domain_scores_gemma":[0.998096,0.0010343995,0.00032490972,0.00015976702,0.00014447686,0.00024046088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006688335,0.00017881748,0.0010065839,0.00025470316,0.000032484026,0.00000891661,0.000081952334,0.000095271644,0.0000733909],"category_scores_gemma":[0.0016149625,0.00009668776,0.000049099694,0.00028562165,0.0007402887,0.00010253736,0.000028522734,0.00040265705,6.099426e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018686445,0.00079259276,0.9201599,0.00122754,0.0003150392,0.0044677835,0.00813877,0.00003120684,0.00013413248,0.000090738446,0.007626105,0.055147544],"study_design_scores_gemma":[0.022361308,0.004751895,0.9329078,0.007828457,0.0010086236,0.020521486,0.0029266025,0.0010147312,0.0021003957,0.002173076,0.0021257745,0.00027982402],"about_ca_topic_score_codex":0.00006190671,"about_ca_topic_score_gemma":0.00007355962,"teacher_disagreement_score":0.05486772,"about_ca_system_score_codex":0.000059873575,"about_ca_system_score_gemma":0.0002308244,"threshold_uncertainty_score":0.39428127},"labels":[],"label_agreement":null},{"id":"W4390933743","doi":"10.25251/skin.8.supp.307","title":"Bimekizumab Efficacy Through 3 Years in Patients with Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from BE BRIGHT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma","keywords":"Medicine; Dermatology Life Quality Index; Plaque psoriasis; Psoriasis Area and Severity Index; Discontinuation; Psoriasis; Adverse effect; Internal medicine; Clinical trial; Dosing; Dermatology","score_opus":0.009459164200808652,"score_gpt":0.24160882969120187,"score_spread":0.23214966549039323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390933743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99062014,0.0062416587,0.00026540476,0.0014098936,0.0009734728,0.00026547193,0.00007304577,0.00002369675,0.00012723966],"genre_scores_gemma":[0.9982303,0.00044872906,0.00007763478,0.00031783295,0.0002131213,0.000003268291,0.00011996703,0.00002886409,0.000560284],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982861,0.00035608548,0.0005943806,0.00025100622,0.0001922002,0.00032018134],"domain_scores_gemma":[0.99867386,0.00060258125,0.00022561185,0.00032622323,0.00011605797,0.00005568967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002867918,0.00027442907,0.0007299388,0.00041091064,0.0000876901,0.000021799686,0.00036388027,0.00016651419,0.000783715],"category_scores_gemma":[0.00005804343,0.00014549623,0.0001640197,0.0008081953,0.00012197224,0.00010135613,0.000041434116,0.00039034412,0.00007778065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11475514,0.0040562134,0.1865273,0.00018866127,0.1364403,0.020637505,0.11655134,0.014820095,0.012286921,0.0002436647,0.02837931,0.36511356],"study_design_scores_gemma":[0.029290626,0.006289527,0.9038136,0.0027085666,0.03757318,0.003978443,0.0010443588,0.000055235712,0.007836238,0.0006694019,0.0056425016,0.0010983029],"about_ca_topic_score_codex":0.00028265943,"about_ca_topic_score_gemma":0.00033099353,"teacher_disagreement_score":0.7172863,"about_ca_system_score_codex":0.00012348613,"about_ca_system_score_gemma":0.000095560405,"threshold_uncertainty_score":0.85811293},"labels":[],"label_agreement":null},{"id":"W4391033331","doi":"10.25251/skin.8.supp.356","title":"Apremilast for the Treatment of Psoriasis in Special Areas in Pediatric Patients in the SPROUT Study","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"Amgen","keywords":"Apremilast; Psoriasis; Medicine; Dermatology; Intensive care medicine; Psoriatic arthritis","score_opus":0.016159876219574692,"score_gpt":0.26458304217604783,"score_spread":0.24842316595647315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391033331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98216033,0.013588518,0.000004389459,0.00082160695,0.0021672717,0.0010119337,0.000017510913,0.0000030192039,0.00022544825],"genre_scores_gemma":[0.9940328,0.00456297,0.0000037485333,0.0000314982,0.001139596,0.000028613993,0.0000068773247,0.000012413804,0.00018147081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982678,0.0005165453,0.0007193505,0.00012879765,0.00013359384,0.00023391002],"domain_scores_gemma":[0.99695325,0.002523997,0.00023152465,0.00021822278,0.000060360013,0.000012670551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010786337,0.0001863882,0.00044773848,0.0003158835,0.000063094565,0.0000062348217,0.0003633993,0.00008821027,0.00007959972],"category_scores_gemma":[0.00016713688,0.000071287905,0.00012175811,0.00044488252,0.00010398538,0.000031411266,0.000015161362,0.0002174626,0.000007434712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009792855,0.007916933,0.5081796,0.00009859255,0.0012764335,0.0010954841,0.17052923,0.00026444643,0.0004802467,0.00009692386,0.0059902915,0.29427895],"study_design_scores_gemma":[0.035176694,0.033281058,0.85222197,0.0006304631,0.0049971007,0.0022032817,0.04401857,0.00003805735,0.0012681358,0.001298454,0.024441654,0.00042459645],"about_ca_topic_score_codex":0.00020944793,"about_ca_topic_score_gemma":0.0017821066,"teacher_disagreement_score":0.3440423,"about_ca_system_score_codex":0.000135197,"about_ca_system_score_gemma":0.000077247816,"threshold_uncertainty_score":0.29070362},"labels":[],"label_agreement":null},{"id":"W4391033341","doi":"10.25251/skin.8.supp.355","title":"Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient PASI and PASI-HD Responses: Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; Queen's University; University of British Columbia","funders":"","keywords":"Dermis; Medicine; Psoriasis; Plaque psoriasis; Dermatology; Pathology","score_opus":0.01578545855335113,"score_gpt":0.2696607524575266,"score_spread":0.25387529390417546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391033341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9456333,0.051520836,0.000020977064,0.0011499213,0.00094932545,0.00054688146,0.00009626042,0.000020555297,0.000061976076],"genre_scores_gemma":[0.9954877,0.003744757,0.00002786724,0.00018127587,0.00027873367,0.00001237517,0.00004599818,0.000034128407,0.00018717595],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664026,0.0013966975,0.0010804352,0.00027157666,0.00022124372,0.00038978033],"domain_scores_gemma":[0.9965102,0.002525461,0.00052181666,0.0002256477,0.00012362463,0.000093266004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001743376,0.00036376138,0.000980594,0.00042300043,0.00017333071,0.00003272657,0.00021180822,0.00022835589,0.00019013112],"category_scores_gemma":[0.00063569675,0.00018616498,0.0000892422,0.00025748584,0.0004022906,0.00011895063,0.000058214577,0.0004914159,0.000009274026],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05176244,0.0024362616,0.013861218,0.00028737288,0.0070042745,0.00370229,0.023112178,0.000024665364,0.014818999,0.000086505985,0.0101566,0.8727472],"study_design_scores_gemma":[0.26969975,0.21234165,0.124432765,0.01816307,0.034908082,0.10992289,0.018928178,0.00006187358,0.06945104,0.0025923215,0.13607588,0.0034224829],"about_ca_topic_score_codex":0.000050293875,"about_ca_topic_score_gemma":0.00010468967,"teacher_disagreement_score":0.8693247,"about_ca_system_score_codex":0.000121255376,"about_ca_system_score_gemma":0.000280455,"threshold_uncertainty_score":0.75915873},"labels":[],"label_agreement":null},{"id":"W4392906163","doi":"10.25251/skin.8.supp.372","title":"Roflumilast Cream 0.15% in Patients with Atopic Dermatitis: Individual Patient Response from the Pooled INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Integument; Roflumilast; Atopic dermatitis; Dermatology; Medicine; Internal medicine; Anatomy","score_opus":0.012671455455694428,"score_gpt":0.2855433712234824,"score_spread":0.27287191576778796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392906163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698604,0.014093964,0.000060764207,0.014558544,0.000591698,0.0006504077,0.00006096449,0.000018465253,0.00010479871],"genre_scores_gemma":[0.9959391,0.00049400434,0.00004362554,0.0031118323,0.00027029644,0.000008593958,0.00003414514,0.000026066498,0.000072342125],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9961588,0.0013792077,0.0012014584,0.00018186112,0.0008126662,0.00026604935],"domain_scores_gemma":[0.9943047,0.0045504733,0.00045723244,0.00030456786,0.00017765489,0.00020534697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019290115,0.0002684672,0.000861454,0.00025760406,0.00010712489,0.000042062984,0.00025847717,0.00008909183,0.00046852682],"category_scores_gemma":[0.0026036191,0.00011183699,0.00010884052,0.0002743716,0.00048225938,0.00012384052,0.000071577604,0.0007008786,0.000010108315],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086530864,0.0047640186,0.19590561,0.00046781712,0.0080819605,0.024806779,0.0803935,0.000031804404,0.0007143085,0.00009777646,0.39254716,0.20565839],"study_design_scores_gemma":[0.08562079,0.0342941,0.66079485,0.027597254,0.017697413,0.049375854,0.037609313,0.00037755517,0.0033838416,0.0044830902,0.07767869,0.0010872219],"about_ca_topic_score_codex":0.000039845185,"about_ca_topic_score_gemma":0.000028104298,"teacher_disagreement_score":0.4648893,"about_ca_system_score_codex":0.00009049884,"about_ca_system_score_gemma":0.00024252164,"threshold_uncertainty_score":0.513004},"labels":[],"label_agreement":null},{"id":"W4392906202","doi":"10.25251/skin.8.supp.375","title":"Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"LEO Pharma; European Academy of Dermatology and Venereology","keywords":"Atopic dermatitis; Clinical trial; Medicine; Dermatology; Internal medicine","score_opus":0.03268452212128633,"score_gpt":0.36459071650208064,"score_spread":0.33190619438079433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392906202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522144,0.0023910499,0.00022821652,0.0008681759,0.00024046516,0.0007958097,0.00021600879,0.0000037154507,0.000035147754],"genre_scores_gemma":[0.99805963,0.0015109986,0.00010053374,0.000071769035,0.00006252599,0.0000048897673,0.00009684266,0.000013580436,0.000079242156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667037,0.0006111715,0.0021150543,0.00011970806,0.00034458417,0.00013911597],"domain_scores_gemma":[0.99544924,0.0028392684,0.00088568014,0.00034049686,0.0003709945,0.00011431396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010801188,0.0001666566,0.0019304698,0.0005028905,0.000019705203,0.000002014615,0.00017148645,0.00008246405,0.00021119404],"category_scores_gemma":[0.00051130936,0.00006848619,0.00043876213,0.0008137417,0.00034334345,0.000035466102,0.000006357317,0.00010711906,3.3626452e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075388476,0.0084538255,0.47156125,0.0006401762,0.06418927,0.0011561427,0.037499692,0.0024742137,0.0005096353,0.00019137116,0.0070574894,0.33087844],"study_design_scores_gemma":[0.040566977,0.06420863,0.78815275,0.0030051162,0.076748334,0.0011584654,0.004639857,0.003081429,0.005762851,0.000305276,0.012097523,0.0002728083],"about_ca_topic_score_codex":0.00014161284,"about_ca_topic_score_gemma":0.00014757241,"teacher_disagreement_score":0.33060563,"about_ca_system_score_codex":0.00009646735,"about_ca_system_score_gemma":0.00027179942,"threshold_uncertainty_score":0.27927858},"labels":[],"label_agreement":null},{"id":"W4392906211","doi":"10.25251/skin.8.supp.376","title":"Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"LEO Pharma; European Academy of Dermatology and Venereology","keywords":"Atopic dermatitis; Medicine; Term (time); Disease; Dermatology; Pediatrics; Disease control; Internal medicine; Environmental health; Physics","score_opus":0.005724724808118464,"score_gpt":0.24956516057734138,"score_spread":0.2438404357692229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392906211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765744,0.013184131,0.00017134435,0.008609855,0.00030437787,0.0008116818,0.000021991113,0.000033446337,0.0002887565],"genre_scores_gemma":[0.99619544,0.0008443588,0.000026094105,0.0018862621,0.00037485236,0.000017950259,0.000009676587,0.000035297613,0.00061009126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982491,0.00016175272,0.0005931453,0.00019027341,0.0004831851,0.0003225245],"domain_scores_gemma":[0.998615,0.0004266111,0.0001531656,0.00027428722,0.00011452655,0.00041636493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017026962,0.0002618964,0.0007100994,0.00027304902,0.000052405387,0.000024183853,0.00016480812,0.000062425825,0.00028828354],"category_scores_gemma":[0.00014808479,0.0001334555,0.00012863976,0.00022509841,0.00022149806,0.000104583014,0.000012597888,0.00030946263,0.000021488313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036654733,0.001337918,0.43093923,0.0018537047,0.002174835,0.42780113,0.0145100225,0.0012287779,0.0001130666,0.00012919898,0.027425388,0.055832017],"study_design_scores_gemma":[0.02450781,0.0053032897,0.79533273,0.01638266,0.00327381,0.14838547,0.0008069049,0.0017113287,0.00012350592,0.00063788996,0.0030836593,0.00045093065],"about_ca_topic_score_codex":0.000048657042,"about_ca_topic_score_gemma":0.0001148498,"teacher_disagreement_score":0.36439353,"about_ca_system_score_codex":0.0001791344,"about_ca_system_score_gemma":0.0003934829,"threshold_uncertainty_score":0.5442157},"labels":[],"label_agreement":null},{"id":"W4392906239","doi":"10.25251/skin.8.supp.391","title":"Maintenance Acne Treatment With Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Acne; Isotretinoin; Medicine; Dermatology; Lotion; Adapalene; Retinoid; Hyperpigmentation; Benzoyl peroxide; Pharmacology","score_opus":0.012655390998048929,"score_gpt":0.2815169935818741,"score_spread":0.2688616025838252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392906239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9356736,0.04806723,0.00014803537,0.014776623,0.0003915733,0.00032900608,0.000002728783,0.000018683175,0.00059249625],"genre_scores_gemma":[0.9882178,0.006457124,0.0002651798,0.0007890802,0.0007160369,0.0000055294013,0.000002031759,0.000023895998,0.003523333],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9987798,0.00007207573,0.0004292595,0.00016535686,0.00032218915,0.00023135274],"domain_scores_gemma":[0.9991174,0.00018336678,0.00014973312,0.00023978531,0.00008710139,0.00022266459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032574366,0.00022613455,0.0005530955,0.00008187024,0.00007756261,0.000017304994,0.000030304505,0.00006581021,0.00027231924],"category_scores_gemma":[0.000027625942,0.00008105745,0.000094171264,0.00012425605,0.00021683724,0.0000535104,0.000019530757,0.00024074846,0.000004231481],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017672759,0.00014880675,0.001240153,0.00023537391,0.0006763344,0.93825215,0.001979982,0.0000049669284,0.0002478518,0.000031152198,0.0036898176,0.051726162],"study_design_scores_gemma":[0.001469707,0.01025365,0.0006749356,0.0019694013,0.0017065672,0.93858725,0.00052935706,0.00010777654,0.00019609657,0.00012376312,0.04428897,0.00009254548],"about_ca_topic_score_codex":0.00013903652,"about_ca_topic_score_gemma":0.00005029621,"teacher_disagreement_score":0.052544165,"about_ca_system_score_codex":0.0001300574,"about_ca_system_score_gemma":0.00014907791,"threshold_uncertainty_score":0.33054268},"labels":[],"label_agreement":null},{"id":"W4392912933","doi":"10.25251/skin.8.supp.400","title":"Concealing Meets Healing in the Treatment of Toenail Onychomycosis: A Review of Concurrent Nail Polish Use With Topical Efinaconazole 10% Solution","year":2024,"lang":"en","type":"review","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Dermatology; Medicine; Nail (fastener); Nail matrix; Clinical efficacy; Clinical study; Nail plate; Cure rate; Dentistry; Surgery","score_opus":0.06807302359266415,"score_gpt":0.3842191934297035,"score_spread":0.31614616983703936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392912933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007166573,0.99509984,0.000008029172,0.0021560327,0.00034767974,0.0014499096,0.00007154001,0.0000065171835,0.0001437851],"genre_scores_gemma":[0.0077458904,0.9911074,0.00003999886,0.00027869036,0.00055217784,0.000026707414,0.00006117007,0.000041136853,0.00014681407],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99590516,0.0005252664,0.0020031994,0.00022454988,0.001032469,0.0003093366],"domain_scores_gemma":[0.99638665,0.00097446813,0.0016422027,0.0005030281,0.00031737844,0.00017628202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007174598,0.0004952952,0.0032793358,0.0002518386,0.00004886881,0.000010499736,0.00030016096,0.00012999887,0.00011698876],"category_scores_gemma":[0.00024569954,0.00018431127,0.00072796416,0.0004716098,0.0003010216,0.000045604458,0.000025138557,0.0004668766,0.0000048335896],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008572676,0.0016824936,0.000056343444,0.119374715,0.0033540332,0.0037605672,0.0018546613,0.000004827251,0.0000023760283,0.00014626987,0.007295329,0.8616111],"study_design_scores_gemma":[0.0020302522,0.006204632,0.000015225036,0.39666408,0.0240985,0.012713121,0.00023726627,0.000008562006,0.000003259971,0.000016902977,0.5578807,0.00012752855],"about_ca_topic_score_codex":0.0002699294,"about_ca_topic_score_gemma":0.00003272313,"teacher_disagreement_score":0.8614836,"about_ca_system_score_codex":0.00045454386,"about_ca_system_score_gemma":0.0007501257,"threshold_uncertainty_score":0.75159955},"labels":[],"label_agreement":null},{"id":"W4392926895","doi":"10.25251/skin.8.supp.366","title":"Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Particle swarm optimization; Phase (matter); Dermatology; Mathematics; Physics; Mathematical optimization","score_opus":0.02849553644203048,"score_gpt":0.301655482586512,"score_spread":0.2731599461444815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392926895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8950501,0.086507514,0.000044881348,0.01497755,0.0019891222,0.00040655799,0.000319852,0.000023647022,0.0006807839],"genre_scores_gemma":[0.97289145,0.025352119,0.00004413996,0.00027805433,0.0008023664,0.0000021690546,0.000054895994,0.000021789387,0.00055300194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967134,0.001467316,0.0011990019,0.00022829835,0.00011981493,0.0002721782],"domain_scores_gemma":[0.9888685,0.010327005,0.00041611496,0.00027105893,0.000062744766,0.00005460837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039096256,0.00025826754,0.0008153857,0.00015031357,0.00018034654,0.000025691143,0.00027551223,0.00020819964,0.00021626441],"category_scores_gemma":[0.0020500359,0.00011549633,0.00011301428,0.0002030617,0.00040512686,0.00006383422,0.000052523574,0.00055951,0.000025133197],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08996267,0.00058880355,0.0004083042,0.000070549235,0.005307163,0.0034291581,0.04356042,0.000030656996,0.074778534,0.0011499943,0.051168162,0.7295456],"study_design_scores_gemma":[0.16185194,0.010940854,0.0091052465,0.006753835,0.010919311,0.060424253,0.019031484,0.00007513928,0.026382208,0.008433201,0.6849084,0.0011741271],"about_ca_topic_score_codex":0.00019771502,"about_ca_topic_score_gemma":0.00011818077,"teacher_disagreement_score":0.72837144,"about_ca_system_score_codex":0.000040812203,"about_ca_system_score_gemma":0.00009412847,"threshold_uncertainty_score":0.47098038},"labels":[],"label_agreement":null},{"id":"W4392927062","doi":"10.25251/skin.8.supp.364","title":"Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Dermatology","score_opus":0.03951776206723881,"score_gpt":0.32725086810167403,"score_spread":0.28773310603443525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392927062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9215634,0.06747816,0.000052558946,0.008279389,0.0014538149,0.00042005238,0.00002482645,0.000015277074,0.00071255665],"genre_scores_gemma":[0.9902506,0.008429262,0.000021850372,0.0003920304,0.00045414848,0.000008169615,0.00001456463,0.000019737954,0.0004096519],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99621093,0.0020468342,0.0010981277,0.00018318564,0.00013165933,0.00032928155],"domain_scores_gemma":[0.99465007,0.0047115167,0.00031428738,0.00023521688,0.000053651114,0.000035267043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049756435,0.00026033496,0.00083339284,0.0003510672,0.000113281465,0.000026884154,0.00036455557,0.00019572847,0.00022985319],"category_scores_gemma":[0.0007578882,0.00011614488,0.00013439155,0.00034339272,0.00025627165,0.00007753465,0.000028146671,0.0006587436,0.00002965545],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02908408,0.002181832,0.00036374343,0.00022547,0.003373427,0.014356547,0.07768668,0.0003039649,0.12912051,0.0027290983,0.034404073,0.70617056],"study_design_scores_gemma":[0.15982187,0.021719694,0.0042974423,0.010524471,0.011332063,0.3306966,0.036294334,0.000633708,0.07798438,0.024874575,0.3196969,0.002123933],"about_ca_topic_score_codex":0.00007817256,"about_ca_topic_score_gemma":0.00011725312,"teacher_disagreement_score":0.7040466,"about_ca_system_score_codex":0.00005095349,"about_ca_system_score_gemma":0.00011361688,"threshold_uncertainty_score":0.47362506},"labels":[],"label_agreement":null},{"id":"W4392928122","doi":"10.25251/skin.8.supp.373","title":"Association Between Early Clinical Responses and Long-Term Outcomes With Ruxolitinib Cream Treatment in Mild to Moderate Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; University of British Columbia; Lynde Centre for Dermatology; Probity Medical Research; University of Calgary","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Medicine; Dermatology; Term (time); Dupilumab; Internal medicine; Myelofibrosis","score_opus":0.034762432166310454,"score_gpt":0.3578718123601323,"score_spread":0.32310938019382185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392928122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638245,0.0034939852,0.000064231936,0.031788237,0.00022985712,0.00031224283,0.000011052488,0.000018774193,0.00025708147],"genre_scores_gemma":[0.99485296,0.0013013956,0.000066736,0.0013848622,0.00040964095,0.0000045371066,0.000004550268,0.000018581612,0.0019567383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980804,0.0003860347,0.0007626174,0.0001408983,0.00039698533,0.00023311141],"domain_scores_gemma":[0.99631965,0.002933706,0.00020850688,0.00017087017,0.00011679323,0.00025044353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007308214,0.00017994193,0.0007568966,0.0002427162,0.000061853374,0.000022541208,0.00009343749,0.00009974835,0.000057331268],"category_scores_gemma":[0.0006816815,0.000088061155,0.00009068638,0.00016335674,0.00014191872,0.00007066859,0.000018647263,0.00035060174,0.000011384497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088587106,0.00012094538,0.98245734,0.00007201893,0.0007337069,0.0065134247,0.0016199984,0.0000038241487,0.0000050310978,0.000010806159,0.0023639817,0.005213039],"study_design_scores_gemma":[0.0022560763,0.0025497589,0.9816318,0.0012837765,0.0013181813,0.009479116,0.00015149591,0.000018121247,0.000079800746,0.00025782062,0.00088703015,0.00008699591],"about_ca_topic_score_codex":0.000052125393,"about_ca_topic_score_gemma":0.00010181661,"teacher_disagreement_score":0.03102842,"about_ca_system_score_codex":0.0001516884,"about_ca_system_score_gemma":0.0001981165,"threshold_uncertainty_score":0.35910296},"labels":[],"label_agreement":null},{"id":"W4392928286","doi":"10.25251/skin.8.supp.382","title":"Early Oligoarticular Psoriatic Arthritis Responds to Treatment With Apremilast: Week 16 Results From FOREMOST - a Phase 4 Randomized Controlled Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital","funders":"Pfizer; Amgen","keywords":"Apremilast; Psoriatic arthritis; Medicine; Randomized controlled trial; Dermatology; Internal medicine; Arthritis","score_opus":0.012300118375394525,"score_gpt":0.28083346937827974,"score_spread":0.2685333510028852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392928286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94870985,0.029621117,0.00046715775,0.012573368,0.0018534742,0.005092319,0.00006533391,0.000050826176,0.0015665515],"genre_scores_gemma":[0.98811436,0.0063191424,0.00038297253,0.00044194507,0.0026478579,0.00013828336,0.000026681506,0.00006444433,0.0018643053],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995635,0.0005259781,0.0018836393,0.00033453768,0.0011598007,0.0004610903],"domain_scores_gemma":[0.9941879,0.004037153,0.00057547004,0.0004834084,0.00026970854,0.00044639528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016466617,0.00048381728,0.0032235312,0.00034984347,0.00018171502,0.000052242565,0.00016673097,0.00009999226,0.00021468381],"category_scores_gemma":[0.0018269824,0.00020483545,0.0006169339,0.00044030667,0.00033513978,0.00007452393,0.000028091052,0.00034520935,0.000040737905],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9256534,0.0007407234,0.0000023368893,0.00001147224,0.0051822676,0.01401719,0.0068528103,0.000010387663,0.00043169293,0.000023568673,0.0021814245,0.044892747],"study_design_scores_gemma":[0.911909,0.05675732,0.000006195682,0.003244105,0.007060685,0.009266987,0.00084510166,0.00018659525,0.0003752719,0.00042289562,0.009752747,0.00017311067],"about_ca_topic_score_codex":0.00051002577,"about_ca_topic_score_gemma":0.00016315647,"teacher_disagreement_score":0.056016594,"about_ca_system_score_codex":0.00037366067,"about_ca_system_score_gemma":0.00030927657,"threshold_uncertainty_score":0.8352947},"labels":[],"label_agreement":null},{"id":"W4392928302","doi":"10.25251/skin.8.supp.361","title":"Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Pfizer Pharmaceuticals; Sanofi Genzyme; Regeneron Pharmaceuticals; Meiji Seika Pharma; Eli Lilly and Company; Bristol-Myers Squibb; LEO Pharma; Incyte; Amgen","keywords":"Placebo; Psoriasis; Dermatology Life Quality Index; Medicine; Generalized pustular psoriasis; Quality of life (healthcare); Placebo group; Index (typography); Physical therapy; Dermatology; Alternative medicine; Pathology","score_opus":0.03282687181193359,"score_gpt":0.25589317684163365,"score_spread":0.22306630502970007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392928302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584212,0.037054658,0.000030080248,0.0020932185,0.0017571285,0.00047319513,0.00007730797,0.0000109021985,0.00008231396],"genre_scores_gemma":[0.9969479,0.0022913155,0.0000111098825,0.00013640875,0.0004371744,0.0000050606745,0.000016174385,0.00001798182,0.00013688044],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941201,0.0037811482,0.0014172645,0.00019079719,0.0002533152,0.00023736812],"domain_scores_gemma":[0.99227583,0.006297177,0.0008269866,0.00042592626,0.00013687444,0.000037171896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056044096,0.00024457154,0.0008153479,0.00013990901,0.00012732642,0.000010049525,0.0005097691,0.00021582087,0.000067899695],"category_scores_gemma":[0.0032292777,0.000100958845,0.00019706132,0.00034639865,0.0005475969,0.00004293547,0.00008151695,0.0004616589,0.0000020606055],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5475665,0.0009170436,0.0350294,0.0003416088,0.011693173,0.00033032606,0.04091898,0.0008132154,0.29317915,0.0006566895,0.009940256,0.058613706],"study_design_scores_gemma":[0.62074953,0.012650407,0.17440186,0.016472766,0.012841817,0.004451707,0.020735499,0.000556871,0.11724167,0.0068686237,0.011374197,0.0016550272],"about_ca_topic_score_codex":0.0024781371,"about_ca_topic_score_gemma":0.0007700765,"teacher_disagreement_score":0.17593747,"about_ca_system_score_codex":0.000051937448,"about_ca_system_score_gemma":0.00014904566,"threshold_uncertainty_score":0.41169822},"labels":[],"label_agreement":null},{"id":"W4392928363","doi":"10.25251/skin.8.supp.396","title":"Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; UCB Pharma; Bausch Health; Swedish Orphan Biovitrum; National and Kapodistrian University of Athens; Insmed; Eisai; Celltrion; XBiotech; Celgene; Amgen; Pfizer; Eli Lilly and Company; Galderma; Incyte","keywords":"Hidradenitis suppurativa; Medicine; Placebo; Double blind; Randomized controlled trial; Clinical trial; Single blind; Internal medicine; Pooled analysis; Meta-analysis; Alternative medicine; Disease; Pathology","score_opus":0.041108410531418754,"score_gpt":0.3781181349803364,"score_spread":0.33700972444891764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392928363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7774269,0.0012359875,0.0010158598,0.21559286,0.0004180122,0.004082825,0.00010562168,0.00002141648,0.00010052355],"genre_scores_gemma":[0.99511963,0.00031393088,0.0003379918,0.00079848606,0.00057568226,0.000080562444,0.000042463136,0.00005932054,0.0026719035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9867672,0.007826922,0.0030334115,0.00049317203,0.0013751517,0.00050414377],"domain_scores_gemma":[0.9751783,0.022296567,0.00075714954,0.00060069066,0.00053425157,0.0006330608],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037353348,0.00054090563,0.0043394295,0.0009323608,0.00026849817,0.00010233348,0.0003400313,0.00019405778,0.0005286823],"category_scores_gemma":[0.010066726,0.0002147477,0.0006320127,0.0014644163,0.00042448263,0.0001763078,0.00009450732,0.0010566623,0.000018245835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94988686,0.0004940112,0.0003887105,0.00001188417,0.008374367,0.02374541,0.008699481,0.00006150627,0.00015126177,0.000016773352,0.0049639074,0.0032058442],"study_design_scores_gemma":[0.936892,0.009590289,0.00043139365,0.001626303,0.018165201,0.028443212,0.0017661245,0.001223374,0.00009443491,0.0002416387,0.0012191961,0.00030687387],"about_ca_topic_score_codex":0.00023076676,"about_ca_topic_score_gemma":0.00024499767,"teacher_disagreement_score":0.21769276,"about_ca_system_score_codex":0.0002405164,"about_ca_system_score_gemma":0.00053254515,"threshold_uncertainty_score":0.9982719},"labels":[],"label_agreement":null},{"id":"W4400930425","doi":"10.25251/skin.8.4.7","title":"Pain Management of Refractory Hidradenitis Suppurativa: Case Report","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hidradenitis suppurativa; Refractory (planetary science); Medicine; Dermatology; Pain management; Physical therapy; Internal medicine; Materials science; Disease","score_opus":0.014687235114499134,"score_gpt":0.2967603647936037,"score_spread":0.28207312967910453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7242039,0.047593866,0.004288977,0.16770503,0.0050852424,0.0021784802,0.000052988533,0.00017637457,0.048715148],"genre_scores_gemma":[0.9910964,0.00155437,0.00050156924,0.000035076282,0.0006777777,0.0000034486113,0.000012507623,0.000041718307,0.0060771448],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972089,0.00030742807,0.0011710672,0.00017279408,0.0008837235,0.0002561147],"domain_scores_gemma":[0.997866,0.0007921423,0.00045054327,0.00042658608,0.0002490005,0.00021574594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022888952,0.00024923257,0.0006546201,0.00028538614,0.000090080925,0.000012211818,0.00016159094,0.000086614134,0.00087452476],"category_scores_gemma":[0.00026335416,0.0001289462,0.00020028725,0.000395521,0.00032363684,0.000116520714,0.00003613017,0.0005058547,0.000018282608],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000316325,0.00015739794,0.00013795686,0.00043596467,0.0010748481,0.95449,0.002382059,7.649967e-7,0.0010139215,0.00013219209,0.0104546,0.02940394],"study_design_scores_gemma":[0.0010385896,0.0026162753,0.000053178326,0.00287873,0.0016751812,0.9713625,0.004076381,0.00006130131,0.000688789,0.000466515,0.014983982,0.00009862012],"about_ca_topic_score_codex":0.00006790109,"about_ca_topic_score_gemma":0.000010425638,"teacher_disagreement_score":0.2668925,"about_ca_system_score_codex":0.0001626515,"about_ca_system_score_gemma":0.00015435796,"threshold_uncertainty_score":0.9575433},"labels":[],"label_agreement":null},{"id":"W4400930442","doi":"10.25251/skin.8.supp.407","title":"Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Placebo; Internal medicine; Clinical endpoint; Randomized controlled trial; Dermatology","score_opus":0.026229748451744,"score_gpt":0.3182034868212671,"score_spread":0.2919737383695231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9572073,0.0374004,0.000020947635,0.0038686497,0.0009664361,0.00028340914,0.000043238153,0.000006756716,0.00020285195],"genre_scores_gemma":[0.9927265,0.006268368,0.00002622938,0.00025705117,0.00018986793,0.0000052791193,0.000005441361,0.000015649615,0.00050558196],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958524,0.002553649,0.0010444468,0.00014736764,0.00013548252,0.00026664068],"domain_scores_gemma":[0.9938738,0.0054052263,0.00040326308,0.00023893573,0.000052649884,0.000026136408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076051448,0.0001912781,0.00074403017,0.000367786,0.000044119322,0.00000962663,0.00033152514,0.00016430015,0.00022211722],"category_scores_gemma":[0.001475128,0.00009114335,0.0001309999,0.00035393136,0.0003406305,0.00006013452,0.000028261162,0.00046870732,0.000010674478],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1283812,0.0012691531,0.0014591363,0.00024470143,0.0027859025,0.016450379,0.082558624,0.000059411508,0.43969405,0.0022764148,0.050548434,0.2742726],"study_design_scores_gemma":[0.13548604,0.027942928,0.0507914,0.015794951,0.00760968,0.20405072,0.045094293,0.00012796489,0.067388386,0.020504858,0.42356715,0.0016416289],"about_ca_topic_score_codex":0.00009070288,"about_ca_topic_score_gemma":0.00010031597,"teacher_disagreement_score":0.3730187,"about_ca_system_score_codex":0.000052443276,"about_ca_system_score_gemma":0.00012994728,"threshold_uncertainty_score":0.3716718},"labels":[],"label_agreement":null},{"id":"W4400930553","doi":"10.25251/skin.8.supp.412","title":"Stability of Long-Term Therapeutic Responses to Tralokinumab in Adults with Moderate-to-Severe Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; University of British Columbia","funders":"","keywords":"Medicine; Atopic dermatitis; Eczema Area and Severity Index; Post-hoc analysis; Clinical trial; Quality of life (healthcare); Dupilumab; Clinical endpoint; Pediatrics; Internal medicine; Dermatology","score_opus":0.014108445610969777,"score_gpt":0.2828125700735875,"score_spread":0.2687041244626177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779542,0.0065724947,0.00038562994,0.013906194,0.00023730808,0.0005003343,0.000010186555,0.000018229262,0.00041540092],"genre_scores_gemma":[0.9973946,0.00035883018,0.00007770914,0.0018505482,0.00014202631,0.000005620817,0.0000025779284,0.00002401994,0.00014402106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798083,0.00030037382,0.0007442954,0.00016375983,0.00054847886,0.0002622704],"domain_scores_gemma":[0.998137,0.00089287147,0.00014685675,0.00033953117,0.000238827,0.00024494488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005293199,0.00020212574,0.0006698171,0.00034531264,0.000044097123,0.000009130407,0.00023682938,0.00006964238,0.00036270666],"category_scores_gemma":[0.00034045507,0.00010447597,0.00008835825,0.00046675705,0.00024563252,0.00007376197,0.00002549657,0.0004090818,0.000011125922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10181663,0.0016290528,0.613052,0.0071017733,0.0020794529,0.095870055,0.08161593,0.0010151704,0.0033635192,0.00026538988,0.015074204,0.07711683],"study_design_scores_gemma":[0.006885728,0.006551984,0.7278927,0.02044385,0.0012747542,0.22270456,0.003249155,0.00043487927,0.008286944,0.0011572118,0.0007207967,0.00039746382],"about_ca_topic_score_codex":0.000030151012,"about_ca_topic_score_gemma":0.00015032035,"teacher_disagreement_score":0.1268345,"about_ca_system_score_codex":0.00009562215,"about_ca_system_score_gemma":0.0003501106,"threshold_uncertainty_score":0.42604065},"labels":[],"label_agreement":null},{"id":"W4400930587","doi":"10.25251/skin.8.supp.404","title":"Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma; Eisai; Torii Pharmaceutical; Amgen","keywords":"Tolerability; Plaque psoriasis; Medicine; Pooled analysis; Clinical trial; Psoriasis; Internal medicine; Dermatology; Adverse effect; Meta-analysis","score_opus":0.04438970228239314,"score_gpt":0.36332345056434967,"score_spread":0.31893374828195653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98674905,0.009103838,0.00022502754,0.0021178585,0.0011070066,0.00047551777,0.00017323007,0.00000832678,0.000040134444],"genre_scores_gemma":[0.9966228,0.0026346392,0.00008333599,0.00013006158,0.00018830199,0.0000065431022,0.000028496002,0.000012845461,0.00029297185],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99495953,0.0023437154,0.002082133,0.00027839662,0.00010100213,0.00023519041],"domain_scores_gemma":[0.99465275,0.0045098774,0.00036727558,0.0003046471,0.000073426825,0.000092018694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043326216,0.00022516135,0.0019108228,0.0006020461,0.000035878675,0.0000090176845,0.00020372328,0.00020679332,0.00035599997],"category_scores_gemma":[0.0010860768,0.00012956184,0.00028942214,0.0007063832,0.000113835165,0.0000423479,0.000039168677,0.00027878387,0.000016334725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08619968,0.0010913806,0.005285228,0.000035390683,0.015024476,0.001452608,0.02913528,0.0037953744,0.02181058,0.000039646417,0.0011190076,0.83501136],"study_design_scores_gemma":[0.30943283,0.11155191,0.19460365,0.009793641,0.1516821,0.014752631,0.033496886,0.0043291952,0.078377545,0.010958499,0.07696679,0.004054312],"about_ca_topic_score_codex":0.0010527915,"about_ca_topic_score_gemma":0.0014294458,"teacher_disagreement_score":0.83095706,"about_ca_system_score_codex":0.00021278944,"about_ca_system_score_gemma":0.00019425746,"threshold_uncertainty_score":0.52833784},"labels":[],"label_agreement":null},{"id":"W4400930719","doi":"10.25251/skin.8.supp.409","title":"Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Dermatology Life Quality Index; Placebo; Medicine; Psoriasis Area and Severity Index; Psoriasis; Clinical endpoint; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Dermatology; Pathology","score_opus":0.030731104938953067,"score_gpt":0.2982840636318148,"score_spread":0.2675529586928617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96153605,0.031529795,0.000074516436,0.0033661164,0.0026418748,0.0005717252,0.00019996129,0.000017029104,0.000062910636],"genre_scores_gemma":[0.9967071,0.001600457,0.00004503345,0.0006306636,0.00064971595,0.000005599582,0.00024394278,0.00002996268,0.000087529115],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99411273,0.0030782234,0.0017460876,0.00033860953,0.00034813513,0.00037622105],"domain_scores_gemma":[0.99392945,0.0037590778,0.001014309,0.0009959032,0.00021906468,0.00008217199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024715476,0.00035003727,0.0012947744,0.00017110797,0.00014042646,0.00001772282,0.0011918332,0.00029390698,0.000568485],"category_scores_gemma":[0.002247029,0.00015726943,0.00016386296,0.00027661864,0.0006815437,0.0001276616,0.00018424087,0.0006542641,0.00003668778],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65786743,0.0033263278,0.19863026,0.00041171597,0.017817311,0.000572481,0.01977551,0.00009805585,0.02575832,0.0006907509,0.039319273,0.035732534],"study_design_scores_gemma":[0.47795254,0.014335848,0.42617998,0.0024162924,0.009530802,0.0034789536,0.011603653,0.00009829199,0.005958863,0.0039027345,0.0427099,0.0018321621],"about_ca_topic_score_codex":0.0024850867,"about_ca_topic_score_gemma":0.00060668413,"teacher_disagreement_score":0.2275497,"about_ca_system_score_codex":0.000056640256,"about_ca_system_score_gemma":0.0005649784,"threshold_uncertainty_score":0.6413261},"labels":[],"label_agreement":null},{"id":"W4400930743","doi":"10.25251/skin.8.supp.406","title":"Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Computer science; Dermatology","score_opus":0.02818014222467983,"score_gpt":0.30170471001867927,"score_spread":0.2735245677939994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8924461,0.08914056,0.000054727967,0.014738859,0.0021131418,0.0004323636,0.0003472713,0.000025511505,0.0007014679],"genre_scores_gemma":[0.9712721,0.026832925,0.000046404748,0.0002812829,0.00084491493,0.0000023573039,0.000057386416,0.000023533383,0.0006391099],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965476,0.0015483623,0.0012459973,0.00024195432,0.0001275815,0.00028853395],"domain_scores_gemma":[0.9891089,0.010038125,0.00044096337,0.00028814148,0.00006518677,0.00005865321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004107199,0.0002734667,0.0008538619,0.00016036286,0.00019050369,0.000027804497,0.0002891888,0.0002150057,0.00021708489],"category_scores_gemma":[0.0019523544,0.0001235148,0.00012264025,0.00021574167,0.00041948972,0.00006928897,0.000056340064,0.0005816698,0.000026858057],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09416894,0.0006348892,0.00038843526,0.000075879056,0.005905161,0.0037269345,0.046236135,0.000035357243,0.07761314,0.0011438659,0.04859599,0.7214753],"study_design_scores_gemma":[0.16115947,0.010309008,0.008601205,0.006697407,0.011123861,0.05758612,0.016285181,0.0000826999,0.025795413,0.008297715,0.69287574,0.0011861885],"about_ca_topic_score_codex":0.00020040224,"about_ca_topic_score_gemma":0.0001222922,"teacher_disagreement_score":0.7202891,"about_ca_system_score_codex":0.000042764827,"about_ca_system_score_gemma":0.00009701909,"threshold_uncertainty_score":0.5036787},"labels":[],"label_agreement":null},{"id":"W4404455102","doi":"10.25251/skin.8.supp.485","title":"Safety and Efficacy of Photodynamic Therapy with ALA 10% Topical Gel Activated by Red Light versus ALA 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Covenant Health","funders":"","keywords":"Actinic keratosis; Photodynamic therapy; Dermatology; Medicine; Red light; Blue light; Keratosis; Chemistry; Internal medicine; Materials science; Organic chemistry; Biology","score_opus":0.018438164768994725,"score_gpt":0.2954829230626983,"score_spread":0.27704475829370356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94784737,0.009577779,0.00010392599,0.038700704,0.00046563818,0.0029559552,0.000021141459,0.000017982502,0.0003095084],"genre_scores_gemma":[0.9884645,0.009789273,0.000020111802,0.00013243232,0.0003943874,0.00006678574,0.0000068785293,0.000043326072,0.0010823015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971486,0.0005412448,0.00097539794,0.0002694444,0.00076790963,0.00029743413],"domain_scores_gemma":[0.988604,0.01000821,0.0005883673,0.00045087558,0.00024737034,0.000101148216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089913845,0.00039215278,0.0014238715,0.00012484382,0.00021728316,0.00001712767,0.0002438478,0.00012587776,0.00022598333],"category_scores_gemma":[0.0004957102,0.00014030431,0.00027385177,0.0003087731,0.00053594337,0.000046102752,0.000026418127,0.0004310241,6.311766e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78467166,0.0020119369,0.000103911174,0.000076988596,0.010572723,0.00009907013,0.018118113,0.000015704287,0.15601406,0.00002249667,0.013234793,0.015058541],"study_design_scores_gemma":[0.48781636,0.072454244,0.0008550271,0.0026577397,0.008736252,0.002059148,0.01438665,0.001028673,0.33480853,0.00005497436,0.074650496,0.0004918992],"about_ca_topic_score_codex":0.00006598374,"about_ca_topic_score_gemma":0.00002461499,"teacher_disagreement_score":0.2968553,"about_ca_system_score_codex":0.0002851195,"about_ca_system_score_gemma":0.00016475191,"threshold_uncertainty_score":0.5721444},"labels":[],"label_agreement":null},{"id":"W4404455104","doi":"10.25251/skin.8.supp.423","title":"Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Phase (matter); Dermatology; Computer science; Physics","score_opus":0.02818014222467983,"score_gpt":0.30170471001867927,"score_spread":0.2735245677939994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8924461,0.08914056,0.000054727967,0.014738859,0.0021131418,0.0004323636,0.0003472713,0.000025511505,0.0007014679],"genre_scores_gemma":[0.9712721,0.026832925,0.000046404748,0.0002812829,0.00084491493,0.0000023573039,0.000057386416,0.000023533383,0.0006391099],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965476,0.0015483623,0.0012459973,0.00024195432,0.0001275815,0.00028853395],"domain_scores_gemma":[0.9891089,0.010038125,0.00044096337,0.00028814148,0.00006518677,0.00005865321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004107199,0.0002734667,0.0008538619,0.00016036286,0.00019050369,0.000027804497,0.0002891888,0.0002150057,0.00021708489],"category_scores_gemma":[0.0019523544,0.0001235148,0.00012264025,0.00021574167,0.00041948972,0.00006928897,0.000056340064,0.0005816698,0.000026858057],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09416894,0.0006348892,0.00038843526,0.000075879056,0.005905161,0.0037269345,0.046236135,0.000035357243,0.07761314,0.0011438659,0.04859599,0.7214753],"study_design_scores_gemma":[0.16115947,0.010309008,0.008601205,0.006697407,0.011123861,0.05758612,0.016285181,0.0000826999,0.025795413,0.008297715,0.69287574,0.0011861885],"about_ca_topic_score_codex":0.00020040224,"about_ca_topic_score_gemma":0.0001222922,"teacher_disagreement_score":0.7202891,"about_ca_system_score_codex":0.000042764827,"about_ca_system_score_gemma":0.00009701909,"threshold_uncertainty_score":0.5036787},"labels":[],"label_agreement":null},{"id":"W4404455106","doi":"10.25251/skin.8.supp.445","title":"Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriatic arthritis; Medicine; Term (time); Dermatology; Internal medicine; Psoriasis; Physics","score_opus":0.012776850158861274,"score_gpt":0.2643596050151742,"score_spread":0.25158275485631293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758124,0.016703887,0.000082035534,0.0037573248,0.0012902203,0.0017583256,0.0003360556,0.000014485464,0.00024528045],"genre_scores_gemma":[0.9911356,0.0068700253,0.0001337566,0.00016843574,0.0014854708,0.0000108737395,0.000054164204,0.000038507143,0.000103168524],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976693,0.00014201461,0.0009609684,0.00022280545,0.00073490944,0.00027003922],"domain_scores_gemma":[0.9946446,0.0039987667,0.00057685986,0.00032322475,0.00032141514,0.00013517903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005310835,0.00027002103,0.00085941266,0.000089620014,0.0001943825,0.000016819436,0.00016810081,0.00007680062,0.00006056483],"category_scores_gemma":[0.0011147276,0.00011621694,0.00014496774,0.00019610686,0.0004248504,0.00006086775,0.000043742933,0.0003808397,0.0000022219126],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5456881,0.0010052365,0.0010704523,0.00012641281,0.0043723746,0.0013400236,0.011542066,0.000011385692,0.000037804475,0.00002924919,0.004511765,0.43026513],"study_design_scores_gemma":[0.67819077,0.08732594,0.18064108,0.020837704,0.010332332,0.007625585,0.0036311217,0.000056280212,0.0003606777,0.001031176,0.009488095,0.00047922527],"about_ca_topic_score_codex":0.00009925815,"about_ca_topic_score_gemma":0.0001342539,"teacher_disagreement_score":0.42978588,"about_ca_system_score_codex":0.000096496646,"about_ca_system_score_gemma":0.00014766905,"threshold_uncertainty_score":0.47391894},"labels":[],"label_agreement":null},{"id":"W4404455125","doi":"10.25251/skin.8.supp.483","title":"Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by blue light in the treatment of facial cutaneous squamous cell carcinoma in situ","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"bioluminescence and chemiluminescence research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"In situ; Basal cell; Dermatology; Medicine; Cancer research; Oncology; Internal medicine; Chemistry","score_opus":0.020685035602132352,"score_gpt":0.3196906771358646,"score_spread":0.2990056415337322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98567134,0.011101217,0.000020989988,0.002706112,0.000099817036,0.00025807077,0.0000060601387,0.0000013270947,0.00013504476],"genre_scores_gemma":[0.9966531,0.0028407304,0.000008638832,0.000041422885,0.00030666604,0.0000023757896,0.0000111599875,0.000009401715,0.00012655399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983404,0.00029842436,0.0005895493,0.00015295792,0.00039359677,0.0002250724],"domain_scores_gemma":[0.99902415,0.0004028737,0.0001977333,0.00023550622,0.00009573855,0.000044004282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007094869,0.00015101404,0.00029443373,0.00006581457,0.000052956195,0.000007747793,0.00032014537,0.00012908911,0.000011119402],"category_scores_gemma":[0.00022194575,0.00006748113,0.000082029015,0.00021682995,0.00031033982,0.0000052899895,0.000036663256,0.0002769924,4.4248836e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012319222,0.00021614744,0.0004857149,0.0000575084,0.000025047366,0.00011404422,0.003088411,0.000032289743,0.9749712,0.0000013567512,0.00021721228,0.019559188],"study_design_scores_gemma":[0.00159832,0.006968228,0.00061238115,0.00016251302,0.00011930667,0.0025089635,0.0021222916,0.00040264236,0.98354423,0.000015541584,0.001853032,0.00009257919],"about_ca_topic_score_codex":0.000086381784,"about_ca_topic_score_gemma":0.00010116396,"teacher_disagreement_score":0.019466609,"about_ca_system_score_codex":0.00005203362,"about_ca_system_score_gemma":0.00013429596,"threshold_uncertainty_score":0.27518007},"labels":[],"label_agreement":null},{"id":"W4404455128","doi":"10.25251/skin.8.supp.432","title":"Bimekizumab 4-year Efficacy in High-impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from BE BRIGHT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Dermatology; Internal medicine","score_opus":0.013005384212936908,"score_gpt":0.25876436658693264,"score_spread":0.24575898237399574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98063344,0.008810038,0.00002129602,0.007587417,0.0019855162,0.00029223567,0.00019109859,0.000028030025,0.00045092386],"genre_scores_gemma":[0.9969088,0.0010980443,0.000050854986,0.00026633043,0.0004848573,0.0000034309526,0.000087361645,0.000033182056,0.0010671259],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975285,0.00064455025,0.0009583967,0.00028033173,0.00016024757,0.00042800253],"domain_scores_gemma":[0.99750406,0.0017447383,0.0002366418,0.00034774587,0.00008263349,0.00008420974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093030283,0.0003239757,0.00076618604,0.00054615526,0.0000759395,0.000021367265,0.00041854373,0.0002586551,0.0005476684],"category_scores_gemma":[0.00043998717,0.00017620971,0.0001444021,0.0005317,0.00010586287,0.00008883786,0.000049358292,0.0006584743,0.00016115991],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21904378,0.002855582,0.002631211,0.00013301212,0.011743093,0.04124756,0.095452264,0.024700157,0.1612021,0.00065235223,0.16631562,0.27402326],"study_design_scores_gemma":[0.2406944,0.027473785,0.22933392,0.030088043,0.012570453,0.12883048,0.015601317,0.00094794,0.18080649,0.02197705,0.10645976,0.0052163745],"about_ca_topic_score_codex":0.001962231,"about_ca_topic_score_gemma":0.00072433084,"teacher_disagreement_score":0.2688069,"about_ca_system_score_codex":0.00026108717,"about_ca_system_score_gemma":0.00021485824,"threshold_uncertainty_score":0.71856236},"labels":[],"label_agreement":null},{"id":"W4404455143","doi":"10.25251/skin.8.supp.446","title":"Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriatic arthritis; Medicine; Term (time); Internal medicine; Arthritis; Physical therapy; Physics","score_opus":0.01979361521127971,"score_gpt":0.29436113465455854,"score_spread":0.27456751944327884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91905016,0.06546754,0.00014189763,0.010610476,0.0023545842,0.0015943913,0.00027535117,0.000017870241,0.00048775523],"genre_scores_gemma":[0.9736273,0.02292041,0.00010833458,0.00021346658,0.0028543703,0.00000886721,0.00003281921,0.000032443855,0.00020196567],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977292,0.0001489845,0.0010685914,0.0002027752,0.0005931576,0.00025730403],"domain_scores_gemma":[0.9937583,0.00507742,0.0005064944,0.00031904163,0.00021098768,0.00012773674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077960786,0.00024080419,0.0008495032,0.000089838984,0.00019036957,0.000016446345,0.00017845252,0.00008492269,0.000087346685],"category_scores_gemma":[0.0015233282,0.00011106129,0.00019575932,0.00018647547,0.0004278445,0.00005086129,0.000047220445,0.00040612076,0.000003340334],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3901344,0.0006271538,0.000089882844,0.00013513709,0.004079449,0.0029302684,0.015316074,0.000009950716,0.00033209453,0.00010269639,0.009486657,0.57675624],"study_design_scores_gemma":[0.74620825,0.0783685,0.032797158,0.028308028,0.015129057,0.04554889,0.009374766,0.00018149451,0.0017864631,0.0044781924,0.037180547,0.0006386301],"about_ca_topic_score_codex":0.00012239245,"about_ca_topic_score_gemma":0.00012395816,"teacher_disagreement_score":0.57611763,"about_ca_system_score_codex":0.00008627015,"about_ca_system_score_gemma":0.00015347733,"threshold_uncertainty_score":0.45289478},"labels":[],"label_agreement":null},{"id":"W4404455153","doi":"10.25251/skin.8.supp.469","title":"Race and Ethnicity Sub-Groups of Alopecia Areata Patients have Differing Clinical Characteristics: TARGET-DERM AA","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Castle Biosciences; Pfizer; Eli Lilly and Company; Galderma; Incyte; National Alopecia Areata Foundation","keywords":"Alopecia areata; Race (biology); Ethnic group; Dermatology; Medicine; Gender studies; Sociology; Anthropology","score_opus":0.01588515999310801,"score_gpt":0.29884443098644325,"score_spread":0.28295927099333523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888839,0.005609615,0.00067584676,0.0028050786,0.000989099,0.00025993565,0.000015511254,0.000018130868,0.0007428415],"genre_scores_gemma":[0.9928075,0.0051531172,0.0000999463,0.0006130015,0.0011118158,8.2765956e-7,0.000012790459,0.00003494874,0.00016602321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743545,0.00018328558,0.0012597811,0.00018103722,0.0006650394,0.00027537803],"domain_scores_gemma":[0.9976202,0.0010519875,0.00040893184,0.0002779245,0.00030269276,0.0003382123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011878103,0.00022639138,0.0009300823,0.00018114437,0.00006461141,0.0000118390735,0.0001980502,0.00013580157,0.0001487244],"category_scores_gemma":[0.0018685653,0.00012347935,0.00015852676,0.00016145965,0.00048513527,0.000071983355,0.000072803006,0.00080612063,0.000006276054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009776399,0.0015204884,0.6794055,0.0027394705,0.0020860338,0.0071103373,0.019005053,0.000014728738,0.010438928,0.00018867162,0.030903023,0.23681135],"study_design_scores_gemma":[0.01463747,0.017408721,0.8772066,0.009460012,0.0046352465,0.025709629,0.0058316733,0.0036544583,0.0032927962,0.0025749553,0.034728948,0.0008594734],"about_ca_topic_score_codex":0.000023451585,"about_ca_topic_score_gemma":0.000013342068,"teacher_disagreement_score":0.23595189,"about_ca_system_score_codex":0.000047625672,"about_ca_system_score_gemma":0.00013013855,"threshold_uncertainty_score":0.5035342},"labels":[],"label_agreement":null},{"id":"W4404455182","doi":"10.25251/skin.8.supp.450","title":"Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Queen's University","funders":"LEO Pharma; Eli Lilly and Company; Bristol-Myers Squibb; Janssen Pharmaceuticals; Genentech; Chugai Pharmaceutical; Amgen","keywords":"Atopic dermatitis; Medicine; Longitudinal data; Dermatology; Data mining; Computer science","score_opus":0.028431092919943782,"score_gpt":0.3357071688554863,"score_spread":0.3072760759355425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97955203,0.011349808,0.00010620734,0.005762218,0.00060145423,0.0003791826,0.00010754588,0.000012132696,0.0021294227],"genre_scores_gemma":[0.9976132,0.0014805929,0.00009910402,0.00023816801,0.0001547811,0.0000029142232,0.000017263508,0.00002100142,0.00037300287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699134,0.00066558376,0.0012540381,0.0001969057,0.00066984503,0.00022228374],"domain_scores_gemma":[0.9951307,0.0032928274,0.0005783502,0.00055315596,0.0002984767,0.00014649838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095886225,0.00022682462,0.0010437663,0.00032455096,0.000059775073,0.000008116209,0.00039878357,0.00009046719,0.00012837735],"category_scores_gemma":[0.0015750641,0.00011346922,0.00023424199,0.00076339504,0.0004837137,0.0000685126,0.00006838395,0.0005694137,0.000004618573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08190141,0.0029138883,0.38255432,0.018730594,0.013814258,0.09686068,0.025083423,0.014568333,0.08928278,0.0010089505,0.24587521,0.027406158],"study_design_scores_gemma":[0.008098755,0.001188944,0.8373271,0.04654899,0.004639365,0.042643968,0.0015161738,0.0011606348,0.046741106,0.0072526457,0.0025061301,0.00037617626],"about_ca_topic_score_codex":0.0005782571,"about_ca_topic_score_gemma":0.00027030657,"teacher_disagreement_score":0.4547728,"about_ca_system_score_codex":0.000097970194,"about_ca_system_score_gemma":0.00034292994,"threshold_uncertainty_score":0.46271408},"labels":[],"label_agreement":null},{"id":"W4404455186","doi":"10.25251/skin.8.6.3","title":"Tissue-Engineered Skin Substitutes for Use in Clinical Dermatological Practice","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Dermatology; Medicine; Dermatological diseases","score_opus":0.053981853303566064,"score_gpt":0.39659422435907066,"score_spread":0.34261237105550457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455186","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3055556,0.03670065,0.06771329,0.57931954,0.0077211373,0.0016869601,0.000013088392,0.00009608052,0.0011936821],"genre_scores_gemma":[0.9881294,0.0033971325,0.0038853788,0.002206601,0.0018860947,0.0000026450873,0.000009366832,0.000023458957,0.00045992155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750316,0.00024106192,0.0012167307,0.00014998883,0.00065249176,0.00023654765],"domain_scores_gemma":[0.9925362,0.0064112474,0.0002627293,0.00019757403,0.00036772183,0.00022456197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035259842,0.00015607021,0.00057911046,0.0002217553,0.00004976386,0.000022347696,0.0001668942,0.00031303673,0.00009648369],"category_scores_gemma":[0.00543424,0.00007389791,0.00014708492,0.0003617618,0.0009797113,0.00013326539,0.000023958322,0.0011697215,0.000008987763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014778913,0.0021860548,0.0009813138,0.0026653365,0.0023085896,0.04279712,0.009329918,0.0006200845,0.013524181,0.041384786,0.20406364,0.6653601],"study_design_scores_gemma":[0.0050537996,0.0054788906,0.0033037893,0.0039827134,0.0019050034,0.16537395,0.001259077,0.013207064,0.0012848258,0.008683564,0.7901913,0.00027604148],"about_ca_topic_score_codex":0.000026121535,"about_ca_topic_score_gemma":0.00001942659,"teacher_disagreement_score":0.6825738,"about_ca_system_score_codex":0.000065155815,"about_ca_system_score_gemma":0.0002576006,"threshold_uncertainty_score":0.6505686},"labels":[],"label_agreement":null},{"id":"W4404455203","doi":"10.25251/skin.8.supp.434","title":"Bimekizumab Clinical Efficacy in Important Body Regions and Health-related Quality of Life in Patients with Plaque Psoriasis: Data from Four Phase 3/3b Comparator-controlled Trial Periods","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"LEO Pharma; Case Western Reserve University; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Sun Pharma; Biogen","keywords":"Plaque psoriasis; Psoriasis; Quality of life (healthcare); Medicine; Clinical trial; Phase (matter); Physical therapy; Physical medicine and rehabilitation; Internal medicine; Dermatology; Nursing; Physics","score_opus":0.08402653805773325,"score_gpt":0.3715673497894008,"score_spread":0.28754081173166757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96962136,0.02533631,0.000014860731,0.0022570358,0.0016584235,0.00095193734,0.00012826982,0.000011589667,0.000020204145],"genre_scores_gemma":[0.99724084,0.0021890025,0.000027730683,0.000097314485,0.00021976154,0.0000042787847,0.00016991067,0.000018309756,0.000032839333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99411374,0.0020809246,0.0030637863,0.00028925322,0.0001792246,0.00027304617],"domain_scores_gemma":[0.9949843,0.0029600875,0.0013633049,0.0005080034,0.0000901741,0.00009412065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041395156,0.00025260125,0.0019003997,0.00025896746,0.00007737744,0.000008744028,0.00041971367,0.00022201441,0.0001291894],"category_scores_gemma":[0.0009144846,0.00013086715,0.000118528114,0.00028553102,0.0003628272,0.00008240009,0.00006423222,0.0006871062,0.0000048578063],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90901923,0.004974779,0.05990712,0.000062673345,0.0047560176,0.00068580895,0.0044067334,0.000015192844,0.00047182452,0.00011042429,0.0055969423,0.009993224],"study_design_scores_gemma":[0.86715317,0.014593159,0.1120128,0.0014498126,0.0014434868,0.0008271023,0.0010013147,0.000120306046,0.000034721626,0.00025932328,0.00082558003,0.00027919674],"about_ca_topic_score_codex":0.00088897906,"about_ca_topic_score_gemma":0.0006909854,"teacher_disagreement_score":0.052105684,"about_ca_system_score_codex":0.00006441331,"about_ca_system_score_gemma":0.00054514105,"threshold_uncertainty_score":0.5336607},"labels":[],"label_agreement":null},{"id":"W4404455223","doi":"10.25251/skin.8.supp.471","title":"Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alopecia areata; Medicine; Patient-reported outcome; Dermatology; Disease; Burden of disease; Quality of life (healthcare); Internal medicine","score_opus":0.03808850697775853,"score_gpt":0.2852042641100399,"score_spread":0.24711575713228137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831617,0.008681977,0.002077679,0.0030686392,0.0014511277,0.0012640674,0.000028627877,0.000055945857,0.00021027419],"genre_scores_gemma":[0.9957758,0.0010976705,0.0008259159,0.0006528249,0.0012866339,0.000028630533,0.00008349816,0.0000878995,0.00016107933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959219,0.00014708204,0.0014957235,0.0004089788,0.0015271134,0.0004991807],"domain_scores_gemma":[0.9964425,0.0009737677,0.000805525,0.0005593756,0.00058512075,0.0006337076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005499844,0.0004245013,0.0008745159,0.0003759849,0.00020602727,0.000084102,0.00032229404,0.00010510607,0.00022814154],"category_scores_gemma":[0.001532381,0.00022363715,0.00021965009,0.00057993486,0.00032270796,0.00038539077,0.000058303365,0.0005512372,0.000007647811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0079183215,0.0005027307,0.86635876,0.0006340396,0.0012839825,0.0140370475,0.009388698,0.00049196323,0.0008152831,0.0000082751885,0.017916966,0.08064396],"study_design_scores_gemma":[0.019434683,0.0138988,0.8415796,0.03097512,0.008232698,0.006850981,0.011258978,0.005742942,0.00092404097,0.0012143566,0.0583127,0.0015750822],"about_ca_topic_score_codex":0.00016406036,"about_ca_topic_score_gemma":0.000025617328,"teacher_disagreement_score":0.07906888,"about_ca_system_score_codex":0.00030871417,"about_ca_system_score_gemma":0.00039347817,"threshold_uncertainty_score":0.91196585},"labels":[],"label_agreement":null},{"id":"W4404455231","doi":"10.25251/skin.8.supp.437","title":"Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"School of Medicine, Indiana University; Universidade de São Paulo; Manchester Biomedical Research Centre; Dalhousie University; National Institute for Health and Care Research","keywords":"Plaque psoriasis; Open label; Psoriasis; Medicine; Internal medicine; Dermatology; Clinical trial","score_opus":0.2612660508904314,"score_gpt":0.4255791209063332,"score_spread":0.16431307001590179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7371882,0.0041661225,0.001519378,0.25288856,0.0014243444,0.0013590532,0.00057018566,0.000012990488,0.0008711515],"genre_scores_gemma":[0.9866758,0.0010337968,0.0011136166,0.008257911,0.0010388033,0.000016253825,0.000014673926,0.00005143087,0.0017977231],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99260765,0.0014183625,0.0048257373,0.00042674135,0.000351266,0.00037023966],"domain_scores_gemma":[0.9863276,0.009956701,0.0025563473,0.0007421354,0.0002260774,0.00019113939],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.028888099,0.00025425592,0.0013405809,0.00048414004,0.00016298796,0.00009042786,0.00095089845,0.00012329246,0.00018052159],"category_scores_gemma":[0.011308024,0.00015123727,0.000074850584,0.0005613399,0.00022163623,0.0003348028,0.000091063426,0.0005845339,0.000060923998],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5658107,0.00065571204,0.0000431785,0.00014135435,0.0005648567,0.00054418435,0.03232499,0.002979836,0.00013398282,0.007279713,0.38758507,0.0019364377],"study_design_scores_gemma":[0.439896,0.03135366,0.000903874,0.019767916,0.0005435092,0.007435816,0.05443029,0.022105394,0.00043222966,0.084590994,0.33679566,0.0017446524],"about_ca_topic_score_codex":0.00273013,"about_ca_topic_score_gemma":0.0008909548,"teacher_disagreement_score":0.24948756,"about_ca_system_score_codex":0.0005804984,"about_ca_system_score_gemma":0.00068632467,"threshold_uncertainty_score":0.99996406},"labels":[],"label_agreement":null},{"id":"W4404455235","doi":"10.25251/skin.8.supp.473","title":"Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Geotab (Canada)","funders":"LEO Pharma; InflaRx; Idorsia Pharmaceuticals; European Academy of Dermatology and Venereology; Eisai; Bundesministerium für Bildung und Forschung; Insmed; Incyte; Celgene; Biogen; L'Oreal USA; European Commission; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hidradenitis suppurativa; Open label; Extension (predicate logic); Phase (matter); Medicine; Dermatology; Internal medicine; Clinical trial; Computer science; Chemistry; Programming language","score_opus":0.07663420508063443,"score_gpt":0.3691144696220155,"score_spread":0.2924802645413811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.849655,0.006902101,0.00003546671,0.14096725,0.00041565453,0.0014489248,0.00028168675,0.00001902905,0.0002749367],"genre_scores_gemma":[0.9943468,0.0033526479,0.00058488554,0.0003419117,0.00051434344,0.000005061554,0.00014695276,0.00005443468,0.00065293844],"study_design_codex":"randomized_trial","study_design_gemma":"case_report","domain_scores_codex":[0.99608743,0.00083829375,0.0013762483,0.00038175102,0.00096845976,0.00034781446],"domain_scores_gemma":[0.9946439,0.0039782533,0.00046967078,0.00047045504,0.00019519411,0.00024248827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036315285,0.00037763207,0.0013606809,0.00015352036,0.0002886136,0.000091200265,0.00027195632,0.00013176819,0.00019351358],"category_scores_gemma":[0.0018317903,0.0001658217,0.00006289746,0.00041303612,0.0005439027,0.00032485047,0.00015533315,0.0007828069,0.0000057727975],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25528398,0.006577853,0.0025257233,0.00021688412,0.0050288877,0.19630611,0.15402956,0.000008261968,0.0068688937,0.00020415038,0.12479204,0.24815765],"study_design_scores_gemma":[0.31794247,0.050088875,0.020882417,0.0166504,0.0064520207,0.43768108,0.006598102,0.00013987569,0.0006670238,0.0016884845,0.14024986,0.00095937826],"about_ca_topic_score_codex":0.00058369484,"about_ca_topic_score_gemma":0.00014276926,"teacher_disagreement_score":0.24719827,"about_ca_system_score_codex":0.00014042668,"about_ca_system_score_gemma":0.00023426104,"threshold_uncertainty_score":0.6762012},"labels":[],"label_agreement":null},{"id":"W4404455251","doi":"10.25251/skin.8.supp.431","title":"Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients with Psoriasis who had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dermatrials Research; Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.009632729964742385,"score_gpt":0.23137510540230313,"score_spread":0.22174237543756076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850898,0.012954018,0.0000015512886,0.0006772806,0.00047882038,0.0002695226,0.00040829074,0.0000051141656,0.000115609975],"genre_scores_gemma":[0.99394476,0.0054338537,0.000017953467,0.000051827756,0.00009012901,0.0000037226998,0.00007868849,0.00001688691,0.000362202],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99886775,0.00020083322,0.0004689593,0.0001801278,0.00006746909,0.00021483959],"domain_scores_gemma":[0.99903053,0.00050221424,0.00017499023,0.0001719895,0.00004065432,0.00007959486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016989611,0.00020954922,0.00047092504,0.00031346444,0.000051708153,0.000009297513,0.000076622324,0.00012775151,0.00012865009],"category_scores_gemma":[0.000047409147,0.00011025747,0.000052598658,0.00013670983,0.00021169169,0.00005481251,0.000012047011,0.00012590046,0.0000048699208],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046208546,0.000578075,0.035040293,0.000034145563,0.0047394126,0.0026599264,0.051637407,0.000036044097,0.0018281986,0.000020646592,0.0009478778,0.8562694],"study_design_scores_gemma":[0.04851959,0.019150428,0.86307126,0.002552192,0.0038554305,0.0030807278,0.0011744541,0.00003612514,0.0013138048,0.00009809636,0.056733478,0.0004144211],"about_ca_topic_score_codex":0.040828623,"about_ca_topic_score_gemma":0.045282535,"teacher_disagreement_score":0.855855,"about_ca_system_score_codex":0.00037136278,"about_ca_system_score_gemma":0.00015676631,"threshold_uncertainty_score":0.9721386},"labels":[],"label_agreement":null},{"id":"W4404455265","doi":"10.25251/skin.8.supp.461","title":"Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Galderma; Pfizer","keywords":"Atopic dermatitis; Dermatology; Medicine","score_opus":0.0079587013863197,"score_gpt":0.26058198014489276,"score_spread":0.25262327875857304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8367663,0.12747522,0.0005361139,0.033122234,0.0007770979,0.00046360228,0.000029302642,0.00002357954,0.00080654386],"genre_scores_gemma":[0.9897777,0.0038975852,0.00067424256,0.0044852966,0.0005926367,0.000010586272,0.000019483941,0.00003490652,0.0005075553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984508,0.0001255438,0.0006500363,0.00021068411,0.00029524157,0.00026769412],"domain_scores_gemma":[0.9984884,0.00075802,0.00020136088,0.0002679492,0.00009414189,0.00019012346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014423812,0.00025221813,0.00067902094,0.00020205804,0.000090054884,0.000025083475,0.00016576986,0.0001282799,0.00045100134],"category_scores_gemma":[0.00014473681,0.00014122539,0.00013231505,0.00015273762,0.0003090164,0.00012053889,0.000023982007,0.00035095392,0.000018366121],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046632253,0.00080196565,0.03427629,0.0016520212,0.002288442,0.055562865,0.0247452,0.00018595778,0.001924391,0.00018649599,0.847635,0.02607816],"study_design_scores_gemma":[0.016503155,0.0030488435,0.11307222,0.010292066,0.0034647838,0.19472352,0.005912297,0.0041138614,0.006213165,0.020593489,0.6212078,0.0008548322],"about_ca_topic_score_codex":0.00006720285,"about_ca_topic_score_gemma":0.000046194,"teacher_disagreement_score":0.22642721,"about_ca_system_score_codex":0.000089806985,"about_ca_system_score_gemma":0.00012190748,"threshold_uncertainty_score":0.57590044},"labels":[],"label_agreement":null},{"id":"W4404455267","doi":"10.25251/skin.8.supp.475","title":"Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Idorsia Pharmaceuticals; LEO Pharma; Incyte; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pooled analysis; Medicine; Internal medicine; Meta-analysis","score_opus":0.016534721351604737,"score_gpt":0.3092758611476984,"score_spread":0.2927411397960937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886319,0.0006507233,0.0006952782,0.008049906,0.0006880131,0.00049252296,0.000216962,0.00002601149,0.00054865546],"genre_scores_gemma":[0.9971731,0.000075131764,0.0006461738,0.0011121895,0.0005674545,0.0000018975626,0.000074543874,0.0000632515,0.00028627404],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9970472,0.00021568143,0.0009070572,0.00029810143,0.0011128525,0.00041911143],"domain_scores_gemma":[0.9982651,0.00041451908,0.00029908825,0.00036231545,0.0002788233,0.00038019117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007303193,0.00035975283,0.00078322913,0.0004473117,0.00015093203,0.000040798426,0.00021328793,0.00009619,0.00015522697],"category_scores_gemma":[0.00023536506,0.0001836399,0.00018342417,0.00043493387,0.000103305414,0.00012396253,0.00006420528,0.00092585734,0.000008698223],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71188086,0.0032866662,0.001574509,0.0006043472,0.0045961197,0.021840297,0.049896017,0.15325196,0.012987186,0.000056120567,0.016297843,0.023728078],"study_design_scores_gemma":[0.05960146,0.28176126,0.044142943,0.14246054,0.01137959,0.034146085,0.013576719,0.40185988,0.00025185337,0.002739338,0.0053223344,0.0027579903],"about_ca_topic_score_codex":0.0006627732,"about_ca_topic_score_gemma":0.000050869145,"teacher_disagreement_score":0.6522794,"about_ca_system_score_codex":0.0010519307,"about_ca_system_score_gemma":0.00062686985,"threshold_uncertainty_score":0.7488618},"labels":[],"label_agreement":null},{"id":"W4404455270","doi":"10.25251/skin.8.supp.441","title":"Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Body surface area; Dermatology; Internal medicine","score_opus":0.024201131398376464,"score_gpt":0.29140096923614606,"score_spread":0.26719983783776957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98266745,0.0100242905,0.000038295377,0.002703925,0.0033236952,0.0007684004,0.00004160515,0.000029853774,0.00040247152],"genre_scores_gemma":[0.99657524,0.0014843396,0.000063866595,0.00022450753,0.00052329653,0.000018367537,0.00003487131,0.000036834448,0.00103869],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969674,0.0008725886,0.0011098622,0.00031623032,0.00021239901,0.00052154844],"domain_scores_gemma":[0.998248,0.0009954771,0.00030817368,0.00021851048,0.00014623538,0.00008360824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016294536,0.00037642298,0.00091319083,0.00049251626,0.00012509656,0.000026679303,0.00036843965,0.0002817053,0.0003775522],"category_scores_gemma":[0.00031583942,0.00023083636,0.00015898955,0.00076796935,0.00017422685,0.00012395975,0.00005755348,0.00078262156,0.000048980844],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34839046,0.0037216127,0.0007231846,0.00015696343,0.0034689761,0.008103637,0.050031573,0.0029076228,0.46473432,0.00019401558,0.06018542,0.057382222],"study_design_scores_gemma":[0.42611095,0.0477872,0.0005164749,0.0083447555,0.003775673,0.03321459,0.022895133,0.0008973479,0.40298983,0.005336687,0.045866407,0.002264947],"about_ca_topic_score_codex":0.00028839055,"about_ca_topic_score_gemma":0.00046279185,"teacher_disagreement_score":0.07772048,"about_ca_system_score_codex":0.00036688842,"about_ca_system_score_gemma":0.00038964555,"threshold_uncertainty_score":0.9413234},"labels":[],"label_agreement":null},{"id":"W4404455273","doi":"10.25251/skin.8.supp.433","title":"Bimekizumab Long-term Efficacy in Patients with Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Ustekinumab; Secukinumab; Medicine; Plaque psoriasis; Adalimumab; Dermatology; Psoriasis; Internal medicine; Tumor necrosis factor alpha; Psoriatic arthritis","score_opus":0.011477805515059185,"score_gpt":0.2361622407124037,"score_spread":0.2246844351973445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915391,0.00366996,0.000045058514,0.0012685816,0.0013518966,0.0005589383,0.0015300356,0.000018353418,0.000018064986],"genre_scores_gemma":[0.99820626,0.00045361102,0.00015461903,0.00020838699,0.00029497172,0.000009291325,0.00023294351,0.00004771383,0.0003922235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977522,0.0003418972,0.00088495197,0.00042429022,0.0002311593,0.00036550435],"domain_scores_gemma":[0.9974734,0.0015793428,0.0003000104,0.0004137458,0.00009215152,0.00014130728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021999588,0.00040589698,0.0009086444,0.00032556304,0.000081908074,0.00003062039,0.00024667743,0.00020936476,0.00040668683],"category_scores_gemma":[0.00010694928,0.00021915595,0.00010839005,0.00026296222,0.00009908102,0.00010493095,0.00007276938,0.00030923844,0.00002121979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36929646,0.0014016976,0.012226159,0.00005288143,0.010037093,0.011319463,0.17566569,0.001131,0.013825521,0.000006252948,0.0026645316,0.40237325],"study_design_scores_gemma":[0.11228654,0.022813728,0.80354065,0.010021028,0.007670859,0.004606312,0.0037083656,0.00009960439,0.029114429,0.00022780806,0.0041781436,0.0017325573],"about_ca_topic_score_codex":0.0039740223,"about_ca_topic_score_gemma":0.002459218,"teacher_disagreement_score":0.7913145,"about_ca_system_score_codex":0.000255703,"about_ca_system_score_gemma":0.00016689065,"threshold_uncertainty_score":0.893692},"labels":[],"label_agreement":null},{"id":"W4404455285","doi":"10.25251/skin.8.supp.463","title":"Impact of Therapeutic Inertia on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the TARGET-DERM AD Registry","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atopic dermatitis; Medicine; Longitudinal study; Dermatology; Patient registry; Pediatrics; Pathology","score_opus":0.022400432095734304,"score_gpt":0.3143109992616946,"score_spread":0.2919105671659603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98130196,0.009270666,0.000057598125,0.0078116576,0.00049622206,0.000691472,0.000019159868,0.000022027418,0.00032922544],"genre_scores_gemma":[0.99802274,0.0001980166,0.000026920057,0.0013987195,0.00016024259,0.000008400333,0.000007994306,0.000031924785,0.00014506467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971011,0.00037954884,0.0012031232,0.00021115859,0.00080458896,0.00030044935],"domain_scores_gemma":[0.9971618,0.0013910169,0.0004680606,0.0005972599,0.0001902096,0.00019164654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043320263,0.00031489323,0.0009618794,0.00023944669,0.00008810038,0.000019310459,0.00034817687,0.00009009957,0.00030913492],"category_scores_gemma":[0.0007260458,0.00013485888,0.0002586117,0.00033213545,0.00021375583,0.000075761156,0.00004878282,0.0007418216,0.000008742427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034026266,0.0011739874,0.94383156,0.00007838769,0.002940008,0.019788846,0.010206996,0.00089455245,0.00017151149,0.000007379288,0.01353942,0.0039647273],"study_design_scores_gemma":[0.0030355991,0.0036545964,0.96586865,0.0016293988,0.0013114755,0.019429954,0.002907855,0.00048644564,0.0001008306,0.0011900985,0.0002266411,0.000158472],"about_ca_topic_score_codex":0.00042550097,"about_ca_topic_score_gemma":0.00019090093,"teacher_disagreement_score":0.022037078,"about_ca_system_score_codex":0.00013991466,"about_ca_system_score_gemma":0.00035490605,"threshold_uncertainty_score":0.54993856},"labels":[],"label_agreement":null},{"id":"W4404455301","doi":"10.25251/skin.8.supp.442","title":"Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology; SKiN Health","funders":"","keywords":"Plaque psoriasis; Medicine; Internal medicine; Psoriasis; Dermatology; Pharmacology","score_opus":0.022981120971243156,"score_gpt":0.29019544373035705,"score_spread":0.2672143227591139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571896,0.0021632863,0.000013863831,0.00026120766,0.00093877775,0.0006851751,0.00017990601,0.0000066196453,0.000032183936],"genre_scores_gemma":[0.9994044,0.00022849234,0.00007269185,0.000051730156,0.00012798172,0.000014938691,0.00006848243,0.000019776235,0.000011524525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997268,0.0014052859,0.000630403,0.00017893949,0.00032025942,0.00019706863],"domain_scores_gemma":[0.9981575,0.0006531016,0.0004205782,0.0001757046,0.0005557499,0.000037381353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018107949,0.0002006171,0.0006415111,0.00042132658,0.00003539213,0.00000510828,0.00017487883,0.00017380237,0.00012924834],"category_scores_gemma":[0.00037788312,0.0001181757,0.00004886659,0.0005303831,0.00014630334,0.0000951351,0.000015906211,0.00029362927,0.0000029067485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56224984,0.0058705066,0.0054521756,0.00011632872,0.004871972,0.00034100463,0.065145,0.0035554706,0.106542215,0.000027491224,0.002264399,0.24356359],"study_design_scores_gemma":[0.514628,0.09621874,0.009053204,0.0054342505,0.009004376,0.00049294037,0.01136818,0.0006897303,0.34923863,0.0022821908,0.0006348947,0.00095486746],"about_ca_topic_score_codex":0.00028844774,"about_ca_topic_score_gemma":0.0008953603,"teacher_disagreement_score":0.2426964,"about_ca_system_score_codex":0.0001834588,"about_ca_system_score_gemma":0.000380808,"threshold_uncertainty_score":0.48190653},"labels":[],"label_agreement":null},{"id":"W4404455317","doi":"10.25251/skin.8.supp.470","title":"Demographics and Disease Characteristics of Patients with Alopecia Areata with Comorbid Atopic Dermatitis, Vitiligo or Anxiety/Depression: TARGET-DERM AA","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Castle Biosciences; Galderma; Incyte; Sanofi; Pfizer; Concert Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Alopecia areata; Vitiligo; Atopic dermatitis; Dermatology; Demographics; Depression (economics); Medicine; Anxiety; Psychiatry","score_opus":0.005028587827783405,"score_gpt":0.22306850765820477,"score_spread":0.21803991983042137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875883,0.006633395,0.000869151,0.0038915547,0.00023017687,0.0003959334,0.000055725803,0.000021775057,0.0003140184],"genre_scores_gemma":[0.9951275,0.0030588266,0.0002620636,0.0010783526,0.00029135577,0.0000022055428,0.000040248768,0.00003588565,0.00010356456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982287,0.00007349075,0.0005505124,0.00015006724,0.00076631596,0.00023089667],"domain_scores_gemma":[0.99833435,0.00027502334,0.00028013389,0.0002795277,0.00032694233,0.00050399493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002091746,0.00023233682,0.0005628406,0.00019183237,0.00008761419,0.0000152231,0.00015353876,0.00006189057,0.00020214621],"category_scores_gemma":[0.0002833449,0.00009933387,0.00005707561,0.00034265677,0.00048580288,0.00009544284,0.000032786458,0.00039263544,0.0000012103235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005825211,0.00035501577,0.9471354,0.0017483424,0.0006149994,0.0053348877,0.0023628604,0.000008400076,0.00006555645,0.000065172215,0.008717797,0.027766341],"study_design_scores_gemma":[0.0082820235,0.005988332,0.91471016,0.010873391,0.0034925875,0.020387247,0.0020270194,0.00047938613,0.00017103582,0.00051690923,0.032647807,0.00042407433],"about_ca_topic_score_codex":0.000012577462,"about_ca_topic_score_gemma":0.000020048761,"teacher_disagreement_score":0.032425232,"about_ca_system_score_codex":0.000023429446,"about_ca_system_score_gemma":0.00032719754,"threshold_uncertainty_score":0.40507177},"labels":[],"label_agreement":null},{"id":"W4404455334","doi":"10.25251/skin.8.supp.462","title":"Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from the TARGET-DERM AD registry","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atopic dermatitis; Medicine; Disease; Longitudinal study; Pediatrics; Dermatology; Internal medicine; Pathology","score_opus":0.01728837496855759,"score_gpt":0.27741785221710435,"score_spread":0.26012947724854674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90223044,0.04447664,0.00022682139,0.052058935,0.0002488838,0.00038878378,0.00006067399,0.000017234255,0.00029158813],"genre_scores_gemma":[0.9948158,0.0013732375,0.000033411456,0.003254895,0.00012343792,0.0000073675983,0.00001482267,0.000021069487,0.00035591034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976652,0.00034693428,0.0009153043,0.00021227775,0.00058409193,0.0002761368],"domain_scores_gemma":[0.9971832,0.0015945904,0.0003209063,0.00044386397,0.0001487059,0.00030872042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004947546,0.00026406714,0.0010883886,0.00045979017,0.000097858036,0.000023526993,0.00029050143,0.00006250333,0.00020794028],"category_scores_gemma":[0.00041047586,0.00012648394,0.00034294074,0.000621197,0.00038192346,0.00006217489,0.000042367123,0.0004897673,0.0000026642608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041056257,0.00026498496,0.9549011,0.0003184186,0.010307413,0.010950435,0.0056353663,0.0037547369,0.000111012145,0.00010781364,0.0060561774,0.0034869025],"study_design_scores_gemma":[0.0025469349,0.00029934917,0.9569403,0.0013656975,0.014946794,0.0024300236,0.0015261794,0.017947989,0.00001607565,0.0012069074,0.00061191455,0.00016186523],"about_ca_topic_score_codex":0.00043971278,"about_ca_topic_score_gemma":0.0009426863,"teacher_disagreement_score":0.09258541,"about_ca_system_score_codex":0.00009340737,"about_ca_system_score_gemma":0.00023056137,"threshold_uncertainty_score":0.5157865},"labels":[],"label_agreement":null},{"id":"W4406295719","doi":"10.25251/skin.9.supp.510","title":"Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From ADjoin","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Atopic dermatitis; Term (time); Dermatology; Medicine; Physics","score_opus":0.00559892539955492,"score_gpt":0.24772969753460658,"score_spread":0.24213077213505166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406295719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894182,0.00079711934,0.00018179322,0.008440781,0.00019804841,0.0005141815,0.000036995556,0.0000072176213,0.00040566997],"genre_scores_gemma":[0.99555993,0.00016269185,0.00013526998,0.0037408061,0.00006399951,0.0000016413775,0.000016479795,0.000013479176,0.00030567302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982632,0.00014506627,0.00080164144,0.00016058133,0.00041556457,0.00021394988],"domain_scores_gemma":[0.998481,0.0004935852,0.00026750044,0.00031441383,0.00023473534,0.00020878804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024060442,0.00017415293,0.00067980075,0.00030350365,0.000048623602,0.0000060115863,0.000195021,0.000073859854,0.00008716519],"category_scores_gemma":[0.0005631765,0.00010544078,0.00004266031,0.00031356845,0.00016606077,0.000045638742,0.000060542643,0.0002879413,0.000004686405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13132577,0.00085452193,0.7442526,0.00046338927,0.0014045007,0.0061020097,0.019847948,0.0006106823,0.000115184375,0.000065384076,0.06623289,0.028725091],"study_design_scores_gemma":[0.016939016,0.0009905697,0.97543037,0.0036793225,0.00039340038,0.0012911363,0.00037332042,0.000025507412,0.00019771313,0.00023896515,0.00033822926,0.000102448226],"about_ca_topic_score_codex":0.000061606246,"about_ca_topic_score_gemma":0.00006898439,"teacher_disagreement_score":0.23117773,"about_ca_system_score_codex":0.000074372736,"about_ca_system_score_gemma":0.00016531002,"threshold_uncertainty_score":0.429975},"labels":[],"label_agreement":null},{"id":"W4406295765","doi":"10.25251/skin.9.supp.517","title":"Lebrikizumab vs Other Systemic Monotherapies for Moderate to Severe Atopic Dermatitis: Network Meta-analysis of Short-term Efficacy","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Argenx; Biogen; Amgen","keywords":"Atopic dermatitis; Medicine; Term (time); Meta-analysis; Dermatology; Internal medicine","score_opus":0.031819005665234025,"score_gpt":0.31437539098779166,"score_spread":0.2825563853225576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406295765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8508209,0.089953996,0.026426032,0.027743228,0.0008992525,0.00207262,0.00006471516,0.000050669878,0.0019686068],"genre_scores_gemma":[0.99215156,0.00043729524,0.00035452924,0.0055077868,0.00023880007,0.000017143018,0.0000064014744,0.000023942466,0.0012625234],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99762154,0.00028083785,0.0012137312,0.00016667791,0.0004202888,0.00029693864],"domain_scores_gemma":[0.99705595,0.0013548738,0.00047531206,0.00049900945,0.00046183556,0.00015302042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068506075,0.0002613424,0.0023300883,0.00046544362,0.00012696254,0.000010498005,0.0003552816,0.00010232302,0.00030414786],"category_scores_gemma":[0.0003035964,0.00014126717,0.0009336807,0.0006822815,0.00019012154,0.00004524216,0.00003295844,0.00022953624,0.0000024934968],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014040378,0.00073340203,0.018060684,0.0018985776,0.67567754,0.0015485539,0.008789124,0.07681824,0.00088117534,0.0013389129,0.19512649,0.005086905],"study_design_scores_gemma":[0.0069170953,0.0016578337,0.017296698,0.0021951955,0.9233952,0.026187614,0.0017158808,0.0046648053,0.0014137016,0.0031110283,0.010928631,0.00051627],"about_ca_topic_score_codex":0.000016976883,"about_ca_topic_score_gemma":0.00003286181,"teacher_disagreement_score":0.2477177,"about_ca_system_score_codex":0.000054744614,"about_ca_system_score_gemma":0.00015498429,"threshold_uncertainty_score":0.57607085},"labels":[],"label_agreement":null},{"id":"W4406296138","doi":"10.25251/skin.9.1.17","title":"Clinical Improvement of Necrobiosis Lipoidica Diabeticorum with Opzelura (Ruxolitinib) Cream: A Case Report","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Skin Diseases and Diabetes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Necrobiosis lipoidica; Dermatology; Ruxolitinib; Medicine; Diabetes mellitus; Internal medicine; Myelofibrosis","score_opus":0.010899593492939943,"score_gpt":0.3138308872178585,"score_spread":0.30293129372491856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406296138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787424,0.0037167238,0.00019290007,0.011762005,0.00067818357,0.0004908353,0.000010055903,0.000019955982,0.004386912],"genre_scores_gemma":[0.9944067,0.00068429153,0.0003824062,0.0026019716,0.00069027796,0.000004376155,0.000005807748,0.000027514685,0.0011966507],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9965917,0.00014253278,0.0019670709,0.00022096792,0.0006943441,0.00038339046],"domain_scores_gemma":[0.9951453,0.0015967537,0.001318806,0.0007323822,0.00081782986,0.00038893588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018683433,0.00026485385,0.0011685271,0.00024891537,0.00010601128,0.000009552735,0.00026766132,0.00011995146,0.00033031902],"category_scores_gemma":[0.0025671164,0.00013082553,0.00030803095,0.00044064363,0.00078755606,0.000042796706,0.000086041895,0.0005533122,0.0000022217782],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017271308,0.0065781386,0.14566502,0.0020918336,0.0075625414,0.5295836,0.0017584398,0.00006936174,0.016057547,0.0005097902,0.13560031,0.13725215],"study_design_scores_gemma":[0.01575243,0.032534644,0.015916685,0.0092495475,0.012414006,0.86871445,0.0070459284,0.00016765235,0.014788704,0.0013324165,0.021625798,0.00045772383],"about_ca_topic_score_codex":0.00014396002,"about_ca_topic_score_gemma":0.000013864988,"teacher_disagreement_score":0.3391309,"about_ca_system_score_codex":0.000073098396,"about_ca_system_score_gemma":0.00062647625,"threshold_uncertainty_score":0.533491},"labels":[],"label_agreement":null},{"id":"W4408493760","doi":"10.25251/skin.10.supp.567","title":"Efficacy and Safety of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Older Adults","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Dermatology; Medicine","score_opus":0.008574743314145362,"score_gpt":0.29102257769441076,"score_spread":0.2824478343802654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408493760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835194,0.0070495913,0.00027556813,0.007406336,0.00017854499,0.00080405636,0.0000092790215,0.000004202391,0.0007530571],"genre_scores_gemma":[0.99643385,0.0020969398,0.00016477672,0.000180889,0.00013109953,0.000006280063,0.0000066332022,0.0000071346713,0.00097242155],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99901575,0.00004950575,0.00050560525,0.00009441398,0.00018863955,0.00014607616],"domain_scores_gemma":[0.99889433,0.0005386657,0.00019450768,0.00014799964,0.00013401377,0.00009047936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001726562,0.0001235986,0.0004652157,0.00014360179,0.00004402016,0.0000019433403,0.00006144723,0.000054021224,0.00008718477],"category_scores_gemma":[0.00022414023,0.0000638854,0.00009322214,0.00012899472,0.000107003914,0.000019225101,0.00001372666,0.00008511356,7.170767e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086578935,0.0046009924,0.03822309,0.0007872675,0.0016009009,0.00070442376,0.0035711925,0.00003277545,0.0015279248,0.00048871356,0.0061982246,0.85568553],"study_design_scores_gemma":[0.13252988,0.023208331,0.79623544,0.010792812,0.0061439667,0.0046208384,0.00171641,0.0009136841,0.0028355417,0.0013607085,0.019379,0.00026338248],"about_ca_topic_score_codex":0.000095763055,"about_ca_topic_score_gemma":0.000031548036,"teacher_disagreement_score":0.8554222,"about_ca_system_score_codex":0.00014870439,"about_ca_system_score_gemma":0.00011139777,"threshold_uncertainty_score":0.26051712},"labels":[],"label_agreement":null},{"id":"W4408493853","doi":"10.25251/skin.10.supp.538","title":"Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Incyte; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Malignancy; Medicine; Dermatology; Internal medicine","score_opus":0.00954215173484367,"score_gpt":0.23473512960486337,"score_spread":0.22519297787001968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408493853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853442,0.011523853,0.00000534284,0.00032336958,0.00082503626,0.00064956356,0.000020621172,0.0000056063454,0.0013024171],"genre_scores_gemma":[0.99761367,0.00081284216,0.0000778302,0.0001190873,0.000041920634,0.000036409365,0.00001671378,0.000012610804,0.0012689445],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99799496,0.00057759054,0.00084269844,0.00014577636,0.00016185905,0.00027713698],"domain_scores_gemma":[0.9982504,0.00064602576,0.0005873718,0.00033329052,0.00016252638,0.000020389343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005891553,0.00022662352,0.0006918066,0.00036728242,0.00002578115,0.0000019709385,0.0003622993,0.00014739117,0.00012548723],"category_scores_gemma":[0.00012979924,0.000112468486,0.00014260091,0.0003410825,0.00040098478,0.00003827057,0.00002372686,0.00021908082,0.0000033675178],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03155309,0.0048065446,0.29878008,0.00021447075,0.00278318,0.001101968,0.05097702,0.00002214457,0.0046538063,0.00022523329,0.0051015015,0.599781],"study_design_scores_gemma":[0.060714975,0.024876678,0.8217933,0.0041472213,0.0047779595,0.0021720398,0.007848782,0.0000041823614,0.006522725,0.0009441058,0.06560462,0.00059339945],"about_ca_topic_score_codex":0.0003421505,"about_ca_topic_score_gemma":0.0007138712,"teacher_disagreement_score":0.59918755,"about_ca_system_score_codex":0.00025317757,"about_ca_system_score_gemma":0.00027756835,"threshold_uncertainty_score":0.45863318},"labels":[],"label_agreement":null},{"id":"W4408497907","doi":"10.25251/skin.10.supp.534","title":"Deucravacitinib in Plaque Psoriasis: Immune Response to and Safety of Pneumococcus and Tetanus Toxoid Vaccines in the POETYK LTE Trial","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Toxoid; Tetanus; Medicine; Immune system; Plaque psoriasis; Immunology; Psoriasis; Microbiology; Vaccination; Biology","score_opus":0.009630359305753027,"score_gpt":0.2599379885476756,"score_spread":0.25030762924192257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408497907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97214234,0.016599573,0.000012354691,0.009528228,0.0008091487,0.00057426025,0.000012888378,0.000004029514,0.0003172027],"genre_scores_gemma":[0.9957299,0.0034375347,0.00002298795,0.00029487538,0.00010250368,0.000008398088,0.0000028839136,0.000008289494,0.00039260625],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.997094,0.0014738708,0.0009551041,0.00014296727,0.00009146214,0.00024260044],"domain_scores_gemma":[0.99592113,0.0033665989,0.00033905098,0.0002637153,0.00008342373,0.00002609203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032623278,0.00020153307,0.00068006717,0.0004236344,0.00010073098,0.0000061687774,0.00034018268,0.00015265902,0.000042705244],"category_scores_gemma":[0.0011109632,0.00010125152,0.000066076944,0.00040560905,0.00018854438,0.000038914346,0.00006187257,0.00035186214,0.0000020264251],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5853014,0.00041994455,0.0031304872,0.00006804496,0.0007316995,0.00072504627,0.019697377,0.00003382014,0.31300855,0.0003082366,0.0012940357,0.07528135],"study_design_scores_gemma":[0.35877055,0.028620388,0.3884337,0.0056083845,0.0037151957,0.042479213,0.0460433,0.000014443444,0.07301505,0.006525914,0.04572731,0.0010465613],"about_ca_topic_score_codex":0.00013117996,"about_ca_topic_score_gemma":0.00021574242,"teacher_disagreement_score":0.3853032,"about_ca_system_score_codex":0.000041653435,"about_ca_system_score_gemma":0.0001070396,"threshold_uncertainty_score":0.41289172},"labels":[],"label_agreement":null},{"id":"W4408498262","doi":"10.25251/skin.10.supp.526","title":"Bimekizumab Maintenance of Response at Every Visit Over 4 Years in Patients with Psoriasis Achieving Clear Skin at Week 16: Results from Four Phase 3 Trials","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Phase (matter); Dermatology; Internal medicine; Chemistry","score_opus":0.016137967611291333,"score_gpt":0.26463942600066387,"score_spread":0.24850145838937254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408498262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936361,0.0035477672,0.00003037582,0.0010577452,0.0009887244,0.00033645693,0.00019463937,0.00000882606,0.0001993912],"genre_scores_gemma":[0.9955181,0.0007620569,0.00006899034,0.00020811796,0.000112776426,0.0000017214379,0.00005208072,0.000021535843,0.0032546478],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960922,0.0018211545,0.0013170303,0.00023340891,0.00021109568,0.00032508565],"domain_scores_gemma":[0.99383456,0.0041741175,0.0013095287,0.0004350351,0.00020401116,0.00004274455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029955392,0.00025783578,0.0010934663,0.0003170184,0.00013518828,0.00000483754,0.0003898292,0.00020694917,0.0005948227],"category_scores_gemma":[0.0025846905,0.00014744906,0.00018776236,0.0002996723,0.00027360392,0.00006137391,0.0001068006,0.0003155572,0.000033804165],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8287718,0.0009303121,0.0056813704,0.000023936953,0.0024819726,0.00067916536,0.0057848967,0.00009306699,0.035965335,0.000004328786,0.044859532,0.07472427],"study_design_scores_gemma":[0.30528098,0.033095364,0.51167697,0.00765902,0.0068859872,0.0025112503,0.0032688084,0.0000150397345,0.050172355,0.00062326033,0.07779035,0.0010205943],"about_ca_topic_score_codex":0.00025216799,"about_ca_topic_score_gemma":0.00026134253,"teacher_disagreement_score":0.52349085,"about_ca_system_score_codex":0.00035127994,"about_ca_system_score_gemma":0.00012882928,"threshold_uncertainty_score":0.65128917},"labels":[],"label_agreement":null},{"id":"W4408498282","doi":"10.25251/skin.10.supp.531","title":"Long-Term Effectiveness of Guselkumab vs. Other Biologic Therapies Among Plaque Psoriasis Patients in the CorEvitas Psoriasis Registry","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Plaque psoriasis; Medicine; Dermatology; Term (time)","score_opus":0.01039560788878543,"score_gpt":0.25438247411742243,"score_spread":0.243986866228637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408498282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98453826,0.012018103,0.000059358892,0.00056520477,0.0017231343,0.00049916474,0.000024687268,0.000010381949,0.00056168786],"genre_scores_gemma":[0.99635535,0.0030180104,0.000009426678,0.00021197872,0.00012372567,0.000013578736,0.00002239612,0.000016066542,0.00022947598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962303,0.0023265332,0.00080598,0.00018530327,0.00014687088,0.0003049951],"domain_scores_gemma":[0.9952751,0.0031984942,0.0008003358,0.0004889206,0.00021686542,0.000020289493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002046535,0.00030316965,0.00082548324,0.00027554116,0.00015469153,0.000007895324,0.00084304705,0.0002753013,0.00016070955],"category_scores_gemma":[0.00048622454,0.0001367815,0.0002046565,0.00042817154,0.0007082586,0.000056846085,0.000051820614,0.00043517357,0.000008785193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012348028,0.0011087199,0.91552913,0.00033074807,0.0034143534,0.0002389741,0.0065370826,0.000040328177,0.0152392285,0.00039530854,0.0033054547,0.041512627],"study_design_scores_gemma":[0.00947065,0.0030169706,0.95578176,0.002346335,0.0016541474,0.0011391311,0.001661201,6.419689e-7,0.02180943,0.0012376765,0.0016320007,0.00025004725],"about_ca_topic_score_codex":0.00021851496,"about_ca_topic_score_gemma":0.00012759744,"teacher_disagreement_score":0.04126258,"about_ca_system_score_codex":0.00008690794,"about_ca_system_score_gemma":0.00007988335,"threshold_uncertainty_score":0.5577788},"labels":[],"label_agreement":null},{"id":"W4409574408","doi":"10.25251/skin.10.supp.573","title":"Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; LEO Pharma; Galderma; Incyte; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Term (time); Medicine; Pediatrics; Dermatology; Physics","score_opus":0.005786183515752849,"score_gpt":0.2590034322650996,"score_spread":0.25321724874934676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409574408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939926,0.0014671041,0.00034056004,0.0033570477,0.000092255,0.0006325623,0.00000770259,0.000005312326,0.00010480856],"genre_scores_gemma":[0.99806195,0.0004715775,0.00006609016,0.0011302284,0.000043612734,0.0000026776308,0.000003245413,0.000010827462,0.0002098093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897987,0.00007077467,0.0004778603,0.00011484822,0.00018624243,0.00017041592],"domain_scores_gemma":[0.999163,0.0002344508,0.00014430306,0.00014723981,0.00014319591,0.00016786109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015931942,0.00013557472,0.0005594997,0.00024528842,0.000041504907,0.000004083636,0.00009953609,0.000056537654,0.000014944808],"category_scores_gemma":[0.00024163496,0.00007987606,0.00003478156,0.00020621806,0.00014794577,0.00003136212,0.000022076036,0.00016065549,4.776943e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09081668,0.00052289193,0.82961434,0.0027982346,0.0006255709,0.004397547,0.011486312,0.00031347005,0.0002848886,0.000054603945,0.007026065,0.052059412],"study_design_scores_gemma":[0.016050477,0.0012172867,0.9573717,0.011464394,0.00047083406,0.012281507,0.00038849132,0.000093300965,0.00036462813,0.00007095977,0.00013320369,0.000093176015],"about_ca_topic_score_codex":0.000022354181,"about_ca_topic_score_gemma":0.000091736496,"teacher_disagreement_score":0.12775742,"about_ca_system_score_codex":0.00003439,"about_ca_system_score_gemma":0.00008487758,"threshold_uncertainty_score":0.32572514},"labels":[],"label_agreement":null},{"id":"W4412600394","doi":"10.25251/gdd40x24","title":"Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"LEO Pharma; Eli Lilly and Company; Concert Pharmaceuticals; L'Oreal USA; Sanofi; Pfizer","keywords":"Alopecia areata; Open label; Dermatology; Medicine; Term (time); Pediatrics; Adverse effect; Internal medicine; Physics","score_opus":0.015270157276328807,"score_gpt":0.3098022576172259,"score_spread":0.2945321003408971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412600394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898858,0.0028452063,0.00004516117,0.00452012,0.00011739122,0.0012352067,0.000028728095,0.0000049138457,0.0013174732],"genre_scores_gemma":[0.99699694,0.0019710048,0.000049959395,0.0006611354,0.00017410764,0.0000020073337,0.000011488399,0.000016613842,0.00011675737],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99790984,0.0002475527,0.0008940006,0.00021894736,0.0005071575,0.00022251692],"domain_scores_gemma":[0.9980909,0.00075408147,0.00037165874,0.0003975679,0.00022163065,0.0001641266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010254496,0.00021852276,0.0007167787,0.00014753306,0.00010024888,0.000016604976,0.00039091086,0.00006512253,0.000022781454],"category_scores_gemma":[0.0010163421,0.00010061266,0.000022239285,0.0003413601,0.00039965994,0.000068564135,0.00012945048,0.0005032171,8.113989e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46780702,0.012057126,0.36555773,0.00048948976,0.0013916148,0.0061483346,0.03998799,0.000019180332,0.000765515,0.000052913736,0.0073873717,0.098335706],"study_design_scores_gemma":[0.3238867,0.014581021,0.61749387,0.02159132,0.0014385391,0.0026976005,0.01700038,0.0000656534,0.000110440495,0.000120837736,0.0007782657,0.00023536003],"about_ca_topic_score_codex":0.00037714373,"about_ca_topic_score_gemma":0.0012944792,"teacher_disagreement_score":0.25193617,"about_ca_system_score_codex":0.00003307327,"about_ca_system_score_gemma":0.00017226601,"threshold_uncertainty_score":0.41028655},"labels":[],"label_agreement":null},{"id":"W4412600525","doi":"10.25251/2cx1vk07","title":"Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Incyte; Sanofi; Pfizer","keywords":"Alopecia areata; Dermatology; Patient satisfaction; Medicine; Family medicine; Nursing","score_opus":0.00935563584456081,"score_gpt":0.2705095618040149,"score_spread":0.26115392595945414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412600525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794945,0.0009182358,0.000019366244,0.0066656335,0.0002268174,0.0003497068,0.000011123826,0.0000043640966,0.012310249],"genre_scores_gemma":[0.9947095,0.0035146447,0.00003789181,0.0011913412,0.0002505086,0.0000025357615,0.000008267528,0.000009189215,0.00027614657],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986826,0.00014203238,0.00057577994,0.00008816073,0.00035426478,0.00015715725],"domain_scores_gemma":[0.9988745,0.00038361785,0.00031767017,0.00023155767,0.00012866652,0.000063984175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025883951,0.00014858852,0.00048631697,0.00021258682,0.000060542385,0.0000055052965,0.000091006186,0.000042146316,0.000046947676],"category_scores_gemma":[0.00015857953,0.000070028014,0.00006311178,0.00032331713,0.00017424712,0.00003100049,0.000012315207,0.00019064517,0.0000012258485],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057239686,0.0011466166,0.22221982,0.00039684257,0.00068611134,0.0019334846,0.026739527,0.000056997287,0.0034363575,0.00071905414,0.014880176,0.72206104],"study_design_scores_gemma":[0.008234855,0.008244972,0.9085007,0.0027863227,0.0016560397,0.0063361484,0.014969033,0.00016115668,0.000835105,0.0019010196,0.046148773,0.00022591943],"about_ca_topic_score_codex":0.0005909753,"about_ca_topic_score_gemma":0.0008000534,"teacher_disagreement_score":0.72183514,"about_ca_system_score_codex":0.00010155777,"about_ca_system_score_gemma":0.00012186777,"threshold_uncertainty_score":0.28556597},"labels":[],"label_agreement":null},{"id":"W4412600941","doi":"10.25251/ed52rz19","title":"Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Galderma; L'Oreal USA; LEO Pharma; Pfizer; Eli Lilly and Company","keywords":"Alopecia areata; Medicine; Dermatology; Clinical trial; Family medicine; Internal medicine","score_opus":0.012535400783838212,"score_gpt":0.32108735056964105,"score_spread":0.30855194978580286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412600941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918732,0.00064434746,0.00017316843,0.0033472637,0.00037809278,0.0011100107,0.00006597298,0.000013770588,0.0023941644],"genre_scores_gemma":[0.99750346,0.00029093868,0.00016888694,0.0013130314,0.00025867118,0.000003955656,0.0002771957,0.000016689928,0.00016716518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99635917,0.00053385325,0.0017928402,0.00019723561,0.0008296677,0.00028721336],"domain_scores_gemma":[0.99655277,0.0015489121,0.00064818724,0.00053687475,0.0005594432,0.00015382125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016107287,0.00023699654,0.001314852,0.000395423,0.00006734808,0.000009255653,0.0004449593,0.00015438918,0.0007569968],"category_scores_gemma":[0.0019864526,0.00009781189,0.00027560635,0.0019466493,0.00050111767,0.00004638753,0.000050410385,0.00084311486,0.0000015446112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.362557,0.003158323,0.48911738,0.000025076348,0.009200219,0.0003747003,0.0020018863,0.0002539708,0.000016489803,0.000044508484,0.02691772,0.10633272],"study_design_scores_gemma":[0.1508288,0.011380009,0.76445943,0.0014179454,0.014508142,0.000062691244,0.0036605615,0.001224855,0.000023535978,0.00023401593,0.051966686,0.00023335911],"about_ca_topic_score_codex":0.0008074528,"about_ca_topic_score_gemma":0.0016886197,"teacher_disagreement_score":0.27534202,"about_ca_system_score_codex":0.0000736155,"about_ca_system_score_gemma":0.0004041382,"threshold_uncertainty_score":0.82885844},"labels":[],"label_agreement":null},{"id":"W4416084832","doi":"10.25251/apx36v88","title":"Real-World Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from Longitudinal Analyses in 6- and 12-month Cohorts From the PPD CorEvitas Atopic Dermatitis Registry","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Eczema Area and Severity Index; Atopic dermatitis; Quality of life (healthcare); Clinical trial; Adverse effect; Rating scale","score_opus":0.021700364962630756,"score_gpt":0.3150602236048239,"score_spread":0.2933598586421931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416084832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9345564,0.05035655,0.00017242575,0.009884038,0.0009941455,0.0011696344,0.00031575197,0.000011801752,0.0025392221],"genre_scores_gemma":[0.98303795,0.014555216,0.000081341735,0.0015524263,0.00040202527,0.000015114887,0.000091797156,0.00003386826,0.00023025827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915422,0.0030307046,0.0032560816,0.00055566384,0.0009877816,0.000627524],"domain_scores_gemma":[0.9818752,0.014620113,0.0016269839,0.001091554,0.00044016604,0.0003459889],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00197353,0.000659544,0.0028650977,0.0007014968,0.00024571194,0.00004452133,0.00085386226,0.00029946308,0.00022260449],"category_scores_gemma":[0.0041428297,0.0004008715,0.00024712304,0.0011872078,0.0012612059,0.00019811951,0.00022893783,0.0014732316,0.000005121117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009646917,0.00060499244,0.9308883,0.0013559024,0.0023977063,0.019756243,0.0072688465,0.002008481,0.00031107024,0.00012335791,0.021004505,0.004633693],"study_design_scores_gemma":[0.010728135,0.00042127445,0.9375519,0.032800764,0.0024928025,0.004091599,0.0033205177,0.00082592224,0.0011457473,0.0057295873,0.0005802713,0.00031147312],"about_ca_topic_score_codex":0.01317742,"about_ca_topic_score_gemma":0.011385308,"teacher_disagreement_score":0.04848152,"about_ca_system_score_codex":0.00031212883,"about_ca_system_score_gemma":0.0007545677,"threshold_uncertainty_score":0.9998443},"labels":[],"label_agreement":null},{"id":"W4416084993","doi":"10.25251/0j9fht97","title":"Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Alopecia areata; Adverse effect; Incidence (geometry); Clinical trial; Safety profile; Pooled analysis","score_opus":0.015743953093950377,"score_gpt":0.33313335284524365,"score_spread":0.31738939975129327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416084993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840873,0.0015690125,0.00041017428,0.007472195,0.0020899454,0.0027673137,0.00022515413,0.000014825006,0.0013641093],"genre_scores_gemma":[0.99469453,0.0011326411,0.00018426651,0.0024780135,0.00069782423,0.0000076264428,0.0003583397,0.00003909216,0.00040767173],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99138284,0.0016558492,0.0042220275,0.00043987652,0.001673621,0.0006257918],"domain_scores_gemma":[0.99224335,0.0034964115,0.0014082552,0.0010809803,0.0013015186,0.0004695096],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040261177,0.00051713415,0.002793746,0.0010487353,0.000121502046,0.000027331771,0.0012558297,0.000341247,0.0018348246],"category_scores_gemma":[0.0056785564,0.00024346502,0.00053595117,0.00571424,0.0010419029,0.00007408588,0.00014847411,0.0018411077,0.000010202913],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5478636,0.003250409,0.15579754,0.000039034578,0.015746715,0.00055115705,0.008398929,0.000623354,0.000009354968,0.00003847776,0.032131217,0.23555021],"study_design_scores_gemma":[0.23785833,0.035616245,0.5231216,0.005662989,0.040916666,0.00008795089,0.021009529,0.001243643,0.00002003417,0.00020632539,0.1336805,0.0005761969],"about_ca_topic_score_codex":0.0013265136,"about_ca_topic_score_gemma":0.00291581,"teacher_disagreement_score":0.36732405,"about_ca_system_score_codex":0.00019684494,"about_ca_system_score_gemma":0.0012140542,"threshold_uncertainty_score":0.9990776},"labels":[],"label_agreement":null},{"id":"W4416140151","doi":"10.25251/9zz14r68","title":"Real-World Comparative Effectiveness of Deucravacitinib vs Apremilast at 6 Months for Plaque Psoriasis: Skin Clearance Outcomes From the RePhlect Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"Janssen Pharmaceuticals; Genentech; LEO Pharma; Ortho Dermatologics; Bristol-Myers Squibb; Eli Lilly and Company; Chugai Pharmaceutical; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Apremilast; Clinical trial; Plaque psoriasis; MEDLINE","score_opus":0.023430808397990298,"score_gpt":0.30673503431089494,"score_spread":0.28330422591290466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673543,0.019824445,0.0002351789,0.0019310201,0.005585479,0.0033253513,0.0003389384,0.000018634948,0.0013866624],"genre_scores_gemma":[0.9920229,0.0042129625,0.000050019393,0.0001991033,0.0005400679,0.00006730007,0.0000352486,0.000045575074,0.0028268707],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9899557,0.006123679,0.0023326904,0.00054637546,0.00035844647,0.00068309007],"domain_scores_gemma":[0.9670509,0.028607277,0.0024240592,0.001058109,0.00077698624,0.00008262916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042425003,0.00082578504,0.003171089,0.00036084166,0.0009239906,0.000019300483,0.0014501177,0.00036339124,0.00035525317],"category_scores_gemma":[0.0009680059,0.0004220958,0.0007026067,0.00073504745,0.0012898927,0.00009074008,0.00022921195,0.0008883021,0.00001758068],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4696588,0.0068102907,0.20869611,0.00090069027,0.07661888,0.00078383787,0.097639434,0.0015418725,0.07062661,0.0008526981,0.033889674,0.03198112],"study_design_scores_gemma":[0.053669754,0.021957232,0.70118904,0.008704624,0.028343273,0.0017284336,0.03240651,0.00006768951,0.13774578,0.0025542576,0.010607007,0.0010264044],"about_ca_topic_score_codex":0.0015122634,"about_ca_topic_score_gemma":0.0032459348,"teacher_disagreement_score":0.4924929,"about_ca_system_score_codex":0.00040056556,"about_ca_system_score_gemma":0.00039191922,"threshold_uncertainty_score":0.9998231},"labels":[],"label_agreement":null},{"id":"W4416140208","doi":"10.25251/gmn1ta26","title":"Lebrikizumab Patients Treated in the Real World: First North American data from the PPD<sup>TM</sup> CorEvitas<sup>TM</sup> AD Registry","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research; Foothills Medical Centre; University of Calgary","funders":"Eli Lilly and Company","keywords":"MEDLINE; Disease; Epidemiology; Incidence (geometry); Data collection","score_opus":0.01739020930894231,"score_gpt":0.27928569984755447,"score_spread":0.26189549053861216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8554866,0.06826945,0.00010439511,0.059046287,0.0035951484,0.004367953,0.002293965,0.00012593913,0.006710294],"genre_scores_gemma":[0.88286245,0.09706369,0.00013345448,0.00910803,0.004291277,0.000055029017,0.0014478992,0.0003026295,0.0047355522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9789004,0.0037776884,0.006866507,0.0020928406,0.0055141496,0.0028484468],"domain_scores_gemma":[0.9751571,0.008795728,0.0059691784,0.0075906124,0.0014963751,0.0009910369],"candidate_categories":["metaepi_narrow","sts","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts"],"category_scores_codex":[0.006536957,0.0026448788,0.004912609,0.0014610619,0.0018737607,0.00035837115,0.0090851635,0.00066901994,0.002416926],"category_scores_gemma":[0.0036697313,0.0014418209,0.001178816,0.007328173,0.005862256,0.00063494244,0.0011788192,0.0049369466,0.00011458174],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082241505,0.004115664,0.056536276,0.0007674275,0.010953173,0.011081761,0.02788627,0.00073129224,0.0016090327,0.000071914175,0.57573825,0.22826743],"study_design_scores_gemma":[0.033153042,0.010482984,0.14289388,0.016069543,0.0125082815,0.0084590595,0.0124983555,0.004860418,0.0001687998,0.00026132623,0.7563453,0.002299017],"about_ca_topic_score_codex":0.008106152,"about_ca_topic_score_gemma":0.03804028,"teacher_disagreement_score":0.2259684,"about_ca_system_score_codex":0.0021732464,"about_ca_system_score_gemma":0.0021704086,"threshold_uncertainty_score":0.99942565},"labels":[],"label_agreement":null},{"id":"W4416140290","doi":"10.25251/vmn4mf70","title":"The Impact of Moderate-to-Severe Atopic Dermatitis on Sleep in Adolescent Patients from the Adelphi Real World Disease Specific Programme (DSP)<sup>TM</sup>","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research; Foothills Medical Centre; University of Calgary","funders":"","keywords":"Atopic dermatitis; Disease; Sleep (system call); MEDLINE; Population","score_opus":0.015322233882585974,"score_gpt":0.2784670552779415,"score_spread":0.26314482139535555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9202321,0.034459982,0.00008457366,0.038126573,0.0019884235,0.0027521877,0.00022402965,0.000027201404,0.0021048973],"genre_scores_gemma":[0.98049873,0.013944286,0.00002083321,0.0034109266,0.0012999977,0.000026523998,0.00006141029,0.00007890231,0.00065836124],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9904852,0.0020639405,0.0033451086,0.00057512,0.00214073,0.0013899322],"domain_scores_gemma":[0.9897849,0.004654499,0.0017066187,0.0017284472,0.0009950054,0.0011305303],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015522101,0.0010007536,0.0020244059,0.00068787404,0.00074890075,0.00009371484,0.0019067503,0.0002563813,0.00063884445],"category_scores_gemma":[0.002317695,0.00046931978,0.0008107762,0.0015866281,0.0015735788,0.0001650327,0.00029874043,0.0021003808,0.00005318879],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052744955,0.006627012,0.39032784,0.0007355601,0.0042715473,0.011811183,0.012064542,0.017470643,0.00007236824,0.00062995305,0.41196784,0.09127655],"study_design_scores_gemma":[0.017011171,0.0031629105,0.91785806,0.020059396,0.0035625808,0.0020278457,0.00308875,0.0076200347,0.00011376278,0.006358806,0.01836443,0.0007722705],"about_ca_topic_score_codex":0.00034293183,"about_ca_topic_score_gemma":0.00049059326,"teacher_disagreement_score":0.5275302,"about_ca_system_score_codex":0.00082710513,"about_ca_system_score_gemma":0.0011968326,"threshold_uncertainty_score":0.9997758},"labels":[],"label_agreement":null},{"id":"W4416140380","doi":"10.25251/14pn6v71","title":"Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Imputation (statistics); Atopic dermatitis; Dosing; Check List; Eczema Area and Severity Index; Medical record","score_opus":0.005441398379629446,"score_gpt":0.24390871564290686,"score_spread":0.2384673172632774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626854,0.0067668143,0.00075953314,0.025046883,0.0013974127,0.001438532,0.000014156852,0.000023993052,0.0018672607],"genre_scores_gemma":[0.98672664,0.00056705216,0.00012020819,0.008741125,0.0003031912,0.000011467244,0.0000070903243,0.00005881648,0.0034643994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932765,0.0016404163,0.0022648943,0.00044628425,0.0013775015,0.0009944327],"domain_scores_gemma":[0.9925217,0.0036675564,0.0012403919,0.00077871,0.0012477572,0.0005438899],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017626295,0.0006910571,0.0017898084,0.0010243675,0.00039971838,0.000049171187,0.00083288515,0.00027183056,0.0004126108],"category_scores_gemma":[0.0075454777,0.00040896912,0.00018864927,0.0012285061,0.0009043362,0.0002860014,0.00017205674,0.0015853314,0.00004924708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3404572,0.0023809462,0.48440444,0.0023961458,0.0025232686,0.053286146,0.012174305,0.006827486,0.000109698674,0.00011710111,0.072587214,0.022736037],"study_design_scores_gemma":[0.034846153,0.009553244,0.8525116,0.046250608,0.0027238969,0.04249174,0.0042308965,0.001193565,0.00043450142,0.0018607919,0.0031158747,0.0007871317],"about_ca_topic_score_codex":0.00009443573,"about_ca_topic_score_gemma":0.00008793728,"teacher_disagreement_score":0.36810714,"about_ca_system_score_codex":0.0005831085,"about_ca_system_score_gemma":0.0021152021,"threshold_uncertainty_score":0.9998362},"labels":[],"label_agreement":null},{"id":"W4416140478","doi":"10.25251/ta5v8k92","title":"Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Incidence (geometry); Adverse effect; Esophageal candidiasis; Nystatin; Oral microbiology; Mycosis","score_opus":0.01726677270135445,"score_gpt":0.2932623388721411,"score_spread":0.27599556617078663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828088,0.011141828,0.000030304005,0.0020495085,0.0023214743,0.0007973734,0.0007722102,0.000004674088,0.00007381559],"genre_scores_gemma":[0.99471235,0.0037990313,0.00015630217,0.00024541168,0.00010313515,0.000007048849,0.000043549633,0.000025608142,0.0009075525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959537,0.0009411846,0.001988375,0.00035587972,0.0002894111,0.00047145705],"domain_scores_gemma":[0.99490273,0.0021397967,0.0013555078,0.0005224768,0.0009712551,0.00010825767],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009425841,0.00047183703,0.0019814232,0.00078936183,0.00012981708,0.000007821153,0.00058861147,0.000267431,0.00011080791],"category_scores_gemma":[0.0012460568,0.0002888943,0.00015780228,0.00093176885,0.000448891,0.00009456672,0.00014479064,0.00043650263,0.000009427698],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6105742,0.0027079682,0.005856889,0.0002247102,0.022300927,0.0008366566,0.16812791,0.0061489493,0.008216543,0.000032585605,0.018938959,0.1560337],"study_design_scores_gemma":[0.3753806,0.09700625,0.07512892,0.036788892,0.025995305,0.0014517781,0.13837902,0.00008753737,0.24012938,0.00215082,0.005176177,0.0023253341],"about_ca_topic_score_codex":0.0017828252,"about_ca_topic_score_gemma":0.0012089147,"teacher_disagreement_score":0.23519361,"about_ca_system_score_codex":0.00022855261,"about_ca_system_score_gemma":0.0004446494,"threshold_uncertainty_score":0.9999563},"labels":[],"label_agreement":null},{"id":"W4416140920","doi":"10.25251/2q1bnf78","title":"Real-World Effectiveness of Guselkumab in Patients With Psoriasis: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriasis; Psoriasis Area and Severity Index; Body surface area; Severity of illness; Longitudinal study; Disease; Clinical trial","score_opus":0.017512896759632787,"score_gpt":0.29013079450370094,"score_spread":0.27261789774406814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97332495,0.020103445,0.00017039373,0.0014047698,0.0030583756,0.00088152906,0.00034903883,0.00000764088,0.0006998503],"genre_scores_gemma":[0.98798865,0.010995021,0.0001125479,0.00007165789,0.00032727007,0.000007105576,0.00015574617,0.00003304348,0.00030898367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932193,0.0036681106,0.0016278605,0.0005506338,0.00041527467,0.00051877525],"domain_scores_gemma":[0.98781216,0.00801238,0.0018515685,0.0017484159,0.0005017724,0.00007367311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003932822,0.0006040293,0.0017156734,0.00038946889,0.00037654466,0.000027111597,0.0017905191,0.00033091282,0.0002429473],"category_scores_gemma":[0.0005336707,0.00029609835,0.00013290235,0.000857467,0.0013209763,0.0001903949,0.00046105002,0.001126858,0.0000031604811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038581427,0.001495945,0.9121489,0.0003518717,0.009927388,0.0003458825,0.0016751953,0.000068944704,0.0015448102,0.00024607516,0.0032904376,0.03032312],"study_design_scores_gemma":[0.018076265,0.0032693776,0.9584311,0.0067280955,0.008299079,0.00045665196,0.0015383313,0.000014316765,0.0011521004,0.00063714286,0.0011114875,0.00028600314],"about_ca_topic_score_codex":0.0022169647,"about_ca_topic_score_gemma":0.0016389233,"teacher_disagreement_score":0.046282247,"about_ca_system_score_codex":0.0002993138,"about_ca_system_score_gemma":0.00068693527,"threshold_uncertainty_score":0.9999491},"labels":[],"label_agreement":null},{"id":"W4416140942","doi":"10.25251/sbrgz434","title":"Impact of Simultaneous Itch Relief and Substantial Skin Clearance With Lebrikizumab in Patients With Atopic Dermatitis: Post-hoc Analysis From ADvocate1/2","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; University of British Columbia","funders":"","keywords":"Clearance; Disease; MEDLINE; Clinical trial; Atopic dermatitis","score_opus":0.0029901312234496243,"score_gpt":0.24328544767987717,"score_spread":0.24029531645642754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672223,0.029615285,0.0002059325,0.0015452943,0.00031242069,0.000691081,0.00010626748,0.00001116935,0.0002902751],"genre_scores_gemma":[0.99372935,0.005221401,0.000106936044,0.0005392287,0.00018303508,0.0000022997283,0.000048400787,0.000045732373,0.00012359134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99482614,0.00073306257,0.0020852364,0.00043286465,0.001260362,0.00066231674],"domain_scores_gemma":[0.99324125,0.0023543062,0.0018117445,0.00079425535,0.0014166276,0.00038181018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051857514,0.00067825173,0.002682399,0.0011737788,0.00018527306,0.000025790485,0.00059454,0.0002725616,0.00042731018],"category_scores_gemma":[0.00066781824,0.0003650975,0.00033829175,0.00218044,0.0016021803,0.00019169235,0.000081506754,0.0011452207,0.0000036357512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06490419,0.0016701483,0.8836138,0.0004892387,0.014212683,0.0072604674,0.0071882363,0.0047347513,0.00006294783,0.000015391204,0.0011917949,0.014656316],"study_design_scores_gemma":[0.017397178,0.009771505,0.9412916,0.006412552,0.01748043,0.0023783706,0.0027778044,0.0016765553,0.0001509104,0.00016641144,0.00010367389,0.00039303058],"about_ca_topic_score_codex":0.0012338453,"about_ca_topic_score_gemma":0.0007413916,"teacher_disagreement_score":0.057677742,"about_ca_system_score_codex":0.0002503808,"about_ca_system_score_gemma":0.0009935836,"threshold_uncertainty_score":0.9998801},"labels":[],"label_agreement":null},{"id":"W4416140988","doi":"10.25251/0262jz84","title":"Lebrikizumab Treatment Improves Lichenification and Other Clinical Signs of Atopic Dermatitis in Adults and Adolescents with Moderate-to-Severe AD and Skin of Color","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"Eli Lilly and Company; Amgen","keywords":"Phototype; Atopic dermatitis; Trunk; Eczema Area and Severity Index; Concomitant; Population; Clinical trial; Randomized controlled trial","score_opus":0.01108067746716104,"score_gpt":0.2914322233988284,"score_spread":0.2803515459316674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96694773,0.02741455,0.00011244939,0.0042695603,0.0001785006,0.00088607427,0.000018230186,0.0000033529054,0.00016953297],"genre_scores_gemma":[0.98476475,0.013947693,0.00010737748,0.00092241284,0.00008708975,0.000005411309,0.0000016419281,0.00001870421,0.00014493044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697644,0.00048826667,0.0016690518,0.0002615557,0.000345625,0.0002590874],"domain_scores_gemma":[0.9973359,0.0008102554,0.00096397666,0.00030401975,0.0003166544,0.00026916072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005766613,0.0003196902,0.0013894531,0.00033848404,0.000079884594,0.000008487441,0.0001563857,0.00019131422,0.000024163803],"category_scores_gemma":[0.0005015867,0.00018384554,0.00007129063,0.00026590656,0.001184742,0.000070108115,0.00005505947,0.0003561547,4.9760865e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069891825,0.0037442055,0.69774693,0.00730654,0.0026241385,0.0020150985,0.028941836,0.00011794323,0.00191176,0.00014914796,0.0020754081,0.18347518],"study_design_scores_gemma":[0.04093344,0.020039847,0.85760605,0.039714765,0.004539235,0.01973114,0.009647069,0.002316697,0.003547183,0.0008173506,0.00070744066,0.00039979914],"about_ca_topic_score_codex":0.00014357101,"about_ca_topic_score_gemma":0.00026942097,"teacher_disagreement_score":0.18307538,"about_ca_system_score_codex":0.00006319725,"about_ca_system_score_gemma":0.0003562892,"threshold_uncertainty_score":0.7497003},"labels":[],"label_agreement":null},{"id":"W4416141077","doi":"10.25251/ej4zcr36","title":"Estimated Conjunctivitis-Related Healthcare Cost Savings With Increased Tralokinumab Use Versus Other Biologics Among Patients With Moderate-Severe Atopic Dermatitis in the United States","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"LEO Pharma","keywords":"Atopic dermatitis; Health care; MEDLINE; Cost analysis; Health economics","score_opus":0.016124761780484255,"score_gpt":0.26677901624789585,"score_spread":0.2506542544674116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826586,0.003699321,0.00016702774,0.010450653,0.0006622005,0.0018895691,0.00012337806,0.000036376146,0.00031282668],"genre_scores_gemma":[0.98989105,0.0018934382,0.000044392953,0.0076349634,0.00007759066,0.00001770225,0.000268786,0.000058810183,0.000113239206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99378777,0.0022682643,0.0016927036,0.00037208144,0.0010408424,0.00083833345],"domain_scores_gemma":[0.9909669,0.0052971826,0.0014629248,0.00069672073,0.0012302274,0.00034601722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009621887,0.00074361643,0.0015457473,0.0007646614,0.00050461653,0.00007450062,0.0007121009,0.00036671167,0.00027459182],"category_scores_gemma":[0.0014376561,0.0003397931,0.00012812014,0.0019122156,0.0023236745,0.00029848944,0.00005736422,0.0019281096,0.0000056655135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030421475,0.0012844299,0.92682123,0.000573215,0.002614729,0.008468814,0.009635281,0.006633602,0.000004415812,0.00016134995,0.011419813,0.0019616636],"study_design_scores_gemma":[0.06173553,0.0086878,0.86752266,0.01888016,0.0056649083,0.011886316,0.013342389,0.00858201,0.00006951629,0.0008410824,0.0020191092,0.0007685007],"about_ca_topic_score_codex":0.003846877,"about_ca_topic_score_gemma":0.0017403659,"teacher_disagreement_score":0.059298534,"about_ca_system_score_codex":0.0003482634,"about_ca_system_score_gemma":0.00080221915,"threshold_uncertainty_score":0.9999054},"labels":[],"label_agreement":null},{"id":"W4416141089","doi":"10.25251/zkfhw160","title":"Demographics, Clinical, and Treatment Characteristics of Patients With Moderate to Severe Chronic Hand Eczema in the United States – A Retrospective Claims Analysis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Contact Dermatitis and Allergies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Retrospective cohort study; MEDLINE; Epidemiology; Population; Chronic disease","score_opus":0.00954346012523469,"score_gpt":0.2772124074548631,"score_spread":0.26766894732962837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857797,0.0032011953,0.00041671086,0.009252352,0.00028601065,0.0009110024,0.00008761961,0.0000032321273,0.000062164916],"genre_scores_gemma":[0.96098334,0.03722633,0.000033150616,0.0013097856,0.00025170468,0.0000042612887,0.000044602442,0.000019327565,0.00012748975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956317,0.00076495315,0.002136436,0.00025989843,0.00082994,0.00037708785],"domain_scores_gemma":[0.99490273,0.0017505342,0.0014011147,0.0005494712,0.0011945602,0.00020161436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014521236,0.00042704854,0.001998245,0.0012234142,0.0002359919,0.00005401668,0.00034795149,0.00013647067,0.000085165484],"category_scores_gemma":[0.0004474383,0.00018838666,0.0002428867,0.002505147,0.0010521127,0.000065674125,0.00006124839,0.0007248633,5.0432277e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01225742,0.0013014941,0.9311361,0.00024633313,0.012298312,0.0008835784,0.022360073,0.0015879077,0.00002576203,0.000091764945,0.00085148384,0.016959822],"study_design_scores_gemma":[0.010445028,0.018780999,0.94053,0.00362843,0.01314136,0.00041341493,0.006555928,0.0042259144,0.000028201692,0.00032936962,0.0017001433,0.00022121132],"about_ca_topic_score_codex":0.0005057733,"about_ca_topic_score_gemma":0.0018061401,"teacher_disagreement_score":0.034025136,"about_ca_system_score_codex":0.0002565618,"about_ca_system_score_gemma":0.00036706746,"threshold_uncertainty_score":0.7682185},"labels":[],"label_agreement":null},{"id":"W4416141127","doi":"10.25251/n1p8w126","title":"Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pfizer","keywords":"Adverse effect; Incidence (geometry); Cohort; Population; Clinical trial; Janus kinase inhibitor; Cohort study","score_opus":0.00892148500178399,"score_gpt":0.25848724744308427,"score_spread":0.24956576244130027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911654,0.0035358288,0.00079044537,0.0016035862,0.00044244307,0.0009217844,0.0013339288,0.000008734215,0.0001978487],"genre_scores_gemma":[0.99653,0.0006566182,0.00033798022,0.001733325,0.00006811372,0.000004488876,0.00051302236,0.000039585047,0.00011687333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944239,0.0006553211,0.002468895,0.0004712142,0.0014729274,0.0005077365],"domain_scores_gemma":[0.9941557,0.0012404931,0.0014843002,0.0014906382,0.0011991626,0.00042972932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005428339,0.0004984572,0.002545477,0.0015658917,0.000084578816,0.000014600797,0.0012613252,0.00021728029,0.0006092652],"category_scores_gemma":[0.0011525524,0.0003097746,0.00017257423,0.0034131238,0.0006560247,0.00018214142,0.00026576515,0.00083543075,0.000004246463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043431617,0.0013841572,0.8502807,0.0005262202,0.015330912,0.0039366623,0.03706774,0.018876754,0.00007595989,0.000020640095,0.010146458,0.018922193],"study_design_scores_gemma":[0.011312147,0.0034831192,0.9361433,0.0139938975,0.015095756,0.0006237209,0.016185617,0.0012892805,0.00022882552,0.00009695275,0.0011690091,0.00037839854],"about_ca_topic_score_codex":0.00080179144,"about_ca_topic_score_gemma":0.0014226277,"teacher_disagreement_score":0.08586259,"about_ca_system_score_codex":0.00015792073,"about_ca_system_score_gemma":0.000822799,"threshold_uncertainty_score":0.99993545},"labels":[],"label_agreement":null},{"id":"W4416141135","doi":"10.25251/6g1c9m39","title":"Phase 2a Randomized, Double-Blinded, Placebo-Controlled Trial of a Topical Nitric Oxide Releasing Solution (NORS) for the Treatment of Plantar Warts (HPV-Warts-01)","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research & Development Corporation","funders":"","keywords":"Plantar warts; Nitric oxide; Placebo; Clinical endpoint; Foot (prosody); Clinical trial","score_opus":0.04270462571932358,"score_gpt":0.3759896381305963,"score_spread":0.33328501241127273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8284506,0.091072045,0.016831357,0.025300935,0.004867593,0.026419843,0.000050767878,0.000020328991,0.0069865203],"genre_scores_gemma":[0.9528637,0.04093408,0.00009913662,0.00021542459,0.0038768055,0.00016386835,0.000008394404,0.000040916337,0.0017977064],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9909806,0.0014625612,0.00424042,0.00035380057,0.0021699304,0.0007926524],"domain_scores_gemma":[0.9732472,0.02179137,0.00234051,0.0007901502,0.001445772,0.0003850248],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006017473,0.0006030839,0.004716917,0.0007889995,0.00044177464,0.000026307305,0.0007059787,0.00034614903,0.0010966554],"category_scores_gemma":[0.0040311045,0.0002696047,0.0017230414,0.0007834273,0.0016804603,0.000076893,0.000071436254,0.00096223305,0.0000024912988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9078455,0.003965547,0.000008037028,0.00051206246,0.0046072677,0.00023988521,0.0026945455,0.0002549105,0.0012878793,0.00032428512,0.0012836634,0.07697641],"study_design_scores_gemma":[0.9364664,0.026598658,0.000015264326,0.00096841686,0.016349653,0.001774221,0.0021802166,0.0067985184,0.00407594,0.0011945037,0.0034010236,0.00017717532],"about_ca_topic_score_codex":0.00096199074,"about_ca_topic_score_gemma":0.00013065065,"teacher_disagreement_score":0.12441306,"about_ca_system_score_codex":0.00075462036,"about_ca_system_score_gemma":0.0018129427,"threshold_uncertainty_score":0.9999756},"labels":[],"label_agreement":null},{"id":"W4416141136","doi":"10.25251/9k281951","title":"Tapinarof Cream 1% Once Daily: Consistent Efficacy Across Age Groups for Children Down to 2 Years of Age with Atopic Dermatitis in Two Pivotal Phase 3 Trials","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Atopic dermatitis; Age groups; Oxidative stress; Aryl hydrocarbon receptor; Agonist; Clinical trial; Psoriasis","score_opus":0.019675538828943413,"score_gpt":0.3610051985971068,"score_spread":0.3413296597681634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96704066,0.019989511,0.0010887752,0.007095234,0.0012634862,0.0028584045,0.00016978773,0.000014582005,0.0004795337],"genre_scores_gemma":[0.9933239,0.0020941014,0.00026127015,0.0028567135,0.0007607482,0.00002203162,0.000039680926,0.000045756737,0.0005957515],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.993093,0.001225442,0.0035162617,0.00038741276,0.0009530096,0.00082485564],"domain_scores_gemma":[0.9896999,0.006552059,0.0020150295,0.00075975474,0.00047757872,0.0004956584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037090033,0.0005553934,0.0034739745,0.000501611,0.00022222319,0.000032678498,0.0008128345,0.00018361119,0.00021776058],"category_scores_gemma":[0.0071625053,0.00035432607,0.0005100019,0.00086640223,0.0015929728,0.00011045315,0.00014332826,0.000892156,0.000006337383],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1172514,0.025964985,0.06403483,0.0059165624,0.02170463,0.14116177,0.1025462,0.0043088086,0.008321724,0.0013788758,0.23880392,0.2686063],"study_design_scores_gemma":[0.3116712,0.037820376,0.35249826,0.06772252,0.023432516,0.15437816,0.021506963,0.00024464665,0.009212732,0.003628707,0.016085044,0.0017988901],"about_ca_topic_score_codex":0.00015325377,"about_ca_topic_score_gemma":0.000251789,"teacher_disagreement_score":0.2884634,"about_ca_system_score_codex":0.00020164574,"about_ca_system_score_gemma":0.00070000754,"threshold_uncertainty_score":0.99989086},"labels":[],"label_agreement":null},{"id":"W4416141157","doi":"10.25251/6m5ykw66","title":"Successful In Vitro and In Vivo Treatment of Tinea Pedis with a Nitric Oxide-releasing Gel","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research & Development Corporation","funders":"","keywords":"Trichophyton rubrum; Nitric oxide; In vivo; Trichophyton; Fungicide; Antifungal; Refractory (planetary science)","score_opus":0.00704809578985545,"score_gpt":0.26791084267878434,"score_spread":0.2608627468889289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93786365,0.056944583,0.000037892474,0.0030229997,0.00021367526,0.0008007447,0.00002040654,0.000004435724,0.001091621],"genre_scores_gemma":[0.9676819,0.030891053,0.000113502065,0.00019230925,0.00027119167,0.000005709627,0.0000029882062,0.000035385223,0.0008059571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625164,0.00035733642,0.0017291255,0.00029263855,0.00082592,0.00054335094],"domain_scores_gemma":[0.99660504,0.0012684291,0.0010724515,0.00042335302,0.00031548244,0.0003152605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004604921,0.00052327994,0.001784,0.0012766953,0.00009118963,0.000014507783,0.00023932601,0.00014307351,0.00015095023],"category_scores_gemma":[0.0003756724,0.0002707008,0.00016337697,0.0014269783,0.0005802379,0.000096224874,0.000046846395,0.00043463262,0.0000012749999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11235563,0.008952764,0.6652651,0.0021428743,0.0038159073,0.04040037,0.0072412807,0.00049802096,0.036209,0.000038332633,0.00051716686,0.12256355],"study_design_scores_gemma":[0.21855389,0.052820798,0.43580094,0.05911718,0.04389039,0.08080388,0.05478684,0.0050075217,0.042515133,0.0019773426,0.0030333675,0.0016927088],"about_ca_topic_score_codex":0.0019958098,"about_ca_topic_score_gemma":0.00027315726,"teacher_disagreement_score":0.22946414,"about_ca_system_score_codex":0.00064123905,"about_ca_system_score_gemma":0.0007287286,"threshold_uncertainty_score":0.9999745},"labels":[],"label_agreement":null},{"id":"W4416141158","doi":"10.25251/gsd1c102","title":"Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Scalp; Young adult; Clinical trial; Severity of illness; Randomized controlled trial","score_opus":0.014469191181411756,"score_gpt":0.2858461746513273,"score_spread":0.2713769834699155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78501916,0.084340736,0.0026446339,0.110937916,0.006024854,0.0018774711,0.0001222372,0.00006122953,0.0089717815],"genre_scores_gemma":[0.9432,0.03733379,0.0002712457,0.012132055,0.003960265,0.0000060879793,0.000038877366,0.00010663541,0.0029510623],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98725814,0.0030859713,0.0052779126,0.00074456434,0.0023078579,0.001325567],"domain_scores_gemma":[0.97489464,0.018208815,0.00275215,0.0010653497,0.0018059243,0.0012730939],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009780218,0.0011314024,0.004093285,0.0018531837,0.00071353005,0.00011781192,0.0011960258,0.00084187766,0.0013217079],"category_scores_gemma":[0.055398382,0.0006862019,0.0006193386,0.002972626,0.0017842028,0.00027192957,0.00026656812,0.0029318796,0.000043158823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18184477,0.0017374515,0.017091539,0.0021988612,0.009617549,0.009919727,0.037687328,0.0002020758,0.028776914,0.0019117087,0.5168951,0.19211698],"study_design_scores_gemma":[0.25475848,0.057877615,0.02851318,0.04966654,0.08990522,0.04420502,0.23307465,0.005708621,0.01048937,0.06791212,0.1523265,0.0055626985],"about_ca_topic_score_codex":0.0006908727,"about_ca_topic_score_gemma":0.00022021547,"teacher_disagreement_score":0.3645686,"about_ca_system_score_codex":0.00032141025,"about_ca_system_score_gemma":0.0020072823,"threshold_uncertainty_score":0.99959123},"labels":[],"label_agreement":null},{"id":"W4416141167","doi":"10.25251/w6str133","title":"Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriatic arthritis; Adverse effect; Psoriasis; Placebo; Imputation (statistics); Drug","score_opus":0.01989010843082884,"score_gpt":0.29351688533544873,"score_spread":0.2736267769046199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81567824,0.14922713,0.00036088945,0.02060339,0.0075885775,0.004633076,0.0007632535,0.000012797833,0.0011326635],"genre_scores_gemma":[0.89499325,0.09977005,0.0000962908,0.00057537685,0.0038954508,0.000017426679,0.00004641415,0.000046622365,0.0005591026],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937955,0.0006818545,0.0032584378,0.0004550206,0.0011441518,0.00066501537],"domain_scores_gemma":[0.979786,0.015592175,0.002697146,0.0008543679,0.0008077605,0.00026256332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020527276,0.0006485459,0.0024405064,0.00022863322,0.0007265175,0.000030244624,0.00061001256,0.0002674914,0.0001963751],"category_scores_gemma":[0.0070904274,0.00033577028,0.00045196663,0.0005066581,0.001553004,0.00009290062,0.00018635677,0.0009912752,0.000003833749],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5733718,0.0013464454,0.00017128237,0.00015023668,0.007104802,0.0010619278,0.01287758,0.000018385685,0.00012177589,0.00009205406,0.0059933276,0.39769036],"study_design_scores_gemma":[0.82983583,0.053046785,0.029461447,0.031969965,0.021329058,0.0063149687,0.014117052,0.000077297744,0.00094634906,0.002972721,0.00941061,0.00051788293],"about_ca_topic_score_codex":0.00032467395,"about_ca_topic_score_gemma":0.00040908318,"teacher_disagreement_score":0.39717245,"about_ca_system_score_codex":0.00025998216,"about_ca_system_score_gemma":0.00057965366,"threshold_uncertainty_score":0.99990946},"labels":[],"label_agreement":null},{"id":"W4416141170","doi":"10.25251/36zrjg92","title":"Tapinarof Cream 1% Once Daily: Maintenance of Low Disease Activity Including Pruritus Through End of the Treatment-freeInterval in a Long-term Extension Trial in Patients Down to 2 Years of Age with Atopic Dermatitis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Atopic dermatitis; Discontinuation; Psoriasis; Skin barrier; Disease; Clinical trial","score_opus":0.01250357248406921,"score_gpt":0.28869931337164745,"score_spread":0.27619574088757826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98921967,0.0051660547,0.000096375654,0.002590638,0.0009177788,0.0017844829,0.000044168493,0.0000035129303,0.00017733757],"genre_scores_gemma":[0.9963937,0.002879697,0.000040566156,0.000378523,0.0001242829,0.00001031408,0.0000047482126,0.000023427876,0.00014478735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995353,0.0009286468,0.001995687,0.00029208342,0.0009737599,0.0004568342],"domain_scores_gemma":[0.9954103,0.0012407919,0.0019009965,0.0008519137,0.0003920941,0.00020386586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065933575,0.00039685928,0.0018186495,0.00043493288,0.000079397585,0.00000587832,0.0006593878,0.00013812886,0.00008384924],"category_scores_gemma":[0.0019603516,0.00022025559,0.00030162942,0.00087587093,0.0013441455,0.00013715378,0.00020207287,0.00056239427,6.8983536e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26390797,0.014008644,0.63563156,0.0035521714,0.001494977,0.013900082,0.020702036,0.00069695344,0.0012012874,0.000081060374,0.0012336761,0.04358959],"study_design_scores_gemma":[0.063848816,0.007666151,0.8832238,0.038593568,0.0015286222,0.00073606556,0.0007761581,0.00006797253,0.002873604,0.00045098577,0.000059879487,0.00017438673],"about_ca_topic_score_codex":0.00041104187,"about_ca_topic_score_gemma":0.00049397117,"teacher_disagreement_score":0.24759223,"about_ca_system_score_codex":0.00038802694,"about_ca_system_score_gemma":0.00075264915,"threshold_uncertainty_score":0.89817625},"labels":[],"label_agreement":null},{"id":"W4416141214","doi":"10.25251/xdxsk580","title":"A Novel Topical Nitric Oxide Releasing Gel Demonstrates Effective Nail Penetration and Potent Antifungal Activity in Onychomycosis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research & Development Corporation; Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Ex vivo; Terbinafine; Nail plate; Penetration (warfare); In vivo; Antifungal; Trichophyton; Nail (fastener)","score_opus":0.008592733521409688,"score_gpt":0.27777260285696126,"score_spread":0.26917986933555155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9648556,0.02560447,0.0015211445,0.005488276,0.0006548942,0.0010213868,0.000011720095,0.0000086478885,0.0008338483],"genre_scores_gemma":[0.9867594,0.011785763,0.00018816987,0.0003932623,0.00053940376,0.000006036606,0.0000030332492,0.00002480614,0.00030010846],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99670494,0.0005448454,0.0010925101,0.00034345756,0.00081465574,0.0004995993],"domain_scores_gemma":[0.99622643,0.0019901535,0.00074575184,0.00032788527,0.0003634395,0.0003463298],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008438059,0.00045712548,0.0011269192,0.00066489744,0.00026219827,0.000043596043,0.00022490609,0.00023551358,0.000055545624],"category_scores_gemma":[0.0015623978,0.0002808996,0.0002099621,0.0008816982,0.00042494116,0.00017218073,0.00007694083,0.0011305755,0.000003736655],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026253927,0.0055174245,0.24374676,0.0015209955,0.0036093078,0.0076258965,0.0023705566,0.00038071087,0.10758134,0.00021631012,0.0011615615,0.6000152],"study_design_scores_gemma":[0.012458271,0.0036109253,0.94753045,0.0074575376,0.005389309,0.014487281,0.0021988652,0.0025536106,0.0032641375,0.0006114517,0.00016695433,0.00027120693],"about_ca_topic_score_codex":0.00068459474,"about_ca_topic_score_gemma":0.00011585608,"teacher_disagreement_score":0.7037837,"about_ca_system_score_codex":0.00057875115,"about_ca_system_score_gemma":0.0005155664,"threshold_uncertainty_score":0.9999643},"labels":[],"label_agreement":null},{"id":"W4416141241","doi":"10.25251/x2k3y515","title":"Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Sanofi","keywords":"Placebo; Chemokine; Exploratory analysis; Inflammation; Monoclonal antibody; Blockade; Atopic dermatitis; Multiplex","score_opus":0.008317057868066989,"score_gpt":0.2776039301126633,"score_spread":0.26928687224459635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624373,0.026580786,0.00001678351,0.008832409,0.00046729922,0.001208998,0.00020295383,0.000015591972,0.00023787908],"genre_scores_gemma":[0.9925989,0.0059600472,0.000028453444,0.0010591628,0.00013772372,0.000010893441,0.000037871072,0.00003452769,0.00013243374],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99387705,0.0014444279,0.0026007344,0.0005957081,0.0010001834,0.00048188673],"domain_scores_gemma":[0.9943347,0.0018778233,0.0016046509,0.0010462694,0.0007349817,0.00040160038],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012736648,0.0006602119,0.0023670085,0.0011436256,0.00033002225,0.00004320044,0.0007148812,0.00023499159,0.00009773537],"category_scores_gemma":[0.0015197995,0.00033579138,0.00017160518,0.0025123328,0.0012837199,0.00030989625,0.00021317479,0.00096115796,7.056337e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1365606,0.01348558,0.31439233,0.0013910241,0.038694065,0.015234482,0.41096795,0.006381052,0.0021009352,0.0000450027,0.006120813,0.054626163],"study_design_scores_gemma":[0.09742314,0.009820663,0.54575515,0.02579697,0.06096504,0.008773185,0.22928873,0.014861822,0.0043660565,0.0016624929,0.00021723563,0.001069481],"about_ca_topic_score_codex":0.00042451016,"about_ca_topic_score_gemma":0.0015614046,"teacher_disagreement_score":0.23136283,"about_ca_system_score_codex":0.00008552007,"about_ca_system_score_gemma":0.00049870147,"threshold_uncertainty_score":0.9999094},"labels":[],"label_agreement":null},{"id":"W4416141242","doi":"10.25251/h3w8px06","title":"Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Probity Medical Research; SKiN Health; Queen's University","funders":"Incyte; Les Laboratories Pierre Fabre; National Alopecia Areata Foundation; L'Oreal USA; Sanofi; Pfizer; Concert Pharmaceuticals; Eli Lilly and Company","keywords":"Tolerability; Context (archaeology); Clinical trial; Adverse effect; Phases of clinical research","score_opus":0.011279431426697174,"score_gpt":0.2933219497264348,"score_spread":0.28204251829973764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.940289,0.026513575,0.00020698906,0.01857697,0.00080168777,0.010695235,0.00011605801,0.000017244562,0.0027832354],"genre_scores_gemma":[0.9836234,0.0145583125,0.00006849055,0.00068213145,0.0006613433,0.000029811332,0.00003446215,0.000041806466,0.00030024946],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910525,0.0018166493,0.0043046437,0.0006266949,0.0014569758,0.0007425524],"domain_scores_gemma":[0.9865777,0.008744999,0.002363907,0.00091799034,0.00086213805,0.000533272],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0074017374,0.00081121083,0.004433976,0.00042449302,0.00030263703,0.00005274811,0.000659693,0.0003437209,0.00008992421],"category_scores_gemma":[0.0066720163,0.00036681665,0.00032094255,0.0009012672,0.0033466273,0.00015650566,0.00017497392,0.0018188746,0.00000147713],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9167155,0.0017558854,0.0022225527,0.0005758302,0.0013727036,0.00054278376,0.01376734,0.00014232266,0.000019602316,0.000025232164,0.00060244306,0.06225781],"study_design_scores_gemma":[0.9434135,0.005279226,0.0019764805,0.026971996,0.004708339,0.0029392573,0.011830314,0.0012998882,0.000054921995,0.0002699387,0.0009454479,0.00031069733],"about_ca_topic_score_codex":0.001209122,"about_ca_topic_score_gemma":0.0013984807,"teacher_disagreement_score":0.061947115,"about_ca_system_score_codex":0.00013667638,"about_ca_system_score_gemma":0.0009435681,"threshold_uncertainty_score":0.9998784},"labels":[],"label_agreement":null},{"id":"W4416141277","doi":"10.25251/9es69b60","title":"Impact of Moderate-to-Severe Atopic Dermatitis on Daily Functioning among Adolescent Patients: A Real-World Study in the United States","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Quality of life (healthcare); Mood; Disease; Activities of daily living; Alternative medicine; Mood swing; Primary care","score_opus":0.01225173217685616,"score_gpt":0.29928422111473846,"score_spread":0.2870324889378823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895461,0.0012927693,0.000092478964,0.0046188678,0.0009912674,0.0016659984,0.00002122914,0.0000106847465,0.0017605816],"genre_scores_gemma":[0.99346757,0.0016229126,0.000004827894,0.0041735456,0.00025036818,0.0000099641375,0.000027850303,0.00003086255,0.0004121075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935011,0.0020902988,0.002284911,0.00027095588,0.0012761147,0.0005765769],"domain_scores_gemma":[0.99418217,0.0024941731,0.0012733855,0.00077088043,0.0009933546,0.00028606056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015539912,0.0005257386,0.0014223608,0.0017168416,0.00033472426,0.000032891767,0.0007667964,0.000120014025,0.0003132977],"category_scores_gemma":[0.0015150601,0.0002627713,0.00028497732,0.0023279325,0.00055390527,0.00011885222,0.00009999016,0.0014661386,0.000008554968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067323307,0.0037684555,0.88902926,0.0003025234,0.0013567065,0.0022382964,0.02019825,0.02105418,0.0000040517084,0.000022968865,0.053529177,0.0017638153],"study_design_scores_gemma":[0.008804146,0.0064008436,0.9516626,0.008505472,0.0020827418,0.0011263771,0.018963479,0.0015614919,0.000018777775,0.00037058734,0.00030482284,0.00019865517],"about_ca_topic_score_codex":0.002034176,"about_ca_topic_score_gemma":0.0008949769,"teacher_disagreement_score":0.06263336,"about_ca_system_score_codex":0.0004598581,"about_ca_system_score_gemma":0.00052584824,"threshold_uncertainty_score":0.9999825},"labels":[],"label_agreement":null},{"id":"W4416141304","doi":"10.25251/21ypnv28","title":"Treatment Patterns and Efficacy in Biologic-Exposed and Biologic-Naive Patients With Moderate-to-Severe Atopic Dermatitis: JADE REAL Post Hoc Analysis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"Pfizer","keywords":"Post-hoc analysis; Eczema Area and Severity Index; Post hoc; Janus kinase inhibitor; JADE (particle detector); Concomitant; Ruxolitinib","score_opus":0.007916708921851867,"score_gpt":0.25394115425868813,"score_spread":0.24602444533683626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798566,0.009786272,0.00008123991,0.008569186,0.00028259555,0.0009853097,0.00008722177,0.000013106057,0.0003384836],"genre_scores_gemma":[0.978181,0.019072575,0.000053876865,0.0023145804,0.00013232019,0.0000079447655,0.000056922087,0.000018214017,0.00016258136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963581,0.000854495,0.0013680609,0.00043829632,0.00040953208,0.00057154347],"domain_scores_gemma":[0.99616396,0.0017550299,0.0007357689,0.00045159884,0.00045613517,0.00043748188],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038758432,0.0005979451,0.0019512379,0.0010473537,0.0002683134,0.000031140353,0.00030493195,0.0002618413,0.00014399647],"category_scores_gemma":[0.00054259883,0.00029399205,0.0001634634,0.00091462163,0.0007546232,0.000090528636,0.00011309756,0.0005232836,0.0000033215647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010726651,0.0011446656,0.9588757,0.00018363215,0.004525311,0.00428959,0.0053793034,0.00033241394,0.000038266473,0.000024651245,0.00038333167,0.014096478],"study_design_scores_gemma":[0.015844692,0.011425351,0.9524878,0.0018997887,0.008846314,0.004419065,0.0039726305,0.0003585522,0.000089966896,0.00016328512,0.00018520885,0.00030731692],"about_ca_topic_score_codex":0.000300595,"about_ca_topic_score_gemma":0.0004788077,"teacher_disagreement_score":0.013789161,"about_ca_system_score_codex":0.00022352647,"about_ca_system_score_gemma":0.00026696472,"threshold_uncertainty_score":0.99995124},"labels":[],"label_agreement":null},{"id":"W4416141338","doi":"10.25251/czq0gz98","title":"Rationale and Design of a Phase 1b Trial Evaluating APG279, the Combination of Half-Life-Extended Anti-IL-13 and Anti-OX40L Monoclonal Antibodies, Compared With Dupilumab in Moderate-to-Severe Atopic Dermatitis","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dupilumab; Atopic dermatitis; Adverse effect; Monoclonal antibody; Pharmacodynamics; Clinical endpoint; Disease; Incidence (geometry)","score_opus":0.030026271463707354,"score_gpt":0.3234356889230727,"score_spread":0.29340941745936533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639345,0.018519703,0.0036967057,0.010729657,0.00046196906,0.0024747537,0.000034375036,0.000006311876,0.00014203673],"genre_scores_gemma":[0.9954127,0.0030236668,0.0004499299,0.000816866,0.0001530713,0.000013275982,0.000017694903,0.000022423212,0.00009035984],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99439734,0.001653179,0.0021988868,0.0002857503,0.0010910918,0.00037377502],"domain_scores_gemma":[0.99292237,0.00379071,0.0016539993,0.00038195137,0.0010222795,0.00022869895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025137367,0.0004174467,0.0018359702,0.00058779126,0.00033813494,0.000030284262,0.0003600517,0.00015372687,0.00008882682],"category_scores_gemma":[0.0025979453,0.00024101249,0.00009830662,0.000659231,0.0013689748,0.0001923103,0.000091507696,0.0006451071,6.199887e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65533584,0.021134289,0.08271009,0.008867882,0.012325214,0.0074090627,0.06674179,0.047328345,0.016454827,0.003282604,0.034407567,0.044002518],"study_design_scores_gemma":[0.52069706,0.018318566,0.11187875,0.020435506,0.00962998,0.039649233,0.016807428,0.249017,0.004359987,0.008160725,0.00020710331,0.000838685],"about_ca_topic_score_codex":0.00011050686,"about_ca_topic_score_gemma":0.00004575526,"teacher_disagreement_score":0.20168866,"about_ca_system_score_codex":0.000072599825,"about_ca_system_score_gemma":0.0013347521,"threshold_uncertainty_score":0.9828204},"labels":[],"label_agreement":null},{"id":"W4416141346","doi":"10.25251/p6a0hd58","title":"C-206 Real-World Prospective Data Assessing the Long-Term Safety of Abrocitinib Treatment in Adults with Moderate to Severe Atopic Dermatitis (AD): Over Two Years of Experience from the CorEvitas AD Registry [1225]","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Genentech; Sanofi; Pfizer","keywords":"Cohort; Incidence (geometry); Prospective cohort study; Poisson regression; Cohort study; Confidence interval; Atopic dermatitis; Observational study","score_opus":0.016281883786891178,"score_gpt":0.33728489574132264,"score_spread":0.3210030119544315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635682,0.022506269,0.00032760206,0.0096664345,0.000582874,0.0015862721,0.00023443426,0.000008400664,0.0015194784],"genre_scores_gemma":[0.9865673,0.011087663,0.0001424829,0.0013653884,0.00025300652,0.000016132943,0.000047127687,0.000032436998,0.0004884509],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951728,0.00091038947,0.0019840435,0.00044662898,0.0010127906,0.000473334],"domain_scores_gemma":[0.9917084,0.0038503339,0.0018678828,0.0019015525,0.000467101,0.00020475713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000801848,0.00048338572,0.0015790757,0.00021455926,0.00026623844,0.000032673375,0.0014851978,0.00011657024,0.0002968311],"category_scores_gemma":[0.0010127474,0.00022852879,0.000155154,0.000888766,0.0017114597,0.0002507448,0.0002870254,0.0008133737,0.00000214432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02307521,0.0016695973,0.8066701,0.0010895861,0.004235108,0.014188137,0.08998681,0.0010558255,0.0003251768,0.00017670744,0.012081331,0.04544637],"study_design_scores_gemma":[0.011619735,0.001045624,0.92240906,0.034448985,0.003042117,0.0074811582,0.017032605,0.00068257435,0.00082589785,0.00061689253,0.0005156135,0.0002797274],"about_ca_topic_score_codex":0.0015464462,"about_ca_topic_score_gemma":0.003988797,"teacher_disagreement_score":0.11573893,"about_ca_system_score_codex":0.00035674128,"about_ca_system_score_gemma":0.001143273,"threshold_uncertainty_score":0.9319134},"labels":[],"label_agreement":null},{"id":"W4416141358","doi":"10.25251/m10xva58","title":"Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Interim analysis; Concomitant; Post-hoc analysis; Psoriatic arthritis; Propensity score matching; Psoriasis; Observational study; Interim","score_opus":0.007972802628403415,"score_gpt":0.24529220213115632,"score_spread":0.2373193995027529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844942,0.012140987,0.000037359776,0.00014673822,0.0017559752,0.0010253642,0.0002274869,0.000004577738,0.00016727638],"genre_scores_gemma":[0.9969549,0.0024509602,0.00002021087,0.000040750758,0.00008012026,0.000011487038,0.00001437011,0.00002432092,0.00040284253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936027,0.003209134,0.002180789,0.00031210078,0.0003178172,0.00037745858],"domain_scores_gemma":[0.9941167,0.0011599569,0.0030303963,0.0009942466,0.00064000656,0.00005869025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001250625,0.0005521441,0.0025199878,0.00066286145,0.00016528342,0.000006112748,0.00083189376,0.00024581482,0.0005408079],"category_scores_gemma":[0.0002025315,0.00024198415,0.0006051136,0.0011939999,0.0014714384,0.00007344475,0.00012254821,0.00034051447,9.718656e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024772977,0.0074220677,0.851837,0.0000830921,0.057167444,0.00007956008,0.029768776,0.0008860963,0.0011281068,0.000038384882,0.000063187494,0.026753306],"study_design_scores_gemma":[0.01931004,0.042591214,0.8393778,0.0022555494,0.068917125,0.00011994159,0.020747596,0.00006410005,0.0059268246,0.00017686647,0.00016023632,0.00035271107],"about_ca_topic_score_codex":0.0015217501,"about_ca_topic_score_gemma":0.002956045,"teacher_disagreement_score":0.035169143,"about_ca_system_score_codex":0.0001910218,"about_ca_system_score_gemma":0.00026068886,"threshold_uncertainty_score":0.98678267},"labels":[],"label_agreement":null},{"id":"W4416141382","doi":"10.25251/36mxmk39","title":"Integrated Safety Analysis of Ruxolitinib Cream: Data From 20 Clinical Studies in Inflammatory Dermatologic Conditions","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Incyte","keywords":"Ruxolitinib; Clinical trial; Safety profile; MEDLINE; Risk assessment","score_opus":0.09100882040484524,"score_gpt":0.43360308264627695,"score_spread":0.3425942622414317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73946416,0.23596327,0.00034583904,0.01905481,0.0018276263,0.0006468742,0.0011712057,0.000015443866,0.0015107743],"genre_scores_gemma":[0.6782463,0.3199171,0.00009510144,0.0007608081,0.0003457692,0.0000024642284,0.0003571992,0.00001843095,0.00025679648],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9876335,0.0035305098,0.0062797354,0.0004633947,0.0014023646,0.0006904424],"domain_scores_gemma":[0.97560364,0.01785456,0.0024062423,0.0018212784,0.0019064167,0.00040786466],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008249417,0.0005149032,0.004111524,0.0021147497,0.00026120764,0.000024729608,0.0019207898,0.0003343865,0.0026350694],"category_scores_gemma":[0.0197474,0.00029669312,0.00051381614,0.0029264593,0.005364794,0.00023762566,0.0005423118,0.002397651,0.000015306434],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0356739,0.005493322,0.40251562,0.0011875754,0.18574741,0.020810565,0.02524389,0.0014719806,0.002739247,0.002614657,0.2746219,0.04187994],"study_design_scores_gemma":[0.05516523,0.012722806,0.16679594,0.08123633,0.041219775,0.013735715,0.2960961,0.035547767,0.00095958874,0.026696391,0.26822862,0.0015957436],"about_ca_topic_score_codex":0.0005320691,"about_ca_topic_score_gemma":0.0020055384,"teacher_disagreement_score":0.2708522,"about_ca_system_score_codex":0.00023385262,"about_ca_system_score_gemma":0.0016752989,"threshold_uncertainty_score":0.9999485},"labels":[],"label_agreement":null},{"id":"W4416141399","doi":"10.25251/t4rkzz84","title":"Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University; Probity Medical Research","funders":"Pfizer","keywords":"Dosing; Adverse effect; Incidence (geometry); JADE (particle detector); Expanded access; Clinical trial","score_opus":0.023100562919750114,"score_gpt":0.356878933342599,"score_spread":0.3337783704228489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9557075,0.00022194731,0.00012891818,0.003626029,0.0006359124,0.033476185,0.000078071076,0.000023690305,0.0061017307],"genre_scores_gemma":[0.9965167,0.00010944358,0.00007614704,0.0016904211,0.0006440387,0.00065033545,0.000025513225,0.000050746847,0.0002366719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99160385,0.0018118545,0.003763249,0.00045880597,0.0016569785,0.00070523284],"domain_scores_gemma":[0.99024177,0.004884992,0.002493326,0.00096178945,0.0011032613,0.00031488496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016139816,0.00063114037,0.0019269296,0.0006847801,0.00049788575,0.000076070435,0.0012918939,0.00019385341,0.0001994251],"category_scores_gemma":[0.0022344969,0.0003328533,0.00016246921,0.0015479055,0.0007110619,0.0003310537,0.00033684875,0.0014585184,0.0000032771065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.094906755,0.003021815,0.83964735,0.00080448115,0.002023009,0.0032530227,0.02984743,0.01031986,0.000030838582,0.000055025663,0.0068255044,0.009264882],"study_design_scores_gemma":[0.06951611,0.004255457,0.8774818,0.02968476,0.0027771713,0.0006613145,0.010650489,0.0010966391,0.00096004934,0.0020581179,0.00035919,0.0004988621],"about_ca_topic_score_codex":0.0019626347,"about_ca_topic_score_gemma":0.0012243659,"teacher_disagreement_score":0.040809166,"about_ca_system_score_codex":0.0002688766,"about_ca_system_score_gemma":0.0011507367,"threshold_uncertainty_score":0.9999123},"labels":[],"label_agreement":null},{"id":"W4416195853","doi":"10.25251/64mgd212","title":"Red Light Photodynamic Therapy with 10% Aminolevulinic Acid Gel Showed Robust Efficacy for the Treatment of Superficial BCC in a Randomized, Vehicle-Controlled, Double-Blind, Multicenter Phase III Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bell (Canada)","funders":"","keywords":"Photodynamic therapy; Lesion; Basal cell carcinoma; Target lesion; Occlusion; Basal cell; Clinical trial","score_opus":0.03080565497281926,"score_gpt":0.33476288269899934,"score_spread":0.30395722772618006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416195853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87416774,0.078590006,0.0006633801,0.01754485,0.0025768913,0.02602884,0.000020956099,0.000015298841,0.0003920331],"genre_scores_gemma":[0.9579834,0.037061516,0.00008380801,0.000372289,0.0020532177,0.00065993017,0.000007218084,0.00011642384,0.0016622368],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9895632,0.0016831928,0.0052867797,0.0007007898,0.0017032683,0.0010627612],"domain_scores_gemma":[0.9793169,0.014409488,0.003256983,0.0013906807,0.0013664351,0.00025950742],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0057746433,0.0012926809,0.0077764755,0.0010690193,0.0005396718,0.000046334266,0.0011880548,0.00028848636,0.00046658053],"category_scores_gemma":[0.0010492877,0.0005401562,0.0012980703,0.001180002,0.0016780164,0.00011260533,0.000091405,0.0010682842,0.0000033447984],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.900602,0.01679491,0.00046356238,0.00014506646,0.020415258,0.0011061813,0.036168154,0.0012902596,0.0030325404,0.000006497696,0.00050371536,0.019471886],"study_design_scores_gemma":[0.88657033,0.059045352,0.00022784033,0.0028657874,0.018905135,0.00086614944,0.021451157,0.004682707,0.003679217,0.000023275235,0.0013044995,0.0003785328],"about_ca_topic_score_codex":0.000487368,"about_ca_topic_score_gemma":0.0014667574,"teacher_disagreement_score":0.08381561,"about_ca_system_score_codex":0.0009695459,"about_ca_system_score_gemma":0.0010648078,"threshold_uncertainty_score":0.9999825},"labels":[],"label_agreement":null},{"id":"W4416195856","doi":"10.25251/9sm0xp66","title":"Safety and Efficacy of Photodynamic Therapy with Aminolevulinic Acid 10% Topical Gel Activated by Red Light versus Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Covenant Health","funders":"","keywords":"Photodynamic therapy; Actinic keratosis; Actinic keratoses; Intense pulsed light; Red light; Clinical endpoint; Blue light; Clinical trial","score_opus":0.021827952059749144,"score_gpt":0.3017234534958868,"score_spread":0.2798955014361377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416195856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9102965,0.033300113,0.0003680143,0.046542097,0.001533675,0.00747521,0.00006747509,0.000019725047,0.00039719034],"genre_scores_gemma":[0.95144117,0.045321215,0.000027327955,0.00035725487,0.0006724914,0.00016261154,0.000014947383,0.0000810459,0.001921917],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913963,0.0021863182,0.0033582489,0.00071553356,0.0015171119,0.000826453],"domain_scores_gemma":[0.9708165,0.023629513,0.0031015163,0.0013575241,0.0008583775,0.00023658208],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023698432,0.0011231565,0.0041755755,0.00035756783,0.00073510414,0.000037277066,0.000920968,0.00044620762,0.00049607287],"category_scores_gemma":[0.0022589166,0.00046673257,0.00075972575,0.0008714128,0.0019299507,0.0001018399,0.00011324945,0.0012591874,0.0000017851817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7608104,0.0048710806,0.00019722793,0.00012689696,0.018786253,0.000060690367,0.015782006,0.000019140856,0.17298052,0.00001649386,0.005091891,0.021257438],"study_design_scores_gemma":[0.4528341,0.06500273,0.0009890712,0.0029171833,0.011986208,0.00043235804,0.017987492,0.0003993101,0.43355986,0.0000376513,0.013350479,0.0005035754],"about_ca_topic_score_codex":0.000101905,"about_ca_topic_score_gemma":0.000073381336,"teacher_disagreement_score":0.30797628,"about_ca_system_score_codex":0.0008083137,"about_ca_system_score_gemma":0.00064098136,"threshold_uncertainty_score":0.99977845},"labels":[],"label_agreement":null}]}